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Background: Tools based on diagnostic prediction models are available to help general practitioners
diagnose cancer. It is unclear whether or not tools expedite diagnosis or affect patient quality of life
and/or survival.
Objectives: The objectives were to evaluate the evidence on the validation, clinical effectiveness,
cost-effectiveness, and availability and use of cancer diagnostic tools in primary care.
Methods: Two systematic reviews were conducted to examine the clinical effectiveness (review 1) and
the development, validation and accuracy (review 2) of diagnostic prediction models for aiding general
practitioners in cancer diagnosis. Bibliographic searches were conducted on MEDLINE, MEDLINE
In-Process, EMBASE, Cochrane Library and Web of Science) in May 2017, with updated searches
conducted in November 2018. A decision-analytic model explored the tools’ clinical effectiveness and
cost-effectiveness in colorectal cancer. The model compared patient outcomes and costs between
strategies that included the use of the tools and those that did not, using the NHS perspective. We
surveyed 4600 general practitioners in randomly selected UK practices to determine the proportions
of general practices and general practitioners with access to, and using, cancer decision support tools.
Association between access to these tools and practice-level cancer diagnostic indicators was explored.
Results: Systematic review 1 – five studies, of different design and quality, reporting on three diagnostic
tools, were included. We found no evidence that using the tools was associated with better outcomes.
Systematic review 2 – 43 studies were included, reporting on prediction models, in various stages of
development, for 14 cancer sites (including multiple cancers). Most studies relate to QCancer® (ClinRisk
Ltd, Leeds, UK) and risk assessment tools.
Decision model: In the absence of studies reporting their clinical outcomes, QCancer and risk
assessment tools were evaluated against faecal immunochemical testing. A linked data approach
was used, which translates diagnostic accuracy into time to diagnosis and treatment, and stage at
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diagnosis. Given the current lack of evidence, the model showed that the cost-effectiveness of
diagnostic tools in colorectal cancer relies on demonstrating patient survival benefits. Sensitivity of
faecal immunochemical testing and specificity of QCancer and risk assessment tools in a low-risk
population were the key uncertain parameters.
Survey: Practitioner- and practice-level response rates were 10.3% (476/4600) and 23.3% (227/975),
respectively. Cancer decision support tools were available in 83 out of 227 practices (36.6%,
95% confidence interval 30.3% to 43.1%), and were likely to be used in 38 out of 227 practices
(16.7%, 95% confidence interval 12.1% to 22.2%). The mean 2-week-wait referral rate did not differ
between practices that do and practices that do not have access to QCancer or risk assessment tools
(mean difference of 1.8 referrals per 100,000 referrals, 95% confidence interval –6.7 to 10.3 referrals
per 100,000 referrals).
Limitations: There is little good-quality evidence on the clinical effectiveness and cost-effectiveness
of diagnostic tools. Many diagnostic prediction models are limited by a lack of external validation.
There are limited data on current UK practice and clinical outcomes of diagnostic strategies, and
there is no evidence on the quality-of-life outcomes of diagnostic results. The survey was limited
by low response rates.
Conclusion: The evidence base on the tools is limited. Research on how general practitioners interact
with the tools may help to identify barriers to implementation and uptake, and the potential for
clinical effectiveness.
Future work: Continued model validation is recommended, especially for risk assessment tools.
Assessment of the tools’ impact on time to diagnosis and treatment, stage at diagnosis, and health
outcomes is also recommended, as is further work to understand how tools are used in general
practitioner consultations.
Study registration: This study is registered as PROSPERO CRD42017068373 and CRD42017068375.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology programme and will be published in full in Health Technology Assessment; Vol. 24, No. 66.
See the NIHR Journals Library website for further project information.
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In the UK, people with cancer tend to die sooner than people with cancer in other European countries.This may be because their cancers are caught at a later stage, perhaps after they have spread. Spotting
cancer earlier in people, and testing them sooner, may extend people’s lives. Researchers have developed
‘diagnostic tools’, which give the probability of having cancer, based on a patient’s symptoms, blood test
results and other information. The tools help family doctors decide who needs further testing for possible
cancer, including cancers of the digestive, urinary and reproductive systems, and in the blood. We do not
know how many family doctors have these tools, or how well the tools work.
We systematically reviewed published studies about how these tools were developed, how good and
accurate they are, and what effects their use has on patients. We found that many tools have been
developed, but there is little evidence that they improve the quality or length of life. We sent surveys
to family doctors all over the UK asking if they had the tools at their practice and if they used them.
Based on the replies we received, we estimate that the tools are in about one in three practices. They
are likely to be used in about half of the practices where they are available. For practices in England
only, we looked for, but did not find, any association between using the tools and the number of urgent
appointments made for cancer testing.
We used a computer model to show what might happen if family doctors used the tools for patients
who have symptoms of bowel cancer. In our model, if general practitioners used the tools, patients
would need fewer appointments before they were referred to a specialist. This should reduce the time
to diagnosis and treatment, compared with not using the tools. However, there is very little evidence
as to whether or not this is indeed the case. Therefore, at the moment, we cannot say whether or not
the use of such tools by general practitioners is better for patients and the NHS. More research is
needed on what effect these tools have on patients, especially as to whether or not quality and length
of life are improved.
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Tools based on diagnostic prediction models are available to help general practitioners diagnose
cancer. It is unclear whether or not they lead to increased or quicker diagnoses, and whether or not
they ultimately affect patient quality of life and/or survival.
Objectives
The objectives were to evaluate the evidence on the validation, clinical effectiveness, cost-effectiveness
(by two different systematic reviews), and availability and use of cancer diagnostic tools in primary care.
Systematic review 1
Methods
Two systematic reviews were conducted to examine the clinical effectiveness (systematic review 1)
and development, validation and accuracy (systematic review 2) of diagnostic prediction models for use
by general practitioners to aid cancer diagnosis. The following electronic databases were searched in
May 2017 and updated in November 2018: MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, EMBASE, the Cochrane Library and Web of Science™ (Clarivate Analytics, Philadelphia, PA,
USA). Titles, abstracts and full texts were screened independently by two reviewers.
Studies of any design were included in systematic review 1 if they assessed the clinical effectiveness
of diagnostic tools in aiding decision-making among general practitioners for symptomatic patients
presenting with features potentially indicative of cancer. An expanded definition of diagnostic tools
was used, which included tools based on scoring systems/algorithms, as well as those based on
prediction models.
Data extraction and assessment of risk of bias were completed by one reviewer and checked by a
second reviewer. Owing to heterogeneity in tools, cancer sites, the outcomes measured and study
design, a narrative review of the studies was conducted.
Results
Five studies met the inclusion criteria, and, between them, assessed three diagnostic tools: the risk
assessment tools (as part of an education resource card in an Australian randomised controlled trial for
lung, colorectal and prostate cancer, and mouse mats and desktop flip charts about colorectal and lung
cancer in a UK-based pre–post study), a skin cancer algorithm (in a randomised controlled trial and a
field trial, both based in Australia), and an online skin cancer recognition toolkit (in a UK-based
case–control study).
Although the field trial and pre–post study reported a positive impact of the tools on outcomes, the
results of the randomised controlled trials and the case–control study found no evidence that use of
the tools was associated with better outcomes.
There is currently very little good-quality evidence to suggest that these tools can help improve
general practitioner decision-making.
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The search strategy was the same as that for systematic review 1. Studies of any design were included
if they contained details on the development, validation or accuracy of diagnostic prediction models.
Data extraction and assessment of risk of bias were completed by one reviewer and checked by a
second reviewer. Owing to the heterogeneity of the tools, the cancer sites, the outcomes measured
and the study design, a narrative review of the studies was conducted.
Results
A total of 43 studies met the inclusion criteria, including two systematic reviews. The searches
identified evidence on 11 different prediction models in total, including risk assessment tools for
15 different cancer sites and QCancer® (ClinRisk Ltd, Leeds, UK) for six cancer sites, plus male and
female versions for multiple cancers. Prediction models exist for 14 cancer sites, including models
for multiple cancers. Colorectal cancer was associated with the greatest number of models (n = 6).
The majority of QCancer models, one risk assessment tool and five other models have been
externally validated.
There are clear gaps in the evidence for further validation of existing models that have the potential to
be implemented in primary care to aid general practitioner decision-making.
Updated review
Methods
A review was conducted to update the findings of a previous systematic review that examined the
association between different durations of time from first symptom to diagnosis or treatment, and
clinical outcomes, across all major cancers. The updated review was conducted to inform the
decision-analytic model and its structural assumptions. It therefore includes a more focused review
of colorectal cancer.
Results
The updated review identified 35 new studies, the overall findings of which were summarised in a
table outlining whether each study reported a ‘positive association’ (i.e. statistically significant more
favourable patient outcomes), a ‘negative association’ (i.e. statistically significant less favourable
outcomes) or ‘no association’ (i.e. the findings were not statically significant).
A more in-depth evaluation was conducted of colorectal cancer, which focused on studies identified
during the updated review (n = 10) and better-quality studies identified in the previous review
(n = 4). No meta-analyses were undertaken because of heterogeneity, which included variability in
the intervals.
The majority of the colorectal cancer studies found ‘no association’ between various intervals and
patient outcomes. A small number of studies (n = 4, but three used the same, or an overlapping,
population) reported a positive association between shorter intervals and patient outcomes, but,
paradoxically, a small number of studies (n = 3) also found a negative association.
These overall findings may reflect the U-shaped relationship between diagnostic interval and patient
outcomes that was identified by some of the included studies, showing that both very short and long
intervals were associated with poor outcomes. The review also identified important biases and other
factors that may affect the findings of studies in this field.
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Data for informing the economic decision model
Methods
The search strategy was designed to retrieve economic decision models for diagnosing or screening
colorectal cancer. Colorectal cancer was the chosen focus for the economic analysis because its
disease history in the UK setting has been researched in recent years. The methodological quality of
the studies included was assessed in detail by two reviewers following the checklist for model studies by
Philips et al. (Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for decision-
analytic modelling in health technology assessment: a review and consolidation of quality assessment.
PharmacoEconomics 2006;24:355–71). Data extraction and assessment of risk of bias were completed
by one reviewer and checked by a second reviewer. A narrative review of the studies was conducted.
Results
The searches identified 18 studies that met the inclusion criteria, which were then included in the review.
Our review found no evidence on the cost-effectiveness of diagnostic tools for managing patients in
primary care with suspected colorectal cancer, but identified one study of faecal immunochemical tests
in the low-risk population of interest that modelled the diagnostic phase. Our critique of the model
identified shortcomings in the way time to referral and mortality were analysed in the diagnostic phase,
which were to be addressed in the de novo model developed in the present study.
Economic decision model
Methods
A simple analytical model of diagnostic pathway was used to illustrate the uncertainty inherent in the
current evidence base, and to ask questions about the probable impact of the diagnostic tools, given
the current evidence base.
The model takes as its starting point symptomatic patients presenting to primary care who undergo an
initial clinical assessment. This model is then combined with an adaptation of an existing disease model
from a published colorectal cancer screening study and used to identify the parameters contributing
most to the overall decision uncertainty about the cost-effectiveness of decision tools, and where
additional research might be targeted in the future. In the absence of evidence on the impact of the
tools on the time to diagnosis, a structural assumption was used to link the sensitivity of diagnostic
strategies with the expected duration of the referral interval. The mechanism of effect of all the
strategies considered in the model is, therefore, a reduction in the time to diagnosis, made possible
by a reduction in the referral interval.
Results
The analysis using the limited available data on current practice in the UK suggests that the survival
benefit of faster referrals for cancer patients is higher than the risks associated with exposing the
overwhelming majority of patients without cancer to colonoscopy. Given the uncertainty in the
evidence base, it is unclear if the overall benefits are worth the additional health-care costs
associated with those referrals.
The sensitivity and threshold analysis revealed that the cost-effectiveness results were particularly
sensitive to uncertainty around the diagnostic accuracy of current standard practice and the specificity
of the tools. Other areas of uncertainty highlighted by the model include the clinical effectiveness of
the tools, the prevalence of cancer in the low-risk population for which these tools are intended, the
cost of colonoscopy and the definition of current practice.
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A cross-sectional postal survey was carried out to determine (1) the proportions of UK general practices
and UK general practitioners with access to cancer decision support tools and (2) the proportion of
general practices that use cancer decision support tools. Data collection occurred in July and August 2017.
Questionnaires were posted to 4600 general practitioners in 975 randomly selected UK practices. Using
data from general practices in England only, ordinary least squares regression subanalyses explored the
association between access to cancer decision support tools and practice-level cancer diagnostic indicators
published by Public Health England. Ethics approval was granted by the University of Exeter.
Results
Responses were received from 473 general practitioners and three registrars in 227 practices, giving
response rates of 23.3% (practice level) and 10.3% (practitioner level). Responding practices had a
median of 6 (interquartile range 4–8) general practitioners, of whom a median of 2 (interquartile
range 1–3) responded to the survey. EMIS Web (EMIS Health, Leeds, UK) was the most frequently
used software (96/227, 42.3%), followed by TPP SystmOne (The Phoenix Partnership, Leeds, UK)
(74/227, 32.6%) and then INPS Vision (In Practice Systems Ltd, London, UK) (32/227, 14.1%).
A total of 112 of the 476 general practitioners (23.5%, 95% confidence interval 19.7% to 27.6%) had
access to a cancer decision support tool in either paper or electronic format, or both. At the practice
level, at least one general practitioner in 83 of the 227 practices (36.6%, 95% confidence interval
30.3% to 43.1%) had access to a tool. Tools were available and likely to be used in 38 of the 227
practices (16.7%, 95% confidence interval 12.1% to 22.2%).
There was no difference in the mean 2-week-wait referral rate between practices that do and practices
that do not have access to either type of tool, after adjusting for Index of Multiple Deprivation (mean
difference 1.8 referrals per 100,000, 95% confidence interval –6.7 to 10.3). Access to either type of
tool was not associated with a change in the proportion of 2-week-wait referrals that resulted in a
diagnosis of cancer, after adjusting for the Index of Multiple Deprivation (mean difference –0.2,
95% confidence interval –1.0 to 0.6).
Discussion
Cancer decision support tools are available to general practitioners in approximately one-third of UK
general practices, but are likely to be used in only one-sixth of practices.
Improvements in training and increasing familiarisation with the tool may increase the levels of uptake
of these tools by UK general practices and general practitioners.
More research is needed to determine the comparative accuracy of the tools in studies that directly
compare them with current standard practice and in the same low-risk suspected symptomatic patient
population in primary care. To inform decisions about the use of the tools to aid diagnosis in primary
care, such studies should aim to measure the impact of the tools on diagnostic intervals and, ideally,
on clinical outcomes.
Conclusions
Our survey indicates that cancer decision support tools are currently not widely used in the UK.
This may reflect our findings in systematic reviews 1 and 2 that there is limited evidence that these
tools have a positive impact on patient outcomes.
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As levels of uptake are currently low, it is possible to carry out a randomised controlled trial to assess
whether or not these tools are genuinely helpful in improving the selection of patients for investigation
for suspected cancer.
Study registration
This study is registered as PROSPERO CRD42017068373 and CRD42017068375.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
programme and will be published in full in Health Technology Assessment; Vol. 24, No. 66. See the NIHR
Journals Library website for further project information.
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Scientific background and rationale
The rate of cancer survival in the UK is lower than the European average for most cancers: for
example, the 5-year survival rate for stomach cancer is 17.2% in the UK, compared with the European
average of 25.1%; for colon cancer, it is 51.8% in the UK, compared with the European average
of 57%.1 Efforts to reduce the time to making a cancer diagnosis have the potential to improve
prognosis,2 because earlier diagnosis is associated with earlier cancer stage at diagnosis,3 and earlier
treatment is associated with improved survival.4 There is also the potential to reduce presentation via
emergency admissions, and to prevent the poorer survival associated with that route of diagnosis.5
National cancer screening programmes in the NHS (for breast, bowel and cervical cancer) and the
National Awareness and Early Diagnosis Initiative (NAEDI) (to increase public awareness of the signs
and symptoms of cancer4) are intended to improve early diagnosis. As many individuals go through
primary care as a route for diagnosis,5 efforts there could improve cancer survival.
Cancer diagnosis in primary care is not straightforward. Symptoms of cancer are commonly seen, but
mostly have non-cancer origins.6 Of those individuals referred from primary care via the 2-week-wait
(2WW) referrals for suspected head and neck cancer, approximately 9% were ultimately diagnosed
with cancer.7 The type and presence of symptoms can vary greatly,8 and it is not surprising that
patients can have multiple general practitioner (GP) consultations before being referred, especially
for those cancers that have less well-known signs and symptoms.9 Thus, tools to help improve cancer
diagnosis in primary care have great potential to affect diagnoses and subsequent treatment options,
leading to better outcomes for patients.
Diagnostic prediction models combine multiple predictors, such as symptoms and patient characteristics,
to obtain the risk of the presence or absence of a disease in an individual patient.10,11 These prediction
models can then be used to develop diagnostic tools (such as a website risk calculator or a mouse mat
detailing estimates of risk depending on features) to assist doctors in estimating probabilities, and can
potentially influence doctors’ decision-making.11 To evaluate diagnostic prediction models, there are three
important stages, or types, of studies: prediction model development, prediction model validation and
assessment of the impact of prediction models in practice (generally implemented as diagnostic tools).
The first two are often conducted as part of the same study, and are generally evaluated using a single
cohort design. These types of studies are commonly found in the diagnostic prediction literature, with
some studies also reporting results of an external validation.12 To assess the impact of the prediction
model (the third stage), comparative studies are required to evaluate the ability of the tool to guide
patient management. In the literature on prediction models in general, very few diagnostic prediction
models that are developed go on to be evaluated for their clinical impact.12
Tools currently available to GPs to help cancer diagnosis, beyond the National Institute for Health and
Care Excellence (NICE) guidelines for suspected cancer referral,6 are based on the following diagnostic
prediction models:
1. the risk assessment tool (RAT) developed by Hamilton et al.,13 which provides estimates of cancer
risk for 17 cancers, based on symptoms alone
2. the QCancer® (ClinRisk Ltd, Leeds, UK) tool, which estimates the risk of 10 cancers, based on
symptoms and patient characteristics, such as age, smoking status and body mass index.
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There are clear differences in the derivation of the RAT and QCancer. The RAT used a case–control
design to predict likely cancer diagnosis, whereas QCancer used a cohort design. Many of the QCancer
prediction models have subsequently been externally validated and reported to have good diagnostic
performance.14,15 There has, however, been no comparison of the clinical effectiveness of these diagnostic
tools in clinical practice, or research on whether or not GPs currently have access to and are using
these tools.
In 2013, Hamilton et al.13 reported an increase in cancer referrals and investigations associated with the
introduction of RATs as mouse mats and desktop flip charts for lung cancer and colorectal cancer (CRC),
and an increase in the awareness of GPs of cancer symptoms, especially those symptoms that are less
known in those cancers.16 A 2015 evaluation of an electronic version of RATs for lung cancer and CRC
highlighted the potential issue of prompt overload from the system, cautioned on potential variation in
data used by the tool, and the extent to which the aid might increase pressure on secondary care owing
to increased referral (a finding that could be generalised to all such diagnostic tools).17
An Australian study using simulated GP consultations explored the implementation of an aid based on
QCancer.18 The study found that GPs agreed that the diagnostic aid was potentially useful in practice,
but noted that different GPs interpreted the same set of symptoms differently, leading to inconsistent
estimates of risk from the QCancer aid. In collaboration with the NAEDI, Macmillan Cancer Support
developed, with BMJ Informatica, and evaluated the introduction of an electronic clinical decision
support (eCDS) containing the RAT and QCancer for colorectal, lung, oesophagogastric, pancreatic
and ovarian cancers. It was found that the impact of eCDSs varied across practice, from no impact on
referrals to increased referrals and investigations in other practices,19 with use of eCDSs leading to
further investigation or referral of the patient that would not have occurred otherwise in 19% of cases.
However, there is very little evidence as to whether or not these tools have led to increased or quicker
cancer diagnoses, and, ultimately, to impacts on patient quality of life or survival. A study protocol for a
randomised controlled trial (RCT) to evaluate eCDSs for assessing symptoms indicative of stomach
cancer was published in 2016.20 Other diagnostic prediction models have been developed in the UK,
such as that reported by Iyen-Omofoman et al.21 for lung cancer and the Bristol–Birmingham (BB)
equation for CRC,22 plus those developed outside the UK, such as Benign, Lonely, Irregular, Nervous,
Change, Known (BLINCK) clues in Australia for skin cancer23 and that developed in the USA for
ovarian cancer,24 which may have the potential to be useful in the NHS context. However, little is
known about whether or not, and how, these diagnostic prediction models and tools affect patient
outcomes, and would affect NHS resources.
Although we are unclear about the evidence on the clinical effectiveness of these diagnostic tools to
affect patient quality of life and survival, a systematic review conducted by Neal et al.25 found a large
number of studies looking at the impact on patient outcomes of reducing diagnostic and/or treatment
intervals for cancer. Only a small number of studies were found to be of high quality, and there was
substantial variation in the type of intervals evaluated and the findings within and between cancer
types. Compared with other cancer types, studies of colorectal, breast, head and neck, and testicular
cancers and melanoma suggested that shorter time intervals were associated with improved patient
outcomes. However, for each of these cancer types, there were also studies reporting no association
between time interval and patient outcome.
The possible trade-offs between the costs and the harms, and the inherent uncertainty, of using these
diagnostic tools in primary care are also unclear, as well as the extent to which reducing times to
diagnosis and/or treatment could affect patient outcomes.
INTRODUCTION
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Aims and objectives
The aim of this project was to evaluate the evidence on the development, validation, clinical
effectiveness and cost-effectiveness of cancer diagnostic tools in primary care, and to understand
the extent to which existing tools are currently used in the primary care setting in the NHS.
The objectives were to:
1. identify evidence evaluating the clinical effectiveness of symptom-based diagnostic tools that that
could be used to inform cancer diagnosis decision-making in primary care (see Chapters 2 and 3)
2. identify and summarise studies reporting the development, validation or accuracy of any diagnostic
prediction model that could be used as a tool to aid cancer diagnosis in primary care (see Chapters 2
and 4)
3. update a previous systematic review25 assessing the association of the durations of different
intervals in the diagnostic process to clinical outcomes, and conduct a more in-depth evaluation of
CRC studies, focusing on methods, to identify studies that are likely to provide the best estimate of
the impact of diagnostic intervals on patient outcomes for informing the decision-analytic mode
(see Chapter 5)
4. use a decision-analytic model to explore uncertainties in the cost-effectiveness of using symptom-
based diagnostic tools, including the impacts on health service resource use, costs and patient
outcomes, using CRC as an example (see Chapters 6 and 7)
5. understand the extent to which GPs currently have access to cancer diagnostic tools and are using
them in primary care to inform their decision-making (see Chapter 8).
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Chapter 2 Systematic reviews 1 and 2:
literature search strategy
Introduction
Two systematic reviews were conducted: systematic review (SR) 1 and SR2.
The research question (SR1) was ‘what evidence is there for the clinical effectiveness and cost-
effectiveness of symptom-based diagnostic tools that could be used to inform cancer diagnosis
decision-making in primary care?’. It was anticipated that limited evidence would be identified;
therefore, a second review was planned (SR2) to identify studies reporting the development and
validation of any diagnostic prediction model that could be used as a tool to help cancer decision-
making in primary care, that is to provide a list of cancer models that might have the potential to be
developed into diagnostic tools. This chapter clarifies the definitions of diagnostic tools and prediction
models used and describes the search methods employed for SR1 and SR2. The results are presented
separately in Chapters 3 (SR1) and 4 (SR2).
Diagnostic prediction models can be categorised according to the different stages of development and
evaluation of the model (Table 1). However, a number of predictive research studies have differed in
what they consider to fall under the ‘predictive model research’ header. This variation primarily related
to whether or not they incorporated predictor finding studies as an initial stage and, at the other end
of the spectrum, whether or not they incorporated impact or implementation studies. For the purpose
of our reviews, we have differentiated between prediction models and prediction tools. Diagnostic
prediction models are defined as multivariate statistical models that predict the probability or risk that
a patient currently has cancer based on a combination of known features of that patient, such as
symptoms, signs, test results and patient characteristics.26 Symptoms could be self-reported by the
patient, or prompted by a physician’s questioning. Signs and test results are identified in primary care
via routine testing (e.g. full blood count, urine dipstick testing, clinical signs), and patient characteristics
are also determined in primary care (e.g. sociodemographic variables, personal and family history). The
prediction tools implement the models to provide a numerical risk of having cancer. As examples,
prediction tools may be mouse mats or desktop flip charts, or may be integrated into information
technology (IT) systems.
As a 2009 study by Moons et al.28 points out, studies assessing the impact of prediction tools need
designs and outcome measures that are different from those used in studies that develop and evaluate
prediction models. Studies of predictive research26,27,29,30 also differ slightly in the way they categorise
studies, based on whether they considered the evaluation of internal validity to be part of the model
development stage or a separate stage.
Table 1 summarises the spectrum of potential study types and clarifies the inclusion and exclusion
criteria for SR1 and SR2.
Methods
The systematic reviews were conducted in accordance with good practice guidelines.31 As the inclusion
and exclusion criteria were very similar for SR1 and SR2, the same search strategy was used for both
reviews; however, two separate protocols were developed for reviewing the evidence. Further details
are presented in this chapter.
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Search strategy
Bibliographic searches of relevant databases [MEDLINE (1946 to May week 1 2017), MEDLINE
In-Process & Other Non-Indexed Citations, EMBASE (1974 to 10 May 2017), the Cochrane Library
and Web of Science™ (Clarivate Analytics, Philadelphia, PA, USA)] were conducted in May 2017, with
updated searches conducted in November 2018. SR1 and SR2 were conducted in parallel using the
same search strategy, but each review had different inclusion and exclusion criteria.
The search strategies were developed by an information specialist (SR) and comprised terms for cancer,
terms for primary care, terms for decision support tools and terms for diagnosis (Table 2). No date,
language, study design or other limits were used. Search filters for clinical prediction models were




used for coding studies Description Exclude or include
Identifying single
predictors
Predictor identification Studies that aim to explore which
predictors out of a number of candidate
predictors independently contribute to the
prediction of (i.e. are associated with) a






Studies in which performance is directly
evaluated using exactly the same data




Internal validation I Studies that use only the original study
sample for both development and
validation using resampling techniques
(e.g. cross-validating, bootstrapping,
jackknifing)
Internal validation II Studies that use only the original study
sample for both development and
validation using split sampling, whereby
part of the sample is used for model
derivation and the other part is used
for validation
External validation External validation Studies that aim to assess and compare
the predictive performance of an existing
prediction model using new participant
data that were not used in the
development process
Model updating Model update External validation studies in which the
model is adjusted or updated in the case of
poor performance, based on the validation
Impact assessment Impact assessment Studies that aim to quantify the effect or
impact of using a diagnostic tool (relative to
not using the tool) on patient or physician
behaviour and management, patient health
outcomes, or cost-effectiveness of care.26
There are two types of analyses:
1. Narrow impact analysis – prospective
demonstration in one setting that use of
the prediction rule improves physicians’
decisions (quality or cost-effectiveness
of patient care), which could be used to
inform decisions in similar settings27
2. Broad impact analysis – prospective
demonstration in varied settings that
use of the prediction rule improves
physicians’ decisions for a wide
spectrum of patients27
Include in SR1
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investigated but none was thought to be fully tested or reliable. A balance was sought between the
sensitivity of the search results and the number of papers to be screened.
The search results were exported to EndNote X7 [Clarivate Analytics (formerly Thomson Reuters),
Philadelphia, PA, USA] and de-duplicated using automatic and manual checking.
Items included after full-text screening were forward and backward citation-chased using Scopus®
(Elsevier, Amsterdam, the Netherlands) to identify additional relevant studies. Once relevant models
and tools were identified from the initial searches, additional searches were conducted to identify
names of tools [e.g. QCancer, RAT, Cancer Prediction in Exeter (CAPER), BB equation, GP Skin Cancer
Toolkit], to ensure that search results were sufficiently comprehensive.
The full search strategies and results are in Appendix 1.
Inclusion and exclusion criteria
For SR1, diagnostic tools were considered initially as diagnostic prediction models that are used in clinical
practice to assist doctors in estimating probabilities to aid decision-making. Pilot searches identified
one study that assessed the impact of implementing diagnostic prediction models. Therefore, the
definition of ‘diagnostic tool’ for SR1 was expanded to include any quantitative tool used to support a
GP in deciding which patient warrants further investigation for cancer. Such investigation could be via
referral to secondary care or involve further testing in primary care. In other words, the diagnostic
tools may be based not only on diagnostic prediction models, but also on scoring systems/algorithms,
etc. Studies were excluded that simply looked at ‘red-flag symptoms’ or symptom lists and (weighted)
TABLE 2 Search strategy for MEDLINE (searched May 2017)
1. exp Neoplasms/
2. (cancer$ or neopla$).tw.
3. (tumour$ or tumor$).tw.
4. or/1-3
5. Primary Health Care/
6. exp General Practice/
7. General Practitioners/
8. (primary care or general practi$ or family practi$).tw.
9. (primary adj3 (healthcare or health care)).tw.
10. Or 5/9
11. Decision Support Systems, Clinical/
12. Decision Support Techniques/
13. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$ or
equation$).tw.
14. or/11-13
15. “Early Detection of Cancer”/
16. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
17. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
18. or/15-17
19. 4 and 10 and 14 and 18
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scores that did not provide a numerical risk of current cancer. Owing to the limited anticipated number
of relevant studies, we sought any study reporting on impact, regardless of study design.
For SR2, diagnostic prediction models are defined as multivariate statistical models that predict the
probability or risk that a patient currently has cancer based on a combination of known features of
that patient, such as symptoms, signs, test results and patient characteristics.26 Symptoms could be
self-reported by the patient or prompted by a physician’s questioning. Signs and test results are identified
in primary care via routine testing (e.g. full blood count, urine dipstick testing, clinical signs), and patient
characteristics are also determined in primary care (e.g. sociodemographic variables, personal and family
history). Studies that simply looked at ‘red-flag symptoms’ or symptom lists and (weighted) scores that did
not provide a numerical risk of current cancer were excluded. Models developed with secondary care data
(i.e. referred patients) were included only if an attempt was made to validate the models with primary
care data.
Inclusion and exclusion criteria for SR1 and SR2 are presented in Table 3.
Selection of studies
Although slightly different inclusion and exclusion criteria were used for SR1 and SR2, the screening of
articles was conducted simultaneously by two reviewers (RL and BG). An algorithm was used whereby
if studies met the mutual inclusion criteria for SR1 and SR2 (population, setting, publication type),
they were then assessed further as to whether they were appropriate for SR1 or SR2 (or excluded).
Titles and abstracts were screened for relevance independently; any disagreements were resolved by
consensus. Pilot screening was undertaken for the first 100 hits to ensure that both reviewers were
interpreting the inclusion and exclusion criteria in the same way. Articles retained were obtained
in full and further screened independently by the two reviewers (RL and BG). Disagreements were
discussed between the two reviewers; if not resolved, a third reviewer (Christopher Hyde) made the
final decision.
For SR2, multiple studies reported the development and validation aspects of particular prediction
models (e.g. the development and internal validation of the prediction model by Hippisley-Cox et al.32 in
one paper, and the external validation in a separate paper.14 All studies related to each specific prediction
model were collated, regardless of whether they refer to the development or validation of that tool.
Results
Studies identified
Search phrases were finalised and searches were run in May 2017 (see Appendix 1). A total of 9352
records were obtained through database searching. Additional reference and citation searches on
tool names resulted in another 4171 records. After de-duplication, 9780 records were obtained.
The database searches were updated in January 2018, resulting in 631 additional new records
(after de-duplication), and again in November 2018, when 702 hits were identifeid. Discussions with
collaborators led to the identification of relevant grey literature, but no such studies were deemed
eligible for inclusion.
As hits were screened simultaneously for inclusion in SR1 or SR2, the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA)33 flow diagram shows the results for both reviews:
260 full-text articles were screened: five studies met the inclusion criteria for SR1 and 41 studies met
the inclusion criteria for SR2 (Figure 1).
Details on the methods for data extraction, on assessing the risk of bias of the included studies and on
the findings of the SRs are presented in Chapters 3 (SR1) and 4 (SR2).
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TABLE 3 Inclusion and exclusion criteria
Criterion SR1 SR2
Population Included: symptomatic patients (with symptoms being indicative of cancer) presenting at primary
care or patients referred with symptoms indicative of cancer
Excluded: asymptomatic patients (screening population)
Technology Included: featurea-based diagnostic tools
implemented/used in primary care to provide
additional information on the risk of cancer. The
tool may be used for the purpose of diagnosing
cancer in primary care (leading to referral for
treatment) or to inform decisions about
referring for further tests (with possible
diagnosis occurring in secondary care)
Included: diagnostic prediction models, based on
two or more features,a that estimate the risk of
prevalent but undiagnosed cancer
Excluded: prognostic or screening prediction models; statistical tools that estimate the probability
of developing cancer over a defined period of time
Setting Included: primary care
Excluded: secondary care; online tools
developed for use by the general population
Exclusion: models developed into tools for
online use by the general population
Study design Included: comparative studies of diagnostic
tools that assessed impact in clinical practice
(RCTs, controlled before and after, and
interrupted time series); studies analysing
national trends in cancer diagnosis before and
after diagnostic tools became available
Included: any design for the development,
validation or accuracy of diagnostic prediction
models (as defined in the ‘Technology’ row of
this table)
Excluded: uncontrolled studies reporting
qualitative data
Comparison Usual care or the use of another diagnostic tool N/A
Outcomes Primary outcomes:
l Patient-related outcome measures (including
the number of cancer diagnoses, time to
cancer diagnosis, stage of cancer at
diagnosis, resection rates, patient health-
related quality of life, other patient-reported
outcome measures)
l Survival
l Economic outcome measures (resource use,
cost per diagnosis, cost per QALY)
l Estimates of the risk of being diagnosed with
cancer (e.g. ORs, HRs)
AND/OR
l Any details on the development, validation or
accuracy of the tool:
¢ Model development – method,
assumptions, predictors, shrinkage,
coefficient weighting
¢ Model evaluation (validation)
¢ Assessing (quantifying) model
performance – discrimination (ability to
discriminate participants with or without
the outcome, e.g. area under the ROC
curve), calibration (agreement between
predicted and observed outcome), overall
performance (for discrimination and
calibration, e.g. R2), classification (e.g.
sensitivity, specificity, predictive values)
Secondary outcome:
l Referral patterns
Excluded: models that report the risk of survival
(or stage at diagnosis, etc.)
Publication type Included: published in full and English-language publication
Excluded: commentaries, letters
HR, hazard ratio; N/A, not applicable; OR, odds ratio; QALY, quality-adjusted life-year; ROC, receiver operating characteristic.
a Features include symptoms and other information, such as elicited signs, patient characteristics and test results.
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in analysis in SR1
(n = 5)
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(n = 41)
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Records identified through additional sources
(n = 4171)
• Through citation chasing, n = 727
• Through searches of identified tool names, n = 3444
Articles excluded
(n = 214)
• Not symptom-based or diagnostic,
    n = 58
• Abstracts only, n = 32
• Duplicates, n = 30
• Not model, guidelines only, n = 30
• Not cancer, n = 18
• Single predictor, n = 17
• Not intended for primary care, n = 9
• Screening, n = 8
• Not primary study, n = 8
• Qualitative only, n = 4
Records identified





FIGURE 1 The PRISMA flow diagram of the included studies for SR1 and SR2.
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Chapter 3 Systematic review 1
Objective
The objective was to identify evidence evaluating the clinical effectiveness of symptom-based
diagnostic tools that that could be used to inform cancer diagnosis decision-making in primary care.
Methods
Identification of studies
Information related to the search strategy, eligibility criteria and selection of studies is provided in
Chapter 2.
Data extraction
To extract relevant data from each included study, standardised data extraction forms were used,
which evolved following piloting and discussion among reviewers. One reviewer (BG) extracted the
data, which were checked by a second reviewer (RL). Extracted data included cancer type(s); study
design; country; sample size; patient recruitment (with inclusion and exclusion criteria); characteristics
of the tool (including whether based on symptoms alone or other features in addition to symptoms);
definition of outcomes (including the number of cancer diagnoses, time to cancer diagnosis, stage of
cancer at diagnosis, resection rates, patient health-related quality of life, other patient-reported
outcome measures); main results, including confidence intervals (CIs); and subgroup analyses,
when available.
Critical appraisal
A risk-of-bias form based on the Cochrane Effective Practice and Organisation of Care group
recommendations34 was used to assess potential features of different study designs that may lead to
biased estimates of clinical effectiveness. This was conducted by one reviewer (BG) and checked by a
second reviewer (RL).
Data synthesis
Owing to the heterogeneity between included studies, a narrative review of the studies was conducted.
Results
Studies identified
The impact of three ‘overarching’ diagnostic tools was assessed by five studies:13,35–38 an algorithm for
differentiating malignant and benign skin lesions, a skin cancer toolkit and the RATs, which have been
developed for various cancer sites. The data extracted from the five included studies are presented
in Appendix 2.
Study design was heterogeneous, consisting of RCTs,35,36 one field trial,37 one cohort study13 and one
case–control study.38
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Three of these studies36–38 assessed two different decision support tools for skin cancer (Table 4).
Del Mar and Green37 and English et al.36 describe two evaluations of an algorithm to improve the
diagnosis of malignant melanocytic lesions and, consequently, reduce the proportion of total lesions
excised that prove to be benign. Both studies were conducted in Australia. The Del Mar and Green37
study was designed as a field trial in two cities: the impact of using the algorithm in one city was
compared with not using it in the second city, which acted as a control.
Gulati et al.38 evaluated the impact of a UK-wide, online, skin cancer recognition toolkit on GP
confidence and knowledge in diagnosing skin cancers and referral behaviour. Additional skin cancer
referral data were obtained to assess the appropriateness of referrals, and a survey was also
conducted to investigate GP confidence in diagnosing skin cancer.
The other two included studies13,35 evaluated the impact of previously developed diagnostic prediction
models in practice. Both evaluated the use of RATs. Hamilton et al.13 investigated the number of times
two RATs39 (one for lung cancer and one for CRC) were used, together with the number of subsequent
referrals and investigations, before and 6 months after the introduction of the tools in general practice
in the UK.
Emery et al.35 evaluated the impact of two complex interventions in rural Australia, a GP intervention
and a cancer awareness campaign, in a 2 × 2 design trial, compared with control groups. The GP
intervention consisted of an ‘education resource card’ that included RATs for colorectal, lung and
prostate cancer, together with summaries of relevant guidelines for colorectal, lung and prostate
cancer, with the addition of guidelines for breast cancer and training on the use of these resources.
The RATs were based on diagnostic prediction models developed using a patient cohort from the UK39
(further details are provided in Chapter 4). Emery et al.35 used the total diagnostic interval (TDI), that is
the time from first symptom to cancer diagnosis, as an outcome measure.
TABLE 4 Systematic review 1: description of the tools assessed












An algorithm for managing
clinically suspicious naevi, aided by
the use of a camera







The toolkit consisted of a referral
decision aid (referral guidelines
based on red flags), lesion
recognition resource (a series of




on a mouse mat
and desktop
flip chart
Hamilton 201313 UK RAT gives risk estimates for
patients aged > 40 years
presenting to primary care with
symptoms of possible cancer,
for single symptoms, pairs of
symptoms and repeat attendances
with the same symptom. The









Emery 201735 UK (RAT), Australia
(guidelines)
Resource card containing the
RAT tables for colorectal, lung
and prostate cancer, as well as
the Australian National Breast
and Ovarian Cancer Centre’s
guidelines for investigating new
breast symptoms
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Critical appraisal
Studies were heterogeneous in how they addressed risk of bias (Table 5). Three of the studies were
not randomised. Allocation blinding was another area of vulnerability for the majority of the studies,
although this could not be assessed for one of them.35 All studies managed to ensure reasonably
similar baseline characteristics and measurements for the study groups. Among the studies included,
Emery et al.35 raised the fewest concerns for risk of bias.
Study outcomes
The outcome that Del Mar and Green37 used was the percentage of lesions excised that were benign.
The study37 observed that use of the algorithm seemed to reduce the ratio of excised benign lesions to
melanomas (from 93.8% to 88.8%; p < 0.001), without reducing the number of melanomas diagnosed.
English et al.36 used a ‘slightly modified’ algorithm that was evaluated by randomising general practices
in Perth, Australia, to use the algorithm, while others were used as controls. The outcome used was the
ratio of excised benign lesions to excised melanomas. The study37 found no reduction in the ratio of
benign to malignant lesions excised.
Gulati et al.38 showed no significant changes in the number of urgent GP referrals for suspected skin
cancer, diagnoses of melanoma or diagnoses of non-melanoma skin cancer between the toolkit users
and the non-users in the study periods, despite increased GP confidence in making skin cancer
referrals. The proportion of appropriate referrals increased with the use of the toolkit; however, the
differences between toolkit users and non-users did not reach statistical significance.
Hamilton et al.13 reported on changes in investigations carried out and rapid referrals before and after
the introduction of the tools. They found an increase of 31% in rapid referrals for lung cancer and
a 4% increase in GP-mandated chest X-ray investigations, as well as a 26% increase in referrals for
CRC and a 15% increase in GP requests for colonoscopies after introduction of the tools. However,
only absolute numbers are reported, without data on total numbers of patients and GP visits, or the
appropriateness of the referral.
Emery et al.35 did not find significant differences in the median or log-transformed (ln) mean time to
diagnosis at either intervention level (community intervention vs. control, GP intervention vs. control)
or when analysed by factorial design, tumour group or subintervals of the TDI.
None of the included studies reported outcomes such as diagnoses made, quality of life, survival or
NHS resource use.
Study results are summarised in Table 6.
Discussion
This review attempted to summarise existing evaluations of feature-based cancer diagnostic tools used
in primary care. Our strategy was able to identify a limited number of heterogeneous studies that
did not provide strong evidence of the impact of feature-based diagnostic tools on patient-related
outcomes or referral patterns. The small number of studies (n = 5) and the heterogeneity in reported
outcomes did not allow for a meta-analysis of the results. The included studies provided limited
evidence of the clinical effectiveness of using diagnostic tools.
A few other reviews have looked at feature-based cancer diagnostic tools in primary care. Williams
et al.40 conducted a systematic review of studies that described, validated or assessed the impact of
CRC diagnostic tools. However, they did not identify any studies that tested whether or not patients
who were diagnosed with the aid of the tool fared better than those who were diagnosed without it.
Schmidt-Hansen et al.41 conducted a similar review of lung cancer tools and found limited evidence to
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English 200336 ✓ ✓ ✓ ✓ ? ✗ ✓ ✓ ?
Emery 201735 ✓ ✗ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Field trials
Del Mar 199537 ✗ ✓ ✓ ✓ ✗ ✗ ✓ ✓ ?
Case–control study
Gulati 201538 N/A N/A ✓ ✓ ? N/A N/A ? ✗
Pre–post study
Hamilton 201313 N/A N/A N/A N/A ? N/A N/A ? ✗




































TABLE 6 Systematic review 1: results reported by the studies
Cancer type(s) Study Prediction tool Country Study design Intended purpose Main results
Melanoma Del Mar 199537 Melanoma ‘algorithm’
(plus camera)
Australia Field trial To evaluate whether or not an
algorithm can reduce the number of
benign lesions being excised without
reducing the excision of invasive
lesions, by comparing numbers of
excised lesions with and the number
without algorithm use
Total number of excised lesions
l At baseline: control city, 752;
intervention city, 606
l After intervention: control city, 2468;
intervention city, 1997
Percentage of excised lesions that are
neither invasive or potentially malignant
l At baseline: control city, 94% (95% CI
92.3% to 95.7%); intervention city,
93.6% (95% CI 91.6% to 95.5%)
(p = 0.731)
l After intervention: control city, 93.8%
(95% CI 92.8% to 94.8%); intervention
city, 88.8% (95% CI 87.4% to 90.2%)
The median number of excisions per doctor
(2.5% and 97.5% percentiles)
l At baseline: control city, 7 (1, 38);
intervention city, 8 (1, 46)
l After intervention: control city, 9 (1, 39);
intervention city, 4 (1, 30)
There were significant differences in the
percentages of benign lesions reported in
the intervention and control cities (88.8%


















































































































































































































































































































































TABLE 6 Systematic review 1: results reported by the studies (continued )
Cancer type(s) Study Prediction tool Country Study design Intended purpose Main results
Melanoma English 200336 Melanoma ‘algorithm’
(plus camera)
Australia RCT To determine whether or not an aid to
the diagnosis of pigmented skin lesions
reduces the ratio of benign lesions to
melanomas excised in general practice
Number of excised skin lesions (including
seborrheic keratoses)
At baseline:
l Control – benign, 1965; melanoma, 61;
ratio 32
l Intervention – benign, 2615; melanoma,
100; ratio 26
Trial period:
l Control – benign, 2037; melanoma, 79;
ratio 26
l Intervention – benign, 2369; melanoma,
81; ratio 29 (p = 0.88)
Provision of the algorithm and camera did
not decrease the ratio of benign pigmented
skin lesions to melanomas excised by GPs




































Cancer type(s) Study Prediction tool Country Study design Intended purpose Main results
Skin cancer Gulati 201538 GP Skin Cancer
Toolkit
UK Case–control To assess the impact of the toolkit by
comparing before-and-after national
skin cancer referral data, data from
cross-sectional questionnaires and data
on urgent skin cancer referrals to two
NHS trusts
21,000 GPs were invited to use the tool;
8163 GPs accessed the tool during the
2012 period. There were no significant
changes in the number of urgent GP
referrals for suspected skin cancer
(Spearman’s rank 0.20; p < 0.001),
diagnoses of melanoma (Spearman’s rank
0.064; p < 0.001) or diagnoses of non-
melanoma skin cancer (Spearman’s rank
0.068; p < 0.001) between the toolkit user
and the non-user groups. The proportion of
appropriate referrals increased from
21.37% in 2011 to 32.3% in 2012, giving
an incidence rate ratio of 3.13 (95% CI
2.21 to 4.42, z-statistic 6.46; p < 0.0001)
The differences in numbers of appropriate
referrals between toolkit users and
non-toolkit users did not reach statistical




Hamilton 201313 RAT for lung cancer






To compare referrals and investigations
for colorectal and lung cancer before
and after the implementation of RATs
Lung cancer: 31% increase in 2-week
referrals (332 before, 436 after); 4%
increase in related investigations
(chest X-ray) (7431 before, 7723 after)
CRC: 26% increase in 2-week referrals
(1173 before, 1477 after); 15% increase in
colonoscopies (1762 before, 2032 after)
No conclusion possible on the clinical


















































































































































































































































































































































TABLE 6 Systematic review 1: results reported by the studies (continued )










To measure the effect of community-
based symptom awareness and
GP-based educational interventions
on the time to diagnosis (i.e. TDI) for
patients presenting with breast,
prostate, colorectal or lung cancer
in rural Western Australia
No significant differences in the median or
ln mean TDI at either intervention level:
l GP intervention vs. control: median TDI
97 vs. 96.5 days; log-transformed mean
difference 0.004 (95% CI –0.18 to
0.19; p = 0.99)
l Community intervention vs. control:
median TDI 107.5 vs. 92 days; log-
transformed mean difference 0.08
(95% CI –0.06 to 0.23; p = 0.27)
No significant differences in the TDI when
analysed by factorial design, tumour group
or subintervals of the TDI




































support the recommendation of any of the identified risk prediction tools, owing to lack of external
validation or cost impact assessment. Similarly, Usher-Smith et al.42 concluded that, even though some
of the prediction models had the potential for clinical application, there remains considerable
uncertainty about their clinical utility.
Other reviews have looked at cancer RATs in primary care.43,44 However, they differ from this review in
that they reported on tools that estimate the risk of developing cancer in the future, rather than the
risk of having an undiagnosed cancer based on current signs and symptoms.
Although the intention of our review was to explore tools based only on prediction models, it was not
clear whether or not, in practice, the impact of such tools could be isolated from other decision-making
tools available to practitioners, such as diagnostic algorithms45 or guidelines.6 With limited evidence
available on the impact of implemented diagnostic models, we decided to report on identified studies
on the algorithm-based tools as well; however, the evidence was still sparse.
Among the limitations of the included studies were lack of randomisation, lack of patient-related
outcomes and use of models developed on different populations. The outcome measures used by
some of the studies make it difficult to interpret reports of an increase in referral rate without
including reasonable assessment of the appropriateness of the referral or subsequent impact on
cancer versus non-cancer diagnosis.
Furthermore, concerns on the quality of the studies make it unclear whether the lack of effect was
due to poor implementation of the tools in practice, insufficient uptake by the GPs or limited marginal
contribution of the tools in assessing the risk of cancer. The best-quality study35 also failed to show
a significant effect; however, the composite intervention used, combining older versions of several
instruments (developed on populations from a different country), could have limited the clinical
effectiveness of the diagnostic tools. These findings could be further obfuscated by publication bias,
whose magnitude on this topic remains unknown.
Conclusion
Current evaluations provide limited evidence of the impact on patient outcomes of using feature-based
cancer diagnostic tools in primary care. Better research is needed to provide these data, possibly
through better study design and choice of outcomes. However, identifying the ideal approach may not
be straightforward. Practical reasons may highlight the potential need for a cluster and pragmatic trial
design. Arguably, by comparing average times to diagnosis, patients not prioritised for quick referrals
are less at risk of being missed. The debate, however, is ongoing on the most appropriate outcomes for
evaluating interventions to improve cancer diagnosis and referral.
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Chapter 4 Systematic review 2
Objective
Systematic review 2 was conducted as a complementary study to SR1, described in Chapter 3. The
objective was to identify and summarise studies reporting the development, validation or accuracy of
any diagnostic prediction model that could be used as a tool to aid cancer diagnosis in primary care.
Methods
Identification of studies
Information related to the search strategy, eligibility criteria and selection of studies is provided
in Chapter 2.
Data extraction
An adaptation of the CHecklist for critical Appraisal and data extraction for systematic Reviews of
prediction Modelling Studies (CHARMS)30 was used to extract the following data from each included
study: country, cancer type(s), study design, data source, sample size, number of participants with
specific cancer, recruitment (including inclusion and exclusion criteria), participant characteristics,
features of the model (what symptoms, test results, patient demographics, etc. are included), how
features are defined and measured, definition of primary and secondary outcomes, how and when
outcomes are assessed, main results (including model performance, validation and estimates of risk)
and features included in final model.
Critical appraisal
Risk of bias was assessed with the use of a form based on the work of the Prediction model Risk Of
Bias ASsessment Tool (PROBAST)46 group. Because a final version of this checklist was not publicly
available at the time of the appraisal, we followed recent recommendations on reporting reviews of
prediction models.47–49 Like the PROBAST checklist, the derived checklist assesses the risk of bias and
applicability of prediction-modelling studies on five domains: participant selection, predictors, outcome,
sample size and missing data, and analysis (Table 7).
Data synthesis
Owing to the heterogeneity between included studies, a narrative synthesis of the studies was conducted.
Results
Studies identified
There were 41 included records from the searches, including two systematic reviews. A further two
studies were identified from one of the reviews. The primary are summarised in Appendix 3.
Systematic reviews
Two included records41,50 are systematic reviews that had some overlap with the included studies
described in this section (Table 8).
Schmidt-Hansen et al.41 conducted a systematic review of the literature to identify risk prediction tools
to be used in primary care to aid diagnosis of lung cancer. Five separate tools were identified: RAT,51
QCancer,52–54 the equation from Iyen-Omofoman et al.,21 and tables from Jones et al.58 and Jordan et al.59
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TABLE 7 Risk-of-bias assessment form based on PROBAST (based on Wolff et al.46)
Domain Items
I. Participant selection 1a. Were appropriate data sources used, for example cohort, controlled trial or nested
case–control study data?
1b. Were all inclusions and exclusions of participants appropriate?
1c. Were participants enrolled at a similar state of health, or were predictors considered to
account for differences?
II. Predictors 2a. Were predictors defined and assessed in a similar way for all participants in the study?
2b. Were predictor assessments made without knowledge of outcome data?
2c. Are all predictors available at the time the model is intended to be used?
2d. Were all relevant predictors analysed?
III. Outcome 3a. Was a prespecified outcome definition used?
3b. Were predictors excluded from the outcome definition?
3c. Was the outcome defined and determined in a similar way for all participants?
3d. Was the outcome determined without knowledge of predictor information?
IV. Sample size and
missing data
4a. Were there a reasonable number of outcome events?
4b. Was the time interval between predictor assessment and outcome determination
appropriate?
4c. Were all enrolled participants included in the analysis?
4d. Were participants with missing data handled appropriately?
V. Analysis 5a. Were non-binary predictors handled appropriately?
5b. Was selection of predictors based on univariable analysis avoided?
5c. Was model overfitting (optimism in model performance) accounted for, for example using
bootstrapping or shrinkage techniques?
5d. Were any complexities in the data (e.g. competing risks, multiple events per individual)
accounted for appropriately?
5e. Do predictors and their assigned weights in the final model correspond to the results
from multivariable analysis?
5f. For the model or any simplified score, were relevant performance measures evaluated,
for example calibration, discrimination, (re)classification and net benefit?
5g. Was the model recalibrated or was it likely (based on the evidence presented,
e.g. calibration plot) that recalibration was not needed?
Note
Partly reproduced from an early version of the PROBAST with permission from Dr Karel GM Moons, Utrecht University,
2020, www.probast.org (accessed 15 January 2020). The current PROBAST has been published previously.48,49
TABLE 8 Systematic review 2: reviews included
Review Aim Overlap with included studies in SR2
Schmidt-Hansen
201741
To review the existing risk prediction tools for
patients presenting in primary care with
symptoms that may indicate lung cancer
Hamilton 2005,51 Hippisley-Cox 2011,52
Hippisley-Cox 2013,53 Hippisley-Cox 201354
and Iyen-Omofoman 201321
Elias 201750 To validate published diagnostic models for their
ability to safely reduce unnecessary endoscopy
referrals in primary care patients suspected of
significant colorectal disease
Fijten 1995,55 Marshall 2011,22 Muris 199556
and Nørrelund 199657
SYSTEMATIC REVIEW 2
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Schmidt-Hansen et al.41 concluded that, so far, none of the tools has been externally validated, yet there is
a need to improve early diagnosis.
Elias et al.50 aimed to identify and validate published diagnostic models to safely reduce unnecessary
endoscopy referrals in CRC. A systematic review of the literature was undertaken and identified
models were validated using a cross-sectional Dutch data set (n = 810). The definition of model used by
Elias et al.50 was very broad and included guidelines and weighted scores. Therefore, although Elias et al.50
identified 18 models, only four are relevant to our review: Fijten et al.55 and Marshall et al.22 were
previously identified from our searches, whereas Muris et al.56 and Nørrelund et al.57 are new inclusions.
Because Elias et al.50 attempted to validate the models they found, their validation of these four models
is included in the results presented later in this chapter.
Prediction models
The 41 included studies (39 identified from the searches plus two identified from Elias et al.50) reported on
12 different prediction models (which are briefly summarised in the following paragraphs): (1) a RAT for
15 different cancer sites; (2) QCancer for six cancer sites, plus male and female versions for all cancers;
(3) a clinical prediction rule for breast cancer;60 (4) the BB equation for CRC;22 (5) the Netherlands model
for CRC;55 (6) a machine-learning algorithm for CRC;61 (7) a Danish model for CRC;57 (8) a UK model for
lung cancer;21 (9) a UK model for pancreatic cancer;62 (10) a European model for abdominal cancers;63
(11) a UK model for paediatric cancers;64 and (12) a Dutch model for multiple cancers.56
The RATs were designed to be used with patients presenting to primary care with ‘low-risk-but-not-no-risk
symptoms’.65 Early versions of RATs were developed using case–control data from Devon, UK, as part of
the CAPER studies.39 Later models were derived using UK-wide primary care data – the Clinical Practice
Research Datalink (CPRD) (formerly known as the General Practice Research Database),66–73 and The Health
Improvement Network (THIN) database.74,75 So far, models for 14 separate cancer sites have been published
(colorectal, oesophageal, lung, ovarian, kidney, bladder, pancreas, breast, uterine, brain, prostate, Hodgkin
lymphoma, non-Hodgkin lymphoma and multiple myeloma), plus one model for metastatic cancer. The RATs
are available as prints on common office objects (e.g. mouse mats) and are integrated into GP software in the
form of the electronic cancer decision support (eCDS). Regardless of the format, they provide risk estimates
for patients with single symptoms of possible cancer, pairs of symptoms and repeat attendances with the
same symptoms. Elias et al.50 used a Dutch data set to externally validate the colorectal version of RATs.
The QCancer series of models can be used in both symptomatic (diagnostic models) and asymptomatic
(prognostic models) patients.42 QCancer was developed in the QResearch database, a large database
comprising > 12 million anonymised health records from 602 general practices throughout the UK, using
the EMIS Health (Leeds, UK) computer system. Initially, several models were developed for each cancer
type in symptomatic populations (colorectal, gastro-oesophageal, lung, renal, pancreatic and ovarian
cancer). An updated approach incorporates multiple risk factors and symptoms into one model to predict
cancer risk. Most of these models have been externally validated in UK-wide populations (e.g. THIN
database76). QCancer is available as an online calculator (www.qcancer.org), which provides estimates
of the absolute risk of any cancer, with a breakdown of type of cancer based on both risk factors
such as age, sex and family history, which increase the likelihood of cancer, and risk markers such as
haemoptysis or features (usually symptoms, e.g. weight loss) suggesting that cancer is already present.
McCowan et al.60 developed a clinical prediction model for breast cancer using secondary care data on
symptomatic patients at one hospital in Scotland. The authors validated the model using data from
202 patients with symptomatic breast problems attending 11 general practices in Scotland.
Marshall et al.22 used data from the THIN data set (> 40,000 participants) to construct a model for CRC,
known as the BB equation, which they validated using the CAPER data set. Data from 290 patients
presenting to GPs in the Netherlands with rectal bleeding (from 1988 to 1990) were used by Fijten et al.55
to develop a prediction model for CRC. Two studies validated this model: Hodder et al.77 used secondary
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care data from the UK, whereas Elias et al.50 used a Dutch data set. Kop et al.61 used a machine-learning
algorithm to develop a prediction model for CRC using the electronic records of almost 220,000 patients
from two general practices in the Netherlands. A Danish CRC model57 has also been developed for use in
primary care; this was externally validated by Elias et al.50 using a Dutch data set.
Iyen-Omofoman et al.21 developed a prediction model for lung cancer using data on > 130,000
participants in the THIN data set. Keane et al.62 also used the THIN data set and developed two
prediction models: one for pancreatic ductal adenocarcinoma and one for biliary tract cancers.
Dommett et al.64 is the only model our searches identified that considers paediatric cancers. The
authors used the CPRD to develop prediction models of bone and soft tissue, central nervous system
and abdominal cancers, and leukaemia and lymphoma. The authors also developed a model to consider
all paediatric cancers.
Muris et al.56 developed a model using data from the Netherlands to predict multiple cancers,
and Elias et al.50 externally validated it.
Holtedahl et al.63 report details of the development of a prediction model for abdominal cancers. These
are defined as all cancers of the digestive organs, female genital organs and urinary organs (including
testis). Data on 61,802 patients, recorded during GP consultations in Norway, Denmark, Sweden,
Scotland, Belgium and the Netherlands over a 10-day period, were used to develop the model. No
validation of the model is reported.
Prediction model characteristics
Colorectal cancer was associated with the greatest number of models (six in total): (1) the BB
equation,22 (2) the Netherlands model,55 (3) the machine-learning algorithm,61,78,79 (4) the Danish
model,57 (5) QCancer80 and (6) the RAT.72,74,81 We identified three models for lung cancer (UK model,21
QCancer52 and RAT51) and three models for pancreatic cancer (UK model,62 QCancer32 and RAT70).
Only versions of QCancer and RAT were found for gastro-oesophageal cancer,71,82 ovarian cancer83,84
and renal cancer.66,85 There are two RATs for blood cancers: one for leukaemia67 and one for myeloma.68
For the other cancer sites, only one model for each was identified, and, apart from the breast cancer
model,60 the metastatic cancer model86 and the abdominal model,63 they are versions of RATs. Two
versions of the QCancer model (one for females53 and one for males54), a Dutch model56 and the UK
paediatric cancers model64 were all developed to evaluate the risk prediction of multiple cancers.
The models are in various stages of development. A total of 18 models (or versions of models) have
assessed only apparent performance, three models have been internally validated using a split-sampling
technique21,52–54 and one model was updated as a result of using a different data source.74 Five of the
QCancer versions,32,80,82,84,85 one RAT version81 and five of the other prediction models22,55–57,60 have been
externally validated, which is the highest level of evidence identified in this systematic review.
All but one of the models were developed in primary care settings. McCowan et al.60 developed a clinical
prediction rule model for breast cancer using secondary care data, but with the intention of the model
being used in primary care. Only four models were developed outside the UK: those by Fijten et al.,55
Kop et al.61 and Muris et al.56 were developed in the Netherlands, and the one by Nørrelund et al.57 was
developed in Denmark. For the models that were externally validated, most were validated in the country
in which they were developed, except for the following: the validation77 of the Netherlands CRC model55
in a UK population, the validation of the Danish CRC model57 in a Dutch population,50 and the validation
of the colorectal version of RATs (UK)81 in a Dutch population.50
Table 9 provides a brief description of the models, their stages of development, the cancer sites
covered and study designs. Owing to the heterogeneity in tools, cancer sites, outcomes measured and
study design, a narrative review of the studies was conducted.
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TABLE 9 Systematic review 2: summary of the prediction models, their stages of development, the cancer sites covered and the study designs
Cancer site and
prediction model Number and categories of descriptors Stage of development Study design Country Source
Bladder
RAT 8; symptoms, medical history, test results Apparent performance Case–control UK Shephard 201269
Blood
RAT (leukaemia) 10 (chronic leukaemia); symptoms Apparent performance Case–control UK Shephard 201667
13 (acute leukaemia); symptoms
RAT (myeloma) 16; symptoms, test results Apparent performance Case–control UK Shephard 201568
Brain
RAT 8; symptoms Apparent performance Case–control UK Hamilton 200787
Breast
Clinical prediction rule 5; patient demographics, symptoms External validation Prospective cohort UK McCowan 201160
Colorectal
BB equation 8; symptoms, test results External validation Retrospective
case–control
UK Marshall 201122
External validation Prospective cohort The Netherlands Elias 201750
The Netherlands model 3; symptoms, patient demographics Apparent performance Prospective cohort The Netherlands Fijten 199555
External validation Prospective cohort UK Hodder 200577
External validation Prospective cohort The Netherlands Elias 201750
Machine learning
algorithm
Numerous models are reported; patient
demographics, symptoms, medical history,
test results
Apparent performance Case–control The Netherlands Kop 2015;61 Kop 2016;79
and Hoogendoorn 201578
Danish model 2; patient demographics, symptoms Apparent performance Prospective cohort Denmark Nørrelund 199657
External validation Prospective cohort The Netherlands Elias 201750
QCancer 6 (females) and 7 (males); symptoms, medical
history, test results
Internal validation II Open prospective cohort UK Hippisley-Cox 201280


















































































































































































































































































































































TABLE 9 Systematic review 2: summary of the prediction models, their stages of development, the cancer sites covered and the study designs (continued )
Cancer site and
prediction model Number and categories of descriptors Stage of development Study design Country Source
RAT 10; symptoms, test results Apparent performance Case–control UK Hamilton 200581
External validation Prospective cohort The Netherlands Elias 201750
RAT 8; symptoms, test results Apparent performance Case–control UK Hamilton 200974
RAT (bowel) 10; symptoms, test results Apparent performance Case–control UK Stapley 201772
Gastro-oesophageal
QCancer 7 (females) and 6 (males); symptoms, test
results, patient demographics
Internal validation II Open prospective cohort UK Hippisley-Cox 201182
External validation Retrospective cohort UK Collins 201388




15; patient demographics, symptoms Internal validation II Case–control UK Iyen-Omofoman 201321
QCancer 9 (females) and 8 (males); symptoms, patient
demographics, test results
Internal validation II Open prospective cohort UK Hippisley-Cox 201152
RAT 13; symptoms, patient demographics Apparent performance Case–control UK Hamilton 200551
Ovarian
QCancer 8; medical history, symptoms, test results Internal validation II Open prospective cohort UK Hippisley-Cox 201184
External validation Retrospective cohort UK Collins 201389
RAT 7; symptoms Apparent performance Case–control UK Hamilton 200983
Pancreas
QCancer 7 (females) and 8 (males); patient
demographics, medical history, symptoms
Internal validation II Open prospective cohort UK Hippisley-Cox 201232
External validation Retrospective cohort UK Collins 201314
RAT 9; medical history, symptoms Apparent performance Case–control UK Stapley 201270
UK models for PDAC
and BTC
13 (PDAC) and 9 (BTC); symptoms, medical
history, test results





































prediction model Number and categories of descriptors Stage of development Study design Country Source
Prostate
RAT 9; symptom, test results Apparent performance Case–control UK Hamilton 200690
Renal
QCancer 7 (females) and 5 (males); medical history
(females), patient demographics, symptoms,
test results
Internal validation II Open prospective cohort UK Hippisley-Cox 201285
External validation Retrospective cohort UK Collins 201391
RAT 15; symptoms, test results Apparent performance Case–control UK Shephard 201366
Uterine
RAT 9; symptoms, test results Apparent performance Case–control UK Walker 201373
Metastatic
RAT 7; symptoms, test results Apparent performance Case–control UK Hamilton 201586
Multiple
QCancer (female) l 7 (uterine)
l 10 (breast, blood)
l 11 (ovarian, renal)
l 12 (cervical)
l 13 (colorectal, gastro-oesophageal)
l 14 (pancreatic)
l 15 (lung)
l 22 (other cancers)
l Medical history, symptoms, test results,
patient demographics
Internal validation II Open prospective cohort UK Hippisley-Cox 201353
QCancer (male) l 3 (testicular)
l 8 (renal tract)
l 12 (colorectal)
l 13 (gastro-oesophageal)
l 14 (prostate, blood)
l 15 (pancreatic)
l 17 (lung)
l 20 (other cancers)
l Medical history, symptoms, test results,
patient demographics


















































































































































































































































































































































TABLE 9 Systematic review 2: summary of the prediction models, their stages of development, the cancer sites covered and the study designs (continued )
Cancer site and
prediction model Number and categories of descriptors Stage of development Study design Country Source
UK paediatric model l 4 (bone and soft tissue)
l 7 (central nervous system, abdominal)
l 12 (leukaemia/lymphoma, all cancers)
l Symptoms
Apparent performance Prospective case–control UK Dommett 201364
Muris (the Netherlands)
model
5; symptoms, patient demographics, test results Apparent performance Prospective cohort The Netherlands Muris 199556
External validation Prospective cohort The Netherlands Elias 201750










































The assessment of risk of bias is summarised in Table 10, and is given in more detail in Appendix 3
(see Tables 41 and 42). Note that for the RATs and QCancer models, only one entry each is shown,
as all versions of the RAT or QCancer model scored the same for each aspect of the risk-of-bias tool
used. Most of the included models were judged as having low risk of bias for participant selection and
aspects of the outcome definition. For a number of studies, there was a high risk of bias surrounding
aspects of the analysis. Much of this stemmed from methods reported for the selection of model
variables based on univariate analyses, a lack of evaluation of calibration or discrimination, or no
accounting for overfitting. For features of the predictors and participant flow, there was much
uncertainty as to what had been done in the studies, and so the risk of bias of the findings could
not be determined.
Discussion
Looking at symptom-based cancer diagnostic prediction models currently under development, we were
able to identify 43 studies in total. The majority of these reported on various aspects of just two such
modelling versions, QCancer and RAT, both developed in the UK. Most of the reported work also
seemed to be located in Europe, with two of the models developed in the Netherlands.
The majority of the models included in this review were developed only with the sample used to derive
the model. With the exception of the RAT (colorectal) model, there were no reports to suggest that
models were being updated based on new available data. Some models were validated using split-
sample techniques. A number of models, in particular the ones developed under the QCancer name,
were externally validated in independent studies.
The two main models highlight important knowledge gaps; the development of the QCancer models
was based on higher-quality data (cohort data) than that of the RATs, and were mostly externally
validated, but lack impact assessment. By contrast, the RAT series has more evidence of impact on
practice, but was developed from case–control studies and has limited external validation.
Our systematic review was limited to the inclusion of diagnostic prediction models; however, the search
strategy also highlighted a number of studies concerned with the development of symptom-based decision
tools that were not based on prediction models, such as scoring systems, as well as the development of
diagnostic prediction models for secondary care. These are listed in Appendix 3 (see Tables 43 and 44)
as a resource for further research.
Evidence suggested that there has been a great deal of external validation work for QCancer, whereas
we found only one attempt at external validation of RATs. Ideally, this is an area for further development
of the RATs and the four other models that have not yet been externally validated.
Conclusion
To our knowledge, this is the first systematic review of diagnostic prediction models for use in primary
care to aid cancer diagnosis. We have identified models that have the potential to be developed into
tools and be used by GPs. However, there are gaps in the literature that we have identified.
Currently, most research on developing symptom-based cancer risk prediction models is concentrated
in Europe and, in particular, the UK. QCancer and RATs are the dominant prediction models. Although
there has been a great deal of external validation work done for QCancer, only one study was identified
that reports the external validation of RATs.
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TABLE 10 Systematic review 2: risk-of-bias assessment of the included models
Model (first author of first version) Stage of development covered
Risk-of-bias domain
I. Participant
selectiona II. Predictorsa III. Outcomea
IV. Sample size and
participant flowa V. Analysisa
RAT (Hamilton) series of models for multiple
sites51,66–74,81,83,86,87,90
Apparent performance ✓ ? ✓ ? ✗
External validation (colorectal)50 ✓ ✓ ✓ ? ?
QCancer (Hippisley-Cox) series of models
for multiple sites and populations
(female/male)14,15,32,52–54,80,82,84,85,88,89,91
Internal validation II ✓ ✓ ✓ ✓ ✓
External validation (not for lung, ‘male’,
or ‘female’)
✓ ✓ ✓ ✓ ✓
Clinical prediction rule (McCowan 201160) for
breast cancer
External validation (developed in
secondary care for use in primary care)
✓ ✓ ✓ ✗ ✗
BB (Marshall)22 model for CRC External validation ✓ ? ✓ ? ✓
External validation (Elias 201750) ✓ ✓ ✓ ? ?
The Netherlands’ (Fitjen 199555) model for CRC Apparent performance ✗ ✓ ✓ ? ✗
External validation (Hodder 200577) ✗ ? ✗ ✓ ?
External validation (Elias 201750) ✓ ✓ ✓ ? ?
The Netherlands’ (Kop)79 ‘machine learning’ for CRC Apparent performance ✓ ? ✓ ? ?
Danish (Norrelund 199657) model for CRC Apparent performance ✓ ? ✓ ? ✗
External validation (Elias 201750) ✓ ✓ ✓ ? ?
The Netherlands’ (Muris 199556) model for CRC Apparent performance ? ✓ ✓ ? ✗
External validation (Elias 201750) ✓ ✓ ✓ ? ?
UK (Iyen-Omofoman 201321) model for
lung cancer
Internal validation II ✓ ? ✓ ? ✗
UK (Keane 201462) model for pancreatic cancer Apparent performance ✓ ✓ ✓ ? ✓
UK (Dommett 201364) model for paediatric cancer Apparent performance ✓ ✓ ✓ ✓ ?
Prediction model for abdominal cancers
(Holtedahl 201863)
Apparent performance ? ✓ ? ✗ ?
✓, low risk of bias; ✗, high risk of bias; ?, unclear risk of bias.




































Chapter 5 Updated review
Introduction
An update of a previous systematic review by Neal et al.25 (published in 2015) was undertaken to examine
the association between different durations of time from first symptom to diagnosis or treatment and
clinical outcomes across all major cancers for symptomatic presentations, to investigate whether or not
a more timely cancer diagnosis is associated with more favourable outcomes. It had been anticipated that
there would be very little evidence on whether or not diagnostic tools have led to increased or quicker
cancer diagnoses and, ultimately, impacts on patient survival. This updated review would therefore
provide important information to inform the proposed decision model of a cancer diagnostic pathway
for assessing the impact of using diagnostic tools.
The cancer diagnostic pathway is complex, incorporating multiple key time points and intervals from the
patient first experiencing symptoms to receiving a definitive diagnosis or treatment (Figure 2). An initiative
to improve the design and reporting of early-cancer diagnosis research included a review of existing






















FIGURE 2 Illustration of the different interval types. T1, time from symptom onset to first seen in primary care (‘patient
interval’); T2, time from symptom onset to referral to specialist care; T3, time from symptom onset to first seen in specialist
care; T4, time from symptom onset to diagnosis; T5, time from symptom onset to treatment; T6, time from first seen in
primary care to referral to specialist care (‘referral interval’); T7, time from first seen in primary care to first seen in specialist
care; T8, time from first seen in primary care to diagnosis (‘diagnostic interval’); T9, time from first seen in primary care to
treatment; T10, time from referral to specialist care to first seen in specialist care; T11, time from referral to specialist care
to diagnosis; T12, time from referral to specialist care to treatment; T13, time from first seen in specialist care to diagnosis;
T14, time from first seen in specialist care to treatment; T15, time from diagnosis to treatment (treatment interval).
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instruments used to measure time points and intervals was undertaken. The project also incorporated
a consensus conference approach combined with nominal group techniques to develop a series of
recommendations for definitions and methodological approaches, which culminated in the Aarhus
consensus statement, published in 2012.92 The Aarhus checklist is a resource for early-cancer diagnosis
research that aims to promote greater precision and transparency in both definitions and methods used.92
The broader evaluation of how reductions in time to diagnosis or treatment can affect patient outcomes
with any cancer not only allows the consideration of the probable impact of using diagnostic tools in these
cancers, but also provides a greater evidence base on the probable impact that could be expected from
reducing time to diagnosis and/or treatment in general. A more in-depth evaluation of CRC studies was
undertaken in this updated review, as this was the focus of our decision-analytic model. This in-depth
evaluation focused on the methodology used in those studies. The decision-analytic model focused on the
use of diagnostic tools in an adult population; therefore, unlike the previous review of diagnostic intervals
by Neal et al.,25 we did not consider childhood cancers as part of the updated review. The previous
review and this updated review considered any type of interval along this pathway, which were grouped
according to accepted definitions, relating to the patient, primary care, secondary care or combinations
of any of those categories.92
Aim
The aim of this review was to update a previous systematic review25 assessing the evidence linking
the durations of different intervals in the diagnostic process to clinical outcomes. A more in-depth
evaluation of CRC studies, focusing on methods, was conducted to identify studies that are likely to





Searches conducted for the previous review and developing the methods for the current update
The previous review25 was conducted in two phases. The original review was conducted in 2008–10,
and then a subsequent review was conducted in 2013–14; both phases were published as a single
review in 2015. The first phase did not include breast cancer or CRC, because of existing systematic
reviews (e.g. Richards et al.;93 Ramos et al.;94 Ramos et al.;95 and Thompson et al.96). However, these
cancer sites were included in the subsequent phase (in 2013–14).
The literature searches for the previous review, which covered multiple databases, were first conducted
during Phase I in 2010 (covering the literature from inception of the databases to February 2010) and
then during Phase II in 2013 (covering the literature from February 2010 to November 2013). Both the
original and subsequent searches (Neal et al.;25 Phases I and II) yielded a very high number of references
to screen. Our estimate from scoping searches was that an update of the Neal et al.25 review from 2013
to 2018 would yield some 25,000 studies to screen. We therefore adopted a pragmatic alternative
method to update this review, using forward citation-chasing.
Search strategy for the current updated review
The forward citation searches for the current update were conducted in August 2017 and updated
in February 2018. Forward citations of the original list of 177 studies included in Neal et al.25 (from
both the 2010 and the 2013 searches) were chased using Scopus and the Web of Science. The search
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results were exported to EndNote X7 and de-duplicated using automatic and manual checking, yielding
2769 studies for screening. The full text of included studies identified from screening were also forward
citation-chased (second-order chasing) in the same way until the investigations were exhausted and all
included studies had been citation-chased.
It is uncertain as to what is the best method for updating systematic reviews.97 The value of alternative
methods of searching is acknowledged, but more research is needed on the clinical effectiveness of
different techniques.98 To test the thoroughness of our novel approach, we sought forward citations of
all the full-text references in the 2010 searches and compared the results with those of the full updated
review carried out in 2013. The citation-chasing approach found 34 of the 71 full-text papers identified
in the 2013 updated review. However, the 2013 review also incorporated some revisions to the inclusion
criteria to make the review more focused, making results less directly comparable.
Selection of studies
Two independent reviewers (RL and BG) screened the titles and abstracts of all records identified by
the searches for relevance, and then assessed the potentially relevant records subsequently retrieved
as full texts for inclusion. Disagreements were resolved by discussion or, if necessary, taken to a third
reviewer (JP).
Eligibility criteria
Studies were included if they fulfilled the following criteria:
l They primarily set out to determine the association of at least one time interval to diagnosis or
treatment with patient outcomes.
l They included symptomatic adult patients with primary cancers (excluding screening- and
biomarker-detected cancers).
l They investigated at least one diagnostic interval (patient, primary care, or a combination), which
could be assessed against accepted definitions (Aarhus statement92). Studies that investigated the
impact of time from diagnosis to treatment were included only if they also reported data on pre-
diagnostic time. (The diagnostic pathway begins at the time of symptom onset and ends at the point
of definitive diagnosis or treatment, whereas the interval between diagnosis and treatment falls
within the treatment pathway and generally relates to secondary care only.)
l They reported data on survival, morbidity, or stage at diagnosis.
l They were available as a full-text paper in English.
Studies comparing two or more diagnostic or referral pathways (e.g. NICE 2WW referrals vs. non-urgent
referrals) were included only if (overall) group-level numeric values for each interval (see Figure 2) were
reported, that is the study also assessed the impact of different intervals on patient outcomes,
irrespective of the referral pathway.
Data extraction
Data extraction was undertaken by one reviewer (RL) and checked by another (JP). For studies of CRC,
this included data on a study’s aims; design; population; location; setting; number of participants sampled
and, subsequently, recruited and analysed; definitions of time duration; data collection methods; outcome
measures used; and the authors’ conclusions. The main results were also extracted, including the methods
used for assessing the association between interval and outcomes, statistical significance, CIs and any
subgroup analysis. A more condensed summary was extracted for studies of other cancer sites.
Critical appraisal
The methodological quality of each CRC study included was assessed using the same bias assessment tool
used in the previous review25 (see Appendix 4, Box 1). Bias assessment was undertaken by two independent
reviewers (RL and JP); there were no disagreements that needed be taken to a third person.
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Waiting-time paradox
The risk-of-bias assessment also included identifying studies that addressed the ‘waiting-time paradox’,
as they are likely to be of better analytical quality.
The observed association between a short diagnostic interval and poor outcomes has been referred
to as the ‘waiting-time paradox’. Two underlying theories have been proposed to explain this effect.
One widely held belief is confounding by severity of disease, whereby high-risk precursors, such as
aggressiveness of the tumour, act as unmeasured confounders that mask the effect of the exposure.99
The underlying assumption here is that rapidly growing or more aggressive tumours are more likely to
present with alarm symptoms that will make the patient or doctor think of cancer, whereas slow-growing
or less well-differentiated tumours result in vague initial symptoms that are difficult to detect.99 To help
mitigate this bias, information is required on factors associated with the aggressiveness of the tumour,
such as histology, grade, stage, tumour volume, genetic factors. The alternative assumption is that the
paradoxical findings reflect confounding by indication, caused by differentiated clinical triage.99 The
assumption here is that GPs expedite patients presenting with high-risk symptoms, especially if they look
ill, and at the same time are more reluctant to refer healthy-looking people with low-risk symptoms.99
To help mitigate this bias, information is required on what triggers the GP to either refer immediately
or adopt a watchful waiting approach.99
In the previous systematic review, studies that addressed the waiting-time paradox were defined as:
. . . articles that undertake an analysis or sub-analysis that specifically includes or excludes patients who
are either diagnosed very quickly (e.g., within 4–8 weeks, although this will vary between cancers),
or have very poor outcomes (e.g., deaths within a short time after diagnosis, e.g., within 4–8 weeks).
Neal et al.25
Papers that simply reported that the waiting-time paradox may have confounded their data were not
classified as having addressed this potential source of bias. In the current updated review, we recorded
whether or not studies had performed adjusted analyses for aspects such as emergency presentation,
severity of presenting symptoms, tumour grade or aggressiveness. This is discussed in more detail in
Colorectal cancer.
Data synthesis
A narrative synthesis was undertaken, which followed the same approach as that used in the previous
review.25 Overall findings were presented in a table format, with studies grouped by cancer location.
Information reported included type of diagnostic interval, and whether the analysis considered patient
outcomes, such as survival or stage of disease, or other outcomes. A key output was to identify the
association between reduced diagnostic interval and improved patient outcome. This information fed
directly into the decision-analytic model and permitted an exploration of the variation in findings from
different studies. The previous review25 identified a large degree of variability between included studies.
In the table of overall findings, studies that reported ‘positive’ associations (i.e. there was evidence of
shorter intervals being associated with more favourable outcomes) were presented first. Studies that
reported no associations were reported next. Studies that reported ‘negative’ associations (i.e. there
was evidence of shorter intervals being associated with less favourable outcomes) were reported at
the end of the table. Within each grouping, studies were ordered by the patient outcomes: survival or
mortality first (for simplicity, both are referred to as survival in the table), followed by stage and then
‘other’ outcomes.
Figure 2 summarises the definitions that were used to categorise the different time (T) durations
evaluated by included studies. Each duration was categorised as one of 15 intervals.
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Data synthesis
The results of the current updated review are first presented for all cancers using the same table format
as in the previous review.25 They are followed by more in-depth evaluation for CRC. No meta-analyses
were planned or conducted as a result of the (anticipated) heterogeneity: the review of CRC therefore
focuses on identifying studies that are likely to provide the best estimate of the impact of diagnostic
intervals on patient outcomes for informing the decision-analytic model.
The CRC review incorporates studies identified during our updated review and better-quality studies
identified during the previous review. We focus only on more recent or better-quality studies as they
are considered to provide more valuable information for our decision model for the following reasons:
l They are more likely to account for the non-linear association between time to diagnosis and stage
or survival.
l They are more likely to account for the waiting-time paradox, whereby patients with more advanced
or aggressive disease are inclined to present earlier and have definitive symptoms, or are prone to
be referred quickly and prioritised for treatment.




Our searches identified 1810 references after de-duplication, of which 104 were considered relevant
and retrieved as full-text studies. Thirty-five studies were identified that met the inclusion criteria
(Figure 3). This includes one study for which the interlibrary loan was still outstanding at the time of
the report; therefore, the data extraction is based on an abstract. This study122 included patients with
well-differentiated neuroendocrine tumours.
A summary of the included studies is provided in Appendix 4 (see Table 51). Two studies considered
multiple cancer sites, whereas the remaining studies evaluated a sole cancer: bladder (n = 1), breast
(n = 4), colorectal (n = 8), lung (n = 5), lymphoma (n = 1), myeloma (n = 1), neuroendocrine (n = 1), oral
(n = 2), ovarian (n = 2), pancreatic (n = 2), penile (n = 1), prostate (n = 1), sarcoma (n = 3) and testicular
(n = 1). The studies were from a wide range of countries. Eight studies were undertaken in the UK, five
in Canada and four in Spain; two studies were undertaken in each of the following countries: the USA,
the Netherlands, Mexico and Japan; and one study was carried out in each of the following countries:
China, France, Islamic Republic of Iran, Israel, Italy, Montenegro, Poland, Rwanda, Sri Lanka and Uganda.
Findings of the previous review
The previous review25 identified a large number of relevant studies (n = 209), with only a small number
considered to be of high quality.25 There was substantial variation in the type of intervals evaluated
and the findings within and between cancer types. Compared with other cancer types, studies of
colorectal, breast, head and neck, and testicular cancers and melanoma suggested that shorter time
intervals were associated with improved patient outcomes. However, for each of these cancer types,
there were also studies reporting no association between time interval and patient outcome. Some of
the included studies also showed that shorter intervals were associated with decreased survival. This
important heterogeneity is likely to have been caused by confounding, as discussed in Waiting-time
paradox. A summary table of the previous review findings is provided in Appendix 4 (see Table 58).
Findings of the updated review
A summary of the findings of the 35 new studies included in the updated review is presented in Table 11,
using the same format as used in the original review. Some studies assessed the impact of longer intervals
or perceived delay on patient outcomes, which we converted to represent the opposite effect associated
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Diagnostic interval T8 Pace 2015103
Seen in primary care to
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T9 Murchie 2015102




Records identified during the initial citation
searches, after de-duplication
(n = 1635)
Records identified during an update
citation search, after de-duplication
(n = 175)
Records rejected on the basis of title and/or
abstract as not relevant to this review
(n = 1706)
Full-text articles retrieved for detailed
evaluation and assessment for inclusion
(n = 104)
Studies included in qualitative synthesis
(n = 35)
Full-text articles excluded, with reasons
• Not assessing interval impact, n = 10
• T15, n = 11
• No relevant outcome data, n = 3
• Childhood, n = 13
• Not English language, n = 3
• Pathway/service studies, n = 13
• Comment, n = 1
• In previous review, n = 4
• Reviews, n = 11
(n = 69)
FIGURE 3 Updated review: the PRISMA flow diagram.
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with shorter intervals. The original interpretation of the results and how each was converted to show the
corresponding impact of short intervals are presented in Appendix 4 (see Table 53). Some of the studies
that evaluated the impact of an interval (e.g. T1) as a categorical variable (e.g. 1–2, > 2–3 and > 3–4
months) reported statistically significant findings for some intervals and not others, the results of which
are also shown in Appendix 4 (see Table 53).
A larger number of studies identified during the updated review reported non-statistically significant
findings or negative association between shorter intervals and patient outcomes. The potential
of a ‘U’-shaped association between time intervals and outcomes is explored in more detail in
Colorectal cancer.
Colorectal cancer
The more in-depth summary for CRC presented here focuses on the 10 studies identified in our updated
review (see Table 11 for overall findings; this included two studies that considered multiple cancer sites)
and four good-quality studies (published between 2011 and 2013) identified in the previous review that
addressed the waiting-time paradox. The broader findings presented in the previous review,25 and other
previous systematic reviews by Ramos et al.94,95 and Thompson et al.,96 are considered to provide a good
summary of the wider (prior) evidence base.




Positive association No association Negative association
Stage







Patient interval T1 Kobayashi 2014134
Stage
Patient interval T1 Kobayashi 2014134
Other (tumour size)
Patient interval T1 Kobayashi 2014134
Urinary tract cancer
Survival
Diagnostic interval T8 bDregan 2013108
NSCLC, non-small-cell lung cancer; SCLC, small-cell lung cancer.
a A positive outcome measure corresponds to better survival outcomes (or reduced mortality) for ‘survival’; having a
less advanced stage at diagnosis for ‘stage’; and having a smaller tumour, no metastases, or no nodal involvement
for ‘other’.
b Study considered multiple cancer sites.
Notes
‘Positive association’= shorter intervals associated with statistically significant more favourable outcomes.
‘No association’ = findings not statistically significant.
‘Negative association’ = shorter intervals associated with statistically significant unfavourable outcomes.
(Favourable outcomes = improved survival, earlier stage at diagnosis, or a less extensive tumour.)
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A more in-depth data extraction was conducted for the 14 included CRC studies. The results are provided
in Appendix 4, presented over three tables summarising each study’s characteristics (see Table 55), critical
appraisal (see Table 56) and results (see Table 57). These results tables include a summary of both the
magnitude and the direction (and statistical significance) of the associations between intervals and patient
outcomes for each included study.
The following section presents the overall findings for the CRC studies, and an evaluation of the included
studies that was conducted to aid the selection of specific studies to inform the decision model.
The overall findings
Five studies were undertaken in the UK, three in Denmark and two in each of the USA, Canada and Spain.
Six studies were based in primary care, six in secondary care (including specialist centres) and two in
both primary and secondary care. Four of the studies undertaken in secondary care were of single sites
(hospitals). The three studies from Demark were by the same authors (i.e. Tørring et al.99,135,136) and included
the same or overlapping study populations. Tørring et al.136 focused solely on CRC, included 268 participants
and data on estimated 3-year survival. Tørring et al.135 analysed data from three population-based studies,
one of which was Tørring et al.136 Tørring et al.99 evaluated the impact of diagnostic intervals in five common
cancers, including CRC. The colorectal cohort for this study appears to be identical to that of Tørring et al.136
(n= 268), but the analysis is based on 5-year survival. As our review is based on a narrative synthesis,
all three studies99,135,136 are included and described below.
The only interval to be evaluated by more than two studies was T8, which is the ‘diagnostic interval’
(time from first seen in primary care to diagnosis). The impact of the diagnostic interval on survival was
evaluated by six studies,99,101,108,135–137 one of which137 evaluated colon and rectal cancers separately, and
another of which136 stratified analysis by whether the presenting symptoms were considered by the GP
as alarm and/or serious versus vague. Four studies99,135–137 found that longer intervals were associated
with statistically significant poorer survival outcomes: one137 in colon cancer only, and one136 for alarm
and/or serious symptoms only. The overall effect sizes that were reported by the studies (see Appendix 4,
Table 57) were small, except for Tørring et al.,135 which reported a medium size effect (odds ratio of
4.74) for the association between a very short interval and survival (Tørring et al.135,136 also reported
wide CIs). The diagnostic interval was analysed as both a categorical and a continuous variable in all
three studies by Tørring et al.,99,135,136 whereas it was evaluated as a dichotomised variable by Pruitt
et al.137 The diagnostic interval, when analysed as multiple categorical variables, was divided into three
groups, based on the interval quartiles. The middle-interval group, which included both the second and
the third quartiles combined, was used as the reference. The findings of the categorical analysis were
statistically significant for the very-short-interval group in both Tørring et al.136 (alarm or serious
symptoms only) and Tørring et al.,99 whereas Tørring et al.135 reported significant results for both the
very short- and the long-interval groups (see Appendix 4, Table 57). Tørring et al.135 specifically aimed to
test the theory of a U-shaped association between the diagnostic interval and mortality after diagnosis
using data from three population-based studies.81,136,138 The analysis of the combined data, from all
three studies,81,136,138 and the analysis of the data from the study based on GP data138 showed that both
the shorter- and the longer-interval groups were associated with a statistically significant increased
risk of mortality at 5 years.135 In all three studies by Tørring et al.,99,135,136 the analysis and the graphical
display of the diagnostic interval assessed as a continuous variable had a convex (U-shaped) association
with mortality (these trends were statistically significant in Tørring et al.99,135). In other words, patients
with very short or very long intervals had higher mortality than the rest. However, for patients
presenting with vague symptoms,136 there was a trend towards a concave association between
diagnostic interval and mortality, but the results were not statistically significant and lacked power.
Two studies112,113 assessed the impact of the diagnostic interval (T8) on stage at diagnosis. Leiva et al.113
measured the interval using two separate data sources (GP and hospital records); Chen et al.112
reported subgroup analysis according to age at diagnosis (< 50 and ≥ 50 years). Leiva et al.113 found
that shorter intervals were associated with more advanced cancer stage at diagnosis, based on data
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from the hospital records only. Chen et al.112 and Leiva et al.113 also assessed the association between
other intervals and stage at diagnosis, including duration between symptom onset and diagnosis (T4)
(both studies) and the ‘patient interval’ (T1) (Chen et al.112 only). Among younger patients (aged
< 50 years), those with stages III or IV cancer had statistically significantly shorter durations for both
T4 and T1 than those with stages I or II disease. One study109 evaluated the association between T4
and survival, and found that longer symptoms-to-diagnosis intervals were not associated with poorer
survival (or advanced stage) in CRC patients (see Appendix 4, Table 57).
Two further interval types were each investigated by two studies: T9106,107 and T12.110,111 Only Patel
et al.111 found one of these intervals (T12) to be associated with statistically significant findings: long-
term survival and the proportion of patients with early-stage cancer were greatest in patients who did
not receive treatment within the recommended 62 days (see Appendix 4, Table 57).
The intervals T11 (between referral to a specialist care and diagnosis)114 and T15 (between definitive
diagnosis and treatment)137 were both evaluated by a single study. Janssen et al.114 did not find shorter
intervals to be associated with an increased likelihood of having distant metastases or a node-positive
tumour. Pruitt et al.137 found that shorter treatment intervals were associated with better survival in
colon, but not rectal, cancer.
Summary of the methods used
Non-linear association
Tørring et al.99,135,136 showed that the association between diagnostic interval and patient outcomes for
CRC is U-shaped, with both very short and long intervals being associated with poor outcomes.99,135,136
Five included studies used spline regression analysis to account for this non-linear relationship.99,107,109,135,136
In the Murchie et al.107 study, the spline curves for the unadjusted analyses showed a statistically
significant non-linear association between time from being seen in primary care and treatment (T9, which
the authors refer to as ‘provider delay’107) and both stage and mortality, but these were no longer present
after adjusting for confounders. Pita-Fernández et al.109 presented spline regression analyses for colon and
rectal cancers, which showed very short symptom-to-diagnosis (T4) intervals to be associated with higher
mortality in those with rectal tumours. In colon cancer, no significant relationship was found between
interval and survival. In addition to analysing the interval as a continuous variable, the study computed
Kaplan–Meier curves for each interval quartile. The Cox regression model, adjusting for age and sex,
showed that patients with cancer of the rectum in the first interval quartile had statistically significant
lower survival than the rest, but this was no longer significant when controlling for stage; no significant
difference was found for colon cancer.
Waiting-time paradox
Six studies99,101,107,108,135,136 collected data on patients seen in primary care. Four studies99,101,136,137
conducted a stratified analysis according to the GP’s perceived seriousness of the presenting
symptoms. Two studies107,113 included the perceived seriousness (vague, serious, alarm) of the
presenting symptom,113 and/or specific (high-risk) symptoms107,113 as covariates in their multivariate
analyses. One study,108 which evaluated the time intervals between specific alarm symptoms and
subsequent cancer diagnosis, also compared the survival of patients with alarm symptoms with that of
patients without alarm symptoms. One study137 stratified diagnostic delay models by the four most
common presenting symptom types as part of their sensitivity analysis, but did not present the results,
noting only that these did not substantially change the findings.
A number of studies controlled for the confounding effect of tumour grade or aggressiveness. Potential
important confounding factors include tumour stage, tumour grade, degree of differentiation, type of
hospital admission (emergency or elective), symptoms and signs. Five studies101,106,109,113,137 used multivariate
analysis that accounted for one or more of these factors. Six studies also conducted stratified analysis
according to stage,137 emergency admission106,110,111 or presenting symptoms (either type of or perceived
seriousness).99,101,137 Emergency admission was also considered as an exclusion criterion in two studies.101,114
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However, some argue that stage at diagnosis can be conceived as a mediator or intermediate factor (longer
delays cause more advanced disease, and more advanced stages are associated with poorer survival), which
means that adjusting for tumour stage will introduce spurious confounding (see Pita-Fernandez et al.109).
However, Pruitt et al.137 found that patients with longer diagnostic delays had earlier-stage disease, which
they state is refuting the common assumption that stage is an intermediate factor in the causal chain
between diagnostic delay and survival. A simpler explanation might be that the first symptom was not
from the cancer, and the diagnostic interval has been artificially inflated.139 However, the findings could
also be a simple reflection of the fact that the association between diagnostic delay and survival is
seriously confounded as an estimate of causal effect.
Clear definitions of diagnostic intervals
All included studies provided clear definitions of the intervals that they were evaluating. However,
only one study99 defined its interval according to the Aarhus statement.92 Two previous studies135,136
conducted by the same authors were published prior to the Aarhus statement.92 Four studies101,107,109,137
used definitions similar to those reported in the Aarhus statement,92 and all but one study101 referred
to the time period as provider, diagnostic, or treatment ‘delay’, rather than using the term ‘interval’,
which the Aarhus statement92 recommends. Three studies110,111,114 used definitions that reflect a
national guideline target. In one study,113 which compared the use of three different data sources,
the defined TDI could have been interpreted differently according to whether the data were obtained
from the hospital records, GP records or patient questionnaires.
Lead time bias or immortal time bias
The previous review25 recommended the use of survival as the ‘gold-standard’ outcome measure.
Methodological issues to consider when interpreting the findings include the potential effect of either
lead time bias or immortal time bias. Lead time bias may be present when early detection advances
what would have been the original date of diagnosis to an earlier point in time, while not necessarily
delaying a patient’s time of death.99 It has been suggested that, when studying diagnostic delay, survival
time should ideally be measured from the date of first symptom,93,94 rather than the date of diagnosis,
to overcome lead time bias.99 This was done by one study;107 however, it may not always be possible,
particularly when using retrospective analyses of administrative data.137 Furthermore, calculating
survival time from the onset of symptoms includes a period before the occurrence of the defined
exposure of interest (i.e. diagnosis), which may, in turn, create an immortal time bias.99 One study135
used data obtained from three previous studies,81,136,138 one of which collected data on date of symptom
onset using patient interview questionnaires.138 To account for ‘immortal person-time’ in the patient-
based study, Tørring et al.135 specified delayed entry (left truncation) from the date of the interview.
Pruitt et al.137 used a case–control design to try to mitigate both these biases. Cases (deaths due to
CRC) and controls (deaths due to other causes or censored) were matched on survival time, and the
association between delay and death was examined using logistic regression.137
Survival as a function of age
Tørring et al.99 adjusted for age at diagnosis, which they state would ensure that any increase in mortality
is not a natural function of becoming older. Most of the studies included age in their multivariate analysis,
but this was incorporated as a simple binary measure in some studies (≤ 69 vs. > 69 years,108 ≥ 70 vs.
< 70 years106 and < 65 vs. ≥ 65 years113). Four studies adjusted for age categorised as multiple groups:
18–59, 60–74 and ≥ 75 years;99 < 50, 50–60, 60–70, 70–80 and > 80 years;109 ≤ 65; 66–69, 70–74, 75–79,
80–84 and ≥ 85 years;137 and 15–44, 45–54, 55–64, 65–74 and ≥ 75 years.101 One study107 included age as
a continuous variable.
Further potential sources of bias or confounding
Most studies were retrospective and set in linked databases. Other data sources for interval data or
timing of events were GP questionnaires, patient records and interviews. Potential limitations include
recall bias and validity and accuracy of the data. Another consideration is the accuracy of the data
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collection conducted as part of the study. The use of multiple sources for the same data is one approach
to augment or validate the data. Janssen et al.114 reported that two investigators independently reviewed
a subset of subject data to obtain a measure of interobserver agreement. No other study reported doing
this. No other study reported using a process to account for the accuracy of interval classification. Some
studies did report excluding cases with missing data or discrepant data for calculating the intervals.
The 2011 study by Tørring et al.136 relied on the GPs retrospectively ascribing a date to relevant milestones
on the diagnostic pathway of each patient. The authors acknowledge that these dates may have been
affected by differential information bias, because of the GPs’ extensive knowledge of their patients. The
subsequent (2012) study by Tørring et al.135 was based on three cohort studies that used different sources
to ascertain the date of first presentation: GP questionnaires (Tørring et al.136), interviewer-administered
patient questionnaires (Korsgaard et al.138) and primary care records (Hamilton et al.81). Leiva et al.113 also
compared data on intervals identified using three different sources of information (patient interviews,
hospital records and GP records), but there was heterogeneity in the types of intervals studied.
Another potential issue that has implications for decision-analytic modelling is that some studies have
shown that rectal and colon cancers have differing results, suggesting that these two should not be
analysed together.137 Only Tørring et al.135 adjusted for the separate cancer sites.
Discussion
Summary of the findings
The current review updates the findings of a previous systematic review25 that examined the
association between different durations of time from first symptom to diagnosis or treatment and
clinical outcomes across all major cancers. Summary details of included studies are presented, along
with an overall assessment of whether or not each study reported an association between shorter
times to diagnosis and a more favourable outcome. A more in-depth evaluation was conducted of CRC
studies to inform the decision-analytic model. Summary details of included studies, including their
results, are presented in structured tables in Appendix 4. No meta-analyses were undertaken because
of heterogeneity, which included variability and how intervals were assessed. The findings of some
of the more recent studies indicate that the relationship between diagnostic interval and patient
outcomes is likely to be U-shaped, with both very short and long intervals associated with poor
outcomes. The review also identified important biases and other factors that may affect the findings
of studies in this field.
Existing reviews of colorectal cancer
Previous systematic reviews conducted by Ramos et al.94,95 found no association between delays and
stage at diagnosis95 or survival94 for CRC. The initial review by Ramos et al.94 included 26 studies,
20 of which showed no associations between delay and survival. In contrast, four studies showed that
the delay was a factor contributing to better prognosis, and two showed that it contributed to poor
prognosis.94 The detailed literature review by Thompson et al.96 also found no strong theoretical basis
for a benefit from earlier diagnosis of symptomatic bowel cancer. Five studies were identified that
demonstrated improvement in survival due to early diagnosis, and 16 studies, paradoxically, showed
worse outcomes associated with prompt treatment. The authors also acknowledged that it was difficult
to draw firm conclusions from observational studies because of the potential biases. The overall
findings of these reviews may be due to the apparent U-shaped association between the interval from
first symptom to diagnosis or treatment and patient outcomes in CRC.
Strengths and limitations of the updated review
The original review,25 which we have updated, was the first systematic review to evaluate the impact of any
pre-diagnostic interval on patient outcomes in any cancer. This meant that the review included a very large
number of heterogeneous studies. As a result, only a broad narrative synthesis was undertaken, with the
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overall findings for all cancer sites presented in a summary table, similar to Table 11. The current review
focused on providing an update of the previous review’s overall findings, and also emphasised whether or
not studies found statistically significant findings, and the direction of the effects of any such findings. The
synthesis of both the previous and the current review essentially represents a ‘vote counting’ process,
and does not take into account the magnitude of the effect (or any potential U-shaped association).
In view of the fact that only a narrative synthesis was feasible, and that the association between the
interval T8 and the outcome survival was the only association to be evaluated by more than two
studies, the current review of CRC studies focused on providing an assessment of the methodology
of included studies; the summary results of individual studies are presented in Appendix 4.
One of the main limitations of relying on statistical significance to identify relevant associations is that
it ignores studies that lack sufficient power to detect small differences. One of the main advantages of
a meta-analysis is that it can improve power by synthesising the findings of multiple studies. Very few
included CRC studies assessed the associations between the same intervals using the same outcome
measure to allow any meta-analysis, and, when they did, they varied in the approach used to analyse
the data; whether the interval was considered as a continuous, categorical or dichotomised variable;
and the selected cut-off points. However, even if a sufficient number of homogeneous studies were
available, accounting for the potential U-shaped association in a meta-analysis is not trivial. The
intervals would need to be considered as a categorical or continuous variable, which may not be
reported in the primary studies.
Another important limitation of the updated review is the likelihood of selective outcome reporting.
Some studies reported evaluating multiple intervals but did not provide the outcome data for all of
them. It is also likely that some studies did not report all the intervals they evaluated, and reported the
findings for selected intervals only. Selective reporting may have been a particular issue with studies
that incorporated a broader aim of evaluating more than just the association between timey diagnoses
and favourable outcomes; for example, they may also have aimed to describe the diagnostic journey
and identify factors associated with delay.
The literature searches for the original review identified > 193,077 references. Our updated review
represents a supplementary review that was conducted to inform the decision model, and needed to
be completed in a timely manner. The impracticality of screening thousands of references in a timely
manner when updating any systematic reviews means that new efficient methods of undertaking this
process are needed. Our updated review used an innovative and pragmatic method for searching the
literature, which can contribute to the future development and availability of such methods. We tested
the appropriateness of the new approach by applying it to the second phase of the previous review25
and comparing the findings with those achieved in the original literature searches. Our novel approach
did not capture all the relevant studies in this test. However, some of this may be because of the
refinement in the inclusion criteria that occurred between Phases I and II of the original review.
It is therefore unclear if the current review has missed any important studies using these pragmatic
search methods. Further work is needed to refine and test this new searching approach.
The original systematic review25 was undertaken in two phases: an initial review was conducted in
2010 and a subsequent review undertaken in 2013 covering the literature published since 2010.
Both phases were published as a single review in 2015.25 The original 2010 phase did not include a
review of CRC studies, as there were existing systematic reviews by Ramos et al.94,95 (one in 200794 for
survival outcomes and another in 200895 for stage) for this cancer site. This means that the previous
review25 included primary studies for CRC published only after 2010. The 2007 Ramos et al.94 review
identified 12 studies that they reported as having used multivariate analysis to evaluate the association
between diagnostic or therapeutic intervals and survival. However, the authors did not report which
studies these were; therefore, we were unable to consider these studies for inclusion in our review as
studies addressing the waiting-time paradox.
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Conclusion
The overall findings of the updated review highlight the uncertainty in the evidence base for the extent to
which reducing times to diagnosis and/or treatment leads to improved patient outcomes. There is still a lack
of firm evidence to demonstrate an association between timely diagnosis and favourable outcomes in those
with CRC. The evidence indicates a U-shaped relationship, but also reflects considerable heterogeneity in
terms of the methods and intervals evaluated, and highlights some important methodological challenges
in evaluating whether or not timely diagnosis leads to better outcomes. The findings support the need to
expedite the diagnosis of symptomatic patients and to work to prevent the preventable delays that some
patients continue to experience.
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Chapter 6 Data for informing the economic
decision model
Objective
The economic decision-analytic model explored the uncertainties regarding the clinical effectiveness
and cost-effectiveness of the tools to aid cancer diagnosis decision-making in primary care in the NHS.
Given the scope of the current study, it was not feasible to model the impact of diagnostic tools for
all common cancer types for which diagnostic tools exist. Instead, at the outset, we chose to model
one common cancer, CRC, to illustrate a case for which we believe there are good a priori reasons why
diagnostic tools in primary care could affect patient outcomes and may be effective and cost-effective.
CRC is among the cancers with the shorter diagnostic intervals (31–60 days); cancers with longer
diagnostic intervals, for example bladder cancer (61–91 days) and lung cancer (91–120 days), would
have greater scope for diagnosis. If clinical effectiveness and cost-effectiveness results are favourable
for CRC, the modelling approach could be extended to other cancers, but this is beyond the scope of
the current study.
We will use the decision-analytic model to link empirically demonstrated impacts on short- and medium-
term outcomes to the effects of treatment, to estimate the impact on longer-term outcomes. In particular,
we will explore the potential impacts on health service resource use, costs and patient outcomes in relation
to CRC. This chapter focuses on the sources of information from previous chapters, a methodological
review of the decision-economic models on CRC that have been published and the data for populating
the decision-analytic model.
Sources of information
The decision-analytic model is informed by the findings from SR1 (clinical effectiveness of the diagnostic
tools), the accuracy of the diagnostic tools (identified in SR2), and by the updating of a previous systematic
review25 which provides evidence on the impact of reducing time to cancer diagnosis and/or treatment
on patient outcomes. Relevant studies were those that evaluated tools in UK primary care patients, and
reported outcomes associated with the use of the tools in terms of referral, diagnostic or treatment
intervals, stage at diagnosis, patient health-related quality of life or survival.
The model is also informed by a review of decision-analytic models that sought to identify the
strengths and limitations of previous models and quality of evidence on parameter values for resource
use, costs and utilities for populating a decision model of primary diagnostic strategies for suspected
cancers. Because modelling the use of the diagnostic tools required a CRC disease model to translate
diagnostic outcomes into clinical outcomes following treatment, and existing studies of CRC screening
were known to us that included whole disease history model for the UK, we extended the scope of our
review of economic studies to include the population of asymptomatic patients so that relevant disease
models could be identified.
Summary of findings for the decision-analytic model
Systematic review 1
Two studies from SR1 were relevant for the CRC decision-analytic model: Hamilton et al.13 and
Emery et al.35
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In the study by Hamilton et al.,13 seven English cancer networks were selected for using the RAT (mouse
mat or desktop flip chart versions) for colorectal and lung cancer, to provide the underdiagnosed cancer
risk estimates in individuals aged > 40 years presenting to primary care with symptoms. The authors13
evaluated the changes of 2WW referrals and request of colonoscopies by GPs for the two 6-month
periods before and after the distribution of the RAT. A total of 614 GPs from 165 practices were
recruited. The RAT for CRC was used and completed 1521 times, and was associated with increases
of 26% (from 1173 to 1477) and 15% (from 1762 to 2032) in 2WW referrals and colonoscopies performed,
respectively; these increases resulted in 10 new additional cases identified (from 134 to 144). Unfortunately,
the authors13 were unable to distinguish which of the additional 270 colonoscopies were ordered for
patients for whom the RAT was used. However, the number of 2WW, routine and urgent referrals
reportedly accounted, respectively, for 49% (702/1433), 12.7% (182/1433) and 10% (144/1433) of
patients evaluated with the CRC RAT.
The study by Emery et al.35 used a 2 × 2 factorial cluster RCT design in rural Western Australia. The
objective of the study was to measure the effect on the TDI of a community-based symptom awareness
and general practice-based educational interventions for individuals presenting with symptoms of breast,
prostate, colorectal or lung cancers. For the decision model, the intervention relevant is the one at GP
level, which consisted of a GP resource card with symptom risk assessment charts (RAT) and local cancer
referral pathways in which the primary outcome was the duration of the TDI. As mentioned in SR1, for
colorectal cancer, the authors did not find statistically significant differences in the median TDI (GP-based
intervention, n= 124; GP control, n = 122) or in the log-transformed (ln) mean difference (0.3, 95% CI
–0.51 to 0.45; p = 0.42) for the GP-based intervention versus control, nor did they find it when the
factorial design was analysed by tumour group or subintervals of the TDI.
Critique of identified data
It is important to note that the data on the diagnostic accuracy for the two tools for which relevant
evidence was identified, QCancer and RAT, are derived from low-risk patient populations, which NICE
has previously defined as constituted by those patients presenting to primary care without symptoms
requiring 2WW referral and whose symptoms place them in the positive predictive value (PPV) range
of 0.1–3.0% risk band.140 The diagnostic accuracy values for QCancer were estimated from a sample
whose prevalence, as determined by a recorded diagnosis of CRC over the 2-year follow-up period
after the first appearance of symptoms, was 0.16% after excluding the red-flag symptoms, in a sample
of 1,223,192 patients.
The prevalence over which the diagnostic accuracy of the RAT was estimated could not be calculated
from the available report.141 However, the recommended use of the tool by its developers is for
patients presenting with signs and symptoms that have a PPV of > 2% to follow the 2WW referral
pathway, those with symptoms having a PPV of 1–2% to be referred for primary care investigations
and those with signs and symptoms having a PPV of < 1% to be managed in primary care using the
GP’s clinical judgement. When patients with signs and symptoms with a PPV of ≥ 3% are excluded
because they are high risk, the resulting prevalence in patients with all the symptoms considered by
the RAT should fall between 0% and 3%. This would be consistent with NICE guideline6 definitions
of a low-risk population of symptomatic patients presenting to primary care, and reflect the range of
risk underlying the reported sensitivity and specificity values for the RAT (Hamilton141).
Systematic review 2
Table 12 summarises the relevant evidence on predictive accuracy of externally validated models in
UK patients, as described in Chapter 4. Of the four models, one reports no diagnostic accuracy data
(the Netherlands model55), and another reports no specific diagnostic threshold to define positive
findings (the BB equation22). A third model has no reported diagnostic accuracy estimates in UK
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patients at a specific threshold (the RAT74). However, these data are available from a doctoral thesis
dissertation, identified after SR2 was completed (William Hamilton, University of Exeter, 2019,
personal communication), in which sensitivity of 69% and specificity of 77% are reported for a score of
35, corresponding to a threshold PPV of 2%.141 The remaining model QCancer, provides sensitivity and
specificity parameter estimates by sex, which may be used to populate a decision model of decision-
making for suspected cancers. However, these values include patients with red-flag symptoms, which
may be deemed appropriate for 2WW referrals, so a more appropriate value for the low-risk patient
primary care population of interest to our study would exclude these cases. Therefore, we calculate
the sensitivity and specificity of QCancer for the top 10% risk threshold, after excluding the top 1%
risk observations (i.e. subtracting the published number of patients and CRC cases in the top 1% risk
from the top 10% risk and cases total, respectively) from the published data,77 to be 61% and 91%,
respectively. These values are derived from analysis of a large database of electronic medical records
of patients seen in routine practice.
Updated review
As discussed in Chapter 5, the evidence identified in the updated review of the relationship between
diagnostic delay and cancer patient outcomes does not allow the derivation of valid estimates on the
effect of expeditious CRC diagnosis on cancer stage or patient survival. In particular, the documented
non-monotonic (e.g. U-shaped) relationship between diagnostic interval and mortality does not infer an
effect mediated through the impact of diagnostic interval on stage of diagnosis. This is because shorter
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a Marshall et al.22 report sensitivity and specificity values without stating the threshold.
b Marshall et al.22 report sensitivity of 32.6% and specificity of 97.8% without stating the threshold used, which in any
case is unlikely to have been the recommended one of 3% for the UK.
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diagnostic intervals are associated with unobserved differences in cancer stage and tumour
aggressiveness, and are affected by lead time and immortal time biases whereby deaths from cancer
may occur outside the observed follow-up at varying degrees across the duration of the diagnostic
interval. Similarly, the observed relationship between diagnostic interval and cancer stage may be
affected by unobserved variation in underlying disease severity and cancer aggressiveness across the
range of the diagnostic interval.
Given the lack of valid surrogate or clinical outcome data for building an economic model of diagnostic
tools or decision-aid models in primary care, our cost-effectiveness analysis was limited to an exploration
of the expected effects of prolonged intervals to diagnosis associated with the relative diagnostic
accuracy of diagnostic tools. This limited aim will naturally account for more sources of uncertainty
than an analysis based on clinical surrogate outcomes, but reflects a realistic approach given the
quality of the data available.
Systematic review of existing economic decision-analytic models for
colorectal cancer
Methods
The systematic review of decision models and evidence used to populate their parameters used a
rigorous but pragmatic approach because of the time constraints of developing a de novo model
consistent with good modelling practice.142,143
Search strategy
The search strategy was designed to retrieve economic decision models in CRC. The following sources
were searched: MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE and Health
Management Information Consortium (HMIC) [all via Ovid® (Wolters Kluwer, Alphen aan den Rijn, the
Netherlands)], NHS Economic Evaluation Database (NHS EED) and the Health Technology Assessment
(HTA) Database (both via the Cochrane Library) and EconLit [via EBSCOhost (EBSCO Information
Services, Ipswich, MA, USA)]. The searches were developed and run by an information specialist (SR)
in September 2017 and updated in September 2018. A search filter was used to limit the searches to
economic studies. No date or language limits were used. The database search results were exported
to, and de-duplicated using, EndNote X7. De-duplication was also performed using manual checking.
The search strategies for each database are detailed in Appendix 5. Studies were selected using
predefined inclusion and exclusion criteria, which are presented in the following sections.
Inclusion criteria
The studies were included if the:
l population considered was adults (aged ≥ 18 years) with symptomatic or asymptomatic CRC,
or at risk of developing CRC
l interventions included diagnosis CRC models, screening programmes to identify CRC in the
population (as long as they also included a disease progression model), or treatment of CRC
l comparator was current clinical practice or other
l outcomes included resource use, costs and health outcomes [which included life-years gained,
quality-adjusted life-years (QALYs) gained, CRC cases prevented, etc.]
l studies were trial- or model-based that included a CRC disease model using the Dukes’ staging or
the Classification of Malignant Tumours of the American Joint Committee on Cancer (AJCC), that is,
a tumour node metastasis (TNM)-based classification staging system (cost-effectiveness, cost–utility)
[both systems are commonly used in the UK and by NICE, although the AJCC’s system is mostly
known in the UK as TNM (classification of malignant tumours). Further explanation of these
classification systems can be found in Appendix 5.].
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Exclusion criteria
Studies were excluded if one or more of the eligibility criteria were not met, if the studies were cost of
illness or burden of diseases, if they reported only methodological issues, or if they were abstracts,
reviews, commentaries, letters or editorials.
Selection of studies
Titles and abstracts obtained from the search were screened independently by two reviewers (PL and BG)
using the inclusion/exclusion criteria. All potential included studies were then screened by a third reviewer
(AML). Full articles were screened for eligibility by two reviewers (PL and AML). Any disagreement was
resolved by consensus.
Data extraction
Standardised data forms were used to extract the relevant information for each of the included
studies. One reviewer (PL) extracted the data and the information extracted was checked by a second
reviewer (AML). The data extracted included author, year, type of model (diagnostic, screening, disease
progression) and study question (Table 13), perspective, population, outcome measure, model duration,
TABLE 13 Overview of studies included
Study Country/region
Pathway of care (screening/
diagnostic/treatment) Objective
Allen 2005144 USA Diagnosis and natural
history
To compare the cost-effectiveness of four
diagnostic strategies for evaluating rectal
bleeding
Tappenden 2007145 England Disease progression To develop a state-transition model to
simulate the life experience of a cohort of
individuals without polyps or cancer through
the development of adenomatous polyps
and malignant carcinoma and subsequent
death in the general population
Tsoi 2008146 Asian countries Screening and disease
progression
To evaluate the cost-effectiveness of FOBTs,
FS and colonoscopy on the basis of disease
prevalence, compliance rate and cost of
screening procedures in Asian countries
Zauber 2008147 USA Screening and disease
progression
To assess life-years gained and colonoscopy
requirements for CRC screening strategies
and identify a set of recommendable
screening strategies
Heitman 2010148 Canada Screening and disease
progression
To perform an economic evaluation of CRC
screening in average-risk North American
individuals considering all relevant screening
modalities and current CRC treatment costs
Lee 2010149 UK Screening and disease
progression
To assess the cost-effectiveness of three-
dimensional CTC vs. OC for colonic imaging
of symptomatic gastroenterology patients
Knudsen 2012150 USA Screening and disease
progression
To assess the clinical effectiveness and costs of
colonoscopy vs. other rescreening strategies
Sharp 2012151 Ireland Screening and disease
progression
To evaluate the cost-effectiveness of a
population-based screening programme
Whyte 2012152 England Screening and disease
progression
To use newly available data to estimate
the cost-effectiveness and endoscopy
requirements of screening options for CRC
to inform screening policy in England
continued
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type of uncertainty analysis, discount rate, base year and prices (Table 14). Additional data extraction
for sensitivity analyses was carried out to assess which parameters had the changes in value that most
affected the incremental cost-effectiveness ratios (ICERs); this information is presented in Appendix 5.
Critical appraisal
The methodological quality of the studies included was assessed in detail by two reviewers (PL and
AML) following the checklist for model studies by Philips et al.162
Results
Studies identified
A first electronic search retrieved a total of 2730 hits; after de-duplication, 2129 were screened, of
which 2109 hits were excluded. In addition, we were aware of two key cost-effectiveness studies that
were missed in the search and decided to run a new search with a more refined set of search terms
(for the revised search, see Appendix 5) to identify more cost-effectiveness models. We assessed the
full text of 20 studies from the first search, seven additional studies from the revised search and one
new study from the updated search. After a more in-depth screening of these 28 studies, 13 papers
were excluded: for nine papers, the disease model description was not based on the Dukes’ or
TABLE 13 Overview of studies included (continued )
Study Country/region
Pathway of care (screening/
diagnostic/treatment) Objective
Goede 2013153 The Netherlands Screening and disease
progression
To evaluate if two-sample FIT screening is
cost-effective compared with one-sample
FIT
Gomes 2013154 The UK Screening and disease
progression
To assess the cost-effectiveness of CTC for
CRC screening
Tappenden 2013155 England Diagnosis and disease
progression
To assess the feasibility and value of
simulating whole disease and treatment
pathways within a single model to provide a
common economic basis for informing
resource allocation decisions
Whyte 2014156 England Awareness campaign,
screening and disease
progression
To estimate the clinical effectiveness of a
CRC awareness campaign
Cantor 2015157 USA Screening using patient
decision aids
To provide a framework for analysing the
cost-effectiveness of decision aid for CRC
screening
Pil 2016158 Belgium Screening and disease
progression
To assess the cost-effectiveness and budget
impact analyses of the CRC screening
Wong 2016159 Hong Kong Screening and disease
progression
To evaluate the cost-effectiveness, by age
and sex, of CRC screening
Coldman 2017160 Canada Disease progression To develop a simulation model to predict
the effect of threshold selection on
outcomes including life-years gained, CRC
incidence and mortality, and costs




To assess the clinical effectiveness of FITs
for primary care triage of people with
low-risk symptoms
CTC, computerised tomographic colonography; FIT, faecal immunochemical test; FOBT, faecal occult blood test;
FS, flexible sigmoidoscopy; OC, optical colonoscopy.
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AJCC staging; three screening models did not include a full disease model; and the last excluded study
was a costing study of setting up a screening programme. Reference-searching led us to three additional
studies; 18 studies, in total, met the inclusion criteria for the review. Further details are presented
in Figure 4.
Study characteristics
Table 13 provides the overview of the included models. Over 50% (10/18) of the studies were
conducted in Europe (seven of these were in the UK), six in North America (four in the USA and two in



































































• Used a different CRC staging,
    n = 9
• Did not include a full disease
     model, n = 3
•  Costing study, n = 1
FIGURE 4 Economic decision-analytic models: the PRISMA flow diagram. a, Revised strategy; b, updated search using
the revised strategy; c, a total of 546 hits were screened with the updated search; and d, further exclusion details are
presented in Appendix 5.
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Over 80% (15/18) of the studies were two-part models, mainly screening and full disease progression
models (12/18); only three studies were diagnosis and natural history disease models. The other three
models included in this review were disease progression models only. Two exceptions were made of
studies that did not meet the inclusion criteria. The study by Cantor et al.157 evaluated a patient
decision aid for CRC screening; it was reviewed as it was deemed to be important for developing the
diagnosis part of the model. Similarly, the model by Zauber et al.,147 which excluded resource use and
costs, was included despite not meeting the inclusion criteria.
In Table 14, the study characteristics are presented. Westwood et al.161 is the only study of a diagnostic
strategy in the population of interest to our study, namely a comparison of faecal immunochemical
tests (FITs) at various thresholds against faecal occult blood tests (FOBTs) in a low-risk symptomatic
population in a primary care setting. Of the two remaining studies of diagnostic strategies, only one144
compared two or more diagnostic strategies, and, although it is conducted in a primary care setting, it
is concerned with a high-risk symptom only (rectal bleeding in a person aged 55 years) in US primary
care. The remaining study, by Tappenden et al.,155 is a whole-disease model, which captures the complete
pathway of CRC patients from a healthy state to clinical disease down to the detail of treatment
sequences used by age and disease stage. This study’s aim is not sufficiently detailed to account for the
diagnostic pathway of low-risk symptoms, although it accounts for the role of a RAT in the transition from
asymptomatic to clinical disease,39 and its main interest to our purposes lies in the methods used to build
the disease history model.
Further, the disease history model in the study by Tappenden et al.145 is used by most of the included
screening studies145,149,154,156 summarised in Table 14 with few modifications. In common with most
models, this model used a lifetime time horizon and considered cases aged 50–60 years.
None of the identified studies evaluated a diagnostic tool. Therefore, attention will be devoted in the
rest of this chapter to reviewing the suitability of identified models to accommodate any evaluation of
such tools, and the quality of the available evidence synthesised by existing models to inform the
assessment of tools using any suitable existing or new model.
Critical appraisal: key model features
The critical appraisal data extracted for the 18 included model-based economic evaluation studies
included are presented in Appendix 5, and the findings are summarised in this section.
Over 60% (11/18) of the studies considered the NHS perspective and only four studies144,147,150,158
included a societal perspective. The perspective in three studies146,157,159 was not explicitly stated, but,
given the costs included, it appears to be their respective health systems’ perspectives.
There were marked differences between the models’ assumptions for the long-term rate of CRC
disease progression. In 40% (8/18) of the studies,145,147,148,151,152,155,156,161 the most common assumption
was to apply an annual disease progression rate, the choice of which was clearly defined by the history
of the disease. The selection of key parameters was justified in all the studies, although the quality of
the chosen parameters was not fully discussed in one study.150
Fifty per cent of the studies (9/18) used the QALY as an outcome measure; life-years were used in six
studies,146,147,150,153,157,159 and three studies149,154,161 included both QALYs and life-years. The parameterisation
into the models was described with sufficient detail and with all the relevant sources of data in most of the
studies (14/18). However, the relevance of the assumptions was difficult to understand in two studies,144,160
and how the data were incorporated into the model was unclear in two studies.159,160
Over 80% (15/18) of the studies addressed properly the different types of uncertainty; in particular,
point estimates and values for sensitivity analyses were stated and justified in most of the studies,
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except for three studies150,159,160 in which assumptions were less clearly described. All studies except for
Pil et al.158 justified the values used for the sensitivity analysis.
Probabilistic sensitivity analysis was undertaken by 55% (10/18) of studies, and one study153 justified
the absence of probabilistic sensitivity analysis based on the lack of evidence on sampling variation
of parameter values. In contrast, this information was vaguely stated in, or missing from, seven
studies.144,146,147,150,157,159,160 The choice of parameter distributions used was clearly reported in 50%
(9/18) of the studies; however, five studies144,154,157,159,160 omitted the information with respect to
second-order uncertainty.
The internal consistency was evaluated in 10 studies only.144,145,147–149,152,153,155,156,161 In the absence of data
on key parameters, the model was calibrated against independent data in eight studies,145,147,148,151–153,155,156
such as the rate of disease progression in asymptomatic CRC states.
Modelling approaches
Five different types of decision models were identified in the review: (1) 11 Markov state-transition
models,144–146,148,149,151,152,154,156,159,161 (2) four microsimulation models,147,150,153,160 (3) one Markov model
combined with a decision tree,158 (4) one decision tree157 and (5) one discrete event simulation
model.155 The colorectal health cancer states were modelled using the AJCC staging (9/18) or the
Dukes’ staging systems (8/18). The model diagnosis by Cantor et al.157 did not consider any staging.
Markov models were preferred because of their flexibility and simplicity in populating and calibration
processes. Specifically, the transition within health states can be easily represented by a cohort in a
Markov model. Given the limited number of data on key disease history model parameters, a Markov
model may be more suitable to synthesise the clinical and economic evidence for evaluating diagnostic,
screening and surveillance strategies in CRC than other types of models such as microsimulation and
discrete event simulation models. The only study that used a discrete event simulation model used
such an approach to accommodate the distribution of time to event survival and disease progression
outcomes of CRC treatment, which were found to have limited importance in the results of the only
diagnostic study of a low risk of suspected cancer in primary care (Westwood et al.;161 see Appendix 5).
Likewise, the three studies150,153,160 that used microsimulation models used such an approach for its
convenience to account for the interactions between individual characteristics and risk factors of the
screening tests and combining cohorts with different characteristics to produce results averaged across
subgroups of the patient population.
Detailed review of individual models
UK models
Tappenden et al.145 constructed a model for England incorporating three elements: (1) a screening
intervention model that included subsequent colonoscopy surveillance; (2) a state-transition model that
simulated the natural history of colorectal neoplasia from normal epithelium, to adenoma and carcinoma
sequence; and (3) a mortality model that considered age-specific other causes mortality, CRC mortality
and mortality from perforation due to endoscopic procedures. Transitions between model health states
were calculated using an annual cycle length until the entire model cohort was absorbed into the dead
state. The model assumed that the incidence of adenomas was 1.60% and that the incidence of cancer
from adenomas was 3.26%. Five screening options versus no screening were evaluated: biennial FOBTs,
for people aged 50–69 and 60–69 years; two once-only flexible sigmoidoscopies, for people aged 55
and 60 years; and the fifth option was once-only flexible sigmoidoscopy for individuals aged 60 years,
followed by biennial FOBTs for individuals aged 61–70 years.
The UK model developed by Lee et al.149 was a two-part model: (1) the evaluation of screening
strategies for CRC and (2) a state-transition Markov model representing the natural history of
colorectal neoplasia (from normal colorectal epithelium to adenoma–carcinoma sequence, to death).
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The four screening strategies evaluated were (1) FOBT every 2 years, (2) flexible sigmoidoscopy every
10 years, (3) optical colonoscopy every 10 years and (4) computerised tomography colonography (CTC)
every 10 years. The authors used data from the study by Tappenden et al.163 and recalibrated the data
to adjust for estimates from recent observational data on CRC incidence, mortality and staging of
cancer at time of diagnosis. The progression from normal epithelium to low-risk adenoma, low-risk
adenoma to high-risk adenoma, and high-risk adenoma to Dukes’ stage A CRC was 1.2%, 2.4% and
3.4%, respectively. The mortality for other causes was modelled as an age-dependent probability based
on UK life tables,164 and the probability of dying as a result of endoscopic perforation from either the
screening procedure or the polyp removal (polypectomy) was included in the model as a potential
complication of the interventions.
The two interlinked models developed by Whyte et al.152 had (1) a model that described the screening
interventions and surveillance of CRC (from invitation to screening, screening test, follow-up,
diagnostic tests and surveillance) and (2) a natural history of colorectal neoplasia model (from normal
colorectal epithelium to adenoma–carcinoma sequence to death). The screening intervention used the
following diagnostic strategies: (1) no screening; 2) biennial guacal faecal occult blood test (gFOBT)
at 60–69 years; (3) biennial gFOBT at 60–74 years; (4) immunochemical faecal occult blood test
(iFOBT) at 60, 65 and 70 years; (5) biennial iFOBT at 60–69 years; (6) biennial iFOBT at 60–74 years;
(7) flexible sigmoidoscopy at age 55 years; (8) flexible sigmoidoscopy at age 55 and 65 years; (9) flexible
sigmoidoscopy at age 55 years and biennial gFOBT at ages 66–74 years; (10) flexible sigmoidoscopy at
age 55 years and biennial iFOBT at ages 66–74 years; (11) flexible sigmoidoscopy at age 55 and iFOBT
at ages 60, 65 and 70 years; (12) flexible sigmoidoscopy at age 55 years and biennial iFOBT at ages
60–74 years; and (13) flexible sigmoidoscopy at age 55 years and biennial iFOBT at ages 56–74 years.
The authors assumed that probabilities associated with the transition to low-risk adenomas, the
transition from low- to high-risk adenomas and the transition from high-risk adenomas to Dukes’
stage A CRC were age dependent.
An interconnected model developed by Gomes et al.154 comprised (1) diagnostic test and the subsequent
adenoma surveillance model for symptomatic patients in secondary care, and (2) a Markov model, based
on CRC natural history in the UK simulating the development of CRC in the population (from normal
colorectal epithelium to adenoma–carcinoma sequence to death). The model assumes a variable annual
rate of polyp development of 1.9% to 3.3% and an annual incidence of CRC from adenomas of 3.4%.
The model evaluated the impact of three-dimensional CTC versus optical colonoscopy to improve the
detection of adenomas and CRC.
Tappenden et al.155 developed a patient-level model that simulates the disease progression and
treatment pathways from pre-clinical disease through detection, diagnosis, adjuvant/neoadjuvant
treatments, follow-up, curative/palliative treatments for metastases, supportive care and eventual
death. The authors assumed a detailed age-specific incidence of CRC and adenoma prevalence based
on Bayesian Markov chain Monte Carlo methods. The whole-disease model considered all the
processes that are linked to CRC from screening, surveillance and treatment.
The model developed by Whyte et al.156 comprised (1) the evaluation of the effect of a campaign to
increase the awareness of the signs and symptoms of CRC and encourage self-presentation to a GP,
and (2) a model to represent the development of CRC in the population (from normal colorectal
epithelium to adenoma–carcinoma sequence to death). The authors assumed an increased presentation
rate of 10% in each CRC Dukes’ stage and an age-dependent incidence of adenomas (low and high risk)
and CRC.
Westwood et al.161 constructed a model for England incorporating three elements: (1) a decision model
reflecting the diagnosis of CRC, (2) a Markov state-transition model to estimate the long-term costs
and effects related to treatment and progression of CRC and (3) a Markov state-transition model to
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estimate effects for patients without CRC. The transitions between the model health states of the
two Markov models were calculated using an annual cycle length until the entire model cohort was
absorbed into the dead state. The model assumed the incidence of adenomas and the incidence of
cancer (from adenomas reported in Tappenden et al.145) to be 1.60% and 3.26%, respectively. The
model evaluated three options of symptomatic individuals that presents to primary care: (1) FITs,
(2) gFOBTs or (3) no triage tests at all (referral straight to colonoscopy).
European models
The Irish study by Sharp et al.151 was a Markov state-transition model with three interlinked
components: (1) the impact of screening and subsequent adenoma surveillance, (2) a natural history
of colorectal neoplasia model (from normal colorectal epithelium to adenoma–carcinoma sequence
to death) and (3) the impact on mortality. The authors assumed that 14% of individuals progressed
from normal epithelium to stage I cancer. The second model component used gFOBT, FIT and flexible
sigmoidoscopy for screening, and the diagnosis used the sensitivity and specificity of colonography and
CTC. Finally, mortality in the model was assumed to be from CRC, endoscopic bowel perforation or
other causes; other causes were obtained from Irish life tables and were modelled to be age dependent
within each Markov cycle. The risk of dying from endoscopic perforation was considered only when
using flexible sigmoidoscopy, diagnostic investigations and adenoma surveillance. The model assumed
that individuals had a higher probability of dying if they had a more advanced cancer stage.
The work by Goede et al.153 was based on the MIcrosimulation SCreening ANalysis (MISCAN)
microsimulation model, which had three integrated components: (1) a model evaluating the screening
strategies of one-sample and two-sample FIT screening with variable intervals, age ranges and cut-off
levels (age at which to start screening: 45, 50, 55 and 60 years; age at which to stop screening: 70,
75 and 80 years; and screening interval at 1, 1.5, 2 and 3 years); (2) the natural history component
part that simulates the development of CRC in the population (from normal colorectal epithelium to
adenoma–carcinoma sequence to death); and (3) a demography component that simulates individual
life histories without CRC to form a population. Authors assumed an age-dependent adenoma incidence
and adenoma progression, whereas the CRC incidence rate was based on the observed incidence rate in
the Netherlands.
The model developed by Pil et al.158 comprised two interconnected submodels: (1) a decision tree to
simulate the screening process based on FITs and (2) a state-transitional Markov model simulating the
natural progression of the disease (from normal colorectal epithelium to adenoma–carcinoma sequence,
diagnosis and treatment, follow-up to death). The authors assumed a sex- and age-dependent adenoma
prevalence varying from 1.6% to 6.01%, and a CRC prevalence ranging from 0.11% to 0.84%.
North American models
Allen et al.144 used a Markov decision model composed of three elements: (1) a model to evaluate four
diagnostic strategies of a patient with rectal bleeding, (2) a model to simulate the natural history of
colorectal neoplasia for patients with rectal bleeding (from no serious pathology to adenoma–carcinoma
sequence and surveillance to death) and (3) a mortality model to estimate mortality among patients with
CRC. The authors assumed that the progression of smaller adenomatous polyps to large polyps would
take an average of 10 years and that the progression of large adenomatous polyps to invasive cancer
would also take an average of 10 years. Once invasive cancer was detected, the average transition of
2 years, 1 year, and 1 year for Dukes’ stage A to B, B to C, and C to D staging, respectively, was assumed.
It was also assumed that 7% of individuals progressed from adenomas to Dukes’ stage A and that the
prevalence of adenomas was 16%. The diagnostic model evaluated (1) watchful waiting, (2) flexible
sigmoidoscopy, (3) flexible sigmoidoscopy with consequent air-contrast barium enema and (4) colonoscopy.
Finally, the mortality estimates used within each stage of cancer were obtained from the Surveillance,
Epidemiology, and End Results (SEER) cancer registry.
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Zauber et al.147 used two previous developed microsimulation models [Simulation Model of Colorectal
Cancer (SimCRC) and MISCAN] to reproduce the natural history of colorectal neoplasia (from no
lesion to adenoma–carcinoma sequence to death). The semi-Markov microsimulation model simulated
the effect of screening and other interventions on the incidence and mortality of CRC. It is a hybrid
model, made of a Markov model and a discrete event simulation that described the progression
of the underlying colorectal disease (e.g. from adenoma to carcinoma sequence) in an unscreened
population. Authors assumed an age-dependent variability of adenoma prevalence varying from
10.2% to 36.7% and a CRC incidence varying from 5.3% to 7.3%. The model evaluated the following
screening strategies: (1) no screening, (2) colonoscopy, (3) FOBT, (4) flexible sigmoidoscopy with biopsy
and (5) flexible sigmoidoscopy combined with FOBT. For each strategy, individuals were evaluated
at the following ages: 40, 50, 60, 75 and 85 years. FOBT strategies considered screening intervals
of 1, 2 and 3 years; for the sigmoidoscopy and colonoscopy strategies, the intervals considered were
5, 10 and 20 years. The prevalence of pre-clinical cancer and adenomas was assumed to be zero.
The two-part model in Heitman et al.148 included (1) the impact evaluation of screening strategies on
average risk in a North American population and (2) a Markov model reproducing the natural history
of the colorectal neoplasia (from normal colon to non-advanced/advanced adenomas, to CRC, to
death). The authors assumed a prevalence of 17% of non-advanced adenomas, 3.8% for advanced
adenomas and 0.1% for CRC. The screening strategies evaluated were (1) gFOBT or FIT annually,
(2) faecal deoxyribonucleic acid (DNA) test every 3 years, (3) flexible sigmoidoscopy or CTC every
5 years and (4) colonoscopy every 10 years. The mortality rate was derived from an age-dependent
population from Canada and the CRC mortality rates observed for patients with CRC according to
their stage at diagnosis.
Knudsen et al.150 developed a microsimulation model based on a previous study147 (SimCRC) to represent
the natural history of colorectal neoplasia (from normal colon to non-advanced/advanced adenomas,
to CRC, to death) and the relative effects of screening strategies. The prevalence, size, location and
multiplicity of adenomas and the incidence of CRC was assumed from the SEER programme. The model
evaluated five rescreening strategies for individuals with a negative colonoscopy result at 50 years of
age: (1) no further screening, (2) continuing colonoscopy every 10 years, (3) rescreening with annual
highly sensitive guaiac-based FOBT, 4) annual FIT or (5) CTC every 5 years. Rescreening was assumed
to begin at 60 years (10 years after the negative colonoscopy result) for all strategies.
Cantor et al.157 developed a decision-analytic model comprising a decision tree to evaluate the impact of
a decision aid for CRC screening. The study does not present a disease model and there is no indication
of patient characteristics. The model evaluated two strategies: use of decision aid and no use of the
decision aid. The decision aid supported the selection of the patients who would undergo screening.
Each patient undergoing screening can have one of three diagnostic tests: (1) flexible sigmoidoscopy,
(2) FOBT or (3) colonoscopy, or not undertake screening. The study assumed a change in the preferences
of the screening, with a consequent increase in the number of tests, number of patients undergoing the
screening and costs.
The model by Coldman et al.160 (OncoSim-CRC) comprised (1) a model to predict the outcomes of
biennial screening in a cohort for eight FIT threshold values of between 50 and 225 ng/ml and (2) a
model simulating the natural history for the development of CRC (from normal colorectal epithelium to
adenoma–carcinoma sequence, to death). The authors assumed that the prevalence of adenomas was
age, sex and size dependent. The age- and sex-specific CRC incidence and mortality rates were derived
from the Canadian population.
Asian models
Tsoi et al.146 developed a Markov model comprising three submodels that evaluated which primary
screening procedure should be adopted to reduce CRC incidence. The diagnostic tests considered were
(1) FOBT, (2) flexible sigmoidoscopy and (3) colonoscopy. The annual mortality rates of CRC diagnosed
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at different stages were based on the Hong Kong Cancer Registry,165 and the mortality due to perforation
of endoscopic tests was considered to be 10%. The authors assumed a prevalence of 10% for the first
stage of CRC and, that 14% of individuals progressed from normal epithelium to stage I cancer.
Wong et al.159 used an approach similar to that of Tsoi et al.,146 but focused on developing a Markov
process model to evaluate five screening strategies: (1) flexible sigmoidoscopy as a primary screening
test every 5 years at the ages of 50, 55, 60, 65 and 70 years; (2) colonoscopy as a primary screening
test every 10 years at the ages of 50, 60 and 70 years; (3) flexible sigmoidoscopy for each female
subject every 5 years at the ages of 50 and 55 years; (4) flexible sigmoidoscopy for each female subject
every 5 years at the ages of 50, 55, 60 and 65 years; and (5) flexible sigmoidoscopy for each female
subject every 5 years at the ages of 50, 55, 60, 65 and 70 years. The age-stratified incidence of CRC of
the Hong Kong population was based on reports from the Hong Kong Cancer Registry.
Model population and time horizon
UK models
In the models developed by Tappenden et al.,145 Lee et al.149 and Whyte et al.,156 individuals were aged
30 years. In the model developed by Westwood et al.,161 individuals entered the model at age 40 years,
and in the models developed by Whyte et al.152 and Gomes et al.,154 individuals were aged 50 years. The
only study that included individuals from birth is Tappenden et al.155 All of the UK models followed
individuals until death.
European models
In line with the UK models, in two of the European models, by Sharp et al.151 and Pil et al.,158 individuals
entered the model at the ages of 30 and 50 years, respectively. However, only the model developed by
Sharp et al.151 followed up individuals until death, whereas, in the model developed by Pil et al.,158
individuals were followed up until the age of 70 years. In comparison, the study by Goede et al.153
modelled the age distribution of the Dutch population in 2005 and all the cohort individuals were
followed up until death.
North American models
In two of the US models,144,147 the cohorts entered at age 40 years and were followed up to the age of
100 years or death. However, Heitman et al.148 and Knudsen et al.150 considered older cohorts (aged
50 years); both studies followed up individuals to death. Although the cohort of the Canadian model148
entered at the age of 45 years and was followed until death, Cantor et al.157 did not specify any age for
their cohort.
Asian models
In both Asian models, the cohort entered at the age of 50 years, but the model developed by Wong
et al.159 followed up individuals to 70 years of age and the model by Tsoi et al.146 followed up individuals
to 80 years of age.
Critique
For the purposes of the current research questions, the review has helped to identify the Westwood
et al.161 model as a useful precursor for the diagnostic phase. This model is important from two perspectives:
first, it is the only evaluation of primary diagnostic tests for CRC identified by our review, and, second,
the population included are the low-risk symptomatic population of interest. The focus of the critique will
therefore be its methodology, as well as the source of the evidence used to populate its key parameters to
inform the approach taken in the novo model. In particular, we will review the mechanisms used to link the
diagnostic pathway to the Markov model of disease treatment used by Westwood et al.161 in terms of their
suitability for incorporating a diagnostic phase that has enough granularity to allow an evaluation of costs
and health benefits of tool-based diagnostic strategies.
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The analysis by Westwood et al.161 informed the NICE Diagnostic Guideline Number 30140 and assessed
the relevant low-risk population for using the diagnostic tools of interest to our study. A strength of the
model is that it considers an intervention, FIT, that has now become the recommended standard practice
in the UK. The model has policy appeal as it considers the option of referring all symptomatic patients
directly to secondary care, a natural option for a country where policy-makers are concerned about
expediting access to diagnosis and treatment as a way to improve cancer survival outcomes.
An attractive feature of the Westwood et al.161 model is that it shows that detecting more CRC cases
with diagnostic tests comes at the cost of imposing more unnecessary use of health-care resources
and health risks from invasive investigations to the great majority of patients who do not have CRC.
When the costs and life-years are calculated over the denominator of all patients presenting with
symptoms of suspected CRC, the importance of the trade-off between sensitivity and specificity
becomes apparent. The costs of colonoscopies and their associated risk are modelled in the Westwood
et al.161 model to explore the trade-offs between gains in sensitivity of diagnostics in primary care at
the expense of exposing more false positives to invasive tests. Our de novo model analysis will follow
a similar approach, which will serve to highlight that gains in sensitivity of diagnostic strategies are
achieved at the expense of their specificity, especially among younger patients who are at lower risk of
CRC. When modelling the impact on colonoscopies, Westwood et al.161 make the simplifying assumption
that the costs of CRC treatment are not linked to the clinical outcomes, but this simplification does not
affect the results in a significant way because of the low proportion of cancer patients.
A limitation of the Westwood et al.161 model is the quality of the evidence on the diagnostic accuracy
of FITs, which was obtained from high-risk patient populations included in studies that, for the most
part, were not conducted in a primary care setting. This weakness is problematic because the values
of FIT of 10 µg haemoglobin (Hb)/g faeces, the recommended new standard, has sensitivity values
close to 100%, which effectively limits the ability of any diagnostic tool to add to the primary care
diagnostic yield (see Chapter 7). Furthermore, although referring all patients to secondary care may
be the least risky option, the low prevalence of CRC means such a strategy is unaffordable and is not
used in practice.140
In terms of methods, the analysis by Westwood et al.161 adopts a linked-data approach, whereby survival
outcomes of FOBTs are driven by the ability of the test to correctly identify patients with CRC before
the disease has progressed to advanced disease stages and become less responsive to treatment. The
model uses disease progression data from the disease history model developed by Tappenden et al.145
and Whyte et al.156 to determine the extent to which delays in referral from lack of diagnostic accuracy
would affect long-term life expectancy. The limitation of this approach is the high degree of uncertainty
in the rates of disease progression underlying any such analysis, which were derived from calibrations
of the disease history model to observed data on CRC incidence and distribution of stage at diagnosis.
We adopt a similar approach in our model, given the lack of more reliable data on the relationship of
delayed diagnosis and stage at diagnosis, but raise this weakness as an area that needs further research.
A further limitation of the diagnostic phase of the Westwood et al.161 model is the way the time to
referral is analysed. In particular, the delays incurred by false-negative cases are not explicitly modelled
in terms of diagnostic accuracy of the tests being compared, but simply assumed to last for an arbitrary
amount of time, which, in their base-case analysis, was 6 months. This adds a high degree of uncertainty in
the absence of any data used by the authors to justify the extent of the delay. We sought to address this
limitation by building a de novo model of the diagnostic pathway that was fully consistent between the
diagnostic accuracy and the number of visits and the referral interval.
In terms of the granularity of the model used to link the diagnostic pathway to the Markov model
of disease treatment, the Westwood et al.161 model uses an annual cycle length to model health
transitions. A limitation of an annual cycle is that it may not have sufficient granularity to measure
the predicted outcomes, especially given small differences involved in accuracy and referral intervals
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between strategies. We addressed this limitation in the de novo model by using a 28-day cycle to link
the diagnostic pathway to the Markov disease model.
The Westwood et al.161 model did not account for the short-term survival benefits of reducing the
time to referral and treatment, as symptomatic patients with CRC who are undiagnosed, and thus
untreated, are subject to increased death risks, relative to those who have been diagnosed and started
treatment, especially in disease stages II/III (Dukes’ stage B/C). We addressed this limitation by building
a de novo model of the diagnostic pathway that accounts for the short-term survival benefits of
reducing the time to referral and treatment.
The effect of delays in diagnosis on the mental health of a patient with CRC is also omitted from
the Westwood et al.161 model. No evidence on the magnitude of such an impact was found in the
literature reviewed for this study, and the studies reviewed failed to explore the importance of that
effect for the cost-effectiveness of diagnostic strategies in primary care. Our de novo model, therefore,
is unable to incorporate these effects. Measures of health-related quality of life among undiagnosed
and untreated CRC patients are lacking, and are difficult to measure because of the very nature of
studying undiagnosed patients.
Conclusions
The review highlights differences between existing economic models of cancer diagnosis and screening.
A common approach to the problem of lack of evidence on clinical outcomes of diagnostic and screening
strategies has been to model long-term outcomes of CRC using a model of CRC disease progression in
asymptomatic disease obtained by calibrating a disease history model to data on CRC incidence and
disease stage at diagnosis.145,147,148,151,152,155,156,161 We applied the same approach in our de novo model,
given that the updated review provided no direct evidence on clinical outcomes of diagnosis, but we
recommend that further research on this issue is undertaken.
Our review found no evidence on the cost-effectiveness of diagnostic tools for managing patients in
primary care with suspected CRC, but identified one study of FITs161 in the low-risk population of interest
that modelled the diagnostic phase. The model explored the trade-offs between gains in sensitivity of
diagnostics in primary care at the expense of exposing more false positives to invasive tests, and is a useful
precursor for the diagnostic phase of our de novo model. In addition, our critique of the Westwood et al.161
model identified three areas in which we could make improvements to the diagnostic phase:
1. Time to referral – time to referral will be explicitly modelled to be consistent with diagnostic
accuracy of the respective test and the distribution of the number of visits before referrals in
electronic health records or retrospective reports from surveys of patients’ experiences. This will
include modelling delays incurred by false negatives. By coherently modelling the sensitivity of
primary care diagnostic strategies and the delay in referrals and treatment, the uncertainty in
relative clinical effectiveness between diagnostic strategies is reduced relative to arbitrary estimates
of diagnostic delay used by the existing model in this area.
2. Cycle length to model health transitions – our model used a 28-day, rather than annual, cycle to get
accurate measure of predicted outcomes, especially because of the small differences involved in
accuracy and referral intervals between strategies.
3. Cancer-related mortality – the short-term survival benefits of reducing the time to referral and
treatment will be explicitly modelled.
The review of existing models also highlighted that the health-related quality-of-life outcomes in the
diagnostic phase have received very limited attention. Our de novo model is similarly unable to explore
the health-related quality-of-life outcomes in the diagnostic phase, as much of the policy focus has
been devoted to improving cancer survival.
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Chapter 7 Economic decision-analytic model
for colorectal cancer
Aim and objectives
The earlier chapters highlight the uncertainty in the evidence base for decision tools, which make it
difficult to assess the cost-effectiveness of the use of risk tools. In this chapter, we use a decision-
analytic model to demonstrate the uncertainty inherent in the current evidence base, and show the
probable impact that use of the tools in clinical practice may have on patient outcomes and NHS
resources. The primary role of the decision modelling is not the estimation of the single most likely
point estimates of costs per QALY associated with each diagnostic tool. Instead, the decision-analytic
model and the evidence that is available are used in this chapter to explore the probable range of costs
per QALY, and to ask questions about the likely impact of the diagnostic tools, given the current
evidence base.
The objectives of the decision-analytic model were to examine the following questions:
l What are the possible impacts on patient quality of life or survival if the diagnostic tools reduce
time to diagnosis?
l Will the benefit to cancer patients who are identified earlier by diagnostic tools outweigh any
disutility in extra patients who do not have cancer being referred for further investigation?
l How big an improvement in quality of life would be needed to warrant the use of these tools if
there are no survival impacts associated with the diagnostic tools? Would this quality-of-life
improvement be justifiable given the evidence we have?
l Could a cancer diagnostic tool be considered cost-effective if it reduces the period of extreme
anxiety for patients by expediting investigation and management?
l Where are the gaps in the evidence base and where is more research needed?
Furthermore, we developed a model that anticipates evidence development and can be used alongside
any studies measuring impact on patient outcome directly in the future to explore implications for
cost-effectiveness. We will also be able to use the model to identify the parameters that contribute
most to the overall decision uncertainty about the cost-effectiveness of decision tools and where
additional research might be targeted using expected value of partial perfect information.166–168 If
considered effective and cost-effective, now or in the future, the model could also be developed to
assess the budget impact of introducing cancer diagnostic tools in different populations.
It was not feasible to model the impact of diagnostic tools for all common cancer types for which
diagnostic tools exist. Instead, we chose to model one common cancer: CRC.
Colorectal cancer was chosen, based on the following criteria, to provide a best-case example of how
the diagnostic tools could affect patient outcomes:
l Tools exist – to compare diagnostic tools with each other and with no tool, we need diagnostic tools
to be available for the specific cancer type. There are existing tools for CRC, as identified in SR2.
In particular, there are RATs75,81 and QCancer80 for CRC, which are now within GP systems and,
therefore, potentially available for GPs to use.
l Common cancer – CRC is the third most common cancer in the UK, accounting for 11% of cancers
in women and 13% in men.169
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l Whole-disease models exist – it is important that whole-disease models exist, and, although not
made available by the original authors, could be replicated by published methods and adapted to
incorporate the diagnostic pathways of interest.
l Wide agreement on patient management –it will be important that there is wide agreement on the
treatment and management of individuals to minimise uncertainties elsewhere in the clinical
pathway. CRC is a cancer for which there is wide agreement on the treatment and management
of individuals.
l Evidence that use of diagnostic tools changes practice – to explore the impact of the tools, it will
be important to identify a cancer type for which there is existing evidence to show where the
diagnostic tools will impact, and what that impact will be. Only a few studies assess the impact of
RATs in SR1 that were related to CRC. These studies reported that increased cancer referrals and
investigations for CRC were associated with use of tools.13,35
l Evidence that change in practice affects patient outcomes – it is not enough that increased referrals
and investigations are associated with use of the tools; there also needs to be existing evidence of
the impact of earlier diagnosis on patient outcomes. This might include earlier stage at diagnosis,
higher resection rates or improved survival, as well as improved quality of life of patients. There is
some evidence to show that long (and very short) diagnostic intervals are associated with increased
mortality in CRC.99,135,137 However, as indicated in Chapter 5 and summarised in Chapter 6, Updated
review, there is great uncertainty associated with estimates of the effect of expeditious CRC
diagnosis on cancer stage or patient survival.
Although the implications of prolonged time to tests, diagnosis and treatment vary by cancer type,
among the low-risk symptoms there are many similarities in the diagnostic options within primary care
(i.e. refer all, watch and wait, refer for further tests). Therefore, the model developed can be viewed as
a template for modelling the effect of diagnostic tools in cancers other than CRC, and can be revised
to include prevalence and test sensitivity/specificity and costs specific to other cancers.
Methods
Conceptualisation of the model
Patient and public involvement
Involving members of the public in health research projects is becoming standard practice, but there
are fewer reported examples of patient and public involvement (PPI) in health economic or modelling
studies.170,171
At the outset of putting together the diagnostic pathway of the model, we organised a workshop
to meet with patients who have experienced bowel cancer diagnosis to seek their advice on our
understanding of the current diagnosis pathway and to listen to their experiences of being diagnosed.
This was facilitated by Dr Emma Cockcroft from the PPI team from the Peninsula Collaboration for
Leadership in Applied Health Research and Care, which is based at the University of Exeter Medical
School. This part of the study did not require separate ethics approval because it was underwritten by
the current ethics approval granted to the PPI group at the University of Exeter.
Dr Cockcroft wrote an invitation to the Bowel Cancer West cancer treatment centre in Plymouth to
participate in the PPI, which was published on their Facebook page (Facebook, Inc., Menlo Park, CA,
USA). After several weeks, two patients contacted us and we opted to have a session in which we
listened to their experiences and journeys through the diagnosis pathway and asked them to tell us
their opinion about our diagrammatic representation and understanding of the diagnostic pathway.
We then asked their opinions about the diagnostic pathway within primary care and our diagrammatic
representation of this.
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Two individuals diagnosed with bowel cancer, who were brother and sister, attended the meeting. Their
bowel cancers were diagnosed through a test to assess whether or not they had inherited the gene
after their father passed away from bowel cancer. Both diagnoses occurred at secondary care, so
neither of them had any experience of diagnosis practice in primary care. Although at this point we
knew that we would not obtain information on the diagnostic pathway in primary care, we decided
to take this opportunity to discuss our understanding and modelled representation of the diagnostic
pathway. After listening to their descriptions of the pathway and their very difficult experiences with
multiple operations, we asked them if they could identify any potential misrepresentation of reality in
an animated presentation covering the progression through the diagnostic pathway in stages, from the
patient attending general practice owing to experienced symptoms to the moment when the GP
decides to refer the patient to secondary care for a colonoscopy. We received very encouraging,
although limited, feedback on our diagnosis pathway.
Other letters of invitation to Bowel Cancer West were published via Facebook, but, after weeks of not
receiving any messages, we decided to focus on the other key stakeholder, the GP.
We opted to conduct this process in two steps. First, we opted to consult with a recently retired GP
from Somerset to assess whether or not our explanations of key economic concepts and our diagnostic
pathway were clear and suitable for presentation to a wider number of health professionals. As a
warming-up task, a short interview was carried out in which we focused on the number of years of
practice by the respondent and her experience with cancer diagnosis, that is number of patients
diagnosed per year, some issues with cases diagnosed at late stage and similar topics, which allowed us
to build a clear picture on the process and interactions taking place at the general practice involving
symptomatic patients with suspected cancer.
What we learnt from this interview corroborated the evidence available:
l too many guidelines, so it is difficult to keep all of them in mind
l very few patients per year picked up at early staging in primary care
l symptoms easily wrongly attributed to other diseases, mainly in those aged > 65 years
with comorbidities.
We then moved to have a more in-depth conversation of the diagnostic pathway with the same retired
GP. However, we changed our prior strategy and let her tell us the different steps that a GP would take
if they suspect that a patient may have bowel cancer. When the reasoning behind the choices was
unclear, we asked for further clarification. Notes were taken that were compared with our preconceived
diagnostic pathway, thereby permitting us to have a better understanding of the current pathway for
bowel cancer at general practices.
A third workshop was organised at a local general practice in Exeter. We prepared a modified diagnosis
pathway, constructed using the current NICE guidelines172 and complemented with the strategies
learnt from the previous interactions with the patients and the retired GP. To this diagnosis pathway
we added the strategy of the ‘diagnostic tool’. The diagnostic pathway was printed on colour A7 pages
that we brought with us for discussion with the GPs.
All the practice’s GPs (n = 7) attended the workshop, as well as two nurses, and the group discussion
was transcribed. The GPs had very different levels of experience in terms of number of years of
practice. Some of their opinions were as follows:
Tools would be useful if you could use as a justification for referral – but currently still have to meet NICE
criteria to get onto 2WW. The criteria are ‘rigid’ and some referrals might get bounced back if the results
from a blood test are borderline.
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We use a ‘tool’ which is a calculated risk in our head.
Consider litigation – normally more likely to get sued for not doing something.
Borderline’ cases often bounced back by secondary care – they would need to accept the ‘clout’ of the
diagnostic tool/aid.
We also asked them if there was any reason why they would not consider using the tool. The answers
were as follows:
Stuck in ways.
Doing similar anyway – just in heads.
Don’t have the tools ‘to hand’.
We asked in what circumstances they would consider using the diagnostic tool:
To verify the ‘gut feeling’ was true, not only for referral, but for reassurance, when deciding against urgent
referral or more tests, etc.
A follow-up question was if the diagnostic tool would help them to decide whether or not a patient
needed referral:
Seemed this would only be the case if a tool had NICE backing.
After these questions, all the different strategies in our diagnosis pathway were discussed, which
resulted in Figure 5. An additional one-to-one meeting was held with one of the GPs to ask for further
clarifications.
The diagnostic pathway
A decision-analytic model was used to investigate the key areas of uncertainty in the economic
evaluation of primary care tools for informing decisions on referrals of suspected cancer patients from
primary to secondary care in England.
The analysis compares costs and clinical outcomes between a diagnostic strategy whereby primary
care doctors use the diagnostic algorithm in conjunction with information from investigations in
primary care to decide whether or not a patient presenting with low-risk symptoms needs to be
referred to secondary care for further investigations, and a strategy of primary care investigations
alone. We compare the intervention strategy of RATs (CAPER)75 or QCancer80 as a triage to primary
care investigations (which, in the model, is represented by FITs) or direct referral to secondary care
(intervention) with the following comparator strategies:
l ordinary referral to secondary care without prior primary care investigations for all patients
(‘refer all’ strategy)
l primary care investigations alone
l send home/wait (‘send home and wait’ strategy).
In Figure 5, we illustrate in the diagnosis pathway for patients with low-risk symptoms who do not fulfil
the 2WW criteria.
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In the absence of clinical studies providing evidence on the clinical outcomes of these strategies, the
effect of the diagnostic algorithm on patient management is modelled using a linked-data approach,
which translates evidence of diagnostic accuracy into clinical outcomes in terms of life expectancy,
health-related quality of life and health-care costs. In the model, the gain in sensitivity with the
algorithm may cause an increase in the number of patients being referred to secondary care, which, in
turn, results in the earlier identification of CRC cases; this is the main driver of outcomes in the model.
An increase in sensitivity may also change the composition of diagnosis by disease stage, but this is
harder to model without further data. The clinical benefits of the diagnostic tools depend on detecting
cases at earlier disease stages than those that would occur under the status quo, without use of the
diagnostic tools.
Population
To implement our model-based analysis, we define the relevant ‘low-risk’ population as those symptomatic
patients presenting for the first time to a GP to seek care for their symptoms. We use prevalence
estimates from Hippsley-Cox and Coupland,80 who obtained data on the number of identified CRC cases
from the electronic records of 224 primary care practices in the UK over a 2-year period (from January
2000 to April 2002) following the first visit of a patient with eligible symptoms to a GP. When patients in
the top 1% risk stratum are excluded, the estimated CRC prevalence rate in this population is 0.16%.80
As the mean age in the sample was 50.1 years, and prevalence reportedly increased ‘steeply’ with age,
for the case of our modelled base-case analysis, aged 70 years, a prevalence rate of 1.5% is used, which
is consistent with the age effects in the risk calculator published by the same authors80 and is consistent
with previous analyses informing policy.140 No other sources of reliable prevalence data were identified.
This patient population is akin to the ‘low risk but not no-risk symptoms’75 population of the CAPER
study.75 The patient population includes the majority of symptomatic patients who do not present
with high-risk symptoms, such as rectal bleeding or severe anaemia, and, therefore, are not diagnosed
through the 2WW referral pathway. These are the populations the tools were developed for.
Interventions
The intervention involves use of the diagnostic tool and referral of those individuals above the
threshold score of 35, which corresponds, approximately, to 2% in RAT and 0.5% in QCancer, to
secondary care for investigation, which, in the model, is assumed to be colonoscopy. Although some
patients undergo alternative tests such as flexible sigmoidoscopy, CTC and barium enema because
of the presence of certain symptoms, older age or patient choice, only colonoscopy was modelled,
as it is the most common test used.155 This assumption was intended to avoid unnecessary complexity,
given the exploratory aims of the model. For those individuals with a score below the threshold,
the diagnostic tool is followed by primary care investigations, which, in the model, are assumed to
consist of FITs at the 20-µg threshold (hereafter referred to as FIT). A subgroup of patients may also
be sent home without a FIT if the presenting symptoms result in a score below a certain minimum
level. We do not have adequate information on diagnostic accuracy for this group of patients deemed
to be at too low a risk to warrant investigation; therefore, it is assumed that all patients below the
threshold undergo a FIT. As a result, our analysis assumes that using the tools will always result in
some further action. Figure 6 shows the decision model for patients with CRC and Figure 7 shows the
decision model for patients without CRC.
A key difference between the diagnostic model for CRC patients and the model for non-CRC patients in
Figures 6 and 7 is that the proportion of patients referred to secondary care is based on the sensitivity
(p1 and p2) of the tests for CRC patients and specificity (p3 and p4) of the tests for patients without
CRC. In addition, patients without CRC are assumed not to return to general practice after a negative
test result.
ECONOMIC DECISION-ANALYTIC MODEL FOR COLORECTAL CANCER































































FIGURE 6 Diagnostic decision model for patients with CRC. p1, number of cases with a positive test result using the diagnostic tool/total number of CRC cases; p2, number of cases















































































































































































































































































































































































































FIGURE 7 Diagnostic decision model for patients without CRC. p3, number of patients with a negative test result using the diagnostic tool/total number of patients without CRC;

































































Faecal immunochemical test given to all
Based on clinical judgement, the standard diagnostic practice involves referral to secondary care after
conducting FITs for all patients. Pragmatically, we assume that the referral decision rule consists of
referring those patients who would have a positive FIT result, and sending home patients with negative
results for watchful waiting. We chose to use this as the relevant comparator based on advice from
local practitioners and current NICE Diagnostic Guideline recommendations,140 and guided by the
forthcoming roll-out of this test as a screening test nationally. Thus, we acknowledge that at the time
this report is published FIT is not yet universally used.
Send home/wait
General practitioners may send a patient home without undertaking any primary care investigations,
and wait until the symptoms fail to subside and the patient makes a repeat visit before ordering such
investigations. We have evaluated this option as a scenario involving an initial visit whereby the patient
is sent home without having undergone primary care investigation and a return visit the following
month where all (undiagnosed) CRC cases and none of the non-CRC patients return for a FIT. We vary
the proportion of non-CRC patients who return for a second visit in sensitivity analyses. All outcomes
and patient management pathway from the second visit are as in the ‘FIT given to all’ pathway.
After the referral decision, those with correct negative results, the true negatives, are assumed not to
return to the general practice. The same applies for those with incorrect positive results, the false
positives. As for CRC patients with incorrect negative test results, the ‘false-negative’ cases, it is
assumed that they will return 1 month later with persistent symptoms. The pathway for these patients
and those correctly identified, the ‘true-positive’ cases, is further determined by the disease model
described further on.
Refer all
A diagnostic strategy may be to refer all low-risk patients to secondary care. Given the low prevalence
of CRC in this low-risk population,80 between 0.1% and 3%,140 this strategy is unaffordable and not
used in practice; therefore, it is not considered further.140
Diagnostic pathway model
To predict the diagnostic interval associated with each of the diagnostic strategies, we made the
following assumptions:
1. In the strategies involving testing, namely the two intervention strategies involving a tool plus FIT
and the FIT-alone investigation strategy, patient management is determined by the result of the
diagnostic test. In our base-case analysis, we allow for partial adherence to the diagnostic protocol,
whereby 20% of positive results do not lead to referral or the referral is not realised.
2. In the intervention strategies whereby the tool produces a score below the threshold so that
there is a sequence of two tests, the tool first and FIT second, we assume that the sensitivity and
specificity of the second test in the sequence is independent of the outcome of the first test. This is
likely to be an optimistic assumption, as discussed further on.
3. A CRC patient who remains undiagnosed after a first symptomatic presentation to a GP will have
repeat monthly GP visits until diagnosis or death. In scenario analyses, we limit the number of
repeat monthly visits to a maximum of 12, after which the GP refers the patient to secondary care
without any further testing.
4. The sensitivity of the overall strategies determines the number of visits and monthly cycles before
referral in the model. This assumption is what ultimately drives the clinical effectiveness in the
model, which may be justified by the evidence available from Lyratzopoulos et al.173 showing that the
number of GP visits before diagnosis of CRC patients is positively associated with the median time
to referral.
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5. In the absence of data, we assume that the accuracy of diagnostic tests is independent of the
disease stage at presentation. Therefore, the same intervention effect on the diagnostic interval
relative to the comparators arising from assumptions 1, 2 and 3 leads to different clinical outcomes
across initial disease stages, given their different rates of disease progression and responsiveness to
treatment (see Disease history model linking test results and clinical outcomes). We obtain an aggregate
predicted outcome for an initial distribution of disease stages in a simulated incidental cohort from
our replication of the model described by Tappenden et al.145
Disease history model linking test results and clinical outcomes
To model the implications of avoidable delays in referral and diagnosis, we employed the updated version of
the disease model developed by Tappenden et al.,145 as described in Whyte et al.156 As we could not obtain
the model from Whyte et al.,156 we replicated it from information published on its methods.145,156,174,175 As this
disease history model was not developed for evaluating diagnostic strategies for identifying cancer patients
in primary care, we adapted it to focus entirely on the symptomatic stage population of present interest.
An illustration of the adapted Markov model of health-state transitions experienced by CRC patients
visiting their GP with symptomatic disease is presented in Figure 8. Briefly, an undiagnosed patient presents
to primary care with symptoms at one of the four possible disease stages and is managed according to
one of the diagnostic strategies investigated in this study. The patient’s disease is detected and he/she
is referred to secondary care for investigation with a certain probability (p), which we assume is equal
to the sensitivity of the strategy, or is missed with a probability of 1 – p. Once in secondary care, the
patient undergoes colonoscopy and, because this investigation has sensitivity approaching 100%, the
transition probability to a cancer diagnosis from being undiagnosed equals the overall sensitivity of
the strategy, p, times the probability of surviving until the end of the cycle, 1 – d.
Colorectal cancer patients missed by the diagnostic strategy remain untreated and are at risk of
progressing to the next stage of disease severity. The probability of disease progression from one cycle
to the next is equal to the probability of a false-negative result with the diagnostic strategy times the
probability of remaining alive by the end of the cycle times the probability of disease progression (q),
q × (1 – d) × (1 – p). If, after repeated cycles of visits to the GP, the patient remains undiagnosed, the
disease stage D would be reached, for which the only possible transition, other than to starting





















p × (1 – dA)
p × (1 – dB)
qAB × (1 – p) × (1 – dA)
qBC × (1 – p) × (1 – dC)
qCD × (1 – p) × (1 – dC)
p × (1 – dC)








FIGURE 8 Markov model of health-state transitions for CRC cases.
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In this model, a patient with CRC who, under the intervention, is identified earlier than under the
control, say Dukes’ stage A or B instead of C or D, derives both short-term and long-term health
benefits. The short-term benefits occur as soon as treatment starts in the form of death risk reduction,
whereas the longer-term benefits arise from avoiding disease progression to Dukes’ stages C or D, for
which treatment options are less effective. In terms of Figure 8, the excess death risk of not receiving
treatment is captured by the relative magnitude of death probabilities on and off treatment for each
of the Dukes’ disease stages A, B, C and D: dTA < dA, dTB < dB, dTC < dC and dTD < dD, respectively. The
long-term survival loss from delays in diagnosis is measured by the positive relationship between the
probability of CRC-related death and disease severity, that is dTA < dTB < dTC < dTD. The reduction in
death risk is assumed to continue for the rest of the patient’s life, apart from the maximum survival
ceiling imposed by the background mortality risks included in the model, as measured in life tables176
for the general English population of the same age and sex. In the scenario analysis, we explore the
effects of adopting the assumption in Whyte et al.,152 whereby patients who remain alive at the end
of the 5-year period after diagnosis have, from then on, the same cycle probability of death as that
of the general population of the same age and sex, that is negligible CRC death risk.
For patients with no CRC, a two-state Markov model was used that followed the initial decision tree
of Figure 5. After the initial decision of whether or not to refer those patients, those referred undergo
colonoscopy and are exposed to its associated small risk of adverse events, whereas those not referred
are spared such exposure. Patients who are alive after colonoscopy or not referred to colonoscopy are
in the alive health state and may transition to death from non-CRC causes, as determined by the death
risks in English life tables, or remain alive at the start of the next cycle.
Mechanism of effect
In the absence of direct clinical effectiveness data, we assume a relationship between the sensitivity of both
the algorithms and routine referral practice and the time to diagnosis. We break the time from symptom
presentation to diagnosis into (1) the time from presentation to primary care to referral for investigation
(the ‘referral interval’ in Chapter 5) and (2) the time from referral to specialist care to diagnosis and
treatment, and assume that the diagnostic algorithms affect only the referral interval, while the time
from referral to diagnosis and treatment remains fixed. Thus, in our analysis, a reduction in the diagnostic
interval associated with any improvement in primary care diagnostic accuracy is equal to the reduction
in the time from presentation to referral that is mediated through the number of primary care visits
before referral.
Given our chosen population, we model the clinical effectiveness as a function of the diagnostic
outcome of the first visit, assuming that, under current clinical practice, true-positive cases are referred
after two visits, to allow for primary care investigations to be conducted and discussed between the
patient and the doctor. False-negative cases would see their symptoms persist and would return for a
third, or possibly more, visits. Because we have no obvious way to infer how a change in primary care
diagnostic accuracy would affect the distribution of second and subsequent visits, we assume that the
sensitivity and specificity are independent across multiple visits to primary care. This may be incorrect
because individuals who are missed on an initial visit are more likely to be missed on a second visit,
and so on. Indeed, we infer the probable extent of this in primary care referral practice in Table 15 and
investigate the implications in sensitivity analyses (see Scenario analyses). Thus, a probability of referral
after two, three, four and five or more visits is calculated, respectively, as:
P(n = 2) = sensitivity. (1)
P(n = 3) = (1 − sensitivity) × sensitivity. (2)
P(n = 4) = (1 − sensitivity)2 × sensitivity. (3)
P(n ≥ 5) = (1 − sensitivity)3. (4)
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Under the diagnostic sensitivity of 0.76 implicit in the results reported by Lyratzopoulos et al.,173 the
predicted frequency for three, four and five or more visits is 18%, 4% and 1%, respectively, which is in
contrast with the actual frequencies of 12%, 5% and 6%, respectively. Consequently, the predicted
median referral interval of 25 days is lower than the actual figure of 29 days (see Table 15).
The length of time to referral (i.e. diagnosis in our model) is derived from the number of primary care
visits from previous research.173 Time to referral and the number of primary care visits before referral
are strongly positively associated, with a threshold of 16 or 17 days discriminating between cancer
patients referred after three or more and two or fewer visits.173
In our Markov model of 28-day cycles, the length of the referral interval is equal to the number of
initial repeat GP visits times 28 days (Table 16). The resulting times to referral implicit in the sensitivity
values of the tests in each strategy adopted for the model are presented in Table 16. These base-case
values correspond to sensitivity and specificity values of 69% and 77%,141 61% and 91%80 and 53% and
99%175 for the RAT, QCancer and FIT of 20 µg Hb/g faeces, respectively, after adjusting for the 80%
compliance with diagnostic results, so that 20% of those testing positive would not be referred but
sent home. These values are an approximation to the model results, which also account for the attrition
caused by death from CRC or other causes before referral, so that the values in Table 16 are greater
than the model outputs by 2–2.5 days. When the sensitivity values implicit in the number of pre-
referral visits reported in a retrospective patient experience survey (Lyratzopoulos et al.173) are used
for FITs, the reduction in the time to referral relative to the comparator is only 7 days for QCancer
and 8 days for the RAT (see Appendix 5).
A note of warning is due as to the lack of comparability between the accuracies of the RAT and
QCancer. Their specificity and sensitivity values were derived from studies using different designs
(a case–control study for the RAT and cohort data from electronic records for QCancer) and populations.
This would render any comparison of the tools biased. We note that similar arguments could also be
raised in relation to the comparison of each tool with the comparator, as this is also based on an indirect
comparison of heterogeneous single-arm accuracy studies; this fact reflects the low quality of data
available for analysis.
To complete the link from diagnostic accuracy outcomes and number of cycles before referral
(which determines the time to treatment because the time from referral to diagnosis and treatment is
assumed to be unaffected) with survival outcomes, we use the relationship between time to diagnosis
















2 visits 0.76 18 0.76 0.76d 18 Analysis of data from the
English National Audit of
Cancer Diagnosis in Primary
Care 2009–10, on 1170 general
practices (≈ 14% of all English
practices)173
3 visits 0.12 39 0.50 0.18 39
4 visits 0.05 56 0.42 0.045 56
≥ 5 visits 0.06 122 1.0 0.01d 122
Weighted
average
1 29 N/A 1.0 25
N/A, not applicable.
a Lyratzopoulos et al.173
b Weighted average calculated by the authors from data reported by Lyratzopoulos et al.173
c Assuming independence of sensitivity values across multiple visits.
d Weighted average calculated by the authors from data reported by Lyratzopoulos et al.173 and predicted frequency
distribution of number of pre-referral visits.
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and disease stage at diagnosis. The only available source for this unobservable parameter is provided
by a calibration exercise of a decision model based on Tappenden et al.155 It reports rates of progressive
transition between (non-clinical) Dukes’ stages A to B, B to C and C to D, and from each of these
to death, which, for stages earlier than D, was exclusively unrelated to cancer. We assume that the
disease progression rates from this source, which were intended to depict the experience of patients
in asymptomatic states, apply to our symptomatic population, but combine these with CRC mortality
rates reported by disease stage in untreated patients (Liu et al.177) Table 17 presents the mean time to
progression from Dukes’ stages A to B, B to C and C to D implied by the disease progression rates adopted.
The reductions in time to diagnosis and treatment made possible by the smaller number of initial
repeat visits to the GP have the ultimate impact of increasing the likelihood of starting treatment
at a stage of disease for which treatment is more effective. We employ data on relative survival
(with respect to the general population) by disease stage at diagnosis, depicted in Figure 9, to model
this longer-term health benefit of earlier access to treatment with more accurate GP diagnosis and
referral.178 We present the expected survival over time of an individual who is diagnosed while at
Dukes’ stage B and the counterfactual, improved survival, scenario that would have been observed
had this simulated case been diagnosed earlier while still in Dukes’ stage A (Figure 10).































1 visit 0.49 28 N/A 28 1 visit 0.55 28 N/A 28
2 visits 0.27 28 0.42 28 2 visits 0.21 28 0.42 28
3 visits 0.12 56 N/A N/A 3 visits 0.13 56 N/A N/A
4 visits 0.07 56 0.24 56 4 visits 0.05 56 0.24 56
≥ 5 visits 0.06 93 0.34 123 ≥ 5 visits 0.06 93 0.34 123
Weighted
average
1 37 1 67 Weighted
average
1 37 1 67
N/A, not applicable.
a Derived from the sensitivity values for the component tests times the 80% rate of compliance of referral practice
with the test results; see Table 19.
b The modelled comparator strategy assumes that every time the patient returns two GP visits are required for a
referral decision to be made, one for the return visit and second, follow-up visit, for the review and discussion of the
results of primary care investigations ordered in return visit.
c Positive test results with the tool result in referral after the first visit, whereas positive test results with a FIT after
negative result with the tool takes two visits.
d Positive test result with FIT alone results in referral after two visits, an initial and a follow-up visit to discuss results.







A to B 58.29 12.3 Authors’ calculations from
reported model-calibrated dataa
B to C 65.55 9.0
C to D 86.48 4.3
a Tappenden et al.145
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In Table 18, the link between diagnostic accuracy and disease stage at diagnosis, which is mediated by the
number of pre-referral visits (cycles) and underpins the clinical effectiveness in the model, is made explicit
for each strategy. The more accurate intervention strategies shift the distribution of disease stage at
diagnosis towards the earlier disease stages of Dukes’ stages A and B, and C (not shown in the table). The




























FIGURE 9 Relative survival of CRC patients diagnosed in 1996–2002 in England. Survival curves by disease stage.





















FIGURE 10 Actual and counterfactual survival curves for a patient who is diagnosed at Dukes’ stage B.



























1/2 visits 0.65 54 0.42 54 1/2 visits 0.68 54 0.42 54
3/4 visits 0.23 51 0.24 51 3/4 visits 0.22 51 0.24 51
5/6 visits 0.08 48 0.14 48 5/6 visits 0.07 48 0.14 48
7/8 visits 0.03 45 0.08 45 7/8 visits 0.02 45 0.08 45
9/10
visits
0.01 42 0.05 42 9/10 visits 0.01 42 0.05 42
≥ 10 visits 0.01 ≤ 40 0.07 ≤ 40 ≥ 10 visits 0.00 ≤ 40 0.07 ≤ 40
Weighted
average
1 52 1 50 Weighted
average
1 53 1 50
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therefore, they differ by about 1 percentage point from the final model estimates, which do account
for such mortality. When the sensitivity values implicit in the number of pre-referral visits reported
in a retrospective patient experience survey (i.e. Lyratzopoulos et al.173) are used for FITs, there is a
1-percentage-point gain in the proportion of patients with Dukes’ stages A/B at diagnosis with both
QCancer and the RAT, relative to the comparator (see Appendix 5). Therefore, an improvement in the
sensitivity of primary care diagnostic testing would be expected to reduce the time to referral and,
provided this is translated into a one-to-one reduction in the time to diagnosis and treatment, increase
the relative frequency of earlier disease stages at diagnosis. Stage at diagnosis would then determine the
long-term clinical outcomes and costs in the model.
The values of key model parameters are presented in Table 19. These values were identified from
reviews of previous decision models in CRC, described in Chapter 6. This choice of data sources was
partly determined by the fact that, in contrast to our research plans, the decision model of Whyte
et al.156 was not made available to our study. As a result, we had to reallocate the research resources
that had been originally assigned for conducting a systematic review of model parameter values to
building the model from scratch by replicating its published methods. Further details of the methods
and data used to populate the disease model parameters are given in Appendix 5.
TABLE 19 Model parameter values used in the base-case analysis
Parameter Value Comment Source
Clinical
Starting age, 70 years
Prevalence of CRC 0.015 Symptomatic low-risk population, as in analysis




Age-specific distribution by Dukes’ stage Simulated by authors from
replicated disease history
model (Tappenden 2007145)
Sensitivity of QCancer 0.610 Based on the top 10% risk score in their tool,
which gives a risk threshold of 0.5% (PPV 1.5%).
We recalculated their sensitivity and specificity of
this threshold to exclude observations in the top
1% risk score range (5.2% risk threshold) and thus
get closer to the low-risk population (0.1–3.0%
prevalence); unfortunately, the source does not
give the required breakdown of results to exclude
people above the 3% threshold
Hippsley-Cox 201280
Specificity of QCancer 0.910
Sensitivity of the RAT 0.69 Based on the 2% risk threshold Hamilton 2005141
Specificity of the RAT 0.77
Sensitivity of the FIT 0.526 FIT 20 µg Hb/g faeces Murphy 2017175











1 Murphy 2017175 reports a value of 0.966 from a
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TABLE 19 Model parameter values used in the base-case analysis (continued )
Parameter Value Comment Source
Probability of bleeding 0.0044 Atkin 2002180
Transition probabilities 4 weekly Whyte 2014156
Dukes’ stage A to B 0.0651 Reported model calibration to CRC incidence
and stage at diagnosis
Tappenden 2007145
Dukes’ stage B to C 0.0787
Dukes’ stage C to D 0.1427
CRC death risk
Dukes’ stage A
0.00 Post Dukes’ stage A at diagnosis Exponential hazard function
fitted to digitised
Kaplan–Meier curves up to
5-year relative survival for
CRC patients (diagnosed




0.00 Post Dukes’ stage B at diagnosis
CRC death risk
Dukes’ stage C
0.01 Post Dukes’ stage C diagnosis
CRC death risk
Dukes’ stage D
0.07 Post Dukes’ stage D at diagnosis
HR untreated CRC in
Dukes’ stage A
1 Survival of patients refusing treatment with newly
diagnosed CRC in Taiwan (Province of China)
during 2004–8. Treatment refusal was defined as
‘not undergoing any cancer treatment within
4 months of confirmed cancer diagnosis177’
Liu 2014177
HR untreated CRC in
Dukes’ stage A
1.22
HR untreated CRC in
Dukes’ stage A
1.22




Cost of FIT £3 Threshold 20 µg Hb/g faeces. Published data,
excludes costs of screening campaign in the
original source
Murphy 2017175
Cost of GP visit £31 PSSRU’s unit cost per surgery consultation
lasting 9.22 minutes, without qualification costs
and including direct care staff costs
Curtis 2018182
Cost of colonoscopy £615 Costs of colonoscopy with or without polypectomy Whyte 2014,156 NHS
reference costs, screening
centre estimates152
Cost of treating bowel
perforation
£5559 Major surgery Whyte 2014,156 NHS
reference costs
Cost of bleeding £304 Cost of admittance for bleeding (overnight stay




£3178 l Lifetime estimate, age specific, figure
presented is for people aged 70–79 years













Cancer free 0.91 Whyte 2014.156 General population utility
decline with age by sex was accounted for
using the linear model proposed by Ara 2010183
Ness 1999184
Dukes’ stage A 0.74
Dukes’ stage B 0.70
Dukes’ stage C 0.50
Dukes’ stage D 0.25
HR, hazard ratio; PSSRU, Personal Social Services Research Unit.
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Calculations of costs and benefits in the model
Our Markov model consists of a repeated iteration of 28-day cycles, whereby patients accrue costs
and benefits depending on the health state occupied in each iteration. We chose this cycle length as the
most appropriate for capturing the frequency with which patients with unresolved symptoms return to
their GPs for care. By aggregating the proportion of patients occupying the various health states in each
28-day cycle across the modelled time horizon of 30 years, we calculated the total time alive and total
time spent in each state. We applied costs and health-state utility values corresponding to the different
states and aggregated across health states and time periods to calculate total health-care costs and total
QALYs. The exception to this method is the estimation of health-care costs of cancer treatment, which are
implemented as a single lifetime cost payoff incurred at diagnosis, as in the original model by Whyte et al.156
The modelled accumulated total life-years, QALYs and lifetime health-care costs for the intervention and the
status quo strategies, over a period of 30 years after an initial presentation with symptoms to the GP, are
presented for a hypothetical cohort aged 70 years at first presentation.We initially focus on the predicted
clinical outcomes for the subgroup of CRC cases and then present the results for the overall cohort
presenting to their GP with symptoms suggestive of CRC.
Table 20 compares the main features of our model with existing models relevant to our study
question. Common to ours and the previous models is the use of a disease history model developed
by Tappenden et al.145 Whyte et al.’s156 model is a model of screening and therefore does not address
the question of interest here. The main differences between our and Westwood et al.’s161 work is
that we explicitly model the time to referral consistent with the diagnostic accuracy of the respective
test strategies and the distribution of the number of visits before referrals; we chose a shorter cycle
length (28 days vs. annual) to allow greater granularity for predicting outcomes; and we model the
short-term survival benefits of reducing the time to referral and treatment. Like Westwood et al.’s161
and Whyte et al.’s156 models, we have implemented a probabilistic sensitivity analysis, but with the
caveat that this type of sensitivity analysis was of limited relevance because most of the uncertainty
derives from structural assumptions, such as how the length of the diagnostic and treatment interval
is determined, defining the status quo diagnostic practice and measuring its diagnostic accuracy.
Consequently, we did not conduct any value-of-information analysis.
Deterministic sensitivity analysis
To investigate areas of uncertainty in our model, we arbitrarily varied clinical parameters by 20%
above and 20% below their base-case analysis values. In addition, we undertook scenario analyses for
the following parameters:
l alternative sensitivity and specificity values for the comparator (inferred from the number of GP visits
before referral173 and from receiver operating characteristic data for version 3 of NICE guidelines22)
l assuming 100% compliance with the test result (i.e. all positive cases are referred and all negative
cases are not referred to secondary care)
l no mortality benefit of treatment in stages A/B, by setting the hazard ratio to 1
l restricting excess CRC-related death risk to first 5 years156
l limit time horizon of analysis to 5 years
l alternative utility values adopting a common value for all CRC disease stages145
l alternative ‘send home/wait’ comparator strategy, whereby, at the initial visit, the GP sends the
patient home without conducting a FIT; from the second visit onwards, they manage the patient as
in the ‘FIT given to all’ strategy
l modified intervention strategy whereby patients who are above the risk threshold of the tool are
referred directly to secondary care, as in the original intervention strategy (see Figure 2), whereas
those below the threshold are sent home, rather than being subjected to primary care
investigations, as assumed in our base-case analysis
l assuming no survival gains and maximum quality-of-life (utility) gains (i.e. zero utility values for
false-negative cases until diagnosis) from more expeditious referral and diagnosis in patients
with CRC.
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TABLE 20 Key model characteristics of the de novo model and previous models
Study Perspective Population
Diagnostic









UK NHS Symptomatic patients
aged ≥ 40 years
presenting to primary
care who are at low
risk of CRC
l QCancer + FIT
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aged ≥ 40 years
presenting to primary
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We present our results in 2017/18 prices. We provide tentative estimates of incremental costs per
life-year gained. We also present results in terms of incremental cost per QALY gained, discounting
costs and QALYs at an annual rate of 3.5%.
Results
Colorectal cancer patients
According to our model predictions, using the diagnostic tool triage interventions allow for sensitivity
of 82–85%, compared with 53% for the current standard strategy of FIT for all.175 The additional
sensitivity of diagnosis would reduce the number of mean visits from 5.6 to 2.6. This, in turn, would
lead to fewer patients dying undiagnosed (from 12% in the status quo to 8% with the diagnostic tools)
and one additional case being diagnosed and treated in disease stages A/B for every 42 CRC patients
[1/(0.009 + 0.015)] presenting to primary care with symptoms and suspected CRC (Table 21). The
largest gains in life for a person aged 70 years occurs among individuals presenting with undiagnosed
CRC of Dukes’ stage B (0.26 years) and stage C (0.31 years), whereas the smallest gain occurs among
those presenting with stage D CRC, who derive a gain of 14 days with either diagnostic tool.
Use of a diagnostic tool is predicted to reduce the amount of time spent in untreated health states by
about 0.6 months (18 days), and to increase the amount of time alive while on treatment by 3 months,
mostly after diagnosis at Dukes’ stage A or B (Table 22). The net effect is to increase life expectancy
by 2.4 months, at an extra cost of between £29 and £36. These figures do not account for costs and
health outcomes in patients without CRC, which are included in the whole-population analysis next.
Whole-population analysis
When the costs and life-years are calculated over the denominator of all patients presenting with
symptoms of suspected CRC, the importance of the trade-off between sensitivity and specificity
becomes apparent. Detecting more CRC cases with diagnostic tool triage comes at the cost of imposing
more unnecessary use of health-care resources and health risks from invasive investigations on the
great majority of patients who do not have CRC. The costs associated with false-positive cases drives
the cost difference between the diagnostic tool plus FIT and FIT alone, resulting in an extra cost of £42
or £105, depending on the diagnostic tool, per patient presenting with symptoms of suspected CRC.
At the 1.5% prevalence rate of this low-risk population, the (undiscounted) additional cost per life-year
saved is (42/0.0031) £13,548 with QCancer and (105/0.0032) £32,813 with the RAT (Table 23).















Life expectancy by Dukes’ stage
at first presentation
A B C D A B C D
Weighted
mean
FIT 53 5.6 16.9 32.3 24.0 14.7 12.1 13.52 9.29 4.47 0.95 7.22
QCancer+ FIT 82 2.6 17.9 33.8 25.4 14.9 8.0 13.68 9.55 4.77 0.99 7.43
Difference:
QCancer – FIT
N/A 6.4 0.9 1.5 1.4 0.0 –4.1 0.16 0.26 0.31 0.04 0.21
RAT + FIT 85 2.4 18.0 34.0 25.6 14.9 7.6 13.69 9.56 4.79 0.99 7.44
Difference:
RAT – FIT
N/A 5.0 1.0 1.7 1.6 0.1 –4.5 0.17 0.28 0.33 0.04 0.23
N/A, not applicable.
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Colonoscopies contribute the largest source of difference in discounted costs, reflecting differences in
specificity between strategies. The difference in colonoscopy costs relative to FIT alone is £42.34 for
the QCancer plus FIT strategy, and £107.67 for the RAT plus FIT strategy (Table 24). Both intervention
strategies have additional costs due to perforation and bleeding with colonoscopy, relative to FIT
alone. Furthermore, there is an accompanying loss of QALYs of 0.0002 (equivalent to a loss of 1.75 full
health-hours of life) associated with this unnecessary exposure to risks from colonoscopy in patients
who do not have CRC, as a result of using the tools.






Mean time spent in each health state (months)
Life-years QALYs Cost (£)A B C D TA TB TC TD
FIT alone 5.6 0.2 0.4 0.3 0.2 29.1 39.0 15.2 2.2 7.22 3.65 4428
QCancer+ FIT 2.6 0.1 0.2 0.1 0.1 30.3 40.4 15.8 2.2 7.43 3.87 4458
QCancer+ FIT minus
FIT alone
–3.0 –0.1 –0.2 –0.2 –0.1 1.2 1.4 0.6 0.0 0.21 0.22 29
RAT + FIT 2.4 0.1 0.1 0.1 0.1 30.3 40.5 15.9 2.2 7.44 3.89 4464
RAT + FIT minus
FIT alone
–3.2 –0.1 –0.3 –0.2 –0.1 1.2 1.5 0.7 0.0 0.23 0.24 36
‘TA’, ‘TB’, ‘TC’ and ‘TD’ refer to Dukes’ stages treated.
TABLE 23 Mean costs and QALYs per patient aged 70 years suspected of having CRC (0.18% prevalence) vs. a FIT of
20 µg Hb/g faeces
Outcome QCancer+ FIT FIT alone
Difference:
QCancer+ FIT




Costs by initial test result (£)
TN 58 62 –4 51 62 –11
FP 65 20 45 135 20 114
TP 44 29 16 46 29 18
FN 23 37 –14 21 37 –16
Total 190 148 42 252 148 105
Life-years
TN 13.8023 14.8650 –1.0627 12.1507 14.8650 –2.7143
FP 1.5159 0.4534 1.0626 3.1674 0.4534 2.7140
TP 0.0732 0.0472 0.0260 0.0766 0.0472 0.0294
FN 0.0382 0.0610 –0.0228 0.0350 0.0610 –0.0260
Total 15.4297 15.4265 0.0031 15.4297 15.4265 0.0032
QALYs
TN 10.1048 10.8827 –0.7780 8.8956 10.8827 –1.9872
FP 1.1098 0.3319 0.7779 2.3189 0.3319 1.9870
TP 0.0399 0.0257 0.0142 0.0417 0.0257 0.0160
FN 0.0182 0.0290 –0.0108 0.0166 0.0290 –0.0123
Total 11.2727 11.2694 0.0033 11.2729 11.2694 0.0035
FN, false negative; FP, false positive; TN, true negative; TP, true positive.
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Tornado analysis
A tornado analysis is used to provide a graphical representation of the degree to which the incremental
cost per QALY gained from tools is sensitive to independent variation by 20% of clinical parameters
(Figure 11). The tornado analysis shows that the source of greatest uncertainty in the incremental
cost per QALY originates from the sensitivity of the standard test strategy. A reduction of 20% in the
false-negative rate, that is an increase in the sensitivity of the FIT from its base-case value of 53% to
62%, increases the discounted cost per QALY gained with the QCancer tool from £28,704 to somewhere
above £48,633 (see Figure 11). A reduction of 20% in the same parameter reduces that figure to £17,842
per QALY gained. The algorithm’s specificity is the second most important economic parameter, as it
determines how much of the increased detection of CRC by the primary care diagnostic workup is
obtained at the expense of patients without CRC who are referred, but have no need, for colonoscopy.
Naturally, the cost of colonoscopy is the single most influential cost parameter in the results; reducing
its cost from £615 to £492 reduces the cost per QALY gained with QCancer to £22,883.
Probabilistic analysis
A probabilistic sensitivity analysis was conducted for the base-case analysis by accounting for sampling
uncertainty in the key model parameters (see the tornado plot in Figure 11 and see Appendix 5, Table 66,
for information on the distributions used for those parameters). The first and third quartiles of the
incremental discounted costs’ distribution were £40 and £44 per patient, respectively, whereas those
for incremental discounted QALYs were 0.0012 and 0.0017, respectively (Figure 12). The probabilistic
estimate of the incremental cost per QALY gained with the tool using the case of QCancer is £28,522,
which is very similar to the deterministic estimate of £28,703.
Figure 13 presents the probability of the tool being cost-effective as a function of the willingness to pay
for one QALY gained. This figure implies a 95% CI for the incremental cost per QALY gained with the
tool of £17,000–50,000. A note of caution is warranted as this figure does not capture the uncertainty
inherent in the assumption that the health benefits with the tool are due to its increased sensitivity, as
it translates to fewer visits and, therefore, shorter times to referral, and that these reduced times in
turn translate into diagnoses at earlier disease stages. Owing to this underestimation of the uncertainty
in this probabilistic sensitivity analysis, we did not attempt to analyse the expected value of additional
research information.
TABLE 24 Breakdown of discounted costs and QALYs in suspected cancer population
Costs and QALYs FIT alone QCancer+ FIT Difference RAT+ FIT Difference
Costs pre diagnosis (£)
GP visits 62.69 59.65 –3.04 56.17 –6.52
FITs 3.14 2.86 –0.28 2.51 –0.63
Colonoscopy 26.68 69.02 42.34 134.36 107.67
Adverse events with colonoscopy 0.47 1.21 0.74 2.36 1.89
Costs post diagnosis (£)
Lifetime cost of treatment 54.84 56.83 1.99 56.97 2.13
Total 147.82 189.58 41.75 252.37 104.54
QALYs
No CRC 8.8281 8.8281 –0.0001 8.8280 –0.0002
CRC pre diagnosis 0.0007 0.0003 –0.0004 0.0003 –0.0005
CRC post diagnosis 0.0482 0.0501 0.0019 0.0502 0.0021
Total 8.8770 8.8785 0.0015 8.8785 0.0015
ICER (£) 28,704 71,863
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Threshold analysis
The tornado analysis has highlighted the sensitivity of the cost per QALY gained to the sensitivity of
the FITs and the specificity of the diagnostic tools. Given the key role of these parameters in the results,
Figure 14 depicts the levels of specificity of the triage tool required for the intervention to meet the
£30,000 threshold of cost-effectiveness, at varying levels of sensitivity of the FIT. At the levels of
sensitivity of ≥ 50% that have been reported for a FIT of 20 µg Hb/g faeces,175 the minimum level of
specificity needed by the tool to serve as a cost-effective triage intervention in primary care is 0.89.






Compliance with test results
Colonoscopy perforation rate
Probability of death due to perforation with colonoscopy
Rate of disease progression from Dukes’ stage A to B
Rate of disease progression from Dukes’ stage B to C
Rate of disease progression from Dukes’ stage C to D
HR Dukes’ stage A
HR Dukes’ stage B
HR Dukes’ stage C
HR Dukes’ stage D
Baseline Dukes’ stage A CRC death risk
Baseline Dukes’ stage B CRC death risk
Baseline Dukes’ stage C CRC death risk
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Cost of bleeding
Lifetime cost Dukes’ stage A
Lifetime cost Dukes’ stage B
Lifetime cost Dukes’ stage C
Lifetime cost Dukes’ stage D
Utility Dukes’ stage A
Utility Dukes’ stage B
Utility Dukes’ stage C
Utility Dukes’ stage D
Incremental cost per QALY gained by tool triage (£000)




















FIGURE 12 Cost-effectiveness plane: diagnostic tool (QCancer) vs. no tool.
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Scenario analyses
A key area of uncertainty in the economic analysis of the diagnostic tools is the diagnostic sensitivity of
current standard practice. The only evidence available on sensitivity is reported from a retrospective
survey,173 in which a sensitivity of primary care referral in routine practice of 76% is implicit. In the
absence of data from this source,173 we assume the specificity of current practice equals the specificity
that corresponds to its sensitivity value in the receiver operating characteristic curve reported for the
NICE version 3 referral guidelines.22 Using these sensitivity and specificity parameters, the intervention
produces negligible and possibly negative (discounted) QALY effects (Table 25). A similar outcome would
arise in younger suspected cancer patients, presenting at 55 years of age. Limiting of the analytical time
horizon to 5 years, instead of the 30-year time horizon in our base-case analysis, increases the cost per
QALY gained by 73–89%, depending on the tool. Imposing a maximum of 12 primary care visits before
referral would have no significant effect on the cost per QALY gained by the tools.
In addition, we explored the uncertainty in the cost-effectiveness of the tools from allowing for a ‘send
home/wait’ comparator strategy, whereby, at the initial visit, the GP sends the patient home without
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FIGURE 14 Threshold analysis.
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strategy. This is a highly uncertain comparator to model as a result of the absence of any information
on the rate of return of both CRC and non-CRC patients after an initial visit resulting in neither
investigation in primary care nor referral to secondary care. To simplify the analysis, we have assumed
that all CRC patients return the following month to seek care for their unresolved symptoms, whereas
only a proportion of non-CRC patients do so. Thus, we show how the cost-effectiveness of the tool
triage strategies vary with the proportion of CRC-negative patients who return to the GP after the first
month. When 0%, 50% and 100% of these patients return, the incremental discounted cost per QALY
gained with the RAT relative to this ‘send home and wait for second visit before FIT’ comparator is
£50,605, £37,245 and £23,993, respectively. The corresponding figures for QCancer are £30,472,
£17,194 and £4023.
We also explored a modified intervention strategy whereby patients who are above the risk threshold
of the tool are referred directly to secondary care, as in the original intervention strategy (see Figure 2),
whereas those below the threshold are sent home, rather than being subjected to primary care
investigations, as assumed in our base-case analysis. In this scenario, the incremental cost per QALY
gained with the tools over the FIT-alone strategy was predicted to be £40,140 for QCancer and
£96,285 for the RAT.

















Base case 104.54 0.0015 71,863 41.75 0.0015 28,704
Higher prevalence rate (2%) 104.52 0.0020 52,470 42.02 0.0020 21,439
Compliance of 100% with
test result
129.87 0.0008 162,183 51.45 0.0009 58,313
Sensitivity of 76% and specificity
of 52% for standard practicea
52.99 0.0003 167,972 20.85 0.0003 62,368
FIT of 10 µg Hb/g faeces;
sensitivity of 92% and specificity
of 86%
91.34 –6 × 10–5 Dominated 35.66 1.6 × 10–5 2.26M
Age 55 years at presentation 110.08 0.0019 57,767 45.38 0.0019 23,516
No mortality benefit
of treatment in stages A/B
(HR = 0)
104.45 0.0014 76,930 41.66 0.0014 30,552
Limit CRC-related death risk
to 5 years
104.54 0.0018 57,485 41.75 0.0018 23,234
Limit time horizon of analysis
to 5 years
104.54 0.0007 148,294 41.75 0.0007 59,902
Restrict maximum number of
GP visits to 12
104.54 0.0015 71,979 41.75 0.0015 28,749
Restrict maximum number of
GP visits to 12
104.36 0.0013 81,505 41.57 0.0013 32,408
Same CRC stage utilities across
disease stages
104.54 0.0017 63,046 41.75 0.0016 25,333
Disutility of colonoscopy (0.0075) 104.54 0.0014 77,211 41.75 0.0014 29,507
HR, hazard ratio.
Note
a Lyratzopoulos et al.173
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We also investigated whether or not there would be any possible value of quality-of-life gains from
more expeditious referral and diagnosis that would be sufficient to make the tools cost-effective, in a
scenario in which more expeditious referrals do not result in survival gains. We found that, even at
zero utility values of time spent in the false-negative health state, that is with undiagnosed CRC, the
tools would not be cost-effective. At such extremely low values, the ICER for QCancer was £68,102
and that for the RAT was £190,294.
Discussion
In this chapter, we present exploratory analyses based on a simple model of the diagnostic pathway
that has as its starting point symptomatic patients presenting to primary care and undergoing an initial
clinical assessment, which is the same starting point considered by NICE Guideline Number 126 and the
Diagnostic Guideline Number 30.140 We then combine the model with an adapted disease history model
for CRC from published studies (see Chapter 6), using a shorter cycle length and accounting for the excess
risk of mortality due to undiagnosed CRC. By developing these features in our model, we were able to
produce predictions in terms of meaningful clinical outcomes. The model was then used to identify the
parameters that contribute most to the overall decision uncertainty about the cost-effectiveness of
decision tools, which are good candidates for assessment as research priorities using expected value of
partial perfect information.166–168 Our model is expected to undergo further refinement as new evidence
emerges, thus becoming an effective live research resource for evaluation and decision-making analysis.
Our analysis of key areas of uncertainty in the economic evaluation of the diagnostic tools led us to the
following findings. First, a key determinant for the relative clinical effectiveness and cost-effectiveness of
a diagnostic tool-based pathway is the diagnostic accuracy of current standard practice, which is currently
unknown.We can only infer what this accuracy might be from the limited data available in a single report
of findings from a retrospective survey.173 Alternatively, as we have also done in this chapter, one may
assume that patients are being managed by the results of the FIT, using the diagnostic accuracy estimates
for this test available in the literature.175 This may be a more consistent approach, but limits the scope
allowed for accounting for clinician’s own judgement in the referral decision-making process.
Second, there is a lack of evidence for evaluating the impact of diagnostic tools in clinical practice. It is
not known how these tools would be used in actual practice and how any impact they might have on
referral intervals would affect clinical outcomes. We have opted for modelling the expected accuracy of
using the diagnostic tools to triage patients for primary care investigation with a FIT, under the strong
assumption that the diagnostic accuracy of FITs does not depend on the outcome of the diagnostic tool
used for triage.
Third, there is little evidence on the prevalence of cancer in the low-risk population in which the
diagnostic tools are intended for use. The value of this parameter is crucial for the cost-effectiveness
of using the tool to detect more cancer patients early, which depends on limiting the cost imposed on
the overwhelming majority of patients who present with symptoms of suspected cancer but turn out
later not to have the disease. Previous analyses, including those informing the NICE Guideline Number
126 and Diagnostic Guideline Number 30,140 have assumed that the CRC prevalence in the low-risk
population of interest here is 1.5% based on expert opinion, which, naturally, is highly uncertain. We
have thus adopted this value in our base-case analyses. In any case, our exploratory analysis suggested
that the specificity of the tools will also determine whether or not these may be used efficiently,
without incurring excessive costs of colonoscopies performed in people without cancer, and are
sustainable for a universal public health system such as the English NHS.
Fourth, the absence of data on the rate of CRC disease progression prior to diagnosis is also of
importance. In our analysis, the slower the rate of progression, the lower the relative clinical effectiveness
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and cost-effectiveness of diagnostic tool triage to primary and secondary care investigations, as the
tool triage would detect fewer extra cases before they had reached advanced disease stages, for which
treatment is less effective, relative to those currently being detected in routine practice. However, the
tornado analysis revealed that the sensitivity of current primary care practice, the specificity of the tool
and the way clinicians would use the tools are more important sources of uncertainty than the disease
progression in the evaluation of these tools.
Fifth, uncertainty regarding the decision-making process currently used in primary care for referring
patients to secondary care owing to suspected CRC prevents drawing conclusions about the optimal
intervention strategy. When we compared the intervention with a strategy of sending symptomatic
patients home on the first visit and using the FIT-alone strategy for those patients who return with
unresolved symptoms for a second visit, the proportion of non-CRC patients who return for the second
visit determines whether or not a diagnostic tool approaches levels of cost-effectiveness. Thus, the
economic value of the tools will depend on the clinical effectiveness of delaying access to colonoscopy
as the alternative strategy for identifying patients who need referral, which may avoid unnecessary use
of health-care resources and health risks of invasive investigations, at the cost of putting some patients
with CRC at risk by delaying their identification and treatment.
Another limitation in our analysis is the lack of evidence on diagnostic accuracy from any direct
comparative study of the modelled strategies. Thus, our sensitivity and specificity values are derived
from single studies that are likely to be different in terms of population, as reflected, for example,
in the underlying prevalence rate, or study design; for example, the evidence from one of the tools is
derived from a case–control study, whereas the evidence for the other tool was obtained from a
cohort study. Therefore, we cannot directly compare QCancer and RATs, as this is likely to lead to
biased results.
In addition, we have not modelled the heterogeneity in current standard practice; therefore, we
have not accounted for the variation in the costs and benefits of using the tools depending on local
situations. It is conceivable that practices with robust referral systems may have little to benefit from
using the tools, whereas areas without a sound referral system may find them beneficial. The model
assumes 100% compliance of GPs with the strategies (both FITs and decision tools). However, it is
clear that, currently, not all GPs use decision tools. More research is therefore needed to understand
how compliance with strategies varies across localities.
The model does not account for the resource constraint effects imposed by limited capacity to do
colonoscopies. Thus, although our model accounts for the benefits of faster access to colonoscopy, it
does not include the opportunity costs of those patients whose access to colonoscopy will be delayed
as a consequence of further demands placed on such service with limited capacity. This is an area of
further research.
Conclusion
The decision-analytic model was developed to analyse the uncertainty inherent in the current evidence
base, and to ask questions about the probable impact of the diagnostic tools, given the current lack of
evidence. The model showed the importance of accounting for the excess mortality effects of CRC
in symptomatic patients who are undiagnosed, and extends previous models in CRC by explicitly
modelling a simple diagnostic referral pathway in primary care. Despite the high degree of uncertainty
on evaluating the effect of the diagnostic tool on primary care referral of suspected CRC and health
outcomes, our model has helped us to identify the parameters for which uncertainties contribute most
to the overall decision uncertainty about the cost-effectiveness of decision tools, namely the sensitivity
of current standard practice, the specificity of the diagnostic tool, the prevalence of CRC in the
relevant primary care patient population and the cost of colonoscopy.
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In the concluding section, we return to the original questions about the probable impact of the
diagnostic tools on the costs and effects for patients presenting with symptoms of suspected CRC. For
each question we summarise the initial findings from the model and highlight where the uncertainties
still remain.
l What are the possible impacts on patient quality of life or survival if use of diagnostic tools reduces
time to diagnosis?
The model-based analysis suggests that the diagnostic tools would reduce the number of CRC
patients who die without a diagnosis from 12% to 8%. The increased accuracy of the tool relative to
the comparator also reduces the referral interval, which equals a reduction in the time to diagnosis
and treatment by assumption. Owing to the challenges of measuring the effect on health-related
quality of life post diagnosis, the amount of this type of benefit is highly uncertain. Overall, our
modelled analysis suggests that, depending on the sensitivity of current practice, the diagnostic
tools may extend life expectancy by somewhere between 4 days and 2 months among symptomatic
patients aged 70 years presenting to their GP with undiagnosed CRC, relative to a hypothetical
current practice of management according to results of a FIT alone. This range of variation
in benefit highlights the importance of establishing current practice and its primary care
diagnostic accuracy.
l Will the benefit to cancer patients identified earlier by diagnostic tools outweigh any disutility in
extra patients referred for further investigation who do not have cancer?
In the absence of evidence, our analysis suggests that the tools may help to improve diagnostic
accuracy in primary care, and result in earlier referrals to secondary care. If the reduction in the
referral interval results in a shortening of the diagnostic interval of the same magnitude, our model
predicts that the amount of benefit to patients with CRC identified earlier outweighs the loss in
quantity and quality of life in those patients referred for further investigation who do not have CRC.
However, although the benefit to cancer patients would more than compensate the risks to life
from exposing the overwhelming majority of patients without cancer to the risks of colonoscopy,
it is unlikely to justify the additional health-care costs associated with such exposure.
A sensitivity analysis was used to explore the uncertainty around the estimated cost-effectiveness
results and to highlight the parameter values that were driving the results. The sensitivity analysis
revealed that the cost-effectiveness results were particularly sensitive to uncertainty around the
sensitivity of current standard practice and the specificity of the tool. In a further threshold analysis,
we explored the levels of sensitivity of current standard practice and the specificity of the tool
in which the decision tool would meet the £30,000 cost-effectiveness threshold. At the levels of
sensitivity of ≥ 50% that have been reported for a FIT of 20 µg Hb/g faeces,175 the minimum level of
specificity needed by the tool to serve as a cost-effective triage intervention in primary care is 0.89.
The limited available data on current practice in the UK suggests that the sensitivity of primary care
referrals is already too high for the diagnostic tools to make a significant impact on CRC patient
survival. Although our base-case analysis produced an estimate of 2 months of life extension with
the tools when compared with a FIT of 20 µg Hb/g faeces, this gain is reduced to 2 weeks when
the sensitivity value derived from the number of visits before CRC diagnosis in routine practice is
used, and to 4 days against a FIT of 10 µg Hb/g faeces. Given the very low prevalence of CRC in the
relevant primary care population, this amount of benefit may be insufficient to outweigh the risks to
life from exposing a vast number of patients without CRC to colonoscopy. Furthermore, whether or
not the tools are cost-effective will depend on the prevalence and the sensitivity of current referral
practice and the specificity of the tool.
l How big an improvement in quality of life would be needed to warrant the use of these tools if
there are no survival impacts associated with the diagnostic tools?
We investigated this question by assuming that the increased accuracy of the tool relative to the
comparator does not result in any survival benefit but would avoid any loss in quality of life arising
from false-negative results, whereas the quality of life of a false-positive result remains unaffected.
The benefits gained from the tools are then largest when the losses from false-negative results
are the biggest, as would occur when quality of life of these false-negative patients falls to zero.
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Our analysis, however, shows that even preventing these extreme losses in quality of life for
false-negative patients is insufficient to make the diagnostic tools cost-effective (the ICER for
QCancer is then £68,102 and for the RAT is £190,294). Thus, without survival benefits, the
quality-of-life benefits of the tools alone would be unlikely to be sufficient to justify their costs.
l Could a cancer diagnostic tool be considered cost-effective if it reduces the period of extreme
anxiety by expediting investigation and management in patients, even if it made no impact on
patient outcome?
The model results do not account for any negative impact of referrals on a patient’s quality of life
due to anxiety, or the impact of colonoscopy on patient quality of life, for which we found no
evidence in the literature. Therefore, we cannot provide an answer to our study question of
whether or not a cancer diagnostic tool reduces the period of extreme anxiety associated with an
uncertain CRC diagnosis by expediting investigations and management. Answering this question
would require prospective studies measuring the outcomes of patients in primary care, but it is
questionable whether or not such a study is feasible given the difficulty to define the patient
population and the low number of cases expected in a single practice each year. Nevertheless,
our exploratory analyses suggest that, even if plausible reductions in the diagnostic interval
brought about by the use of the tools were to equate to reductions in the amount of time patients
experience extreme anxiety, the tool would not be cost-effective without extending patient survival.
l Where are the gaps in the evidence base and where is more research needed?
The updated review showed that the statistical relationship between diagnostic delay and cancer
patient outcomes is not suitable for deriving valid estimates of the effect of expeditious CRC
diagnosis on cancer stage or patient survival. In particular, the documented non-monotonic
(e.g. U-shaped) relationship between diagnostic interval and mortality does not imply an effect
mediated through the impact of diagnostic interval on stage of diagnosis. Given the lack of valid
surrogate or clinical outcome data for building an economic model of diagnostic tools or decision-
aid models in primary care, our cost-effectiveness analysis was limited to an exploration of the
expected effects of time delays to diagnosis associated with the relative accuracy of the diagnostic
tools. This limited aim will naturally be subject to more sources of uncertainty than an analysis
based on clinical surrogate outcomes, but reflects a pragmatic approach given the quality of the
data available.
In the absence of direct clinical effectiveness data, we assumed a relationship between the sensitivity
of both the diagnostic tool and current routine referral practice and the time to diagnosis. In the
model, the time from symptom presentation to diagnosis consists of (1) the time from presentation in
primary care to referral for investigation (the referral interval; see Chapter 5) and (2) the time from
referral to specialist care to diagnosis. We then assumed that the diagnostic algorithm affects only
the referral interval, while the time from referral to diagnosis and treatment remains fixed. Thus,
in our analysis, we assume that the improvement of primary care diagnostic accuracy with the tool
results in fewer visits to the GP before referral, and that the reduction in the accompanying time to
referral is equal to the reduction in the time to diagnosis and treatment. We have explicitly modelled
the average time to referral and diagnosis and treatment, based on the number of repeat appointments
to make the mechanisms of effect transparent and open to scrutiny. The relationship between the
number of repeat appointments and the time to referral is supported by evidence from a retrospective
patient experience survey.173 More research is needed on the impact of the different strategies on the
number of GP appointments before referral and diagnosis.
The review highlighted that there was a lack of direct comparative accuracy evidence between the
strategies/tests involved in the model. Our model is therefore based on indirect comparisons of
single-arm accuracy studies and assumptions about how the tools would be used to triage patients
for investigations in secondary care. There is limited evidence on the diagnostic accuracy of decision
aid tools in the UK low-risk population of interest, and the methods used to evaluate the tools that
have any relevant evidence, QCancer and the RAT, differ in terms of how the relevant low-risk
population is defined, that is ‘top 1 to 9% risk’ versus ‘low risk but not no-risk’,75 and the study design
used to develop or evaluate them, that is observational cohort versus case–control, respectively.
As QCancer was developed from a large cohort from electronic medical records, data were
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not prospectively collected and may thus lack relevant predictors to primary care practitioners.
The RAT, in contrast, warrants validation in a large representative UK primary care population,
because evidence on its diagnostic accuracy is based on a retrospective patient selection design.
In addition, the added value of these tools is highly uncertain as the status quo has not been defined
or rigoroursly evaluated, as reflected by the poor quality of the evidence informing the latest NICE
guidance (Diagnostic Guideline Number 303), including the FIT, which has been recommended by
such guidance but is not yet universal at the time of writing.
More research is also needed to verify the relationship between diagnostic delay and cancer patient
outcomes. This is a difficult area to study because of unobserved confounding factors, but one for
which access to electronic medical health records with information to construct detailed symptoms
libraries has opened new opportunities for fruitful research.
The sensitivity analysis revealed that the cost-effectiveness results were particularly sensitive to
uncertainty around the diagnostic accuracy of current standard practice and the specificity of the
tool. We assume that all patients in the population of interest, who we defined as those with ‘low
risk but not no-risk symptoms’,75 are akin to the CAPER study population.75 This patient population
includes the majority of symptomatic patients who do not present with high-risk symptoms such
as rectal bleeding or severe anaemia, and therefore are not diagnosed through the 2WW referral
pathway. The best available evidence on accuracy of the tool is for the QCancer tool, as it is based
on a large cohort analysis. However, even these sensitivity and specificity parameters were not for
the same population of interest here, as QCancer values include patients with red-flag symptoms,
who may be deemed appropriate for 2WW referrals. Therefore, in our model, we calculated the
sensitivity and specificity of QCancer for the top 10% risk threshold after excluding the top 1%
risk observations from the published data77 to be 61% and 91%, respectively. In a further threshold
analysis, we explored the levels of accuracy of current standard practice and the specificity of the
tool in which the decision tool would meet the £30,000 cost-effectiveness threshold. At the levels of
sensitivity of ≥ 50% that have been reported for a FIT of 20 µg Hb/g faeces,175 the minimum level of
specificity needed by the tool to serve as a cost-effective triage intervention in primary care is 0.89.
More research is clearly needed on the specificity of these tools among the population of interest.
In addition, we have not modelled the heterogeneity in current standard practice; therefore, we
have not accounted for the variation in the costs and benefits of using the tools depending on local
situations. It is conceivable that practices with robust referral systems may have little to gain from
using the tools, whereas areas without a sound referral system may find them beneficial. The model
assumes 100% compliance of GPs with the strategies (both FITs and decision tools). However,
it is clear that, currently, not all GPs use decision tools. More research is therefore needed to
understand how compliance with strategies varies across localities.
The model does not account for the resource constraint effects imposed by limited capacity for
colonoscopies. Thus, although our model accounts for the benefits of faster access to colonoscopy,
it does not include the opportunity costs of those patients whose access to colonoscopy will be
delayed as a consequence of further demands placed on such service with limited capacity. This is
an area of further research.
Finally, there were insufficient data to evaluate one of the a priori aims of the model, which was to
explore whether or not the tools will become cost-effective if they reduce the period of extreme
anxiety, even if they made no further impact on patient outcome. Answering this question would
require prospective studies measuring the outcomes of patients in primary care, but is questionable
whether or not such a study is feasible given the difficulty to define the patient population and the
low number of cases expected in a single practice each year.
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Chapter 8 General practitioner survey
Introduction
Diagnosing cancer quickly once patients become symptomatic remains an important priority in the
UK.185–187 A key part of the UK’s strategy for early cancer diagnosis was to lower the threshold for
fast-track referrals of symptomatic patients for investigation from an estimated 5% to an explicit
3% risk of undiagnosed cancer. This was implemented via the 2015 revision of NICE guidelines on
recognition and referral for suspected cancer.6 A potential source of diagnostic delay remains the
UK’s ‘gatekeeper’ system, whereby a GP decides whether or not a symptomatic patient meets the
criteria for investigation for suspected cancer.188 Indeed, fast-track referrals for cancer are less likely
when patients present with ‘low-risk but not no-risk’75 symptoms of cancer than when they present
with ‘alarm’ symptoms.189
A number of models and algorithms have been developed to quantify the risk of an undiagnosed
malignancy in symptomatic patients (see Chapters 3 and 4).42,44 Some of these models have been
translated into cancer decision support tools for clinical use, helping GPs to identify patients who
warrant investigation for suspected cancer.
Systematic review 1 (see Chapter 3) identified two tools that are available to support doctors assess
the risk of undiagnosed skin cancer.36–38 These tools are adapted to Australian guidelines and have
limited applicability in the UK. For the internal cancers, there are two main types of cancer decision
support tools available in the UK: RATs and QCancer. RATs are available for a number of specific
cancer sites, and use symptoms and test results to estimate the risk that a patient has an underlying
cancer.51,66,69–71,73,81,83,90 They were identified in SR1 (see Chapter 3) as having been evaluated in their
mouse mat and desktop forms. QCancer tools estimate the risk of undiagnosed cancer based on
symptoms, test results and patient risk factors. They are available for specific cancer sites,32,52,80,82,84,85
and also in sex-specific, person-centred forms, which estimate an individual’s risk that they have a
number of different cancers.53,54 QCancer tools were identified as validated cancer prediction models in
SR2 (see Chapter 4).
In 2013, Macmillan Cancer Support, BMJ Informatica, the Department of Health and Social Care, and
Cancer Research UK collaborated to incorporate RATs and QCancer into GP IT systems, renaming
them collectively as ‘electronic cancer decision support tools’. RATs are fully integrated with the GP
IT software INPS Vision (In Practice Systems Ltd, London, UK) and will soon be available via SystmOne
(The Phoenix Partnership, Leeds, UK). QCancer is available via EMIS Web (EMIS Health, Leeds, UK),
and QCancer tools are also freely available on the internet (www.qcancer.org). NHS Digital data
indicate that, together, EMIS Web and Vision had 62% of the market share of GP IT systems in
2015.190 In addition, RATs are available in mouse mat and flip chart forms; in January 2012, they were
distributed to all 10,000 general practices in England as part of the National Cancer Action Team’s
Supporting Primary Care Project.185 Information about QCancer and RATs is available via the Cancer
Research UK and Macmillan Cancer Support websites.191,192
The electronic cancer decision support tools have three main functions:
1. alert/prompt – cancer risk scores appear automatically on opening a patient’s record
2. cancer risk assessment – GPs can request a patient’s cancer risk score, using the symptom checker
3. searches/report – GPs can routinely search records and produce summaries indicating patients who
may need follow-up (‘safety-netting’).
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Existing research
There is little existing research on the clinical effectiveness and cost-effectiveness of cancer decision
support tools (see Chapters 3 and 4).
Independent and external validations of the QCancer algorithms for colorectal,15 pancreatic,14 renal
tract,91 gastro-oesophageal88 and ovarian89 cancers concluded that these tools are useful for identifying
undetected cases of these cancers in primary care (see Chapter 4). The performance of the CRC RAT
was compared with that of the 2005 NICE guidelines for referral for suspected cancer.172 The RAT
(area under the receiver operating characteristic curve 0.91, 95% CI 0.89 to 0.93) performed better
than the 2005 NICE guidelines (area under the receiver operating characteristic curve 0.75, 95% CI
0.72 to 0.79) in discriminating patients with undiagnosed CRC.22,172 No comparison with the current
NICE guidelines6 has been carried out; however, these guidelines draw heavily on an evidence base
dominated by RATs and QCancer publications.
A cohort study compared the numbers of cancer investigations and diagnoses before and after the
introduction of CRC and lung cancer RATs in primary care in the UK. The introduction of RATs was
associated with increased diagnostic activity and additional diagnoses of lung and colorectal cancer.13
By contrast, a 2 × 2 design trial of a GP intervention, which included the colorectal and lung cancer
RATs, did not report any evidence that the GP intervention was associated with faster time to
diagnosis of cancer in rural Australia.35 The clinical utility of cancer decision support tools in primary
care remains uncertain.42 No studies have investigated the association between the use of cancer
decision support tools and the use of the urgent referral pathway for suspected cancer.
Qualitative studies of cancer decision support tools in UK primary care suggest that they are more
likely to be embedded in clinical practice if they are perceived to support, but not supersede, a doctor’s
clinical judgement, and with better training and improvements in design. In particular, their use of screen
prompts added to the barrage of alerts generated by GP software systems, thereby increasing the risk
of ‘prompt fatigue’ and disengagement. Positive aspects of the tools included raising awareness of
cancer and of its symptoms, and prompting GPs to reflect on their decision-making around referrals.13,16,17
A recent qualitative study aimed to improve the understanding of how cancer decision support tools
are used by GPs. It analysed responses from a convenience sample of 126 GPs, most of whom worked
in the South West Peninsula. The study reported that 18.3% of GPs used either a RAT or a QCancer,
and that awareness of these tools was low (Chisnell et al., submitted).
No studies have quantified the proportion of general practices and GPs in the UK that have access to
and use cancer decision support tools. This is essential for increasing our understanding of the tools’
clinical effectiveness and cost-effectiveness.
Research aims
The primary aims of this study were to quantify the proportion of:
l general practices and GPs in the UK that have access to the two main types of cancer decision
support tools, either through a paper-based desktop tool or via their IT software (i.e. RATs
and QCancer)
l general practices where at least one GP reports using these tools.
Secondary aims of the study were to investigate the association between access to cancer decision
support tools and cancer diagnostic activity. Diagnostic activity was assessed using two indicators.
The first is a diagnostic process indicator, namely the age- and sex-adjusted number of 2WW referrals
per 100,000 head of population for the general practice. The second is a diagnostic outcome indicator,
namely the proportion of patients referred via the urgent 2WW pathway who are subsequently
diagnosed with cancer.193
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Methods
A cross-sectional postal survey was designed and conducted in line with conduct and reporting
guidelines for surveys.194
Questionnaire design
The questionnaire was drawn up by the lead researcher (SP) and was refined following feedback
from Professors Hamilton, Hippisley-Cox and Coupland (the originators of RATs and QCancer), and
members of the research team. Images of the paper-based tools and screenshots of the electronic
cancer decision support tools were included in the questionnaire (courtesy of In Practice Systems Ltd
and EMIS Health) to ease their identification by the participants. Copies of the questionnaire, covering
letter and information sheet are included in Appendix 6. Each questionnaire included the general
practice identifier, but not the name of the responding GP.
The questionnaire was finalised following feedback from five local GPs in terms of its utility, clarity
and design. The final questionnaire comprised 10 questions. Questions 1–3 asked GPs about desktop
RATs, including whether or not they were available and how likely they were to be used. Questions
4–8 asked about electronic cancer decision support tools (i.e. RATs and QCancer), again focusing on
availability and likely use, and training. Questions 9 and 10 asked how many years the GP had been
practising and how many sessions per week they worked at the practice. Participants were also asked
to select, from a list, aspects of the tools that they found helpful. The contents of the list were
informed by the qualitative study findings on the positive aspects of the lung cancer and CRC tools
discussed above.13,16,17
Sample
The survey was conducted at the practice level, reflecting how decisions are made about the IT
software and whether or not to download or activate electronic cancer decision support tools.
The target population was general practices in the UK and the GP partners/principals, sessional GPs
(including salaried and locum GPs) and GP registrars working there. GPs who had retired or who were
not currently practising were excluded.
We estimated that a sample size of 392 general practices would be large enough for a 95% CI to have
a margin of error of no more than 5%. We assumed a response rate of 40%, which is considerably less
than the mean value of 61% (95% CI 59% to 63%) reported in a pooled analysis of 361 postal surveys
published between 2000 and 2009.195
Survey administration
The postal survey was administered by Binley’s (Basildon, UK; www.binleys.com). This commercial
company was selected because it maintains a database of all 46,000 GPs in the UK, and all general
practices, which is verified every 6 months. This enabled us to obtain a random probability sample of
975 general practices. Questionnaires were sent to all the GPs (n = 4350) and GP registrars (n = 250)
working in these practices. Copies for GP registrars were colour coded, to facilitate separate analyses of
their responses, as these GPs are not on the General Medical Council’s GP register. The questionnaires
were sent on 5 July 2017, with a follow-up questionnaire pack sent to non-responding practices
on 2 August 2017. The data collection stopped on 15 November 2017. To incentivise participation,
a charitable donation of £7.50 was made per completed questionnaire, capped at the first 400. The
£3000 donation was shared equally between Cancer Research UK and Macmillan Cancer Support.
Data entry and coding
The data were entered into a Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA)
spreadsheet by Binley’s, and double-checked for accuracy by a second data entry analyst at Binley’s.
The questionnaire did not include a free-text comments section; however, any comments that were
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written on the returned questionnaires, or sent by e-mail or telephone, were recorded and are
reported in Appendix 6. The paper copies of the questionnaire were sent to the University of Exeter for
reference and archiving. The numbers of general practices and individual GPs in a practice who failed
to respond were recorded. If one GP reported that they had access to cancer decision support tools, it
was assumed that this was true for all other GPs at that practice.
Analyses
Descriptive statistics are reported for the responses to each question, along with the numbers of missing
data. GP-level data were used to estimate the proportion (95% CI) of GPs in the UK with access to the
tool. Responding practices were categorised in two ways: first, by whether or not at least one GP had
access to a tool, and, second, by whether or not at least one GP used a tool. From this, we estimated the
proportion (with 95% CI) of UK general practices with access to a cancer decision support tool, and the
proportion of UK general practices that use the tool.
Two subanalyses examined data from general practices in England only.
Ordinary least squares regression analyses tested the association between access to cancer decision
support tools and a practice-level diagnostic process indicator, namely the number of urgent 2WW
referrals for suspected cancer. The dependent variable was the number of sex- and age-adjusted 2WW
referrals for suspected cancer per 100,000 head of population. The independent variable was a dummy
variable indicating whether or not at least one GP at the practice had access to a tool. The analysis
adjusted for the general practice’s Index of Multiple Deprivation (IMD). This is a population-weighted
composite measure of 37 different measures of deprivation, taking a value between 0 and 100.
The higher the score, the higher the level of deprivation.196,197
Ordinary least squares regression was also used to test the association between access to cancer
decision support tools and a practice-level diagnostic outcome indicator, namely the proportion of
2WW referrals that result in a cancer diagnosis (also known as the conversion rate). This also adjusted
for the practice-level IMD.196,197
The 2WW and conversion rate data and practice-level IMD data for the period 2016–17 are
published by Public Health England and are publicly available at http://fingertips.phe.org.uk/profile/
cancerservices (accessed December 2019). Survey responses were mapped to Public Health England
data using the general practice identifier.
Results
Sample characteristics
Responses were received from 473 GPs and from three GP registrars based in 227 practices.
Responses from the GP registrars were not analysed separately, because of the small number of GP
registrars providing responses. The response rate at the practice level was 23.3%; at the practitioner
level, it was 10.3%. The responding practices had a median of 6 [interquartile range (IQR) 4–8] GPs,
of whom a median of 2 (IQR 1–3) responded to the survey. The mean within-practice response rate
was 43.7% (95% CI 39.3% to 48.1%). Unprompted comments written on incomplete surveys returned
by practice managers, or messages received by e-mail or telephone (see Data entry and coding) indicated
that lack of time (n = 12) and lack of awareness of the tools (n = 6) were the most common reasons for
non-response.
Of the 476 respondents, 294 (61.8%) had been practising as a GP for ≥ 11 years, and 299 (62.8%)
worked between five and eight sessions per week (Table 26).
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EMIS Web was the most frequently used IT software (96/227, 42.3%), followed by TPP SystmOne
(74/227, 32.6%) and then INPS Vision (32/227, 14.1%). These relative frequencies largely reflect the
national market share (Table 27).
The IMD profile of the sample is generally representative of that of the national population (Figure 15).
TABLE 27 General practice software




EMIS Web (QCancer) 96 42.3 52.4
TPP SystmOne (none) 74 32.6 33.0
INPS Vision (RAT) 32 14.1 9.9
Egton Medical Information Systems PCS (none) (EMIS Health) 11 4.9 0.01
Egton Medical Information Systems LV (none) (EMIS Health) 5 2.2 0.02
Other (none) 6 2.2 3.3
Microtest (none)a 3 1.3 1.4
Total 227 100 100
a Microtest Health, Bodmin, UK.










> 30 38 8.0
Missing 48 10.1
Total 476 100.00






> 10 5 1.1
Missing 52 11.0
Total 476 100.0
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Paper-based risk assessment tools
Access to a paper-based RAT in mouse mat or flip chart form was reported by 63 of the 476 (13.2%)
GPs. At the practice level, at least one GP reported access to a tool in 51 of the 227 (22.5%, 95% CI
17.2% to 28.5%) responding general practices (Table 28). The ‘other’ tools are listed in Appendix 6;
all were national guidelines, or summaries thereof, rather than cancer decision support tools.
Of the 63 GPs with access to a mouse mat or flip chart, 39 (61.9%) reported that they were unlikely or














FIGURE 15 Index of Multiple Deprivation profiles.
TABLE 28 Responses to questions asking about availability of risk assessment tools,





Mouse mat or flip chart 63 13.2
Other 30 6.3
None of these 326 68.5
Missing, not answered 57 12.0
Total 476 100.0
Likelihood of using paper-based RAT
Very likely 5 7.9
Likely 14 22.2
Unlikely 29 46.0
Very unlikely 10 15.9
Missing, not answered 5 7.9
Total 63 100.0
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The most popular probable uses of the paper-based RATs were for:
l assessing cancer risk in patients with non-specific (n = 28/63, 44.0%) or multiple (n = 25/63,
40.0%) symptoms
l increasing the GP’s certainty of decision-making (n = 25/63, 40.0%).
Other likely uses were less popular, namely:
l discussing cancer risk (n = 19/63, 30.2%)
l reassuring anxious patients (n = 16/63, 25.4%)
l increasing awareness of cancer as a possible diagnosis (n = 17/63, 27.0%) and awareness of cancer
symptoms (n = 10/63, 15.9%)
l prompting referrals the GP would not otherwise have made (n = 13/63, 20.6%), or investigation
(n = 9/63, 14.3%)
The option ‘none of these reasons’ was selected by 8 of the 63 (12.7%) GPs.
Electronic clinical decision support tools
The electronic clinical decision support tool was downloaded or activated on the IT system of 58 of
the 476 responding GPs (12.2%) (Table 29), which equates to a practice level of 42 out of 227 (19.0%,
95% CI 14.0% to 24.6%). Practices using EMIS Web and INPS Vision were equally likely to have
downloaded/activated the software (EMIS Web: n = 32/96, 33.3%; INPS Vision: n = 10/32, 31.3%)
(Table 30). Of the 476 GPs, 174 (36.6%) were unaware of the electronic tools, and 39 (8.2%) reported
that they would like to have them but they are not available for their system.
Of the 58 GPs with access to the electronic clinical decision support tools, 17 (29.3%) reported having
integrated it into their practice, and nine (15.5%) reported receiving training. The proportion who
had both received training and had integrated the tool into their practice was low (5/58, 8.6%). At
the practice level, training had been received by at least one GP in six of the 42 (14.3%) practices
with access to the tool. The tool was integrated into the practice of at least one GP in 15 of the
42 (35.7%) practices.
The ‘alert prompt’ and ‘symptom checker’ functions were ranked as being the most useful by 16
(27.6%) and 14 (24.1%), respectively, of the 58 GPs with access to the tool. The ‘searches report’ was
ranked least useful by 12 of the 58 GPs (20.7%)




Unaware of eCDS 174 36.6
eCDS is downloaded/activated for my IT system 58 12.2
eCDS is available for my IT system, but my practice has not downloaded/activated it 23 4.8
eCDS is available for my IT system, and my practice has plans to download/activate it in future 6 1.3
To my knowledge, eCDS is not available for my IT system 108 22.7
eCDS is not available for my IT system but I would like to have it 39 8.2
Missing, not answered 68 14.3
Total 476 100.0
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Functions of the electronic clinical decision support tools that were considered helpful included:
l assessing cancer risk in patients with non-specific symptoms (20/58, 34.5%), or with multiple
symptoms (21/58, 36.2%)
l discussing cancer risk with a patient (17/58, 29.3%).
Other functions were less popular:
l increasing the awareness of cancer as a possible diagnosis (13/58, 22.4%)
l reassuring anxious patients (10/58, 17.2%)
l prompting referrals that would otherwise have not have made (8/58, 13.8%)
l increasing the certainty of clinical decision-making (7/58, 12.1%)
l increasing the awareness of cancer symptoms (7/58, 12.1%).
Discussing investigation with symptomatic patients was not a popular function (3/58, 5.2%). Approximately
one-third of GPs opted to select none of the functions listed (17/58, 29.3%). When asked how likely they
were to use the electronic clinical decision support tool to assess a patient whose symptoms may be
caused by cancer, 39 (67.2%) reported that they would be unlikely or very unlikely to do so.
Combined tools
Of the 476 GPs, 112 (23.5%, 95% CI 19.7% to 27.6%) had access to a cancer decision support tool in
either paper or electronic format, or both. At the practice level, this equates to at least one GP with
access in 83 of the 227 practices (36.6%, 95% CI 30.3% to 43.1%). Of the 227 general practices,
38 (16.7%, 95% CI 12.1% to 22.2%) contained at least one GP who had access to the tools and was
likely or very likely to use them.
Association between the use of tools and 2-week-wait referral activity
Regression analyses were carried out for the 173 practices in England, for which Public Health England
publish age- and sex-adjusted 2WW referral and conversion rates. Of these 173 practices, 68 had
access to either a paper RAT or an electronic clinical decision support tool. There was no difference in
the mean 2WW referral rate between practices that do and practices that do not have access to either
type of tool, after adjusting for IMD (mean difference 1.8 referrals per 100,000 head of population,
95% CI –6.7 to 10.3 per 100,000 head of population) (Table 31).
TABLE 30 General practices with access to the electronic clinical decision support tools
General practice IT software
Access to electronic clinical decision support, n (%)
Total (n)No Yes
EMIS Web (QCancer) 64 (66.7) 32 (33.3) 96
EMIS LV (none) 5 (100.0) 0 (0.0) 5
EMIS PCS (none) 11 (100.0) 0 (0.0) 11
INPS Vision (RAT) 22 (68.8) 10 (31.3) 32
TPP SystmOne (none) 73 (98.7) 1 (1.3)a 74
Microtest (none) 3 (100.0) 0 (0.0) 3
Other (none) 5 (80.0) 1 (20.0)a 6
Total 183 (80.6) 44 (19.4) 227
a Practices that do not use either EMIS Web or INPS Vision cannot have access to electronic clinical decision support
tools, so these responses are assumed to be errors on the part of the GP answering the question and are not
included in the analysis.
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The normal probability plot of the residuals was approximately linear (data are not shown), supporting
the assumption of linear regression that the error terms are normally distributed.
Access to either type of tool was not associated with a change in the proportion of 2WW referrals that
resulted in a diagnosis of cancer (the conversion rate), after adjusting for IMD (mean difference –0.2,
95% CI –1.0 to 0.6) (Table 32).
Discussion
To the best of our knowledge, this is the first UK-wide survey of the availability of cancer decision
support tools. Based on the responses received, cancer decision support tools, in either paper or
electronic format, are available to GPs in approximately one-third (36.6%, 95% CI 30.3% to 43.1%) of
UK practices. The proportion of general practices where at least one GP had access to the tools and
was likely or very likely to use them was 16.7% (95% CI 12.1% to 22.2%). There are no current plans to
re-release the paper-based tools, so the expectation is that electronic clinical decision support tools will
become the norm. For this reason, it is useful to report separately the availability of electronic clinical
decision support tools in UK general practices, which was 19.0% (95% CI 14.0% to 24.6%). Currently,
the tools are available only via EMIS Web and INPS Vision, and approximately one-third of the practices
using these software systems had opted to download or activate them. The software will shortly be
integrated into SystmOne, which is estimated to have 33% of the market share in the UK. Between
them, EMIS Web, SystmOne and INPS Vision represent > 95% of the general practice software systems
available;190 therefore, in the near future, it is reasonable to assume that nearly 100% of GPs will have
access to the electronic clinical decision support tools, should they choose to download/activate them.
There was no evidence that access to the tools was associated with a change in either the rate of
2WW referrals or the proportion of those who were referred transpiring to have cancer.
Strengths and limitations
The main strength of this study is that we used random probability sampling methods, allowing for
every general practice in the UK to have an equal chance of receiving the survey. This increases the
TABLE 32 Regression analysis output: dependent variable sex- and age-adjusted conversion rate (i.e. proportion of 2WW
referrals that result in a diagnosis of cancer)a
Proportion of 2WW referrals resulting in a cancer diagnosis
p-valueMean difference 95% CI
Availability of tool (yes/no) –0.18 –0.97 to 0.62 0.663
IMD –0.05 –0.09 to –0.02 0.005
a n= 172; R2 = 0.0511.
TABLE 31 Regression analysis output: dependent variable sex- and age-adjusted urgent 2WW referrals per
100,000 populationa
Referral rate (per 100,000)
p-valueMean difference 95% CI
Availability of tool (yes/no) 1.81 –6.72 to 10.34 0.676
IMD 0.63 0.25 to 1.01 0.001
a n= 173; R2 = 0.06555.
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generalisability of our results to the UK. Further strengths include the thorough preparation and
testing of the survey before distribution to ensure that it was short, clear and user friendly, including
images for easy identification of the cancer decision support tools in question. Postal surveys, with
personalised letters and prepaid return envelopes, plus a financial incentive by way of a charity
donation, were also used, as recognised methods of increasing the response rate.198
Despite these steps, our sample size fell short of the intended size, resulting in wider CIs than planned.
The main reason for the low response rate was probably large GP workloads, as volunteered by
practice managers and reported elsewhere.199 The potential for responder bias is an important issue to
consider here, particularly because the response rate was low. If responders were more likely to have
access to, and be engaged with, the tools than non-responders, then our results will be overestimates.
One way to explore this is to look at the number of practices with access to computer systems that
support the electronic tools to see if they were over-represented in our sample. As seen in the results,
the electronic tools were available in only two (Vision and EMIS Web) of the three (Vision, EMIS Web
and SystmONE) main general practice IT systems in the UK. In our sample, ≈ 57% of practices had
Vision and EMIS systems; this is very similar to the national picture of 62%, and would suggest that
the response rate was not related to access to the tools.
Our subanalyses did not provide any evidence of an association between access to the tools and
practice-level diagnostic activity. This is perhaps not surprising, given that the electronic tools, in
particular, have been available for a only short time and our survey suggests that they are not yet
embedded in clinical practice. However, for the conversion rate analyses, there is a separate issue of
the reliability of this diagnostic outcome indicator. This metric has drawn criticism for not being able
to distinguish reliably between general practices because of the small numbers of cancer diagnosed
per practice per year.193 Future analyses should therefore focus on diagnostic process indicators,
such as the age- and sex-adjusted 2WW referral rate, which distinguish between practices reliably.
What this research adds
To our knowledge, there is no comparable literature on the uptake of cancer decision support tools in
the UK or elsewhere. Existing qualitative studies shed light on why the uptake of cancer diagnostic
tools is relatively low: they suggest that improvements in design and training may improve the uptake
of tools, which is in line with our finding of relatively low levels of training in the use of electronic
clinical decision support tools.13,16,19 Indeed, there was some variability within a general practice in
terms of its response to the question asking about tool availability. Some GPs in a practice reported
that they have access to the tools and others reported that they are unaware of them. This suggests
that there is the potential to increase uptake through increased training in use and awareness. Any
training should encourage GPs to maximise the amount of information coded into a patient’s records.
This is because the algorithms rely solely on coded data, and omission of data recorded in text fields is
associated with bias.200
Conclusion
Our survey indicates that cancer clinical decision support tools are currently not widely used in the
UK. This may contribute to our findings in SR1 (see Chapter 3) and SR2 (see Chapter 4) that there is
limited evidence that these tools have an impact on patient outcomes. The upcoming integration of the
tools into SystmONE will further increase the potential use of these tools.
As the levels of uptake are relatively low, it remains possible to carry out a RCT to assess whether or
not these tools are genuinely helpful in improving the selection of patients for investigation. The
attendant benefits of improved selection would include better targeting of investigation resources,
potentially earlier diagnosis and reduced treatment costs.13–15,19,88,89,91,186 Such a trial should include a
study of barriers to tool use, and ways to overcome them, as well as a health economics arm.
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Chapter 9 Discussion
To our knowledge, this is the first piece of work to bring together evidence on the validationclinical effectiveness, cost-effectiveness, and availability and use of cancer diagnostic tools to
aid decision-making in primary care in the UK. To better understand the clinical effectiveness and
cost-effectiveness of cancer diagnostic tools to aid decision-making in primary care, SR1, SR2 and the
updated review followed prespecified systematic review protocols. Alongside these reviews, a decision
model was developed to explore the likely trade-offs in using cancer diagnostic tools in practice, and
will be available for updating when new evidence becomes available. Finally, to explore the extent to
which GPs currently have access to and use cancer diagnostic tools, a survey of GPs was undertaken.
The main findings are discussed in this chapter, as well as gaps in the literature and the strengths and
limitations of the research.
What evidence exists on the clinical effectiveness and cost-effectiveness of
cancer diagnostic tools in primary care? (Systematic review 1)
Systematic review 1 identified a limited number of heterogeneous studies that provided weak evidence
of the impact of these diagnostic tools on patient-related outcomes or referral patterns. This finding
is in line with previous reviews across different types of cancers,40,44 confirming the uncertainty
surrounding the clinical utility of diagnostic tools in primary care. Only two RCTs were identified, and
the only existing trial of RATs found no statistically significant difference in time to diagnosis between
the intervention and control groups. No studies evaluating the cost-effectiveness of these tools was
identified, even though the definition of diagnostic tool used in SR1 was extended to include the
implementation of any diagnostic model or algorithm.
The results of SR1 are limited by heterogeneity between the studies in terms of the tools evaluated,
the populations and the outcomes used. Furthermore, the findings are constrained by the design of the
included studies, for example non-randomised designs and infrequent use of patient-reported outcomes.
What diagnostic prediction models exist in the literature that have the
potential to be used as tools in primary care? (Systematic review 2)
Eleven site-specific cancer diagnostic prediction models were identified, and covered a range of
common and less common cancer sites. These included different versions of the QCancer and RAT
models, both developed in the UK. All of the models identified had been developed in Europe.
The risk of bias across studies reporting the development or validation of models was mixed. Notably,
the QCancer models were developed using cohort data, and most have been externally validated, but
lack impact assessment. In comparison, the RAT models have gathered more evidence of impact on
practice, but have been developed from case–control studies, and with limited external validation.
With the exception of the CRC RAT model, there were no reports to suggest that models were being
updated based on new available data.
What evidence exists on the association between different diagnostic
interval durations and patient outcomes? (Updated review)
The findings of a previous systematic review25 were updated (see Chapter 5) to further examine the
association between different durations of time from first symptom to diagnosis or treatment and
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clinical outcomes across all major cancers. A more in-depth evaluation was conducted of CRC to inform
the model.
The literature suggests a U-shaped relationship between diagnostic interval and unfavourable
outcomes, which suggests the clinical need to expedite the diagnosis of symptomatic patients to avoid
the preventable delays that some patients continue to experience. The review also identified important
biases and other factors that may affect the findings of studies in this field.
The majority of the CRC studies found ‘no association’ between various intervals and patient
outcomes. A small number of studies (n = 4, although three used the same or overlapping population)
reported a positive association between shorter intervals and patient outcomes, but, paradoxically,
a small number of studies (n = 3) also found a negative association.
What is the likely impact that use of the tools in clinical practice may have
on patient outcomes and NHS resources? (Economic model)
There are clear gaps and uncertainties in the evidence base that need to be addressed to fully assess
the clinical effectiveness and cost-effectiveness of the tools. There is no available evidence that using
the tools has an impact on clinical practice.
To explore trade-offs in the benefits, harms and associated NHS resources related to the use of diagnostic
tools in primary care, we developed a simple model of the primary care diagnostic pathway for patients
with symptoms suspected to be caused by CRC. Exploration of the model indicates uncertainty as to
whether or not the amount of benefit to patients who are identified earlier by diagnostic tools and
confirmed as having cancer outweighs the loss in quantity and quality of life in those patients referred
for further investigation who do not have cancer. In the absence of good-quality evidence, our model
predicts that use of a diagnostic algorithm would extend life expectancy by between 4 days and
approximately 2 months among symptomatic patients aged 70 years presenting to their GP with
undiagnosed CRC, relative to a hypothetical current practice of management according to results of
a FIT alone. Although this amount of benefit may be larger than the loss of life from exposing the
overwhelming majority of patients without cancer to the risks of colonoscopy, it is unlikely to justify
the additional £25 incurred in health-care costs with the tool per low-risk patient presenting to primary
care suspected to have CRC.
The ability to fully evaluate the cost-effectiveness of using diagnostic tools in primary care is restricted
because of a lack of evidence on their impact on clinical practice and diagnostic intervals, as well as
on current standard practice. In the absence of such evidence, our analysis had to rely on two key
assumptions: first, about the relationship between the sensitivity of the test and number of GP visits
before referral, which has previously been shown to correlate with time to referral, and, second, about
the relationship between the time to referral and time to diagnosis and treatment, so that a reduction
in the referral interval was assumed to correspond to an equal reduction in the time to diagnosis
and treatment.
Because of the uncertainty behind these assumptions, cost-effectiveness analysis was not the objective
of our study. However, we were able to identify that, in addition to research to verify the validity of
these assumptions, other key sources of uncertainty in the evidence should be the focus of research,
including an evaluation of the tools in comparative studies in low-risk populations and relative to
current primary care diagnostic practice. It is noted that the diagnostic accuracy studies should be
conducted across the low-risk subpopulation, defined by age and prevalence, and that the sensitivity
of standard practice and the specificity of triage tools are two of the most influential parameters for
cost-effectiveness, which is also driven by the cost of colonoscopy.
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To what extent do general practitioners have access to and use existing
cancer decision support tools? (General practitioner survey)
We conducted a UK-wide survey of GPs on the availability of cancer decision support tools. Cancer
decision support tools, in either paper or electronic format, were available to GPs in 36.6% (95% CI
30.3% to 43.1%) of UK practices. The proportion of general practices where at least one GP has
access to the tools and was likely or very likely to use them was 16.7% (95% CI 12.1% to 22.2%).
The proportion of general practices in the UK with access to an electronic clinical decision support
tool was 19.0% (95% CI 14.0% to 24.6%).
The survey indicates that cancer clinical decision support tools are currently not widely used in the
UK. There was no evidence that access to the tools was associated with a change in the rate of 2WW
referrals, or the proportion of those referrals transpiring to have cancer. The subanalyses also did
not provide any evidence of an association between access to the tools and practice-level diagnostic
activity. This is, perhaps, not surprising, given that the electronic tools, in particular, have been available
for only a short time and our survey suggests that they are not yet embedded in clinical practice.
Strengths
Systematic reviews 1 and 2, and the updated review, followed prespecified systematic review
protocols, and the team conducting the reviews are independent and experienced in systematic review
methodology. The decision model was specifically developed to reflect the primary care pathway for
patients with symptoms suspected to be caused by CRC. We were able to represent key relationships
required to produce predictions in terms of meaningful clinical outcomes and identify the main
parameters contributing to uncertainty in the model. The model is expected to undergo further
refinement as new evidence emerges, and to be used as a template for modelling the effect of
diagnostic tools in other cancers.
The GP survey is the first UK-wide survey of the availability and use of cancer decision support tools.
It is also the first national study to attempt to link use of the tools with changes in the rate of 2WW
referrals or cancer diagnoses.
Limitations
The reviews and decision model were limited by a lack of evidence, and poor study quality. The best-
quality study in SR135 was conducted in Australia, and used a composite intervention including RATs
(with older versions of several instruments that were developed using populations from a different
country). Not only does this limit the generalisability of results, but it also hinders examination of
why no impact of patient outcomes was found. For instance, could it be due to low uptake, poor
implementation or limited marginal contribution of the tools in assessing the risk of cancer?
Systematic review 2 identified a number of potential models for use in primary care, yet considerable
gaps in the literature exist. There is a disparity in the available evidence on the impact of the tools and
the extent to which models have been validated (e.g. whether or not they have been validated at all,
and if so, if it has been in the appropriate populations). Comparison of the identified models is limited
by heterogeneity between different prediction models for different cancers.
Because there was heterogeneity between studies in the updated review of diagnostic intervals,
a ‘vote-counting’ approach was taken, which does not account for the magnitude of any effect.
The potential for selective outcome reporting also limits the interpretation of the evidence on an
association between duration of pre-diagnostic intervals and patient outcomes. It is therefore very
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difficult to say whether or not there is an association between different interval durations and patient
outcomes, although the more recent evidence of a U-shaped relationship requires further examination.
The decision model has several limitations as it relies on a linked-data approach in a context of little
available evidence. In particular, in the absence of direct clinical effectiveness data, we assume a
relationship between the sensitivity of both the algorithm and routine referral practice and the number
of primary care visits before referral, which has been shown to be associated with the referral interval,
and that any difference between diagnostic strategies in the implied referral interval equals their
difference in time to diagnosis and treatment. The lack of relevant data on the diagnostic accuracy of
the current referral practice in primary care, and on the prevalence of cancer in populations at low risk
are identified, not surprisingly, to be crucial in calculating the magnitude of the trade-offs in the decision
model. Crucially, we do not know how the tools are being used and our main analysis of a diagnostic
tool that is used to select patients for direct referral to secondary care and manage the rest by standard
investigation may not necessarily be relevant to many localities using the tool. Furthermore, there were
insufficient data to evaluate the effect of the tools on quality of life that is mediated by a reduction
in the diagnostic interval and associated experience of severe anxiety by patients and their relatives,
although our optimistic exploratory analysis revealed that this effect is unlikely to render the tools
cost-effective, without further impact on patient survival.
The survey was limited by a lower than expected response rate, with a small likelihood of response
bias (those aware and using the tools may have been more likely to respond). This may limit the
ability to conclude that the tools do not lead to increased diagnostic activity or, indeed, the ability
to characterise referral systems that may be able to benefit more from the tools.
Uncertainties
There are clear gaps and uncertainties in the evidence base that need to be addressed to fully assess
the clinical effectiveness and cost-effectiveness of the tools. There is uncertainty about the relative
accuracy of the tools, as there is no single study that has compared them, or evaluated any one of
them relative to standard practice or against any comparator. The tools that we focused on had
evidence from single-arm studies of different designs and population prevalence. Our model-based
evaluation was undertaken in the context of the recent publication of a policy recommendation for
FITs to replace FOBTs as routine tests. In primary care, the evidence on FITs is limited as the tests
have not been evaluated in the population relevant to our study. This means that even the evidence
from indirect comparisons of the tools with FITs is limited to diagnostic accuracy data that may not be
valid for our study purposes.
Moreover, there is uncertainty about the interaction between GP, tool and the patient. The intervention
is not just the tool, but how the GP interacts with the tool. A better understanding of this may help to
disentangle uncertainties on whether or not a lack of evidence of the clinical effectiveness of the tools
is due to poor implementation, insufficient uptake or the assumptions on which the tools are based.
Given the uncertainities in the evidence base, it is also possible that rapid referral can do more harm
than good, or at least more harm than people might expect. As well as the false positives, there is the
likelihood that expediting investigation in one group will lead to fewer resources being available for
the group that are not expedited. The group not expedited will contain cancer cases, as sensitivity is
around 50%, and slower diagnosis could lead to worse outcomes for these cases. These uncertainties
and the associated potential for an inappropriate allocation of resources suggests the need for future
research to address these issues, as outlined in Chapter 10, Recommendations for research.
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Given the difficulty of conducting robust clinical studies of diagnostic tools for suspected cancer
referrals in primary care, evaluations may pragmatically focus on intermediate outcomes, such as
referral intervals, time to diagnosis and treatment initiation. In addressing the structural uncertainty
arising from translating an effect on referral intervals into an effect on the time interval until diagnosis,
observational studies may fruitfully exploit routine electronic health-care records in which, for example,
changes in referral policy guidance could opportunistically be used as a natural experiment to assess the
impact of earlier referrals on the diagnostic interval.
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Current evaluations of feature-based cancer diagnostic tools in primary care provided limited andmixed evidence of the impact on patient outcomes. QCancer and RATs are the dominant risk
prediction tools identified for use in primary care for any cancer. These tools have the potential to
be used by GPs on a wider scale once the knowledge gaps highlighted in the review are addressed.
The research has been conducted in the UK, the Netherlands and Australia, suggesting limited
geographical application.
The lack of robust clinical effectiveness data is an important limiting factor in assessing the cost-
effectiveness of diagnostic tools. Better-quality and more research is needed to provide these data,
for example more robust study designs and a wider selection of outcomes. However, identifying the
ideal approach may not be straightforward. For example, there is an ongoing debate as to the most
appropriate outcome for evaluating interventions to improve cancer diagnosis and referral.201–203
Moreover, by comparing average times to diagnosis, patients not prioritised for quick referrals are
at increased risk of being missed.
The cancer clinical decision support tools are not widely used, and this could explain the limited
evidence evaluating their clinical effectiveness. This paucity of evidence, however, makes assessment
of the impact of their use on patient outcomes difficult. The levels of uptake of the tools are relatively
low, leaving sufficient numbers of general practices to act as controls in future RCTs to assess whether
or not these tools are genuinely helpful in improving the selection of patients for investigation.
Recommendations for practice
The uncertainties about the clinical effectiveness of cancer diagnostic tools in primary care, compounded
by continued lack of clarity about the relationship between delay to diagnosis or treatment and outcome,
suggest that further recommendations for increased use of these tools may be premature. It may be
that the limited uptake of the tools observed in our survey is appropriate, given the limited and mixed
evidence base we have found.
Recommendations for research
It is undeniable that the rationale for cancer diagnostic tools in primary care is strong. Therefore, the
priority should be for further research to confirm or refute the potential of cancer diagnostic tools to
improve cancer outcomes. QCancer and RATs are well-established tools. We therefore tentatively
suggest that further research should concentrate on QCancer and RATs.
The research on these tools should include:
1. Continued model validation – RATs should try to emulate the validation methods employed by
QCancer. Adhering to good conduct and reporting guidance on studies of prediction tools is
essential to maximise the value of the studies and to improve the ability to review them.
2. QCancer versus RATs – the performance of the two tools should be compared. It would be
particularly helpful to see how similar the risks predicted by the two tools are for identical patients.
3. Assessment of clinical effectiveness – although some assessment of the clinical effectiveness of
RATs has been performed, this has been inconclusive, so there is a need for this to be performed
for both tools. Studies should collect information on time to diagnosis and treatment and stage at
diagnosis, as well as health outcomes (if feasible). In terms of design, cluster randomised trials have
been shown to be feasible, and are preferable to quasi-experimental designs already attempted.
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Given the likely small effect on health outcomes in particular, it is essential that the sample size
of any study is appropriately large. A Phase II cluster RCT evaluating the impact of RATs for
gastro-oesophageal cancer is ongoing.20
4. Assessment of the tool in GP patient consultations – as the tool is not used in isolation, research to
understand the complex nature of the intervention is warranted to investigate the interaction
between GP, tool and patient. This may be part of an interventional study.
5. Assessment of quality-of-life implications of delayed and incorrect diagnosis. We do not know what
the effect of delayed diagnosis is on the health-related quality of life of cancer patients and their
families during the diagnostic delay and after delayed diagnosis. The anxiety caused by persistent
unresolved symptoms would require retrospective observational studies recruiting subjects in large
secondary care centres.
6. Assessment of cost-effectiveness – although the main current limitation is the absence of clinical
effectiveness evidence, researchers should anticipate how cost-effectiveness will be addressed when
such evidence becomes available. Incorporating assessment of cost-effectiveness into trials may be
one approach, but experience suggests that, to generalise and extrapolate from the trial results,
continued enhancement of the economic model developed in this project should be pursued and
used to synthesise the latest evidence from points 1 to 3 above. Thus, our model may provide an
iterative framework for informing the design of studies described in point 3, and be populated by
the results of those studies.
7. Assessment of impact on other referral pathways – clinical effectiveness studies should consider not
just the referral/diagnosis time in expedited pathways, but also the impact on the other pathways,
as cancer cases might be slowed by a shift in resources to the expedited pathway.
8. Finally, the challenges of interpreting observational data exploring the relationship between delay
and outcome continues, as demonstrated in the updated review. For further studies answering this
question to be useful, they need to address issues of unmeasured confounding such as grade and
stage, as well as problems of survivor time or selection bias implicit in the period of follow-up over
which the studies are conducted. These are problems limiting the quality of existing evidence, some
of which may be improved by developing agreed standards for providing complete and accurate
reporting of all methods used and outcomes measured.
CONCLUSIONS
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Date range searched: 1946 to May week 1 2017.





2. (cancer$ or neopla$).tw.
3. (tumour$ or tumor$).tw.
4. or/1-3
5. Primary Health Care/
6. exp General Practice/
7. General Practitioners/
8. (primary care or general practi$ or family practi$).tw.
9. (primary adj3 (healthcare or health care)).tw.
10. or/5-9
11. Decision Support Systems, Clinical/
12. Decision Support Techniques/
13. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or ation$).tw.
14. or/11-13
15. “Early Detection of Cancer”/
16. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or
prognos$).tw.
17. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
18. or/15-17
19. 4 and 10 and 14 and 18.
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid
Date range searched: 10 May 2017.
Date searched: 11 May 2017.
Searcher: SR.
Hits: 270.
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Search strategy
1. (cancer$ or neopla$).tw.
2. (tumour$ or tumor$).tw.
3. or/1-2
4. primary care or general practi$ or family practi$).tw.
5. (primary adj3 (healthcare or health care)).tw.
6. or/4-5
7. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or equation$).tw.
8. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or
prognos$).tw.
9. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
10. or/8-9
11. 3 and 6 and 7 and 10.
EMBASE
Host: Ovid.
Date range searched: 1974 to 10 May 2017.





2. (cancer$ or neopla$).tw.
3. (tumour$ or tumor$).tw.
4. or/1-3
5. Primary Health Care/
6. exp General Practice/
7. General Practitioners/
8. (primary care or general practi$ or family practi$).tw.
9. (primary adj3 (healthcare or health care)).tw.
10. or/5-9
11. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or equation$).tw.
12. exp decision support system/
13. 11 or 12
14. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagnos$ or
prognos$).tw.
15. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
16. Early Cancer Diagnosis/
17. or/14-16
18. 4 and 10 and 13 and 17.
Cochrane Database of Systematic Reviews and Cochrane Central Register of Controlled Trials
Host: Cochrane Library.
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Date ranges searched: Cochrane Database of Systematic Reviews (CDSR) – issue 5 of 12, May 2017;
Cochrane Central Register of Controlled Trials – issue 4 of 12, April 2017.




1. MeSH descriptor: [Neoplasms] explode all trees
2. (cancer* or neopla*):ti,ab,kw
3. (tumour* or tumor*):ti,ab,kw
4. #1 or #2 or #3
5. MeSH descriptor: [Primary Health Care] explode all trees
6. MeSH descriptor: [General Practice] explode all trees
7. MeSH descriptor: [General Practitioners] explode all trees
8. (“primary care” or “general practi*” or “family practi*”):ti,ab,kw
9. (primary near/3 (healthcare or “health care”)):ti,ab,kw
10. #5 or #6 or #7 or #8 or #9
11. MeSH descriptor: [Decision Support Techniques] this term only
12. MeSH descriptor: [Decision Support Systems, Clinical] this term only
13. (tool or tools or aid* or model or models or checklist* or “check list” * or rule or rules or algorithm*
or equation*):ti,ab,kw
14. #11 or #12 or #13
15. MeSH descriptor: [Early Detection of Cancer] this term only
16. (predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagnos* or prognos*):ti,
ab,kw
17. (2ww or “2 week wait” or “two week wait” or “2 week rule” or “two week rule”):ti,ab,kw
18. #15 or #16 or #17
19. #4 and #10 and #14 and #18.
Science Citation Index and Conference Proceedings Citation Index – Science
Host: Web of Science.
Date range searched: not applicable.




1. TS=((cancer* or neopla*))
2. TS=((tumour* or tumor*))
3. #1 or #2
4. TS=((“primary care” or “general practi*” or “family practi*”))
5. TS=((primary near/2 healthcare))
6. TS=((primary near/2 “health care”))
7. #3 or #4 or #5
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8. TS= ((tool or tools or aid* or model or models or checklist* or “check list*” or rule or rules or
algorithm* or equation*))
9. TS=((predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagnos*
or prognos*))
10. TS=((2ww or “2 week wait” or “two week wait” or “2 week rule” or “two week rule”))
11. #9 or #10
12. #3 and #7 and #8 and #11
13. Indexes=SCI-EXPANDED, CPCI-S Timespan=2004-2011.
DocType=All document types; Language=All languages.
Search results
The following table shows the number of hits per database and in total.
Database Hits (n)
MEDLINE 2008
MEDLINE In-Process & Other Non-Indexed Citations 270
EMBASE 3867
Cochrane Library (CDSR and CENTRAL) 391
Web of Science (SCI and CPCI-S) 2816
Total records 9352
Duplicates 3743
Total unique records 5609
SCI, Science Citation Index.
The updated searches were carried out on 30 January 2018. The next table shows the number of hits
per database and in total for the updated searches.
Database Hits (n)
MEDLINE 168
MEDLINE In-Process & Other Non-Indexed Citations 1
EMBASE 336
Cochrane Library (CDSR and CENTRAL) 29
Web of Science (SCI and CPCI-S) 181
Total records 715
Duplicates 84
Total unique records 631
SCI, Science Citation Index.
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Appendix 2 Systematic review 1:
supplementary tables
TABLE 33 Systematic review 1: included studies, study characteristics





Melanoma Australia Field trial To assess the algorithm’s ability
to reduce the number of benign
lesions being excised without
reducing the excision of invasive
lesions by comparing the numbers
of excised lesions with algorithm






Melanoma Australia RCT To determine whether or not an
aid to the diagnosis of pigmented
skin lesions reduces the ratio of
benign lesions to melanomas






Skin cancer UK Case–control To assess the impact of the
toolkit by comparing before
and after national skin cancer
referral data, cross-sectional
questionnaires and urgent skin




RAT for lung cancer
and CRC in two
formats: mouse mat
and desktop flip chart
Lung cancer,
CRC
UK Cohort study To compare referrals and
investigations for colorectal and
lung cancer before and after the





the RAT for colorectal,
lung and prostate













To measure the effect of
community-based symptom
awareness and general practice-
based educational interventions
on the time to diagnosis in rural
patients presenting with breast,
prostate, colorectal or lung cancer
in Western Australia
DOI: 10.3310/hta24660 Health Technology Assessment 2020 Vol. 24 No. 66
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Medina-Lara et al. under the terms of a commissioning contract issued by the Secretary of
State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
147
TABLE 34 Systematic review 1: included studies, study design
Study Population
Recruitment (plus inclusion




in general practice, in each




5823 melanocytic skin lesions
excised over the intervention
period (2 years) and in the
preceding 6 months
Two provincial cities in central
Queensland were selected for
the trial on the basis of their
similarity; one city was
randomly selected to
implement the use of
algorithm, the other city was
used as a control
53 medical practitioners
(45 GPs, seven surgeons and
one dermatologist) in the
control community; 52
medical practitioners (48 GPs
and four surgeons) in the
intervention community
An algorithm for managing
clinically suspicious naevi,
aided by the use of a camera
Change in lesion characteristics:
size, outline, colour, elevation,
surface change, daughter




Data on examined and/or
excised skin lesions
suspected of being malignant,
reported by general practices
in Perth, WA, Australia
General practices from Perth,
WA, Australia, were




l 223 randomised practices
(468 GPs)
l Intervention: 111 practices
(245 GPs)
l Control: 112 practices
(228 GPs)
An algorithm for managing
clinically suspicious naevi,
aided by the use of a camera
Change in lesion characteristics:
size, outline, colour, elevation,
surface change, daughter
lesions, tingling or itching; and
aged > 40 years
Gulati
201538
2WW referral data from
2456 practices were obtained
for 4 months during the
launch of the toolkit
(July–October 2012) and
compared with referral habits
in the same months in the
previous year (July–October
2011). Referral habits during
these two time periods were
also measured in 3693
practices where the GP Skin
Cancer Toolkit was not used.
Appropriateness of the 2WW
referrals based on data from
Homerton University
Hospital and Royal London
Hospital between July and
October 2011 and between
July and October 2012
Data on participating practices
were based on website usage
data (www.doctors.net.uk).
Cancer Waiting Times data
were obtained through PHE’s
National Cancer Registration
Service (East Midlands) and
taken from the National
Cancer Waiting Times
Monitoring Dataset, provided
by NHS England. A total of
276 GPs referring to Barts
Health NHS Trust and
Homerton University Hospital
NHS Foundation Trust were
analysed for appropriateness
according to NICE referral
guidelines
Impact on referral statistics:
2456 practices that used the
toolkit as cases; 3693
practices as controls.
Appropriateness of urgent
referral: 2011 – 365 referrals
from 214 GPs; 2012 – 387
referrals from 183 GPs
(114 GPs had access to
toolkit)
The toolkit consisted of
a referral decision aid (referral
guidelines based on red flags),
lesion recognition resource
(a series of images), clinical









































and 2WW referrals from
practices and local NHS
trusts for the two 6-month
periods before and after the
distribution of the tools
A selected GP cancer lead
from seven of the 28 English
cancer networks recruited
local general practices to
which the RATs were
supplied. A total of 614 GPs
from 165 practices were
recruited; 2593 assessments
were included
614 GPs from 165 practices RAT gives risk estimates for
patients aged > 40 years
presenting to primary care
with symptoms of possible
cancer, for single symptoms,
pairs of symptoms and repeat
attendances with the same
symptom. The values are




rectal bleeding, abdominal pain,
abdominal tenderness, abnormal
rectal examination), loss of
weight, haemoglobin (levels




Two trial areas in Western
Australia
Inclusion criteria: adults aged
> 18 years; diagnosed with
breast, lung, colorectal or
prostate cancer between
1 January 2012 and the
recruitment end date of
31 March 2014; and resident
of trial areas at the time of
cancer diagnosis
1358 patients (497 in trial
area A, 861 in trial area B)
Resource card containing the
RAT tables for colorectal, lung
and prostate cancers, as well























































































































































































































































































































































TABLE 35 Systematic review 1: included studies, results







excised during the 2-year
intervention period
Number of excisions
performed in each city
was measured at baseline
(6 months before
implementation of the
intervention) and 2 years
after; percentage of
excised lesions that are
neither invasive nor
potentially malignant;
and median number of
excisions per doctor
Total number of excised lesions:
l At baseline – control city, 752;
intervention city, 606
l After intervention – control city, 2468;
intervention city, 1997
Percentage of excised lesions that are
neither invasive nor potentially malignant:
l At baseline – control city, 94% (95% CI
92.3% to 95.7%); intervention city,
93.6% (95% CI 91.6% to 95.5%)
(p = 0.731, χ2 test)
l After intervention – control city, 93.8%
(95% CI 92.8% to 94.8%); intervention
city, 88.8% (95% CI 87.4% to 90.2%)
The median number of excisions per
doctor (2.5% and 97.5% percentiles)
l At baseline – control city, 7 (1, 38);
intervention city, 8 (1, 46)
l After intervention – control city,
9 (1, 39); intervention city, 4 (1, 30)
English
200336
Malignant lesion – an in
situ or invasive melanoma
benign lesion – naevus
(including dysplastic
naevus) or a seborrhoeic
keratosis
Ratio of benign pigmented
lesions to melanomas
excised
Number of excised skin lesions (including
seborrheic keratoses):
l At baseline –
¢ Control: benign, 1965; melanoma,
61; ratio 32
¢ Intervention: benign, 2615;
melanoma, 100; ratio 26
l Trial period –
¢ Control: benign, 2037;
melanoma, 79
¢ Intervention: benign, 2369;
melanoma, 81; 1.03 times higher
(95% CI 0.71 to 1.50, p = 0.88)
Gulati 201538 Number of urgent (2WW)
cancer referrals; proportion
of appropriate urgent
referrals (based on the
NICE guidelines);
melanoma and non-






21,000 GPs were invited to use the tool;
8163 GPs accessed the tool during the
2012 period. There were no significant
changes in the number of urgent GP
referrals for suspected skin cancer
(Spearman’s rank 0.20; p < 0.001),
diagnoses of melanoma (Spearman’s rank
0.064; p < 0.001) or diagnoses of non-
melanoma skin cancer (Spearman’s rank
0.068; p < 0.001) between the toolkit user
and non-user groups. The proportion of
appropriate referrals increased from
21.37% in 2011 to 32.3% in 2012, giving
an incidence rate ratio of 3.13 (95% CI
2.21 to 4.42, z-statistic 6.46; p < 0.0001);
the differences in numbers of appropriate
referrals between toolkit users and non-
users did not reach statistical significance
by Spearman’s rank test and ANOVA
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TABLE 35 Systematic review 1: included studies, results (continued )




2-week referral to the
appropriate specialty, or a




Lung cancer: 31% increase in 2-week
referrals (332 before, 436 after); 4%
increase in related investigations
(chest X-ray: 7431 before, 7723 after)
Colorectal cancer: 26% increase in
2-week referrals (1173 before, 1477
after); 15% increase in colonoscopies
(1762 before, 2032 after)
Emery 201735 TDI, as the time from first
symptom to cancer
diagnosis
TDI, as the time from first
symptom to cancer
diagnosis
No significant differences in the median or
ln mean TDI at either intervention level:
l GP intervention vs. control – median
TDI 97 vs. 96.5 days; ln mean
difference 0.004 (95% CI 0.18 to
0.19; p = 0.99)
l Community intervention vs. control –
median TDI 107.5 vs. 92 days; ln mean
difference 0.08 (95% CI 0.06 to 0.23;
p = 0.27)
No significant differences in the TDI
when analysed by factorial design, tumour
group or subintervals of the TDI
ANOVA, analysis of variance.
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High risk (use of the
intervention was not
blinded)
Low risk (‘data analysis
was performed before
the code identifying
the city was broken’)
Low risk Unclear risk








Low risk Low risk Unclear risk High risk (‘after
randomisation, participants
and research assistants
who visited practices were
not blinded to assignment’)




Low risk Unclear risk
Gulati 201538 High risk (voluntary
selection of
participants)
High risk (use of the
intervention was not
blinded)
Low risk Low risk Unclear risk Unclear risk (based on
reported use of the
toolkit)
Unclear risk Unclear risk High risk (only 39%
of GPs who had













High risk (the GPs were
not blinded, irrespective of

















Low risk Low risk Low risk Low risk (research staff
who collected outcome
data and the trial
statistician were blinded to
group allocation)
Low risk (measures





media avoided in the
control areas)
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TABLE 37 Systematic review 2: included studies, study characteristics (1)
Study
Prediction






RAT Bladder UK Primary care Case–control Apparent
performance




RAT Leukaemia UK Primary care Case–control Apparent
performance
GPRD (now called the CPRD)
Shephard
201568
RAT Multiple myeloma UK Primary care Case–control Apparent
performance




RAT Brain UK Primary care Case–control Apparent
performance

















patients attending the symptomatic
breast clinic at Ninewells Hospital,
Dundee (Scotland), who were referred
by a GP between February and
June 2007
Validation cohort: all women who
attended for an initial consultation
regarding symptomatic breast
problems in 11 participating general
practices in the region between












CEDAR study: patients referred to
endoscopy centres by participating


































model Cancer type(s) Country Setting Study design
Stage of
development Data source









290 consecutive patients with rectal
bleeding presenting to 83 GPs in
Limburg (the Netherlands) from
September 1988 to April 1990.
Predictors: questionnaires completed
















Patients referred from primary care
with colorectal symptoms over a









CEDAR study: patients referred to
endoscopy centres by participating
Dutch primary care practices. 2009–12
Kop 201561 No name
(machine
learning)




Anonymised electronic records from
two general practice database systems
in the Utrecht region, the Netherlands,











Patients presenting to GPs with first
episode of rectal bleeding
l Study 1: 750 GPs, 1989–91








CEDAR study: patients referred to
endoscopy centres by participating
Dutch primary care practices. 2009–12
Hippisley-Cox
201280




























































































































































































































































































































































TABLE 37 Systematic review 2: included studies, study characteristics (1) (continued )
Study
Prediction





RAT Colorectal UK Primary care Case–control Apparent
performance
Patients attending all 21 general
practices in Exeter, UK. Cases
identified from the cancer registry at
the Royal Devon and Exeter Hospital




CEDAR study: patients referred to
endoscopy centres by participating
Dutch primary care practices. 2009–12
Hamilton
200974
RAT Colorectal UK Primary care Case–control Model updating THIN database
Stapley 201772 RAT Bowel UK Primary care Case–control Apparent
performance














Stapley 201371 RAT Gastro-oesophageal UK Primary care Case–control Apparent
performance

















RAT Lung UK Primary care Case–control Apparent
performance
Patients attending all 21 general
practices in Exeter, UK. Cases
identified from the cancer registry at




















































RAT Ovarian UK Primary care Case–control Apparent
performance















Stapley 201270 RAT Pancreatic UK Primary care Case–control Apparent
performance
GPRD (now called the CPRD)






RAT Prostate UK Primary care Case–control Apparent
performance
Patients attending all 21 general
practices in Exeter, UK. Cases
identified from the cancer registry at
















RAT Renal UK Primary care Case–control Apparent
performance



















































































































































































































































































































































TABLE 37 Systematic review 2: included studies, study characteristics (1) (continued )
Study
Prediction




Walker 201373 RAT Uterine UK Primary care Case–control Apparent
performance






UK Primary care Case–control Apparent
performance


















QCancer Males – multiple cancers
(including lung, colorectal,
gastro-oesophageal,
pancreatic, renal tract, blood,
prostate, testicular)
























Colorectal, yet Muris 1995
contains multiple cancers




CEDAR study: patients referred to
endoscopy centres by participating
Dutch primary care practices. 2009–12

































TABLE 38 Systematic review 2: included studies, study characteristics (2)









l Cases – patients with a first diagnosis of
bladder cancer between January 2000
and December 2009 inclusive; aged
≥ 40 years; a minimum of 1 year of data
before diagnosis. The first instance of a
bladder cancer code was assigned the
date of diagnosis: the index date. The
index date for controls was the index
date for their matched case
l Controls – up to five controls were
matched on sex, general practice,
and to 1 year of age of the case
43 symptoms and 104 abnormal test
results were considered initially.
However, only six symptoms and
seven abnormal test results
occurred in at least 5% of cases
Bladder cancer within
1 year of presentation
26,633 NR
Exclusion criteria: metastatic cancer of the
bladder from a non-bladder primary,
diagnosis before 2000, or no consultations





l Cases – aged ≥ 40 years, diagnosed
with leukaemia between 2000 and
2009 inclusive
l Controls – up to five for each case,
matched on age, sex and
general practice
50 symptoms were considered
initially
Leukaemia diagnosis






chronic and 4214 for
acute)
NR
Exclusion criteria: cases with
reticuloendothelial cancer or thrombocytic
leukaemia and their matched controls;
< 1 year of records before the index date;
cases without controls; controls with
leukaemia; and controls who had not



















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Cases – aged > 40 years with a
diagnosis of myeloma between
January 2000 and December 2009.
Date of diagnosis was the first
myeloma code, which served as the
index date for the matched controls
l Controls – up to five for each case,
matched for age, sex and practice
62 symptoms and 22 abnormal test
results were considered initially
where they occurred in at least 2%
of cases or controls
Myeloma within




Exclusion criteria: < 1 year of records
before the index date; cases without
controls; controls with myeloma; controls






l Cases – patients aged ≥ 18 years with
a brain tumour diagnosed between
May 1988 and March 2006
l Controls – all potential controls were
matched on sex, general practice
and age
Libraries of codes for clinical
variables previously described with
brain tumours were assembled and
occurrences of these variables in the
6 months before the index date in
cases and controls were identified.
Variables were retained only if they
occurred in at least 1% of cases
or controls
Diagnosis of brain






l Cases and controls – < 2 years of data
before the first tumour code; no
consultations in the 6 months
before diagnosis









































l Inclusion criteria – consecutive patients
referred by a GP between February
and June 2007
l Exclusion criteria – attending for
reasons related to cosmetic surgery or
previous conservative breast surgery;
patients who were included in the
validation cohort
Age, socioeconomic status (as
assessed by the Carstairs Index),
obesity classification, smoking
history, menopausal status, regular
periods, current pregnancy,
contraception, hormone replacement
therapy, hysterectomy, number of
pregnancies, past breast problems
history, signs after examination, lump















l Inclusion criteria – all women who
attended for an initial consultation
regarding symptomatic breast problems
in 11 participating general practices in
the region between January 2006 and
June 2007
l Exclusion criteria – consultation related
to issues around cosmetic surgery or
breastfeeding problems; refusal to




















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )









l Cases – patients aged ≥ 30 years
with a diagnosis of CRC between
January 2001 and July 2006
l Controls – seven controls per case,
matched for practice, sex and age
Constipation episode, laxative
prescription, diarrhoea episode,
antimotility prescription, change in
bowel habit (diarrhoea), change in
bowel habit (constipation), change
in bowel habit (no diarrhoea/
constipation), IBS diagnosis,
antispasmodic prescription, rectal
bleeding or melaena, faecal occult
blood present, weight loss of > 10%
in 2 years, weight loss of 5–10% in
2 years, unknown/no weight loss,
abdominal pain/tenderness,
abnormal rectal examination,
anaemia with low levels of Hb, iron
prescription, flatulence, diabetes,
BMI of > 30 kg/m2, DVT/PE,
abdominal mass, mean cell volume
of < 80 fl
Diagnosis of CRC Derivation: cases, 5477;
controls, 38314
NR
Exclusion criteria: cases with < 2 years of
data before diagnosis
Discrimination based on
two data sets: derivation
(THIN) data set and
CAPER data set (349
cases; 1744 controls)
Elias 201750 Inclusion criteria: lower abdominal
complaints for at least 2 weeks with
rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight
loss, sudden onset in elderly, and/or
physical examination suggestive of
colorectal disease
N/A. Used BB equation (Marshall
201122)







































Fijten 199555 Inclusion criteria: overt rectal bleeding
reason for GP visit, or history of recent
rectal blood loss (within the previous
3 months)
Relevant items were identified from
literature. Data collected by:
1. GP questionnaire after the
first consultation, containing
70 variables; history, physical
examination and initial
management
2. Patient questionnaire, containing
150 (somatic and psychological)
questions
3. Laboratory tests: Hb levels,
ESR (several cut-off points), WBC
and occult blood in the faeces
Diagnosis of CRC
within at least 1 year










l 21 patients lost to
follow-up
l Age and sex of these
patients no different
from those included
Exclusion criteria: patients aged < 18 or
> 75 years, pregnant, urgent admission to
a hospital (e.g. for a massive bleeding or




All patients referred from primary care
with colorectal symptoms from
October 1999 to October 2002
N/A. Used Fijten 199555 Diagnosis of CRC 3302 patients, 156
diagnosed with cancer
NR
Elias 201750 Inclusion criteria: lower-abdominal
complaints for at least 2 weeks with
rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight
loss, sudden onset in elderly, and/or
physical examination suggestive of
colorectal disease





















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )





Kop 201561 Patients aged ≥ 30 years
l Cases: a 6-month period preceding
the diagnosis
l Controls: a 6-month period was
randomly chosen between 1 July 2006
and 31 December 2011
Age; sex; number of times each of
720 ICPC codes were recorded;
number of times each of 86
medication (ATC) code was
prescribed; number of times patient
was referred to a specialist for
each of the 94 referral codes;
33 attributes, each representing
whether or not a patient is currently
in a certain (medical) condition;
number of times Hb was inside/
outside threshold; number of times
a patient’s cell volume value was
inside/outside the desired range;
number of times blood was found/
was not found in a patient’s stool;
whether or not patient’s medical
history contains a certain temporal
pattern






Inclusion criteria: aged ≥ 40 years,
presenting with first episode of rectal
bleeding within previous 6 months
l Weight loss, abdominal pain,
changes in bowel
habits, discomfort
l Patient perceptions of cause
of bleeding
l Age, sex
CRC l Study 1: 208,
including
32 with CRC




Study 1: 1989–91; study 2: 1991–2
Exclusion criteria: known inflammatory
bowel disease, colonic polyps, polyposis
coli, CRC, predisposition to haemorrhage
(e.g. coagulation defect), melaena stool
Conducted follow-up in 1994: 0 (study 1)






































Elias 201750 Inclusion criteria: lower abdominal
complaints for at least 2 weeks with
rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight
loss, sudden onset in elderly, and/or
physical examination suggestive of
colorectal disease
N/A. Used Danish (i.e. Nørrelund
199657) model





Inclusion criteria: patients aged 30–84 years
registered between 1 January 2000 and
30 September 2010
l Current first onset of rectal
bleeding, loss of appetite, weight-
loss symptom or abdominal pain
l First onset (within the previous
12 months) of abdominal
distension, constipation,
diarrhoea, change in bowel habit
or tiredness
l Age, BMI, alcohol status, smoking
status, Townsend deprivation
score (postcodes), family history
of gastrointestinal cancer,
previous diagnosis of cancer
apart from CRC, IBD (Crohn’s
disease, ulcerative colitis, coeliac














for BMI, alcohol intake
and smoking status
Exclusion criteria: missing a postcode-
related Townsend deprivation score;
history of pancreatic cancer at baseline;
red-flag symptoms recorded in the
12 months before the study entry date
Inclusion criteria: patients from general
practices using EMIS computer system for
a minimum of 1 year
Collins 201215 l Inclusion criteria: patients registered
between 1 January 2000 and
30 June 2008, and recorded on THIN
database
l Exclusion criteria: prior diagnosis of
CRC, patients registered < 12 months
with the general practice, had invalid
dates, aged < 30 years or > 85 years





during the 2 years
after study entry
2,135,540 patients,
including 3712 cases of
CRC (1676 women and
2036 men)
Multiple imputation
using all predictors plus
the outcome variable





















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Cases – patients aged ≥ 40 years with
a primary CRC, diagnosed between
1998 and 2002 in one hospital
l Controls: five for each case matched on
sex, general practice and age
All related features (symptoms and
variables) were investigated; only
features occurring in at least 2.5%
of either cases or controls were
analysed
Diagnosis of CRC





Exclusion criteria (cases and controls):
unobtainable records; no consultations in
the 2 years before diagnosis; previous
CRC; or residence outside Exeter at the
time of diagnosis
Elias 201750 Inclusion criteria: lower-abdominal
complaints for at least 2 weeks with
rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight
loss, sudden onset in elderly, and/or
physical examination suggestive of
colorectal disease






l Cases – all patients with CRC, aged
≥ 30 years, diagnosed between
January 2001 and July 2006
l Controls – up to seven for each case,
matched for practice, sex and age
23 candidate variables (features)
were identified from a review of
the literature
Diagnosis of CRC





Exclusion criteria: < 2 years of data








































l Cases – patients with IBD and CRC,
aged 18–49 years at diagnosis, between
January 2000 and December 2013
l Controls – three controls were
matched on sex, general practice,
and to 1 year of age of the case
All symptoms, physical signs or
abnormal investigations related to
CRC/IBD that occurred in ≥ 5% of
cases or controls were retained
Diagnosis of either
IBD or CRC within
1 year of presentation
with symptoms
l CRC: 1661 cases;
3979 controls
l IBD: 9578 cases;
22,947 controls
NR
Exclusion criteria: cases and controls with
no consultations in the year before the
index date; controls that had a previous





Inclusion criteria: patients aged 30–84
years, registered with practices between
1 January 2000 and 30 September 2010
Current first onset of dysphagia,
haematemesis, loss of appetite,
weight-loss symptom or abdominal
pain; recent GP consultation for
tiredness; age; BMI; smoking status;
alcohol status; Townsend
deprivation score; family history of
gastrointestinal cancer; previous













for BMI, alcohol intake
and smoking status
Exclusion criteria: patients without a
postcode-related Townsend deprivation
score, history of gastro-oesophageal
cancer at baseline, red-flag symptoms
recorded (dysphagia, haematemesis, loss
of appetite, weight loss and abdominal
pain) in the 12 months prior to the study
entry date
Inclusion criteria: patients from general
practices using EMIS computer system for
a minimum of 1 year
Collins 201388 Inclusion criteria: patients registered
between 1 January 2000 and 30 June
2008, and recorded on THIN database
Exclusion criteria: prior diagnosis of CRC,
patients registered < 12 months with the
general practice, had invalid dates, aged
< 30 or > 85 years





in the 2 years after
study entry
2,135,540 patients,




using all predictors plus
the outcome variable





















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Cases: patients aged ≥ 40 years
with an oesophago-gastric tumour
diagnosed between 1 January 2000
and 31 December 2009, and with at
least 1 year of data
l Controls: up to five for each case,
matched by year of birth, sex
and practice
All symptoms, physical signs or
abnormal investigations that












Exclusion criteria: any individuals without
a consultation in the year before the
diagnosis/index date; cancers from other
sites that had spread to the oesophagus







l Cases – all cancers diagnosed between
1 January 2000 and 28 July 2009;
aged ≥ 40 years; a minimum of 1 year
of data before diagnosis
l Controls – matched on age, sex and
general practice
l All symptoms, diagnoses and
investigations in 2 years prior to
lung cancer diagnosis/index date





features suggestive of metastasis
from lung cancer, cervical/
supraclavicular lymphadenopathy,





l Assessed records of chest X-rays,















































l Inclusion criteria: patients aged
30–84 years, drawn from patients
registered with practices between
1 January 2000 and 30 September 2010
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
history of lung cancer at baseline;
red-flag symptoms (haemoptysis, loss
of appetite, or weight loss) recorded
in the 12 months before the study
entry date
l Inclusion criteria: patients from general
practices using EMIS computer system
for a minimum of 1 year
Current first onset of haemoptysis,
loss of appetite or weight-loss
symptom; recent (within 12 months)
GP consultation for cough,
dyspnoea, tiredness or hoarseness;
BMI; smoking status; chronic
obstructive airways disease
diagnosed ever; Townsend
deprivation score; family history of
lung cancer; previous diagnosis of
cancer apart from lung cancer;
asthma diagnosed ever; pneumonia
















l Cases – residents of Exeter, UK,
aged ≥ 40 years who had a primary
lung cancer diagnosed during
1998–2002, inclusive
l Controls – five for each case matched
on sex, general practice, and age; alive
at time of case diagnosis
All related features (symptoms and
variables) were investigated. Only
features occurring in at least 2.5%
of either cases or controls were
analysed
Diagnosis of lung





Exclusion criteria (both): unobtainable
records; no consultations in the 2 years
before diagnosis; previous lung cancer;




















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Inclusion criteria: patients aged
30–84 years registered between
1 January 2000 and 30 September 2010
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
history of bilateral oophorectomy or
ovarian cancer at baseline; red-flag
symptoms recorded in the 12 months
before the study entry date, aged
< 30 or > 84 years
l Current first onset of loss of
appetite, weight loss symptom,
abdominal pain, abdominal
distension, rectal bleeding or
postmenopausal bleeding




l Age, BMI, smoking status, alcohol
use, Townsend deprivation score,
previous diagnosis of cancer apart
from ovarian cancer, anaemia
Diagnosis of ovarian
cancer during the








for BMI, alcohol intake
and smoking status
Collins 201389 l Inclusion criteria: patients
registered between 1 January 2000
and 30 June 2008 on THIN database
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
history of bilateral oophorectomy or
ovarian cancer at baseline; red-flag
symptoms recorded in the 12 months
before the study entry date; aged
< 30 or > 84 years














l Cases – all women with primary
ovarian cancer, aged ≥ 30 years,
diagnosed between 2000 and 2007
l Controls – five for each case, matched
for practice, sex, and age; alive at the
time of diagnosis of their matched case
Only symptoms occurring in at
least 5% of either cases or controls
were studied
Diagnosis of ovarian





l 11 practices declined
to participate
Exclusion criteria: medical record
unobtainable, no entry in the records
in the year before diagnosis, previous
ovarian cancer or bilateral oophorectomy,









































Inclusion criteria: patients aged 30–84 years
registered between 1 January 2000 and
30 September 2010; missing a postcode-
related Townsend deprivation score;
history of pancreatic cancer at baseline;
red-flag symptoms recorded in the
12 months before the study entry date,
aged < 30 or > 84 years
l Current first onset of dysphagia,
loss of appetite, weight loss
symptom, abdominal pain or
abdominal distension
l Recent (within 12 months) GP
consultation for constipation,
diarrhoea, tiredness, itching
l Age, BMI, smoking status, alcohol
status, Townsend deprivation
score, derived from patients’
postcodes, diabetes, pancreatitis
(acute/chronic/none) at study
entry, previous diagnosis of
cancer apart from pancreatic









for BMI, alcohol intake
and smoking status
Collins 201314 l Inclusion criteria: patients registered
between 1 January 2000 and 30 June
2008 on THIN database
l Exclusion criteria: missing data; history
of pancreatic cancer at baseline;
red-flag symptoms recorded in the
12 months before the study entry date,
aged < 30 or > 84 years










using all predictors plus
the outcome variable






l Cases – patients aged ≥ 40 years with a
pancreatic tumour diagnosed between
1 January 2000 and 31 December 2009,
with at least 1 year of data before the
first diagnostic code
l Controls – up to five controls, matched to
the case by year of birth, sex and practice
All symptoms, physical signs or
abnormal investigations that








Exclusion criteria: those with no
consultations in the year before cancer
diagnosis/index date; controls excluded if



















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )





Keane 201462 l Cases: patients with a Read code
diagnosis of PDAC or BTC between
1 January 2000 and 31 December 2010
l Controls: no PDAC or BTC diagnosis,
matched to cases on age, sex, practice
and year of diagnosis (random
consultation date)
l Two years of data available prior to the
index date
l Only included general practices that
had acceptable mortality recording and
computer usage
‘Alarm’ symptoms and commonly
performed blood test results were
identified based on clinical
knowledge and the existing
literature. Only symptoms with a
frequency of > 5% were identified
as potential alarm symptoms. Age,
sex, time period and Townsend
deprivation score, smoking status
and BMI were selected as potential
confounders
Diagnosis of PDAC or
BTC within 2 years of
presentation
2773 cases with PDAC,







l Cases – residents of Exeter, UK aged
≥ 40 years who had a prostate cancer
diagnosed from 1998 to 2002, inclusive
l Controls – five for each case matched
on sex, general practice, and age; alive
at time of index date (case diagnosis
date)
All related features (symptoms and
variables) were investigated; only
features occurring in at least 2.5%
of either cases or controls were
analysed
Diagnosis of prostate





Exclusion criteria (both): unobtainable
records; no consultations in the 2 years
before diagnosis; previous prostate









































l Inclusion criteria: patients aged
30–84 years registered between
1 January 2000 and 30 September 2010
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
history of renal tract cancer at
baseline; red-flag symptoms recorded
in the 12 months before the study
entry date, aged < 30 or > 84 years
l Current first onset of
macroscopic haematuria, loss of
appetite, weight-loss symptom or
abdominal pain
l Recent (within 12 months) GP
consultation for constipation,
diarrhoea or tiredness
l Age, BMI, smoking status, alcohol
use, Townsend deprivation score,




diabetes (type 1/type 2/no
diabetes), previous diagnosis of
cancer apart from renal tract
cancer at study entry, anaemia
Diagnostic of renal
tract cancer within







for BMI, alcohol intake
and smoking status
Collins 201391 l Inclusion criteria: patients registered
between 1 January 2000 and
30 June 2008 on THIN database
l Exclusion criteria: missing data; history
of renal cancer at baseline; red-flag
symptoms recorded in the 12 months
before the study entry date, aged < 30
or > 84 years








using all predictors plus
the outcome variable





















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Cases – patients with a first diagnosis
of kidney cancer between January
2000 and December 2009, inclusive;
aged ≥ 40 years; a minimum of 1 year
of data before diagnosis
l Controls: up to five controls were
matched on sex, general practice, and
to 1 year of age of the case
l Features potentially associated
with kidney cancer were




l Only those reported in > 5% of
cases or controls were
considered further
Diagnosis of kidney





Exclusion criteria: metastatic cancer of the
kidney from a non-kidney primary,
diagnosis before 2000, or no consultations





l Cases – women aged ≥ 40 years with a
diagnostic code for uterine tumour,
between 1 January 2000 and
31 December 2009
l Controls: five controls were matched
on sex, general practice, and to 1 year
of age of the case
All symptoms, physical signs or
abnormal investigations related
to uterine cancer, that occurred
in ≥ 2% of cases or controls
were retained
Diagnosis of uterine







diagnosis before 1 January 2000; controls
diagnosed with uterine cancer before the
index date; metastatic cancer from a non-
uterine primary cancer; women with a
recorded hysterectomy before the index
date; and women with no consultations in









































l Cases – deceased with a prior record
of breast, colorectal or prostate cancer
and radiologically or histologically
proven metastatic cancer
l Controls – two controls per case,
alive at the time of the diagnosis of
metastatic cancer in the case, matched
for practice, sex, age; one with same
(non-metastatic) cancer, one
without cancer
NR. 207 separate ‘features’ were
identified in > 2% of cases
Diagnosis of
metastatic cancer








Exclusion criteria: primary cancer
considered incurable at the time of initial
diagnosis, or metastatic spread had
occurred within 6 months of diagnosis of
the primary cancer; cases for whom the
primary cancer was diagnosed before
40 years of age; patients whose
metastases occurred before registration
at the current practice; cases, the full
record for which had been archived



















































































































































































































































































































































TABLE 38 Systematic review 2: included studies, study characteristics (2) (continued )








l Inclusion criteria: females aged
25–89 years registered with
participating practices between
1 January 2000 and 1 April 2012
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
red-flag symptoms recorded in the
12 months before the study entry date
l Inclusion criteria: patients from general
practices using EMIS computer system
for a minimum of 1 year
Red-flag symptoms and more
general symptoms, plus risk factors:
age, BMI, smoking status, alcohol
use, Townsend deprivation score
(postcodes), previous diagnosis
of cancer, anaemia, family history
of breast cancer, family history of
gastrointestinal cancer, family
history of ovarian cancer, benign
breast disease, chronic pancreatitis,
type 1 diabetes, type 2 diabetes,
endometriosis, endometrial
hyperplasia or polyp, fibroid,
polycystic ovarian disease,
rheumatoid arthritis, systemic lupus
erythematosus, a HIV infection or
AIDS, oral contraceptive use,
hormone replacement therapy
Diagnosis of cancer







used in the validation
cohort to replace




l Inclusion criteria: males aged 25–89
years registered with participating
practices between 1 January 2000 and
1 April 2012
l Exclusion criteria: missing a postcode-
related Townsend deprivation score;
red-flag symptoms recorded in the
12 months before the study entry date
l Inclusion criteria: patients from general
practices using EMIS computer system
for a minimum of 1 year
Red-flag symptoms and more
general symptoms, plus risk factors:
age, BMI, smoking status, alcohol
use, Townsend deprivation score
(postcodes), previous diagnosis of
cancer, anaemia, family history of
gastrointestinal cancer, family
history of prostate cancer, chronic
pancreatitis, type 1 diabetes, type 2
diabetes
Diagnosis of cancer







used in the validation
cohort to replace










































l Cases – all children aged 0–14 years,
with cancers diagnosed between
1 January 1988 and 31 December
2010 from > 600 general practices
across the UK
l Controls – up to 13 controls per case
registered with the practice on the
index date of the case, never diagnosed
with cancer, matched on age (within
1 year), sex and practice
Three or more consultations,
upper respiratory tract infection,
musculoskeletal symptoms, vomiting,
cough, headache, lymphadenopathy,
rash, abdominal pain, childhood
infection, fever, abnormal
movement, abdominal mass, pain,
fatigue, lump mass swelling (below
neck excluding abdomen), eye
swelling, shortness of breath,
bruising, pallor, bleeding, lump mass














Muris 199556 Inclusion criteria: aged 18–75 years,
consulting GP for new abdominal
complaints lasting at least 2 weeks,
consenting to participate
Age and sex. WBC count, ESR, low
Hb level, positive FOBT. Low
somatisation score, no depression,
high self-esteem, social inadequacy,
plus 23 symptoms
Multiple cancers 933, including ≈ 18
having cancer
NR
Elias 201750 Inclusion criteria: lower-abdominal
complaints for at least 2 weeks with
rectal bleeding, change in bowel habit,
abdominal pain, fever, diarrhoea, weight
loss, sudden onset in elderly, and/or
physical examination suggestive of
colorectal disease





AIDS, acquired immunodeficiency syndrome; ATC, Anatomical Therapeutic Chemical; BMI, body mass index; BTC, biliary tract cancer; DVT, deep-vein thrombosis; ESR, erythrocyte
sedimentation rate; GPRD, General Practice Research Database; HIV, human immunodeficiency virus; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; ICPC,


















































































































































































































































































































































TABLE 39 Systematic review 2: included studies, model development and performance




Conditional logistic regression. Variables
with an independent association with cancer
(p < 0.001) were included in the final
multivariable model. Variables were then
grouped for multivariable analysis, collecting
together variables that were similar (such as
visible and non-visible haematuria), using a
p-value threshold of ≤ 0.05. The final stage
of multivariable analysis used all variables
surviving the previous stages, and used a
p-value threshold of 0.01. All excluded
variables were checked against the final model
PPVs were estimated for predictors shown to be
independently associated with cancer in the
multivariable analysis. This was repeated for pairs of
symptoms and for second attendances with the




Conditional logistic regression. Variables with
p < 0.1 from univariable analyses were
grouped by similarity, those with p < 0.05
entered final model, at which point those with
p < 0.01 were retained in model
l PPVs were calculated for those aged > 60 years,
targeting patients around the average age of
leukaemia diagnosis
l Chronic leukaemia highest PPV was 0.34% for
lymphadenopathy. Lymphadenopathy with cough
PPV of 0.27%. Many combinations were too rare
for PPV calculation
l Acute leukaemia highest combined PPV was
fever with infection, PPV 0.13%
Shephard
201568
Non-parametric methods in univariable
analysis, a p-value threshold of ≤ 0.1 was
used to identify candidate variables for
multivariable analysis These were then
grouped into small clinically coherent groups
containing similar variables in the first stage of
multivariable analysis, with retention requiring
a p-value of ≤ 0.05. A final multivariable model
used the surviving variables from the previous
stages, using a p-value threshold of 0.01




Variables associated with tumours in
univariable analyses with p ≤ 0.1 were entered
into the staged multivariable analyses;
discarded variables were checked against the
final model. Seven clinically plausible internal
interactions were tested in the final model
PPVs:
l Headache: 0.09% (95% CI 0.08% to 0.10%)
l Motor loss: 0.026% (95% CI 0.024% to 0.030%)
l New-onset seizure: 1.2% (95% CI 1.0% to 1.4%)
l Confusion: 0.20% (95% CI 0.16% to 0.24%)
l Weakness: 0.14% (95% CI 0.11% to 0.18%)
l Memory loss: 0.036% (95% CI 0.026%
to 0.052%)





Logistic regression. Univariable associations
for the explanatory variables were
investigated and those with a threshold
of < 0.01 were used in the multivariate
regression model
The regression coefficients from the derivation
cohort were applied to individuals in the validation
cohort and used to generate expected and observed
probabilities of breast cancer. The numbers of
expected vs. observed cancers were also plotted by
decile of predicted risk, based on the derivation
model. Hosmer–Lemeshow goodness-of-fit test for
the calibration of the model showed no significant
difference between expected and observed breast
cancers (7.02, p = 0.73), but the plot suggested that
the number of cancers was overestimated for those
at highest risk
APPENDIX 3
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )




Multivariable conditional logistic regression
analysis. Initial univariable conditional logistic
regression analysis was carried out with the
initial predictor variables and some variables
were combined. Variables associated with CRC
with p < 0.1 were entered into multivariable
conditional logistic regression
ROC curves, sensitivity, LRs and PPVs also reported
In the CAPER data set, AUCs: BB 0.92 (95% CI 0.91
to 0.94); CAPER 0.91 (95% CI 0.89 to 0.93); NICE
guidelines 0.75 (95% CI 0.72 to 0.79)
Elias 201750 N/A. Used BB equation22 l NPV: 100 (95% CI 98 to 100)
l PPV: 7 (95% CI 5 to 9)
l Sensitivity: 97 (95% CI 85 to 100)
l Specificity: 36 (95% CI 32 to 40)
l AUC: 0.84 (95% CI 0.77 to 0.90)
Fijten 199555 Forward stepwise logistic regression analysis.
Variables showing an association (p < 0.1) with
cancer were included in the multivariate model
l Diagnostic index: AUC 0.97 (no estimate of
variance reported). Also reported sensitivity,
specificity, predictive values, ORs
l Diagnostic index+ presence of polyps: AUC 0.92




Used Fijten 199555 risk prediction model. Also
assessed performance of guidelines and scores
that were not based on risk prediction models
(results not reported here)
AUC of 0.775 (SE 0.02)
Elias 201750 N/A. Used Fijten 199555 l NPV: 99 (95% CI 95 to 1000)
l PPV: 10 (95% CI 7 to 14)
l Sensitivity: 98 (95% CI 83 to 100)
l Specificity: 29 (95% CI 24 to 34)
l AUC: 0.72 (95% CI 0.62 to 0.81)
Kop 201561 Models were generates using logistic
regression, RF, SVM and the CART algorithm
A priori algorithm: the records are scanned first to
create frequent patterns of size 1. These patterns
are used to generate successively larger patterns,
that is k patterns are used to obtain frequent k + 1
patterns. Generating a k+ 1 pattern is, however,
more elaborate than for standard a priori, because
the generated candidate patterns need to
accommodate for multiple possible (successions)
and (occuring) relations. This results in more k+ 1
patterns being tested for frequency than with
standard a priori, increasing the complexity
Hippisley-Cox
201280
l Cox proportional hazards. Rubin’s rules
were used to combine the results across
the imputed data sets
l Fractional polynomials used for non-linear
risk relationships. Fitted full model,
variables retained if HR < 0.80, HR > 1.20
and a p < 0.01
Females:
l R2 (%): 64.8 (95% CI 63.2 to 66.3)
l D-statistic: 2.78 (95% CI 2.68 to 2.87)
l AUC: 0.89 (95% CI 0.88 to 0.90)
Males:
l R2 (%): 66.7 (95% CI 65.3 to 68.0)
l D-statistic: 2.90 (95% CI 2.81 to 2.98)
l AUC: 0.906 (95% CI 0.899 to 0.913)
Collins
201215
N/A. Used QCancer (colorectal), see
Hippisley-Cox 201280
Men:
Multiple imputation (m= 10) (n = 1,059,765)
l R2 (%): 68.32 (95% CI 67.32 to 69.32)
l D-statistic: 3.00 (95% CI 2.93 to 3.07)
l c-statistic: 0.918 (95% CI 0.913 to 0.923)
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
Complete case (n = 417,560)
l R2 (%): 65.30 (95% CI 63.71 to 66.89)
l D-statistic: 2.81 (95% CI 2.71 to 2.91)
l c-statistic: 0.901 (95% CI 0.892 to 0.910)
Women:
Complete case (n = 1,075,775)
l R2 (%): 65.81 (95% CI 64.62 to 67.01)
l D-statistic (95% CI) 2.84 (95% CI 2.76 to 2.92)
l c-statistic (95% CI) 0.909 (95% CI 0.903 to 0.915)
Nørrelund
199657
Mann–Whitney and chi-squared tests, and
logistic regression. No further details reported
Study 1 (apparent performance I):
l Age > 69 years: sensitivity 75%, specificity 76%,
PPV 36%, NPV 94%
l Age > 69 years plus change in bowel habits:
sensitivity 44%, specificity 94%, PPV 56%, NPV 90%
l Change in bowel habits plus patient belief
bleeding is due to cancer: sensitivity 22%,
specificity 97%, PPV 58%, NPV 87%
Study 2 (apparent performance II), new bleeders:
l Age > 69 years: sensitivity 46%, specificity 72%,
PPV 18%, NPV 91%
l Age > 69 years plus change in bowel habits:
sensitivity 15%, specificity 88%, PPV 13%, NPV 85%
l Change in bowel habits plus patient belief
bleeding is due to cancer: sensitivity 0%,
specificity 95%, PPV 0%, NPV 87%
Study 2 (apparent performance II), new or changed
bleeders:
l Aged > 69 years: sensitivity 45%, specificity 75%,
PPV 23%, NPV 91%
l Aged > 69 years plus change in bowel habits:
sensitivity 23%, specificity 88%, PPV 24%, NPV 87%
l Change in bowel habits plus patient belief
bleeding is due to cancer: sensitivity 5%,
specificity 96%, PPV 14%, NPV 86%
Elias 201750 N/A. Used Danish (Nørrelund 199657) model l NPV: 93 (95% CI 71 to 99)
l PPV: 8 (95% CI 6 to 12)
l Sensitivity: 95 (95% CI 80 to 99)
l Specificity: 6 (95% CI 3 to 9)
l AUC: 0.60 (95% CI 0.48 to 0.72)
Hamilton
200581
Variables associated with cancer in univariable
analyses, using a p-value of ≤ 0.1, entered the
multivariable analysis. In the first stage, similar
variables were grouped together; in the
second stage, analyses were repeated with the
new groups
Nine features [constipation, diarrhoea, rectal
bleeding, loss of weight, abdominal pain, abdominal
tenderness, abnormal rectal examination, anaemia
(Hb level 10−13 g/dl; Hb < 10 g/dl) and a blood
sugar concentration of > 10 mmol/l] were
associated with CRC before diagnosis. The PPVs
(95% CI%) of these were rectal bleeding 2.4%
(1.9% to 3.2%), weight loss 1.2% (0.91% to 1.6%),
abdominal pain 1.1% (0.86% to 1.3%), diarrhoea
0.94% (0.73% to 1.1%), constipation 0.42% (0.34%
to 0.52%), abnormal rectal examination 4.0% (2.4%
to 7.4%), abdominal tenderness 1.1% (0.77% to
1.5%), a Hb level of < 10.0 g/dl 2.3% (1.6% to 3.1%),
positive FOBT 7.1% (5.1% to 10%) and a blood
glucose concentration of 410 mmol/l 0.78% (0.51%
to 1.1%); all p-values < 0.001. See figure 2 of the
publication81 for additional PPVs
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
Elias 201750 N/A. Used RAT (colorectal) model81 l NPV: 99 (95% CI 98 to 100)
l PPV: 8 (95% CI 6 to 10)
l Sensitivity: 95 (95% CI 82 to 99)
l Specificity: 45 (95% CI 41 to 49)
l AUC: 0.81 (95% CI 0.75 to 0.88)
Hamilton
200974
Variables with a univariable association with
cancer significant with a p-value of < 0.1 were
entered into a staged multivariable analysis
PPVs were estimated
Six symptoms and two abnormal investigations
(anaemia and microcytosis) were independently
associated with CRC. The PPVs (95% CIs) of
symptoms were as follows: rectal bleeding, to PPV for
a male aged ≥ 80 years 4.5% (3.5% to 5.9%), change
in bowel habit 3.9% (2.8% to 5.5%), weight loss 0.8%
(0.5% to 1.3%), abdominal pain 1.2% (1.0% to 1.4%),
diarrhoea 1.2% (1.0% to 1.5%) and constipation
0.7% (0.6% to 0.8%). PPVs were lower in females and
younger patients. Only 27% of patients had reported
either of the two higher-risk symptoms
Stapley
201772
Conditional logistic regression. Variables
independently associated with pancreatic
cancer with a p-value of < 0.1 were entered
into the multivariable analysis multivariable
analysis performed in three stages; final model
used a threshold p-value of< 0.02
PPVs were derived, using national incidence data to




Cox’s proportional hazards. Rubin’s rules
were used to combine the results across the
imputed data sets. Fractional polynomials
were used to model non-linear risk
relationships with continuous variables.
Fitted full model, variables retained if
HR< 0.80, HR> 1.20 and p < 0.01
Females:
l R2 (%): 71.2 (95% CI 69.2 to 73.2)
l D-statistic: 3.22 (95% CI 3.06 to 3.37)
l AUC: 0.89 (95% CI 0.87 to 0.91)
Males:
l R2 (%): 72.5 (95% CI 71.1 to 73.8)
l D-statistic: 3.32 (95% CI 3.21 to 3.43)
l AUC: 0.92 (95% CI 0.91 to 0.93)
Collins
201388
N/A. Used QCancer (gastro-oesophageal), see
Hippisley-Cox 201182
Men:
Multiple imputation (m= 10) (n = 1,077,977)
l R2 (%): 74.4 (95% CI 73.0 to 75.8)
l D-statistic: 3.49 (95% CI 3.35 to 3.62)
l c-statistic: 0.93 (95% CI 0.92 to 0.94)
Complete case (n= 852,532)
l R2 (%): 74.9 (95% CI 73.3 to 76.5)
l D-statistic: 3.53 (95% CI 3.38 to 3.69)
l c-statistic: 0.94 (95% CI 0.93 to 0.95)
Women:
Multiple imputation (m= 10) (n = 1,062,217)
l R2 (%): 75.6 (95% CI 74.6 to 76.5)
l D-statistic: 3.60 (95% CI 3.51 to 3.69)
l c-statistic: 0.94 (95% CI 0.94 to 0.95)
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
Complete case (n = 1,075,775)
l R2 (%): 65.81 (95% CI 64.62 to 67.01)
l D-statistic: 2.84 (95% CI 2.76 to 2.92)
l c-statistic: 0.909 (95% CI 0.903 to 0.915)
Stapley
201371
Conditional logistic regression. Variables
independently associated with oesophago-
gastric cancer with a p-value of < 0.1 were
entered into the multivariable analysis.
Significant variables (at p < 0.05) were
grouped together and those variables
significant at a p-value of< 0.01 remained
in the final model
PPVs for the risk of oesophago-gastric cancer in
patients consulting in primary care. PPVs (%):
dysphagia 1.5 (95% CI 1.3 to 1.8), dyspepsia 0.2
(95% CI 0.19 to 0.22), nausea/vomiting 0.18 (0.17
to 0.20), abdominal pain 0.08 (95% CI 0.08 to 0.09),
reflux 0.19 (95% CI 0.18 to 0.22), chest pain 0.05
(95% CI 0.05 to 0.06), epigastric pain 0.28 (95% CI
0.24 to 0.32), weight loss 0.26 (95% CI 0.23 to
0.31), constipation 0.07 (95% CI 0.06 to 0.07),
low Hb 0.07 (95% CI 0.07 to 0.08), abnormal
hepatic enzymes 0.04 (95% CI 0.04 to 0.05), raised
inflammatory markers 0.08 (95% CI 0.08 to 0.09)





Analyses conducted separately for features
4–12 and 13–24 months before diagnosis/
index date
Logistic regression. Included features
statistically significant (p < 0.05) in univariate
analyses. From multivariate model removed
variables that were not significant, and
features not significant in univariate analyses
were rechecked for significance in multivariate
model
Model based on features 4–12 months before
diagnosis/index date. Area under the ROC curve
of 0.88
Sensitivities (%) and specificities (%), respectively,
reported at different risk score cut-off values:
l –3: 93.98, 59.67
l –2.5: 88.31, 70.43
l –2: 79.57, 78.81
l –1.5: 68.40, 86.05
l –1.25: 61.52, 89.51
l –1: 53.07, 92.13
l –0.5: 35.30, 96.04
l 0: 21.24, 98.32
l 0.5: 10.07, 99.36
Hippisley-Cox
201152
Cox proportional hazards models with age as
the underlying time variable were used to
develop separate risk equations in males
and females
Variables included if HR < 0.80, HR > 1.20 and
a p-value of 0.01
Females:
l R2 (%): 71.70 (95% CI 70.30 to 73.10)
l D-statistic: 3.25 (95% CI 3.15 to 3.37)
l AUC: 0.92 (95% CI 0.91 to 0.93)
Males:
l R2 (%): 72.11 (95% CI 71.04 to 73.18)
l D-statistic: 3.29 (95% CI 3.20 to 3.38)
l AUC: 0.92 (95% CI 0.91 to 0.93)
Hamilton
200551
Variables associated with cancer in univariable
analyses, using a p-value of ≤ 0.1, entered the
multivariable analysis
18 clinically plausible interactions were tested
in the final model; analyses were repeated
excluding data from the last 180 days of the
730-day period studied. PPVs for individual
variables and for pairs of variables were
calculated from the LR and the observed
incidence of cancer during the study
Colour-coded PPVs are reported in figure 2 of the
publication51
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )




Cox’s proportional hazards model was used to
estimate the coefficients for each risk factor
using robust variance estimates to allow for
the clustering of patients within general
practices. Rubin’s rules were used to combine
the results across the imputed data sets.
Fractional polynomials for modelling non-
linear risk relations with continuous variables.
Fitted full model, variables retained if HR
< 0.80, HR > 1.20 and a p-value of 0.01
l R2 (%): 57.6 (95% CI 54.8 to 60.4)
l D-statistic: 2.38 (95% CI 2.24 to 2.51)
l AUC: 0.84 (95% CI 0.83 to 0.86)
Collins
201389
N/A. Used QCancer (ovarian), see
Hippisley-Cox 201184
l R2 (%): 59.9 (95% CI 57.7 to 62.0)
l D-statistic: 2.50 (95% CI 2.38 to 2.62)
l AUC: 0.86 (95% CI 0.84 to 0.87)
Hamilton
200983
Symptoms independently associated with the
outcome, with a p-value of < 0.1, were
retained for multivariable analyses. The
resulting 99 variables were placed in eight
groups and each group was analysed by
multivariable conditional logistic regression.
Symptoms still associated with cancer were
rearranged into two larger groups (abdominal
symptoms and other symptoms) for the final
model. Discarded symptoms were checked
against the final model. Five clinically plausible
interactions were tested in the final model





Cox proportional hazards models with age as
the underlying time variable were used to
develop separate risk equations in males
and females
Variables included if HR < 0.80, HR > 1.20 and
p < 0.01
Females:
l R2 (%): 58.7 (95% CI 55.4 to 61.9)
l D-statistic: 2.44 (95% CI 2.27 to 2.60)
l AUC: 0.84 (95% CI 0.82 to 0.86)
Males:
l R2 (%): 62.0 (95% CI 59.1 to 64.8)
l D-statistic: 2.61 (95% CI 2.45 to 2.77)
l AUC: 0.87 (95% CI 0.85 to 0.88)
Collins
201314
N/A. Used QCancer (pancreas), see
Hippisley-Cox 201232
Multiple imputation (m= 10)
l Women (n= 1,082,730)
¢ R2 (%): 60.0 (95% CI 56.6 to 63.5)
¢ D-statistic: 2.51 (95% CI 2.32 to 2.70)
¢ c-statistic: 0.89 (95% CI 0.87 to 0.90)
l Men (n= 1,067,592)
¢ R2 (%): 66.6 (95% CI 64.1 to 69.2)
¢ D-statistic: 2.89 (95% CI 2.72 to 3.07)
¢ c-statistic: 0.92 (95% CI 0.91 to 0.93)
Complete case
l Women (n= 873,026)
¢ R2 (%): 62.0 (95% CI 58.4 to 65.7)
¢ D-statistic: 2.61 (95% CI 2.40 to 28.3)
¢ c-statistic: 0.90 (95% CI 0.88 to 0.91)
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
l Men (n= 823,873)
¢ R2 (%): 66.1 (95% CI 63.2 to 69.0)
¢ D-statistic: 2.86 (95% CI 2.66 to 3.05)
¢ c-statistic: 0.91 (95% CI 0.90 to 0.93)
Stapley
201270
Conditional logistic regression. Variables
independently associated with pancreatic
cancer with a p-value of < 0.1 were entered
into the multivariable analysis. In the first
stage, similar variables were grouped together;
in the second stage analyses were repeated
with the new groups (with p < 0.05); in the
third stage, the final model was built with the
retained variables (with p < 0.01)
PPVs for the risk of pancreatic cancer in patients
consulting in primary care were calculated using
Bayes’ theorem; see figure 2 in publication70
PPVs for patients aged > 60 years were < 1%, apart
from jaundice at 22% (95% CI 14% to 52%), although
several pairs of symptoms had PPVs of > 1%
Keane 201462 l Multivariable logistic regression was used
to estimate ORs. Linear regression was
used to estimate adjusted mean differences
in clinical measures between patients with
and patients without cancer
l Ignored skewed laboratory test data on
basis that sample size was large. Accounted





Conditional logistic regression. Variables
associated with cancer in univariable analyses,
using a p-value of ≤ 0.1, entered the
multivariable analysis. In the first stage, similar
variables were grouped together; in the
second stage, analyses were repeated with the
new groups (with p < 0.05); in the third stage,
the final model was built with the retained
variables (with p < 0.01)
PPVs were calculated from the LRs and the
observed annual incidence of cancer during the
study, see figure 2 in publication90
Eight features were associated with prostate cancer
before diagnosis. Their PPVs against a background
risk of 0.35% were as follows: urinary retention
3.1% (95% CI 1.5% to 6.0%); impotence 3.0%
(95% CI 1.7% to 4.9%); frequency 2.2% (95% CI
1.3% to 3.5%); hesitancy 3.0% (95% CI 1.5% to
5.5%); nocturia 2.2% (95% CI 1.2% to 3.6%);
haematuria 1.0% (95% CI 0.57% to 1.8%); weight
loss 0.75% (95% CI 0.38% to 1.4%); abnormal rectal
examination, deemed benign 2.8% (95% CI 1.6%
to 4.6%); abnormal rectal examination, deemed
malignant 12% (95% CI 5.0% to 37%). All p < 0.001,
except for hesitancy (p = 0.032), nocturia (p = 0.004)




Cox proportional hazards models with age as
the underlying time variable were used to
develop separate risk equations in males
and females
Variables included if HR < 0.80, HR > 1.20 and
a p-value of 0.01
Females:
l R2 (%): 74.8 (95% CI 73.2 to 76.5)
l D-statistic: 3.53 (95% CI 3.37 to 3.68)
l AUC: 0.91 (95% CI 0.90 to 0.93)
Males:
l R2 (%): 75.5 (95% CI 74.6 to 76.4)
l D-statistic: 3.60 (95% CI 3.51 to 3.69)
l AUC: 0.95 (95% CI 0.94 to 0.96)
Collins
201391
N/A. Used QCancer (renal), see Hippisley-Cox
201285
Multiple imputation (m= 10)
l Women:
¢ R2 (%): 74.4 (95% CI 73.0 to 75.8)
¢ D-statistic: 3.49 (95% CI 3.36 to 3.62)
¢ c-statistic: 0.92 (95% CI 0.91 to 0.94)
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
l Men:
¢ R2 (%): 74.2 (95% CI 73.4 to 75.1)
¢ D-statistic: 3.47 (95% CI 3.40 to 3.55)
¢ c-statistic: 0.95 (95% CI 0.94 to 0.95)
Complete case
l Women:
¢ R2 (%): 74.0 (95% CI 72.1 to 75.5)
¢ D-statistic: 3.43 (95% CI 3.28 to 3.59)
¢ c-statistic: 0.92 (95% CI 0.91 to 0.94)
l Men:
¢ R2 (%): 74.0 (95% CI 73.0 to 75.1)
¢ D-statistic: 3.46 (95% CI 3.36 to 3.55)
¢ c-statistic: 0.95 (95% CI 0.94 to 0.96)
Shephard
201366
Conditional logistic regression: features
associated with cancer with p-values of ≤ 0.1
were grouped for the first multivariable
analysis, with retention requiring a p-value
of ≤ 0.05. A final multivariable model was
compiled from the features of the previous
stage for which p < 0.01
l PPVs were produced for all features shown to
be independently associated with kidney cancer,
see figure 2 of publication66
l The PPV for visible haematuria (the most
powerful single predictor) in patients aged




Conditional logistic regression. Variables
independently associated with pancreatic
cancer with a p-value of < 0.1 were entered
into the multivariable analysis. In the first
stage, similar variables were grouped together;
in the second stage, analyses were repeated
with the new groups (with p < 0.05); in the
third stage, the final model was built with the
retained variables (with p < 0.05)
PPVs were estimated for features shown to be
independently associated with uterine cancer in
the multivariable analysis, using Bayes’ theorem.




Conditional logistic regression. Univariable
analyses were performed initially, retaining
variables with a p-value of < 0.1 to enter into
multivariable analyses; only variables that
were present in > 2% of the cases were
studied. Cancer controls and healthy controls
were used in separate analyses, and the
cancer sites were analysed separately, and also
merged and a unified analysis performed.
Clinically plausible interaction terms were
added to each model, and LR testing was






Multinomial logistic regression was used to
estimate the coefficients for each predictor
variable for each type of cancer. Fitted full
model and variables retained if p ≤ 0.01.
Fractional polynomials were used to model
non-linear risk relationships with continuous
variables
l Discrimination (table 6): all ROC statistic values
for each cancer type were > 0.79, except for
cervix (0.73). The highest ROC values were for
lung cancer (0.91) and uterine cancer (0.91)
l Calibration (figure 1): compared mean predicted
and observed risks. Overall, the model was
well calibrated for each cancer type except
for ‘other cancer’, which showed a degree of
over prediction
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TABLE 39 Systematic review 2: included studies, model development and performance (continued )
Study Model development Model performance
l Classification measures (table 7): symptoms with
the highest PPVs for any cancer (regardless of
type) were as follows: breast lump (11%),
haemoptysis (8%), dysphagia (8%) and post-
menopausal bleeding (7%). The PPV for anaemia
was 6% and for venous thromboembolism
was 5%
l Used validation cohort to define thresholds for
1%, 5% and 10% risk. Calculated sensitivity,
specificity, NPV and PPV at these thresholds
Hippisley-Cox
201354
Multinomial logistic regression was used to
estimate the coefficients for each predictor
variable for each type of cancer. Fitted full
model and variables retained if p ≤ 0.01.
Fractional polynomials were used to model
non-linear risk relationships with continuous
variables
l Discrimination (table 6): all ROC statistic values
for each cancer type were > 0.82, indicating very
good discrimination. The highest ROC values
were for renal tract cancer (0.94), gastro-
oesophageal cancer (0.93) and lung cancer (0.92).
The lowest was for testicular cancer (0.82)
l Calibration (figure 1): compared mean predicted
and observed risks. Overall, the model was well
calibrated for each cancer type except for the
‘other cancer’ model, which showed a degree of
over prediction
l Classification measures (table 7): symptoms with
the highest PPVs for any cancer (regardless of
type) were anaemia (19%), urinary retention
(14%), dysphagia (13%), haematuria (13%),
weight loss (11%), neck lump (10%) and
haemoptysis (10%). The PPV for venous
thromboembolism was 6%. The sensitivity of
single symptoms was generally low, with the
highest value being 16% for abdominal pain
l Used validation cohort to define thresholds for
1%, 5% and 10% risk. Calculated sensitivity,
specificity, NPV and PPV at these thresholds
Dommett
201364
Conditional logistic regression. Variables
occurring in at least 2% of either cases or
controls with a univariable p-value of ≤ 0.1
entered the multivariable conditional logistic
regression. A p-value of < 0.01 was used for
retention in the final model. PPVs were
calculated using Bayes’ theorem
12 predictors had a PPV of ≥ 0.04%
Muris 199556 Variables for which p < 0.25 in univariate
analyses were entered into multiple stepwise
forward logistic regressions
NR
Elias 201750 N/A. Used Muris 199656 model l NPV: 99 (95% CI 97 to 100)
l PPV: 6 (95% CI 4 to 8)
l Sensitivity: 97 (95% CI 86 to 100)
l Specificity: 28 (95% CI 25 to 31)
l AUC: 0.62 (95% CI 0.54 to 0.70)
AUC, area under the curve; CART, classification and regression tree; HR, hazard ratio; LR, likelihood ratio; N/A, not
applicable; NPV, negative predictive value; NR, not reported; OR, odds ratio; RF, random forest; ROC, receiver
operating characteristic; SE, standard error; SVM, support vector machine.
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TABLE 40 Systematic review 2: included studies, results




Development data set only Symptoms:
l Visible haematuria – LR 59
(51 to 67), OR 34 (29 to 41)
l Dysuria – LR 9.4 (8.0 to 11),
OR 4.1 (3.4 to 5.0)
l Abdominal pain – LR 2.0 (1.8
to 2.3), OR 2.0 (1.6 to 2.4)
l Constipation – LR 1.8 (1.6 to
2.0), OR 1.5 (1.2 to 1.9)
Findings support investigation of
all patients aged > 40 years with
visible haematuria
Disease:
l Urinary tract infection – LR
5.2 (4.8 to 5.8), OR 2.2 (2.0
to 2.5)
Investigations:
l Raised levels of creatinine –
LR 1.8 (1.6 to 1.9), OR 1.3
(1.2 to 1.4)
l Raised levels of inflammatory
markers – LR 1.8 (1.6 to 2.1),
OR 1.5 (1.2 to 1.9)
l Raised WBC count – LR 2.8





Development data set only Ten symptoms were
independently associated with
chronic leukaemia, OR (95% CIs):
infection 1.5 (1.3 to 1.6), cough
1.2 (1.1 to 1.4), hypertension 1.2
(1.1 to 1.4), shortness of breath
1.3 (1.1 to 1.5), fatigue 2.1 (1.8
to 2.6), diarrhoea 1.4 (1.1 to 1.7),
lymphadenopathy 22 (13 to 36),
malaise 1.7 (1.3 to 2.3), weight
loss 3.0 (2.1 to 4.2) and bruising
2.3 (1.6 to 3.2)
PPVs too small, with benign
alternative explanations much
more likely for the symptoms
Thirteen symptoms were
independently associated with
acute leukaemia, OR (95% CIs):
infection 1.5 (1.3 to 1.8),
shortness of breath 2.5 (1.9 to
3.2), fatigue 4.4 (3.3 to 6.0), chest
pain 1.5 (1.1 to 2.1), abdominal
pain 1.7 (1.2 to 2.2), diarrhoea 2.2
(1.5 to 3.1), malaise 3.4 (2.2 to
5.2), vomiting/nausea 1.8 (1.2 to
2.6), bruising 3.7 (2.3 to 5.8),
fever 5.3 (2.7 to 10), nosebleeds
and/or bleeding gums 5.7 (3.1 to
10), flu 3.9 (2 to 7.5) and weight
loss 3 (1.5 to 5.8)
No individual symptom or
combination of symptoms had a
PPV of > 1%
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
Shephard
201568
Development data set only Symptoms:
l Back pain – LR4.6 (4.2 to 5.0),
OR 2.2 (2.0 to 2.4)
l Chest pain – LR 3.4 (3.0 to
3.8), OR 1.6 (1.4 to 1.8)
l Chest infection – LR 1.9 (1.7
to 2.1), OR 1.4 (1.2 to 1.6)
l Shortness of breath – LR 1.9
(1.7 to 2.2), OR 1.3 (1.1 to 1.5)
l Nausea – LR 3.2 (2.6 to 3.9),
OR 1.5 (1.1 to 2.1)
l Fracture – LR 3.6 (2.9 to 4.6),
OR 3.1 (2.3 to 4.2)
l Joint pain – LR 1.5 (1.2 to
1.8), OR 1.6 (1.2 to 2.2)
l Combined bone pain – LR 4.3
(3.3 to 5.6), OR 2.1 (1.4 to 3.1)
l Weight loss – LR 5.6 (4.2 to
7.1), OR 3.0 (2.0 to 4.5)
l Rib pain – LR 7.7 (5.4 to
11.0), OR 2.5 (1.5 to 4.4)
l Nosebleeds – LR 4.4 (3.2 to
6.0), OR 3.0 (1.9 to 4.7)
Although no single symptom is
a strong indicator of myeloma,
repeated occurrences of back
pain or back pain combined with
nosebleeds or rib pain suggest
initial testing of inflammatory
markers, at the discretion of
the GP
Investigations:
l Cytopenia – LR 5.3 (5.0 to
5.7), OR 5.4 (4.6 to 6.4)
l Raised levels of inflammatory
markers – LR 6.8 (6.3 to 7.4),
OR 4.9 (4.2 to 5.8)
l Raised levels of creatinine –
LR 2.9 (2.6 to 3.1), OR 1.8
(1.5 to 2.2)
l Raised mean corpuscular
volume – LR 6.2 (5.3 to 7.3),
OR 3.1 (2.4 to 4.1)
l Hypercalcaemia – LR 26 (18




Development data set only New-onset seizure 87.0 (42.0 to
180.0), weakness 23.0 (7.1 to
77.0), headache 6.7 (5.6 to 8.0),
confusion 11.0 (7.6 to 16.0),
memory loss 2.7 (1.7 to 4.2),
visual disorder 2.0 (1.2 to 3.3),
motor loss 1.8 (1.5 to 2.2) and
motor loss with weakness 0.2
(0.06 to 0.8)
Findings suggest that isolated
headache presented to primary
care has too small a risk of an
underlying brain tumour to
warrant investigation; however,





External validation Independent clinical predictors
(adjusted OR and 95% CIs):
increasing age by year, 1.10 (1.07
to 1.13); presence of a discrete
lump, 15.20 (4.88 to 47.34);
breast thickening, 7.64 (2.23 to
26.11); lymphadenopathy, 3.63
(1.33 to 9.92); and lump of 2 cm,
5.41 (2.36 to 12.38). All eight
patients with skin tethering had
breast cancer
The clinical prediction rule
discriminates between patients at
high risk and patients at low risk
of breast cancer
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TABLE 40 Systematic review 2: included studies, results (continued )





with THIN data set
l BB validated with CAPER
data set
Model predictors and ORs
(95% CIs): constipation, 2.06
(1.88 to 2.26); diarrhoea, 2.38
(2.14 to 2.66); change in bowel
habit, 13.83 (11.70 to 16.34);
abdominal pain, 3.82 (3.49 to
4.18); rectal bleeding, 20.11
(17.35 to 23.32); Hb level of
13–13.99 g/dl, 1.33 (1.18 to
1.50); Hb level of 12–12.99 g/dl,
1.63 (1.42 to 1.87); Hb level
of 11–11.99 g/dl, 2.54 (2.16 to
2.99); Hb level of 10–10.99 g/dl,
5.18 (4.19 to 6.39); Hb level of
9–9.99 g/dl, 8.08 (6.13 to 10.65);
Hb level of < 9 g/dl, 15.94 (11.78
to 21.57); mean cell volume of
80–84.99 fl, 2.71 (2.30 to 3.19);
mean cell volume of < 80 fl,
7.67 (6.23 to 9.44); weight loss
of ≥ 10%, 2.92 (2.39 to 3.57);
and weight loss of 5–10%,
1.37 (1.09 to 1.73)
Both multivariable BB and
CAPER equations performed
significantly better than NICE
referral guidelines172
Elias 201750 External validation Elias ranked the BB equation as
sixth out of 19 models evaluated
The top-ranked model was the
NICE guidelines. Note that Elias
used a very broad definition of
prediction model, which included
guidelines and weighted scores
Fijten 199555 Development data set only l Diagnostic index= –6.7+ 2.1
[(age – 50)/10]+ 2.3 if change
in bowel habit+ 2.1 if blood
mixed with or on stool.
(Hosmer–Lemeshow p= 0.507),
log likelihood= –17.9)
l Cut-off point for maximising
sensitivity (100%) and
specificity (90%) was 0.042
l Diagnostic index with
presence of polyps:
–4.8 + 1.4 [(age – 50)/10] + 1.9
if change in bowel habit+ 2.1 if
blood mixed with or on stool.
(Hosmer–Lemeshow p= 0.49),
log likelihood= –32.4)
l Cut-off point for maximising
sensitivity and specificity
was 0.058
The combination of age, change
in bowel habit and blood seen
mixed with or on stool can serve
as a useful diagnostic tool for the




External validation The Netherlands model had better discrimination than the Harvard
model, but inferior discrimination compared with the weighted
numerical score
Elias 201750 External validation CEDAR data set included
participants older than those in
original Fijten 199555 derivation
data set. Based on the results,
Elias et al. ranked the Fijten
199555 model as 13th out of
19 models
The top-ranked model was NICE
guidelines. Note that Elias 2017
used a very broad definition of
prediction model, which included
guidelines and weighted scores
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
Kop 201561 Five subsets were selected
and four machine-learning
algorithms were applied to
them in a fivefold cross-
validation fashion:
1. Non-temporal (941 non-
temporal attributes +
age/sex)
2. Temporal (n temporal
patterns + age/sex)






age and sex only)
AUCs and 95% CIs for subsets:
l Non-temporal – LR 0.792
(0.771 to 0.813); RF 0.883
(0.866 to 0.900); SVM 0.804
(0.784 to 0.824); CART 0.819
(0.799 to 0.839)
l Temporal – LR 0.893 (0.877
to 0.909); RF 0.882 (0.865 to
0.899); SVM 0.861 (0.843 to
0.879); CART 0.863 (0.845
to 0.881)
l All – LR 0.796 (0.775 to
0.817); RF 0.881 (0.864 to
0.898); SVM 0.832 (0.813 to
0.851); CART 0.818 (0.798
to 0.838)
l Knowledge driven – LR 0.854
(0.836 to 0.872); RF 0.896
(0.880 to 0.912); SVM 0.867
(0.849 to 0.885); CART 0.860
(0.842 to 0.878)
l Age/sex only – LR 0.844
(0.825 to 0.863); RF 0.838
(0.819 to 0.857); SVM 0.862
(0.844 to 0.880); CART 0.828
(0.808 to 0.848)
Study suggests metabolic
syndrome as potential predictor
Nørrelund
199657
Validated in study 2 Only age was found to be a
statistically significant predictor
of cancer from study 1:
l Age 70–79 years: adjusted
OR 9.26 (95% CI 3.32 to
25.82); age ≥ 80 years:
adjusted OR 9.90 (95% CI
2.03 to 48.36)
Reported symptoms of weight
loss, abdominal pain, change in
bowel habits or discomfort were
not found to be predictors of
CRC in either study 1 or 2
No statistically significant
variables were found in study 2
to predict cancer
Elias 201750 External validation Elias et al.50 ranked the Danish
(i.e. Nørrelund et al.57) model as
18th out of 19 models evaluated
The top-ranked model was NICE
guidelines. Note that Elias 2017
used a very broad definition of
prediction model, which included





Predictors and (fully adjusted)
HR (95% CI):
l Females – family history of GI
cancer 1.39 (1.02 to 1.89), Hb
level of < 11 g/dl 3.26 (2.84 to
3.74), current rectal bleeding
32.3 (27.7 to 37.6), current
abdominal pain 6.90 (5.91 to
8.06), current appetite loss
2.43 (1.70 to 3.47), current
weight loss 7.70 (5.32 to 11.1)
l Males – trivial drinker 1.07
(0.95 to 1.20), light drinker
1.20 (1.06 to 1.35), moderate/
heavy drinker 1.43 (1.25 to
1.63), family history of GI
State that the algorithm
performed well, with good
discrimination and calibration
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
cancer 1.52 (1.12 to 2.07), Hb
level of < 11 g/dl 3.33 (2.86 to
3.87), current rectal bleeding
27.0 (23.5 to 31.1), current
abdominal pain 6.78 (5.76 to
7.97), current appetite loss
2.15 (1.53 to 3.03), current
weight loss 4.07 (3.42 to
4.85), change in bowel
habit in previous years
2.25 (1.47 to 3.46)
Collins
201215
External validation with a
different cohort
Model calibration is very good, with close agreement between
predicted and observed CRC risks across all tenths of risk
Hamilton
200581
Development data set only ORs (95% CIs): rectal bleeding
15 (9.0 to 2.4), weight loss 2.7
(1.7 to 4.6), number of episodes
of abdominal pain 2.2 (1.7 to
2.8), constipation 2.0 (1.2 to 3.3),
number of episodes of diarrhoea
1.6 (1.3 to 2.0), rectal disease on
examination 13 (4.7 to 37),
tenderness on palpitation of
abdomen 3.6 (1.7 to 7.8),
positive FOBT 81 (20 to 330),
Hb level of 12.0–12.9 g/dl
2.5 (0.95 to 6.8), Hb level of
10.0–11.9 g/dl 4.3 (2.1 to 9.0),
Hb level of < 10 g/dl 13 (6.2 to
28), blood sugar concentration of
> 10 mmol/l 2.0 (1.3 to 3.1)
10 symptoms, signs or
investigation results were
independently associated with
CRC. Five of these remained
associated with cancer 180 days
before diagnosis
Interaction terms, ORs (95%
CIs): abdominal pain with
tenderness 0.56 (0.38 to 0.82),
positive FOBT with a Hb level of
< 10 g/dl 0.020 (0.0015 to 0.27)
Elias 201750 External validation Elias ranked the RAT (CRC)
model as 10th out of 19 models
evaluated. The top-ranked model
was the NICE guidelines
Note that Elias used a very broad
definition of prediction model,




Development data set only ORs (95% CIs): rectal bleeding
20 (17 to 23), change in bowel
habit 14 (12 to 17), abdominal
pain 3.9 (3.6 to 4.3), diarrhoea
2.4 (2.1 to 2.7), constipation
2.1 (1.9 to 2.3), weight loss of
5.0–9.9% 1.2 (0.99 to 1.5),
weight loss of ≥ 10% 2.5 (2.1 to
3.0), Hb level of 12.0–12.9 g/dl
1.7 (1.5 to 1.9), Hb level of
11.0–11.9 g/dl 2.8 (2.4 to 3.2),
Hb level of 10.0–10.9 g/dl
5.9 (4.8 to 7.2), Hb level of
9.0–9.9 g/dl 9.3 (7.1 to 12),
Hb level of < 9 g/dl 18 (14 to 25),
mean red cell volume of < 80 fl
6.5 (5.3 to 7.9)
There is a need to improve
identification of CRC among
the large number of patients
presenting only with low-risk
symptoms
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
Stapley
201772
Development data set only OR (95% CIs) for CRC: diarrhoea
7.7 (4.3 to 14), abdominal pain
6.0 (4.2 to 8.7), rectal bleeding
54 (26 to 110), change in bowel
habit 58 (21 to 160),
constipation 7.9 (4.3 to 14),
nausea/vomiting 2.7 (1.4 to 5.1),
rectal mass 190 (51 to 720),
raised levels of inflammatory
markers 3.1 (2.0 to 4.7), low Hb
level 5.2 (3.2 to 8.5), low mean
red cell volume 4.3 (2.3 to 8.0)
Rectal bleeding and change in
bowel habit are strongly predictive







Predictors and (fully adjusted)
HR (95% CI)
l Females – ex-smoker 1.33
(1.11 to 1.60), light smoker
1.96 (1.43 to 2.68), moderate
smoker 2.51 (1.93 to 3. 26),
heavy smoker 3.11 (2.26 to
4.28), current dysphagia
131 (97.5 to 175), current
abdominal pain 4.74 (3.54 to
6.33), current appetite loss
10 (5.28 to 19), current
haematemesis 25.2 (14.4 to
44.2), current weight loss
3.97 (3.06 to 5.16), Hb level
of < 11 g/dl 2.32 (1.84
to 2.93)
l Males – ex-smoker 1.38
(1.22 to 1.57), light smoker
1.89 (1.51 to 2.37), moderate
smoker 2.18 (1.77 to 2.67),
heavy smoker 2.00 (1.52 to
2.63), current dysphagia
143 (108 to 189), current
abdominal pain 378 (3.32 to
4.30), current appetite loss
3.87 (2.82 to 5.32), current
haematemesis 7.62 (6.08 to
9.55), current weight loss 5.64
(4.67 to 6.81), Hb level of
< 11 g/dl 1.79 (1.44 to 2.23)
The algorithm developed and
validated in the study performed
well in quantifying the absolute





External validation Model calibration was good, with reasonable agreement between
predicted and observed gastro-oesophageal cancer risks across all but
the last tenth of risk
Stapley
201371
Development data set only Sixteen features were
independently associated with
oesophagogastric cancer, OR
(95% CI) (all p < 0.001):
dysphagia, 139 (112 to 173);
reflux, 5.7 (4.8 to 6.8); abdominal
pain, 2.6 (2.3 to 3.0); epigastric
pain, 8.8 (7.0 to 11.0); dyspepsia,
6 (5.1 to 7.1); nausea and/or
vomiting, 4.9 (4.0 to 6.0);
constipation, 1.5 (1.2 to 1.7);
chest pain, 1.6 (1.4 to 1.9);
weight loss, 8.9 (7.1 to 11.2);
The tool can be used to guide
GPs on referral for
oesophagogastric cancer.
Evidence suggests that reliance
on ‘red-flag’ symptoms solely has
limited use
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
thrombocytosis, 2.4 (2.0 to 2.9);
low level of Hb, 2.4 (2.1 to 2.7);
low MCV, 5.2 (4.2 to 6.4); high
levels of inflammatory markers,
1.7 (1.4 to 2.0); raised levels of
hepatic enzymes, 1.3 (1.2 to 1.5);
high WBC count, 1.4 (1.2 to 1.7);
and high cholesterol,





Split sampling validation Clinical and sociodemographic
features that were independently
associated with lung cancer were
patients’ age, sex, socioeconomic
status and smoking history. From
4 to 12 months before diagnosis,
the symptoms/clinical features
that were independently
predictive of lung cancer were as
follows, OR (95% CI):
11–20 GP consultations 1.23
(1.16 to 1.29), > 20 GP
consultations 1.36 (1.28 to 144),
cough 1.63 (1.53 to 1.75),
haemoptysis 8.70 (6.75 to
11.20), dyspnoea 1.41 (1.29 to
1.55), weight loss 2.66 (2.13 to
3.29), lower respiratory tract
infections 1.56 (1.38 to 1.76),
non-specific chest infections 1.55
(1.44 to 1.68), chest/shoulder
pain 1.39 (1.28 to 1.51),
hoarseness 1.79 (1.28 to 2.49),
upper respiratory tract infections
1.15 (1.02 to 1.30) and chronic
obstructive pulmonary disease
1.61 (1.46 to 1.78)
Risk prediction model performed






Predictors and (fully adjusted)
HR (95% CI):
l Females – current
haemoptysis 23.9 (20.6 to
27.6), current appetite loss
4.14 (3.15 to 5.45), current
weight loss 4.52 (3.80 to
5.38), cough in previous
12 months 1.90 (1.56 to 2.32),
Hb level of < 11 g/dl 1.75
(1.38 to 2.22), ex-smoker 3.37
(2.38 to 4.01), light smoker
6.57 (5.37 to 8.03), moderate
smoker 8.32 (7.05 to 9.82),
heavy smoker 10.6 (8.49 to
13.2), prior diagnosis non-lung
cancer 1.33 (1.09 to 1.63),
chronic obstructive airways
disease 1.82 (1.57 to 2.11),
Townsend deprivation score
1.17 (1.08 to 1.27)
The algorithm developed and
validated in the study performed
well in quantifying the absolute
risk of having existing, but as yet
undiagnosed, lung cancer
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
l Males – current haemoptysis
21.5 (19.3 to 23.9), current
appetite loss 4.71 (3.69 to
6.00), current weight loss 6.09
(5.33 to 6.95), cough in
previous 12 months 1.47
(1.23 to 1.75), Hb level of
< 11 g/dl 1.89 (1.54 to 2.32),
ex-smoker 2.13 (1.87 to 2.43),
light smoker 3.70 (3.20 to
4.27), moderate smoker 4.95
(4.26 to 5.76), heavy smoker
6.35 (5.43 to 7.43), chronic
obstructive airways disease
1.51 (1.34 to 1.69), Townsend




Development data set only ORs (95% CIs): appetite loss 86
(3.6 to 2100), haemoptysis 32
(13 to 81), dyspnoea 4.7 (2.7 to
8.0), weight loss 4.3 (2.2 to 8.2),
fatigue 3.2 (1.7 to 6.0), chest
pain 2.9 (1.8 to 4.7), second
attendance with cough 2.7
(1.7 to 4.4), finger clubbing 18
(1.7 to 190), thrombocytosis 9.3
(3.4 to 26), abnormal spirometry
7.5 (2.8 to 21), current smoker 9.7
(5.3 to 18), ex-smoker 5.9 (3.0 to
12), smoking status unknown 5.4
(2.8 to 10), dyspnoea with fatigue
0.28 (0.11 to 0.73), appetite loss
in patients aged > 70 years 0.13
(0.024 to 0.76)
The study provides an evidence
base for selection of patients for
investigation of possible lung
cancer, both for clinicians and for
developers of guidelines
After excluding variables reported










Predictors and (fully adjusted)
HRs (95% CIs): family history of
ovarian cancer 9.8 (5.4 to 17.9),
Hb level of < 110 g/l in the
previous year 2.3 (1.7 to 2.9),
current abdominal pain 7.0
(6.1 to 8.0), current abdominal
distension 23.1 (18.2 to 29.4),
current appetite loss 5.2 (3.4 to
7.9), current rectal bleeding
2.0 (1.4 to 2.8), current
postmenopausal bleeding
6.6 (5.1 to 8.5), current weight
loss 2.0 (1.3 to 3.1)
The algorithm developed and
validated in the study performed
well in quantifying the absolute




External validation Model calibration was good with reasonable agreement between
predicted and observed ovarian cancer risks across all tenths of risk,
with a slight overprediction
Good predictive ability for identifying patients with undetected
ovarian cancer
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
Hamilton
200983
Development data set only Seven symptoms and one
interaction term were associated
with ovarian cancer in
multivariable analysis. The
univariable PPVs (95% CIs) and
multivariable ORs (95% CIs),
respectively, for these were 2.5%
(1.2% to 5.9%) and 240 (46 to
1200) for abdominal distension;
0.5% (0.2% to 0.9%) and 24
(9.3 to 64) for postmenopausal
bleeding; 0.6% (0.3% to 1.0%)
and 17 (6.1 to 50) for loss of
appetite; 0.2% (0.1% to 0.3%)
and 16 (5.6 to 48) for increased
urinary frequency; 0.3% (0.2% to
0.3%) and 12 (6.1 to 22) for
abdominal pain; 0.2% (0.1% to
0.4%) and 7.6 (2.5 to 23) for
rectal bleeding; and 0.3% (0.2%
to 0.6%) and 5.3 (1.8 to 16) for
abdominal bloating
Study findings suggest that early
symptoms may be useful in the
identification of ovarian cancer




In 181 (85%) cases and 164
(15%) controls, at least one of
these seven symptoms was
reported to primary care before
diagnosis. After exclusion of
symptoms reported in the 180
days before diagnosis, abdominal
distension, urinary frequency
and abdominal pain remained
independently associated with a






Predictors and (fully adjusted)
HR (95% CI):
l Females – ex-smoker 0.97
(0.77 to 1.23), light smoker
1.53 (1.04 to 2.25), moderate
smoker 2.32 (1.74 to 3.10),
heavy smoker 2.39 (1.65 to
3.48), type 2 diabetes 2.07
(1.66 to 2.58), chronic
pancreatitis 3.15 (1.17 to
8.46), current appetite loss
3.90 (2.61 to 5.82), current
weight loss 3.27 (2.35 to
4.56), current abdominal pain
4.09 (3.46 to 4.84), current
abdominal distension 3.04
(1.68 to 5.50)
l Males – ex-smoker 1.37
(1.12 to 1.67), light smoker
1.44 (1.03 to 2.03), moderate
smoker 1.63 (1.20 to 2.20),
The algorithm developed and
validated in the study performed
well in quantifying the absolute
risk of having existing, but as yet
undiagnosed, pancreatic cancer
continued
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
heavy smoker 1.88 (1.36 to
2.61), type 2 diabetes 2.11
(1.76 to 2.52), chronic
pancreatitis 3.94 (1.93 to
8.01), current appetite loss
2.46 (1.43 to 4.23), current
weight loss 12.5 (7.84 to
19.9), current abdominal pain
5.23 (4.48 to 6.11), current
dysphagia 2.56 (1.60 to 4.10),
constipation in previous year
1.91 (1.35 to 2.71)
Collins
201314
External validation QCancer (pancreas) increasingly overpredicts risk, with increases
across the tenths of risk
Stapley
201270
Development data set only Nine features were associated
with pancreatic cancer, OR
(95% CI) [all p < 0.001 except for
back pain, (p = 0.004)]; jaundice,
OR 1000 (95% CI 430 to 2500);
abdominal pain, 5 (4.4 to 5.6);
nausea/vomiting, 4.5 (3.5 to 5.7);
back pain, 1.4 (1.1 to 1.7);
constipation, 2.2 (1.7 to 2.8);
diarrhoea, 1.9 (1.5 to 2.5); weight
loss, 15 (11 to 22); malaise, 2.4
(1.6 to 3.5); and new-onset
diabetes 2.1 (1.7 to 2.5)
Most previously reported
symptoms of pancreatic cancer
were also relevant in primary
care, providing a basis for
selection of patients for
investigation, especially with
multiple symptoms, although
predictive values were mostly
small
Keane 201462 Development data set only l Independent predictors and
adjusted (age, sex, time,
deprivation) PDAC symptoms
and signs, OR (95% CIs):
weight loss 6.6 (5.54 to 7.86);
abdominal pain 6.38 (5.81 to
7.02); nausea and vomiting
3.43 (3.00 to 3.91); bloating
3.1 (2.48 to 3.89); dyspepsia
2.56 (2.30 to 2.85); new-onset
diabetes 2.46 (2.16 to 2.80);
change in bowel habit 2.17
(1.98 to 2.39); pruritus 1.73
(1.43 to 2.10); lethargy 1.42
(1.25 to 1.61); back pain 1.33
(1.18 to 1.49); shoulder pain
0.78 (0.65 to 0.93); and
jaundice 246 (172 to 351)
l PDAC tests and BMI
coefficient: bilirubin 15.3
(95% CI 12.99 to 17.60)
Findings could improve the
symptom-based cancer decision
support tools used for
identification of BTC and PDAC
l BTC symptoms and signs, OR
(95% CIs): weight loss 3.17
(2.32 to 4.34); abdominal pain
4.68 (4.01 to 5.47); nausea
and vomiting 2.99 (2.44 to
3.66); bloating 2.35 (1.57 to
3.53); dyspepsia 21.70 (1.40
to 2.08); change in bowel
habit 1.77 (1.51 to 2.09);
pruritus 3.75 (2.96 to 4.74);
and jaundice 445 (302 to 658)
l Bilirubin 15.3 (95% CI 12.99
to 17.60)
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TABLE 40 Systematic review 2: included studies, results (continued )




Development data set only ORs (95% CIs): urinary retention
11 (5 to 25.5), second
presentation with weight loss 9.2
(2.7 to 31), impotence 5.3 (2.8 to
9.8), frequency 3.2 (1.9 to 5.4),
hesitancy 2.9 (1.1 to 7.5),
nocturia 2.6 (1.3 to 5),
haematuria 2.4 (1.3 to 4.7),
benign abnormal rectal
examination 3.7 (1.9 to 7.3),
malignant abnormal rectal
examination 70 (13 to 380)
The predictive values for
symptoms present in most men
with prostate cancer will help
guide GPs and patients about the
value of further investigation
Loss of weight, impotence,
frequency and abnormal rectal
examination remained associated
with cancer after excluding the






Predictors and (fully adjusted)
HR (95% CI):
l Females – ex-smoker 1.23
(1.01 to 1.49), light smoker
1.83 (1.31 to 2.57), moderate
smoker 2.41 (1.87 to 3.12),
heavy smoker 2.32 (1.55 to
3.46), history of prior cancer
(not renal) 1.47 (1.13 to 1.91),
current haematuria 119 (85.3
to 167), current appetite loss
2.45 (1.34 to 4.46), current
abdominal pain 2.38 (1.97 to
2.89), current weight loss 2.56
(1.75 to 3.74), anaemia 1.98
(1.51 to 2.61)
l Males – ex-smoker 1.47
(1.32 to 1.63), light smoker
2.24 (1.84 to 2.73), moderate
smoker 2.49 (2.05 to 3.04),
heavy smoker 2.50 (1.95 to
3.20), current haematuria
148 (123 to 177), current
abdominal pain 3.06 (2.35 to
3.98), current weight loss 5.67
(3.20 to 10.0), anaemia 1.57
(1.27 to 1.94)
The algorithm developed and
validated in the study performed
well in quantifying the absolute




External validation Model calibration showed good agreement across those aged
30–69 years, whereas it overpredicted the risk of renal tract cancer
in those aged between 70 and 84 years
The model showed good predictive ability for identifying patients with
suspected undiagnosed renal tract cancer who would benefit from
further clinical investigation
continued
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
Shephard
201366
Development data set only Fifteen features were
independently associated with
kidney cancer, OR (95% CI):
visible haematuria 37 (28 to 49),
abdominal pain 2.8 (2.4 to 3.4),
microcytosis 2.6 (1.9 to 3.4),
raised inflammatory markers
2.4 (2.1 to 2.8), thrombocytosis
2.2 (1.7 to 2.7), low level of Hb
1.9 (1.6 to 2.2), urinary tract
infection 1.8 (1.5 to 2.1), nausea
1.8 (1.4 to 2.3), raised creatinine
levels 1.7 (1.5 to 2.0), leukocytosis
1.5 (1.2 to 1.9), fatigue 1.5 (1.2 to
1.9), constipation 1.4 (1.1 to 1.7),
back pain 1.4 (1.2 to 1.7), abnormal
liver function 1.3 (1.2 to 1.5) and
raised blood sugar 1.2 (1.1 to 1.4)
Visible haematuria is the
commonest and most powerful
single predictor of kidney cancer,





Development data set only Nine features were significantly
associated with uterine cancer,
OR (95% CI): postmenopausal
bleeding 154.5 (100.4 to 237.8),
excessive vaginal bleeding
22.3 (11.9 to 41.8), irregular
menstruation (one GP visit)
41.5 (27.3 to 63.0), irregular
menstruation (two GP visits)
69.0 (31.6 to 150.7), vaginal
discharge 13.7 (10 to 21),
haematuria 8.7 (5.0 to 15.1),
abdominal pain (one GP visit) 2.0
(1.4 to 2.8), abdominal pain (two
GP visits) 3.4 (2.0 to 5.8), low Hb
2.1 (1.5 to 2.9), raised platelets
1.5 (1.0 to 2.3) and raised glucose
1.4 (1.1 to 1.8); all p < 0.01,
other than raised platelet count
(p = 0.05) and raised glucose
concentrations (p = 0.02)
Findings of the study, in
particular the importance of
postmenopausal bleeding and
haematuria, for uterine cancer
may inform GPs in the selection
of women for investigation
In the year before diagnosis,
1725 (63%) cases had a record
of abnormal vaginal bleeding,
compared with 135 (1%)
controls. The PPV of uterine
cancer with postmenopausal
bleeding was 4%, and was higher





Development data set only Adjusted OR (95% CI):
l Vs. cancer controls: groin pain
10.2 (1.2 to 8.2), pleurisy/
pleural effusion 10.2 (1.1 to
9.2), shoulder pain 5.3 (1.6 to
1.8), loss of appetite 4.0 (1.2
to 1.3), vomiting 3.5 (1.3 to
9.4), low-back pain 2.5 (1.1 to
5.6), abnormal liver function
3.5 (1.6 to 7.5)
The scarcity of specific symptoms
and the fairly common
occurrence of non-specific
symptoms (vomiting and loss of
appetite) may explain delays in
the diagnosis of metastases
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
l Vs. healthy controls: vomiting
3.6 (1.3 to 1.0), 4.2 (1.5 to
1.2), flank/loin pain 19.4
(1.8 to 2.10), chest pain
musculoskeletal 5.3 (1.7 to
1.6), oedema 3.4 (1.1 to 10),







Each cancer model contained the
following number of predictors
(see additional tables on www.
qcancer.org for details) for these
cancers: breast 10, cervical 12,
ovarian 11, uterine 7, blood 10,
colorectal 13, gastro-oesophageal
13, lung 15, pancreatic 14, renal
11, other cancers 22
A new algorithm designed to
estimate the absolute risk of







Each cancer model contained the
following number of predictors
(see additional tables on www.
qcancer.org for details) for these
cancers: prostate 14, testicular 3,
blood 14, colorectal 12, gastro-
oesophageal 13, lung 17,
pancreatic 15, renal tract 8,
other cancers 20
A new algorithm designed to
estimate the absolute risk of





Development data set only Models were developed for the
following cancer groups, plus all
cancers: leukaemia/lymphoma
(12 predictors), central nervous
system tumours (seven
predictors), bone tumours and
soft tissue sarcomas (four
predictors), abdominal tumours
(seven predictors)
Twelve features of childhood
cancers were identified, each of
which increased the risk of
cancer at least 10-fold
Predictors, adjusted ORs
(95% CIs) and PPVs (95% CIs),
respectively, for all cancers’
model:
1. Pallor: 83.7 (18.0, 390.5);
0.41% (0.12%, 1.34%)
2. Head and neck lump mass
swelling: 16.9 (5.2, 54.9);
0.30% (010%, 0.84%)
3. Lump mass swelling:
21.8 (9.6, 49.7); 0.11%
(0.06%, 0.20%)
4. Lymphadenopathy: 10.1 (5.9,
17.4); 0.09% (0.06%, 0.13%)
5. Abnormal movement:
16.4 (7.8, 34.9); 0.08%
(0.04%, 0.14%)
6. Bruising: 12.3 (5.5, 27.8);
0.08% (0.05%, 0.13%)
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TABLE 40 Systematic review 2: included studies, results (continued )
Study Model evaluation Results Interpretation and discussion
7. Fatigue: 7.7 (3.8, 15.8);
0.07% (0.04%, 0.12%)
8. Bleeding: 9.9 (4.9, 20.2);
0.06% (0.03%, 0.10%)
9. Headache: 6.1 (3.8, 9.9);
0.06% (0.04%, 0.08%)
10. Visual: 10.4 (4.4, 24.3);
0.06% (0.03%, 0.10%)
11. Pain: 7.3 (4.0, 13.4); 0.04%
(0.03%, 0.06%)
12. Musculoskeletal symptoms:
5.3 (3.6, 7.7); 0.04%
(0.03%, 0.07%)
When each of these 12
symptoms was combined singly
with at least three consultations
in a 3-month period, the
probability of cancer was
between 11 and 76 in 10,000
Muris 199556 Apparent performance Statistically significant predictors
[adjusted ORs (95% CI)] were:
l No specific character to pain:
5.70 (1.97 to 16.51)
l Weight loss: 4.36 (1.72 to
11.11)
l ESR of > 20 mm/hour:
3.00 (1.10 to 8.17)
l Male sex: 2.37 (1.20 to 6.99)
l Greater age (years): 1.08
(1.04 to 1.11)
The aim of the study was to
identify predictors for organic
disease, with a secondary
analysis looking at predictors
for neoplasms
Elias 201750 External validation Elias et al.50 ranked the
Muris et al.56 model as 13th
out of 19 models evaluated
The top-ranked model was
the NICE guidelines. Note that
Elias 2017 used a very broad
definition of prediction model,
which included guidelines and
weighted scores
AUC, area under the curve; BMI, body mass index; BTC, biliary tract cancer; CART, classification and regression trees;
CEDAR, Cost-Effectiveness of a Decision rule for Abdominal complaints in Primary care; ESR, erythrocyte sedimentation
rate; GI, gastrointestinal; HR, hazard ratio; IBD, inflammatory bowel disease; LR, likelihood ratio; MCV, mean corpuscular
volume; OR, odds ratio; PDAC, pancreatic ductal adenocarcinoma; RF, random forest; SVM, support vector machine;
WBC, white blood cell.
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Marshall 201122 Yes Yes Yes Low risk Yes Yes Yes Unclear Unclear risk Yes Yes Yes Yes Low risk
McCowan 201160 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Dommett 201364 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Keane 201462 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Fijten 199555 No Yes Yes High risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hodder 200577 No Unclear Yes High risk Yes Yes Yes Unclear Unclear risk Yes No Yes No High risk
Kop 201561 Yes Yes Yes Low risk Yes Yes Yes Unclear Unclear risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201353
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201354
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Collins 201215 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201280
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Collins 201388 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201182
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
2011c52
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Collins 201389 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201184
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Collins 201314 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hippisley-Cox
201232
Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
































































































































































































































































































































































































































Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 201586 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Shephard 201568 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Shephard 201269 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Stapley 201772 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 200787 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 200581 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 200974 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Stapley 201371 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 2005b51 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 2009b83 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Stapley 201270 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Hamilton 200690 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Walker 201373 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Shephard 201667 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Shephard 201366 Yes Yes Yes Low risk Yes Unclear Yes Yes Unclear risk Yes Yes Yes Yes Low risk
Iyen-Omofoman
201321
Yes Yes Yes Low risk Yes Unclear Yes Yes Unclear risk Yes Yes Yes Yes Low risk
Elias 201750 Yes Yes Yes Low risk Yes Yes Yes Yes Low risk Yes Yes Yes Yes Low risk
Nørrelund 199657 Yes Yes Yes Low risk Yes Unclear Yes Unclear Unclear risk Yes Yes Yes Unclear Low risk































































































































Marshall 201122 Yes Yes Yes Unclear Unclear risk Yes Yes Yes Yes Yes Yes Yes Low risk
McCowan 201160 No Yes No Yes High risk Yes No No Yes Yes Yes No High risk
Dommett 201364 Yes Yes Yes Yes Low risk Yes No Unclear Yes Yes Yes Unclear Unclear risk
Keane 201462 Yes Yes Yes Unclear Unclear risk Yes Yes Yes Yes Yes Yes Yes Low risk
Fijten 199555 Unclear Yes Yes Yes Unclear risk Yes No No Yes Yes Yes No High risk
Hodder 200577 Yes Yes Yes Yes Low risk Unclear No No Yes Yes Yes No Unclear risk
Kop 201561 Yes Yes Yes Unclear Unclear risk Yes Yes Unclear Unclear Unclear Unclear Unclear Unclear risk
Hippisley-Cox
201353
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201354
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Collins 201215 Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201280
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Collins 201388 Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201182
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201152
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Collins 201389 Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201184
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Collins 201314 Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hippisley-Cox
201232
Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk




















































































































































































































































































































































































































































Yes Yes Yes Yes Low risk Yes Yes Yes Yes Yes Yes Yes Low risk
Hamilton 201586 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Shephard 201568 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Shephard 201269 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Stapley 201772 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Hamilton 200787 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Hamilton 200581 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Hamilton 200974 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Stapley 201371 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Hamilton 200551 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Hamilton 200983 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Stapley 201270 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Hamilton 200690 Yes Yes Yes Unclear Unclear risk Yes No Unclear Yes Yes No Unclear High risk
Walker 201373 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Shephard 201667 Yes Yes Yes Unclear Unclear risk Yes No No Yes Yes No No High risk
Shephard 201366 Yes Yes Yes Unclear Unclear risk Unclear No No Unclear Yes No No High risk
Iyen-Omofoman
201321
Yes Yes Yes Unclear Unclear risk Unclear No No Unclear Yes No No High risk
Elias 201750 Yes Unclear No Unclear Unclear risk Unclear N/A N/A N/A N/A Yes Unclear Unclear risk
Nørrelund 199657 Yes Yes Unclear Unclear Unclear risk Unclear Yes No No No Yes No High risk

































TABLE 43 Studies excluded from the review but highlighted for interest: studies with secondary care (i.e. referred or
diagnosed) populations
Study Prediction tool Cancer type(s) Country Population
Adelstein 2010204 No name
(multiple variable
model for CRC)
Colorectal Australia Patients referred for colonoscopy,
NSW Australia
Baicus 2006205 No name
(generic cancer)
Multiple Romania Patients admitted to a hospital in
Romania (January–September 2003)
with involuntary weight loss
Ewing 2016206 No name
(Swedish – non-
metastatic CRC)
Colorectal Sweden Patients with cancer
Galvin 2014207 Prediction rule
for breast cancer
Breast Ireland Prospective cohort of consecutive
patients with breast cancer symptoms
reviewed at the symptomatic breast
units in Beaumont hospital (Ireland)






Patients diagnosed with dyspepsia
and referred to a tertiary referral
gastroenterology clinic in Tehran
(Islamic Republic of Iran) from
2002 to 2009
Moore 2011209 Risk of Ovarian
Malignancy
Algorithm
Ovarian USA Premenopausal and postmenopausal
women aged ≥ 18 years presenting to
a generalist (defined as a general
gynaecologist, internist, family
practitioner gastroenterologist or
general surgeon) with an ovarian cyst
or an adnexal mass and subsequently
scheduled to undergo surgery
Saraiva 2016210 No name
(uses of AI to
aid diagnosis of
GI cancers)
GI Brazil Patients with GI cancer
Reeves 2003211 BREASTAID Breast USA Referred and follow-up patients
Robertson 2006212 No name Colorectal UK Patients referred with rectal bleeding
Simpkins 2017213 No name Colorectal USA Patients newly referred with GI
symptoms from primary care to two
secondary care centres
Koning 2015214 No name Colorectal The Netherlands Patients referred for colonoscopy
Kim 2009215 No name Ovarian The Republic of
Korea
All referred/screened patients
Høgdall 2011216 No name Ovarian Denmark Complex laboratory equipment
required – Biomek® 2000 (Beckman
Coulter Inc., Brea CA, USA); primary
care availability unlikely
AI, artificial intelligence; GI, gastrointestinal.
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TABLE 44 Studies excluded from the review but highlighted for interest: studies not on prediction models
Study Prediction tool Cancer type(s) Country Comment
Bourne 201223 BLINCK Melanoma Australia Algorithm (clinical and
dermatoscopic criteria)
Dolianitis 2005217 Dermoscopic algorithms:
seven-point checklist, the
ABCD rule and the
Menzies method218
Melanoma Australia Algorithms
Emery 2010219 PCSA Melanoma UK/
Australia
Does not calculate risk of cancer
(score)
Gerbert 2000220 Decision support
software
Melanoma CA, USA Algorithm (clinical and
dermatoscopic criteria)
Rogers 2016221 TADA Melanoma NY, USA Algorithm (dermatoscopic criteria)





Melanoma UK MoleMate is a ‘computerised
diagnostic tool’ involving a novel
imaging technique (SIA); seven-
point checklist is an algorithm
Walter 2013223 Original and weighted
seven-point checklist
Melanoma UK Does not calculate risk of cancer
(score) diagnosis of pigmented
skin lesions (including melanoma)
in primary care; based on RCT
reported in Walter 2012,222 record
6175, currently included in SR1
Hodder 200577 Netherlands model;
Harvard model; weighted
numerical score
CRC UK Develop a system to compare and
validate referral guidelines (is this
SR2 external validation rather
than SR1-impact assessment?)
Ballal 2010224 Weighted numerical
score
CRC Wales (UK) Does not calculate risk of cancer







CRC UK Does not calculate risk of cancer
(score)
Smith 2006226 Weighted numerical
score
CRC UK Does not calculate risk of cancer
(score)





Image processing system for skin
cancer detection
Grewal 2013228 No name (scoring system
derived from Hamilton
2009 et al.83 data)
Ovarian UK Scoring system derived from
Hamilton 200983 data
Shahzad 2015229 No name Ovarian Pakistan Index score
Rossing 2010230 No name Ovarian USA Index score
Lim 2012231 No name Ovarian UK Scoring system
Law 2014232 No name Colorectal Malaysia Index score derived from
Selvachandran 2002225 data
ABCD, asymmetry, borders, colours, differential structure components; BLINCK, Benign, Lonely, Irregular, Nervous,
Change, Known clues; PCSA, primary care scoring algorithm; SIA, spectrophotometric intracutaneous analysis;
TADA, triage amalgamated dermoscopic algorithm.
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TABLE 45 Systematic review 2 (updated searches): included studies, study characteristics (1)
Study
Prediction





































TABLE 46 Systematic review 2 (updated searches): included studies, study characteristics (2)







493 GPs recruited via





































period of 10 days for
patients aged ≥ 16 years.
If abdominal symptoms




using a pro forma
GPs also identified all
those with a diagnosis of
abdominal cancer within
6 months after the GP
survey, regardless of
whether or not the
patient attended during
the survey period
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TABLE 47 Systematic review 2 (updated searches): included studies, model development and performance
Study Model development Model performance
Holtedahl 201863 Cox proportional hazards models.
Report univariate and multivariate
analyses (for the most frequent
symptoms and combinations of
symptoms adjusted for sex)
Sensitivity, specificity, likelihood ratios and
PPVs reported for individual symptoms and
combinations of symptoms (by age group
or sex)
Authors report no evidence to reject
proportional hazards assumption
Main analyses included all patients
with new abdominal cancer diagnosis
within 180 days. Other analyses
looked at all cancers, or abdominal
cancers also beyond 180 days
0.05 level of statistical significance used
TABLE 48 Systematic review 2 (updated searches): included studies, results
Study
Model




l Abdominal pain (upper, single
symptom): 4.8 (1.9 to 11.8)
l Abdominal pain (lower, single
symptom): 5.8 (2.4 to 14.3)
l Constipation (single
symptom): 6.8 (2.1 to 21.8)
l Rectal bleeding (single
symptom): 19.1 (8.7 to 41.7)
l Any other single symptoms
(grouped): 4.7 (2.8 to 7.9)
l Two abdominal symptoms
4.6 (2.5 to 8.5)
l Three or more abdominal
symptoms: 14.0 (9.1 to 21.6)
The strength of the association between
abdominal symptoms and cancers highlights
the importance of responding to these
symptoms. But, as some new cancers did
not involve these symptoms, clinical
suspicion is needed
HRs (95% CIs) were also
reported for combinations
of symptoms – see table 4
of Holtedahl 201863
APPENDIX 3
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Holtedahl 201863 Yes Yes Unclear Unclear risk Yes Yes Yes Yes Low risk Unclear Yes Unclear Yes Unclear risk
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TABLE 51 Systematic review 2: updated searchesa
Author and







how interval was analysed Outcome measures







To estimate the effect













l Symptom onset to
treatment (T5);














model adjusting for, among
others, stage and sign and
symptoms. Analysis also
stratified by stage
No evidence of this






























primary care to first






l Stage (III or IV)
l Analysis of survival
based on 850 patients,
and stage based on
777 patients
l Restricted cubic spline
curves. OR (99% CI)
obtained from logistic
regression (stage: III/IV





others, grade, and signs
and symptoms)
No evidence of this
Weeks; continuous variable,
and modelled as four
periods: 4 (reference), 13,
26, and 39 corresponding to









































how interval was analysed Outcome measures








and risk factors for,
patient and system
delays in breast cancer
diagnosis in Rwanda
Women who presented















l First presentation to
diagnosis (T8)





tumour grade) used to
obtain OR (95% CI)
(presented as a forest
plot only)
No evidence of this
l Months; divided into four
groups: <3 (reference),






health system delay and
clinical disease stage in
patients with breast
cancer
l Patients referred to























problem (via symptoms or




to first treatment (T14)
Stage (advanced) l Cox regression model




(stage 0–I, II, III, IV,
unknown); analysis did
not control for whether




used to estimate the
average marginal effects




breast cancer (stages III
and IV). This analysis was
adjusted for the means
of problem identification
(symptoms vs. screening)
as well as five other
patient characteristics)
l Outliers (total delay
≥50 months) were
excluded. Data on




No evidence of this.
Patients with delay of





















































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures






























l Symptoms onset to first
treatment (surgery) (T5)
l First GP referral to first
treatment (T12)
l Symptoms onset to first
GP referral to
secondary care (T2)











l Tumour size (> 2 cm)




stage and tumour size. Cox
regression also used to




No evidence of this
l Days; divided into long
and short intervals for
each T: T5 ≤ 110 vs.
> 110; T12 ≤ 68 vs.
> 68; T2 ≤ 14 vs. > 14;
T10 ≤ 28 vs. > 28; T14





or not referral and
diagnosis through the
2WW pathway confers
a survival advantage on
these patients
Patients diagnosed with





but not in the analysis










Referral to initial treatment
(T12)
Survival (median OS) Kaplan–Meier methods
(log-rank test)





and after 62 days,
excluding emergency
presentations)
l Analysis of T12 for
2WW, urgent, and
routine referrals only




developed for two groups:








































how interval was analysed Outcome measures


























those aged <50 years and










diagnosis (defined as the
sum of ‘symptom duration’
and ‘workup duration’) (T4)
Symptom duration:
symptom onset to initial
visit (T1)
Workup duration: first
medical visit to date of
pathological diagnosis (T8)
Stage (III and IV) l 253 had young-onset
CRC, and 232 were
diagnosed at age
≥ 50 years. First
medical visit was
primary care for 320
(70%) patients, and
emergency department
for 113 (25%) patients
l Stage stratified as
advanced (III or IV) and
non-advanced (Stage I




stage cancer with those
with non-advanced
stage cancer, the
difference in median T1
in young-onset CRC was
30 days, and for T4 it
was 40 days. It was
≤ 14 days for all other
interval comparisons
l Assessed extent of
intervals, compared




or not longer periods
were associated with
more extensive disease




but do not account
for this in the main
analysis of delay vs.
stage at diagnosis
Days; median intervals
compared for advanced and
non-advanced stage at




















































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures
































l Total wait time:
patient’s index contact
to first treatment (T9)




l Diagnostic wait time:
index contact to date of
diagnosis (T8)
l Treatment wait time:
date of diagnosis to first
treatment (T15)
Survival (5-year OS) l Only 1307 out of 1628
patients contributed to
the analysis of T9













into quartiles: 0 to ≤ 43
(reference), > 43 to
≤ 95, > 95 to ≤ 166,






To evaluate local wait




Patients referred to and
subsequently seen by
the gastroenterologist
















Assessed whether or not
local wait times (from
referral) were in accordance
with guidelines, but also
evaluated the effect of wait
time on the presence of
node positivity, and distant
metastases at diagnosis.
Compared the outcomes of
patients who were seen
within the guidelines with
the outcomes of patients
seen outside the guidelines





of patients had alarm
symptoms at referral
Days; divided into









































how interval was analysed Outcome measures








the diagnosis of CRC by
using three different
sources of information




according to the source
of information
Patients diagnosed with















hospital records and GP
records
For hospital and GP
records, diagnostic interval
defined as first registry of
symptoms to diagnosis (T8)
For patient-recall,
diagnostic interval defined
as onset of symptoms to
diagnosis (T4)























methods used to assess
independent predictors
of shorter interval using













estimated for each TNM
stage (classified as 0, 1,
2, 3, 4, unknown), and
cumulative distribution of
the three intervals also
plotted for four stage




















































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures






































l Survival (from date
of presentation;
2 years’ follow-up)
l Analysis of survival
based on 958 patients,
and of stage based on
868 patients
l Restricted cubic spline
curves. OR (99% CI)
obtained from logistic
regression (stage) or Cox
survival models using
sequential adjustment









and modelled as four
periods: 4 (reference), 20,
40 and 60 corresponding to




To determine the impact
of compliance with the
62-day pathway on
outcomes in patients
with CRC in the
long term
Patients treated for CRC




electively or in an
emergency setting (with
patients who did not go
on to have surgery
within 72 hours of
admission reclassified as





Initial GP referral to first
treatment (T12)
Survival (mean OS from
diagnosis based on
≥ 6 years’ follow-up);
and stage (C or D vs. A
or B)
l Statistical analysis




for patients seen within













on being seen within 62-day
standard or not; divided into
four groups: standard met
(elective), standard met
(emergency), standard









the interval from first
symptom to diagnosis
and survival in CRC
Patients diagnosed with






‘Diagnostic delay’: onset of
symptoms to diagnosis
(biopsy or direct surgery)
(T4)
Survival (5 years, from
diagnosis)
Kaplan–Meier curves (log-




adjustment for stage (initial
model adjusted for age and
sex). Stratified analysis
colon and rectal
No evidence of this
Months; analysed as a
continuous variable (using
penalised splines), and
quartiles: < 1.5, 1.5 to
3.4, 3.4 to 6.4, > 6.4
months, with Kaplan–Meier
curves developed and








































how interval was analysed Outcome measures







To assess the wait time
to diagnose NSCLC and
the cost of diagnosis
and treatment based on













First diagnostic test for
lung cancer to a definitive
diagnosis (T13)
Stage (IIIb–IV) Stratified by stage and
analysed descriptively
Study measured wait time
to diagnosis and evaluated
the cost of diagnosis and
treatment based on stage of
diagnosis. Assessed records
for diagnostic testing in the
12 months prior to date
of diagnosis
Time to diagnosis from the
initial diagnostic test was 5
months for stage IV patients
vs. 6.2 months for stage I
(mean ranged from 5 to
6.2 months for all stages).
Multivariate regression
analysis found that stage
was the only significant
independent predictor of
total health-care cost
(p<0.001 for stage I vs.
stage II, IIIa, IIIb, or IV)
No evidence of this
Months; comparison of
mean (SD) interval for each
stage (I, II, IIIa, IIIb, IV);




To analyse the delays
in the diagnosis and
treatment of lung cancer
in our health area, the
factors associated with




















diagnosis to start of
first treatment (T15)
l First specialist




























































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures




l Days; each interval
divided into three or four
categories with first used
as reference: T3 and T14
≥30, 31–60, 61–90, >90
days; T11 and T15 ≥30,
























l Initial chest X-ray
(used as a proxy for
the beginning of the
diagnostic interval) to
diagnostic biopsy (T13)
l Diagnostic biopsy to
first treatment (T15)




out to identify factors
associated with delays
(including, among others,
stage and histological type).






features to wait time
paradox
Days; ‘delay’ defined as:
T14 ≥ 78, T13 ≥ 38, T15
≥ 51 days; estimated the
adjusted odds of being in
the delay category for each





influence on survival of
delays in the diagnosis























symptoms to first visit to
the GP (T1)
‘Doctor’s delay’; first visit
to GP to diagnosis (T8)








from first visit to doctor
to first visit with





onset to treatment but
did not assess their
impact on survival
No evidence of this
Days; median used to divide
into two groups: T1: ≤30 vs.
>30 days (shorter delays
used as reference); T4: ≤42
vs. >42 days (longer delay
used as reference). [Note:
‘Doctor’s delay’ was
inconsistently defined as time
from first doctor/GP visit to
diagnosis (T8) and treatment








































how interval was analysed Outcome measures







or not waiting times and
delays in diagnosis and
treatment of patients




treated for lung cancer






l Symptoms’ onset to first
consultation with
doctor (T1)
l Onset of first symptoms
to diagnosis (T4)





delay’ (T1) and ‘total delay’
(T4), which included patient
and health-care delay
(primary care ‘doctor’s
delay I’ and specialist
medical services delay
‘doctor’s delay II’) by
comparing the cumulative
survival for those seen
within or after 8 weeks.
There were no significant
difference between the
Kaplan–Meier curves for
the assessment of either
interval (p> 0.05)
No evidence of this
l Weeks, divided into
two groups: ≤8 vs.









with DLBCL and the
impact of delays on
clinical outcomes
Patients treated for







l First health-care contact
to first haematologist
contact: ‘diagnostic wait
time’ (T7) (date of
histopathology diagnosis
categorised as occurring
prior to or following
initial haematologist
contact)







used to assess survival
(Mantel–Cox log-rank
test used for comparing
survival curves for
different intervals, and
Cox regression used to


























































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures






stages) and delays in
diagnosis and treatment
l Also define patient
delay (T1), but do not
report results
Weeks/months; categorised
into three or four groups.
T7: 0–1 week, > 1 week to
1 month, > 1 month; T14:
0–6 weeks, > 6 weeks to
3 months, 3–6 months,
> 6 months. ‘Delay’ defined
as: T7 > 6 months,
T14 > 4 months
l [Diagnostic delay was
defined as a time to
diagnosis of > 6 weeks,
and treatment delay as
time to treatment of
> 4 weeks]





























l (n= 5524: urinary














up to 4 years’ follow-up)
l Adjusted HR (95% CI)




l Also analysed risk of
death according to
presence or absence of
alarm symptoms
No evidence of this
Days; divided into five
groups: < 15, 15–90
(reference), 91–180,








































how interval was analysed Outcome measures

















CRC, breast cancer, lung
cancer or prostate
cancer who presented
to a GP with a cancer




















care to diagnosis (T8)
Survival (5 years) EHR (95% CIs) computed
using a generalised linear
model with a Poisson
error structure. Separate
multivariable models built
for each cancer site
adjusting for, among
others, the effects of
period of cancer plan
implementation, Dukes’
stage, tumour subsite
(for CRC) and tumour
differentiation. Also
included stratified analysis





l Months for CRC, lung
cancer and prostate
cancer; divided into four
groups: <1 (reference),
1–2, 3–6, and >6 months
l Weeks for breast cancer;
divided into four groups:
< 1 (reference), 1–2, 3–4,





or not clinical and
laboratory data could
provide early clues to
multiple myeloma
diagnosis and whether







pain, and who were











First signs and symptoms
of myeloma (‘combination’
of symptoms and













impact of mean interval










l Included a period of
2 years before diagnosis
No evidence of this
Months; mean and
categorised into three
groups: < 2, 2–12 and
> 12 months. Also
compared Kaplan–Meier



















































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures







Note that the data
extraction for this study
is based on an abstract
as the inter-library loan
for the full text is still
outstanding
To investigate the
association of delay in
diagnosis with stage,
grade, symptoms,
primary site of the
tumour and survival




















l Patients with a longer











the time of first noticing
symptoms and definitive
diagnosis, and its
association with stage at






















Time taken to reach a
specialty centre after being
referred: ‘patient-delay 2’
(T10)
Stage [III–IV (vs. I–II)] l Possible associations
were analysed using
chi-squared test





of T1; 44 patients who
did not have a referral
date were excluded
from analysis of T10
No evidence of this
Months/weeks; divided
into two groups based
on presence or absence
of ‘delay’ defined as:
> 3 months for T1,








































how interval was analysed Outcome measures







To study the situation of
professional delays and







treats head and neck
cancer in the Islamic
Republic of Iran
Oral cancer patients










Onset of symptoms to
initiation of treatment (T5)
Stage (advanced) Multivariate logistic
regression used to obtain
OR (95% CI) adjusted for
a number of patient
characteristics (including
symptoms) and grade
Also assessed predictors of
patient (onset of symptoms
to first visit to physician)
and professional (initial
investigation symptoms
to treatment) delay in
diagnosis and treatment
of oral cancer. Assessed
association between ‘total




addresses this to any
extentDays; stratified into two
groups based on median,
with higher than median





To analyse data on
time to diagnosis and





























provider as a result of any
symptoms related to
epithelial ovarian cancer) to
diagnosis (T8)
Survival (from diagnosis;







early (stage I–II, n=210)






































































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures





identified via screening or
imaging for unrelated
condition) (n=67)







Lim 2016;125 UK To compare time to






























primary care to diagnosis
(T8)
Stage (advanced) l Assessed relationship
between patient/
diagnostic intervals and
FIGO stage for type I
and type II cancers
separately using the
Wilcoxon rank-sum test
l It was hypothesised that
longer time to diagnosis
would be associated
with more advanced
stage in type I invasive
epithelial ovarian














No evidence of this
Months; categorised into
four: 0 to < 3, ≥ 3 to < 6,








































how interval was analysed Outcome measures






























survival according to the
Cox proportional hazards
model. Covariates included
stage (stage I–II vs. stage
III–IV), among others
Diagnostic delay was one
of the factors with a
significant and independent
prognostic value; stage was




(p< 0.0001), with longer
delays associated with poor
survival




curves for three thresholds:
< 4, 4–6 and > 16 weeks
Jooste 2016;128
France
To estimate patient and
treatment delays in
patients with pancreatic
cancer and to measure
their association with




the first time (2009–11)













l ‘Overall delay’ (based on
‘patient’ plus ‘treatment’
delay): onset of symptoms
to treatment (T5)
l ‘Patient delay’: onset
of symptoms to first
consultation with
practitioner (most















delay’ only. ‘Patient delay’





































































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures

















categorised into two: T1
< 1 or ≥ 1 month; T9 < 29
or ≥ 29 days. Overall delay
(T5) analysed as four
categories based on the
‘patient’ and ‘treatment’
delay categories:
1. T1 < 1 month and T5
< 29 days (reference)
2. T1 < 1 month and T5
≥ 29 days
3. T1 ≥ 1 month and T5
< 29 days





To ascertain risk factors
resulting in delayed
treatment-seeking and












Symptom onset to first
medical consultation (T1)
l Survival (OS) rate:
≥ 2 vs. < 2 years, and
≥ 5 vs. < 5 years
l Stage




l 254 patients enrolled in




regression used to assess
impact of different
intervals on OS and lesion
characteristics, with OR
(95% CI) (Fisher’s exact








size, stage, lymph node
involvement and
distant metastases
No evidence of this
Months; divided into four










































how interval was analysed Outcome measures



















for prostate cancer at





l [Medical records and
patient inteviews]

















interval groups and stage
found in univariate analysis




but results based on
univariate analyses
Days; dichotomised: T8
≤ 100 vs. > 100 days;






primary delay and the
cancer stage of HIV
Kaposi’s sarcoma
patients on diagnosis of














presentation to a clinician
(any health professional)
(T1)
Stage (poor-risk stage) Multivariable logistic
regression used to estimate
OR of having poor-risk
stage vs. low-risk stage at
presentation, adjusted for






Measured pain. But it
was not included in
multivariate analysis
Months; dichotomised:



















































































































































































































































































































































TABLE 51 Systematic review 2: updated searchesa (continued )
Author and







how interval was analysed Outcome measures







To investigate delay in
diagnosis by both
patients and doctors,
and to evaluate its










l [GP records (GPs


















assess delays, but did
not assess impact of
each of these
on survival
No evidence of this
Months/days;
dichotomised: T4
< 4 vs. ≥ 4 months;




or not the duration from
initial symptoms to
specialist consultation




at a single specialist
hospital (2001–11).
Excluded patients seen





l [Patient records and
hospital database]
Onset of symptoms to
specialist consultation (T3)
Survival (5-year OS rate;








tumour size, depth, and
histological grade used to
obtain HR (95% CIs)
Data on delay available
for 142 patients with
soft-tissue sarcoma, of
whom 142 had non-small
cell sarcoma and were
included in survival analysis
Excluded patients
seen within 1 month
(most were second-
opinion patients)Months; divided into two











































how interval was analysed Outcome measures







To clarify the effect of










l [Cancer registry and
medical records]
Symptom onset to first
medical consultation at
cancer centre or associated
institution (no appointment
needed, so system issues
were absent) (T1)
l Survival (5-year OS
rate, from diagnosis)
l Stage (I vs. II–III)










used to obtain HR
(95% CIs). Differences
between interval groups





l Also evaluated shift in
consultation time the
last two decades




No evidence of this
Months; divided into two




DLBCL, diffuse large B-cell lymphoma; EHR, excess hazard ratio; FIGO, Fédération Internationale de Gynécologie et d'Obstétrique (International Federation of Gynaecology and Obstetrics); HIV, human
immunodeficiency virus; HMO, Health Maintenance Organization; M, metastasis; N, node; NKI-AvL, Nederlands Kanker Instituut Antoni van Leeuwenhoek; NSCLC, non-small-cell lung cancer; OR, odds ratio;
OS, overall survival; PFS, progression-free survival; SCLC, small-cell lung cancer; SD, standard deviation.


















































































































































































































































































































































TABLE 52 Description of studies included in the updated review
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Aslam 2017110 Survival T12 <> Median OS Log-rank test comparing median survival
from Kaplan–Meier curves. The study also
included patients referred via screening,
survival analysis limited to emergency,
2WW, urgent and routine referrals.
Analysis also conducted excluding
emergency
There was no significant difference in
overall survival between the two interval
groups (for 2WW, urgent, and routine
referrals combined): < 62 days group:
7.1 years vs. > 62 days group: 6.54 years
(p = 0.620)




Median interval (days) from symptom
onset and/or workup to diagnosis were
compared for advanced and non-advanced
stage at diagnosis (but not statistically)
within each age group
The authors noted that the longest time to
diagnosis (T4) was observed in patients
aged < 50 years with non-advanced CRC
at diagnosis (stage I and II) followed by
patients aged < 50 years with advanced
CRC at diagnosis (stages III and IV)
(median days 174 vs. 124)
l Aged < 50 years, non-advanced vs.
advanced stage
¢ Median symptom duration (T1): 90
vs. 60 days
¢ Median workup duration (T8): 39 vs.
29 days
l Aged ≥ 50 years, non-advanced vs.
advanced stage:
¢ Median symptom duration (T1): 21
vs. 30 days
¢ Median workup duration (T8): 31 vs.
17 days



































intervala Association Outcome description Statistic test/method of analysis Results
Dregan 2013108 Survival T4 <> Overall mortality
(from diagnosis)
Adjusted HR (95% CI) obtained from Cox
regression model (adjusted for age and sex).
(Also analysed risk of death according to
presence or absence of alarm symptoms)
l ≤ 14 days (n = 79) 1.07 (95% CI 0.65 to
1.77); p = 0.794
l 15–90 days (n = 217), reference
category
l 91–180 days (n= 56) 1.28 (95% CI
0.73 to 2.25); p = 0.386
l 181–365 days (n= 44) 0.76 (95% CI
0.38 to 1.54); p = 0.448
l > 365 days (n = 55) 0.92 (95% CI
0.45 to 1.85); p = 0.806
Patients with no preceding alarm
symptoms had shorter survival from




Survival T9 <> 5-year OS Adjusted HR (95% CI) and p-values
obtained from multivariate Cox
proportional hazards model using
bootstrap resampling. Important
confounders adjusted for included, among
others, stage, emergency presentations and
location. Emergency presentations were
also analysed separately. Also conducted
analysis limited to stage I–III CRC
(excluding stage IV and ‘unknown’)
Increased total wait time quartile was not
associated with worse survival (p = 0.4898)
l Q1 0 to ≤ 43 days (n = 175): reference
l Q2 (n = 135) > 43 to ≤ 95 days: 0.93
(95% CI 0.73 to 1.19)
l Q3 (n = 115) > 95 to ≤ 166 days: 0.90
(95% CI 0.69 to 1.16)
l Q4 (n = 113) > 166 to ≤ 513 days: 0.82
(95% CI 0.64 to 1.06)
When total wait time was considered as a
continuous variable (days), it was still not





T11 <> Node positivity, and
presence of distant
metastases
Chi-squared tests l Node positive in < 60 days group:
42/102 (41%) vs. > 60 days group:
52/144 (36%) (p = 0.42)
l Distant metastases in < 60 days group:
12/102 (12%) vs. > 60 days group:



















































































































































































































































































































































TABLE 52 Description of studies included in the updated review (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Leiva 2017113 Stage
(advanced)
T8 l – (Hospital)
l <> (GP)
TNM tumour stage
(0, 1, 2, 3, 4,
unknown)
The Mann–Whitney U-test and the
Kruskal–Wallis test were used to assess
association between diagnostic intervals
and various patient and clinical
characterises (including, among others
stage, emergency presentation, location,
symptoms at presentation, and perceived
seriousness of symptoms). The independent
effect of variables was assessed using Cox
regression and then the extension of the
multivariate Cox proportional hazards
model with time-dependent covariates
l Comparing three different information
sources for estimating ‘diagnostic
intervals’: patient recall, hospital records
and GP records. Interval defined as date
from first registry of symptoms to date
of diagnosis for GP and hospital records
(T8), but, for patient recall, this was
time from patient first experiencing
symptoms to date of diagnosis (T4)
l Univariate analysis indicated that a
shorter diagnostic interval was
associated with more advanced tumour
stage using both GP and hospital
records, but this was significant for
hospital records data only (p = 0.021)
l Stage was not an independent predictor
of a shorter interval in the multivariate
analysis of hospital and GP data
T4 <> (patient) TNM tumour stage
(0, 1, 2, 3, 4,
unknown)
As above l Univariate analysis indicated that a
shorter diagnostic interval was
associated with more advanced tumour
stage for patient recall, but this was
not significant
l Stage was identified as one of the
independent predictors of shorter
interval in the multivariate analysis for
patient-recorded data (but not in the







































T9 <> Dukes’ stage was
collapsed into a
binary variable: early
(A or B) vs. advanced
(C or D)
OR (99% CI) obtained from logistic
regression model with a restricted cubic
spline (to allow for non-linear relationship),
following sequential adjustment (using
1–4 models; 1 representing unadjusted)
of patient and tumour factors (including,
among others, tumour grade, and signs
and symptoms). Time to treatment was
modelled using four knots corresponding
to the 25th, 50th, 75th and 100th centile
l The spline curves showed a significant
non-linear (p = 0.04) (and unadjusted,
p = 0.002) association between provider
delay and stage. Delays of between 4
and 34 weeks were associated with
earlier stage, and intervals beyond this
with later stage disease. However, the
plot based on a fully adjusted model
showed wide CIs
l According to the fully adjusted model,
provider delays of 40 and 60 weeks
were associated with later-stage disease
at presentation, but the OR did not
reach statistical significance
¢ 4 weeks (reference)
¢ 20 weeks 0.87 (99% CI 0.54 to 1.39)
¢ 40 weeks 1.46 (99% CI 0.93 to 2.31)
¢ 60 weeks 1.58 (99% CI 0.96 to 2.61)
Murchie
2014107
Survival T9 <> All-cause survival
(from date of first
presentation)
HR (99% CI) obtained from Cox survival
models, both with a restricted cubic spline
(to allow for non-linear relationship),
following sequential adjustment (1–4
models) of patient and tumour factors
(including, among others, tumour grade,
emergency admission, and signs and
symptoms). Time to treatment was
modelled using four knots corresponding
to the 25th, 50th, 75th and 100th centile.
Stratified analysis also conducted for rectal
and colon cancer
The spline curves showed a significant non-
linear (p < 0.001) (and unadjusted inverse,
p < 0.001) association between provider
delay and mortality. In the univariate
analysis, diagnostic interval of < 4 weeks
was associated with poor survival, but this
was no longer present after adjusting for
confounders. According to the fully
adjusted model, provider delays of 40 and
60 weeks were associated with later-stage
disease at presentation, but the OR did not
reach statistical significance
l 4 weeks (reference)
l 20 weeks 0.99 (99% CI 0.76 to 1.27)
l 40 weeks 1.17 (99% CI 0.92 to 1.48)



















































































































































































































































































































































TABLE 52 Description of studies included in the updated review (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Patel 2018111 Survival T12 – Long-term (mean)
survival
Proportion of patients still alive at long-
term follow-up (October 2011), and log-
rank test comparing Kaplan–Meier curves.
Also assessed 30-day postoperative
mortality and cause of death
l Long-term survival was greatest in
elective patients who did not receive
treatment > 62 days (52% alive),
compared with elective cases treated
≤ 62 days (34% alive). This was supported
by the log-rank analysis (p< 0.001)
l Operative mortality was higher in
patients treated ≤ 62 days (7% elective,
20% emergency) than in those who
were treated > 62 days (4% elective,
7% emergency). The most common
cause of death was CRC in all groups




l Proportion of early-stage disease (Dukes’
stage A–B) was highest in elective
patients treated > 62 days (50%)
(p< 0.01) and lowest in emergencies
treated ≤ 62 days (30%) (p= 0.26)
l Later-stage disease (Dukes’ stage C–D)
was most common in emergency patients
treated ≤ 62 days (58%) and lowest in


































intervala Association Outcome description Statistic test/method of analysis Results
Pita-Fernández
2016109







The influence survival was analysed in
two ways:
1. Kaplan–Meier survival curves were
computed for each interval quartile,
and compared using the log-rank test
2. the interval was treated as a continuous
variable using restricted cubic splines
with four knots and using the 50th
percentile (3.4 months) as reference
point
The 5-year HRs (95% CI) were estimated
as a function of the length of the delay
interval and adjusted for age and sex
(model 1), and subsequently stage (model 2),
using proportional hazard Cox regression
l The Cox regression model adjusting for
age and sex showed that, in rectum
cancers, patients within the first interval
quartile had lower survival (p = 0.003),
but this was no longer statically
significant when also adjusting for
stage (p = 0.084)
l No significant differences were found
for colon cancer when adjusting for age
and sex (p = 0.282) or also adjusting for
stage (p = 0.160)
l Longer intervals were not associated
with poor survival in CRC patients.
From age-, sex- and stage-adjusted
model:
¢ < 1.5 months (reference)
¢ 1.5–3.4 months, 0.97 (95% CI 0.71
to 1.32)
¢ 3.4–6.4 months, 0.76 (95% CI 0.55
to 1.04)
¢ > 6.4 months, 0.77 (95% CI 0.56 to
1.05)
l The cubic splines regression analysis
revealed that, for rectum cancer, 5-year
mortality progressively increases for
intervals less than the median
(3 months) and decreases as the delay
increases until approximately 8 months.
In colon cancer, no significant






T4 <> TNM tumour stage
(I, II–III, IV)
The association between the interval
(categorised into quartiles) and tumour
stage analysed using multivariate logistic
regression (adjusting for age and sex)
The interval was not found to be significantly
associated with stage at diagnosis
[stage I: 3.6 months; stage II–III: 3.4 months;
stage IV: 3.2 months (p= 0.728)], even after



















































































































































































































































































































































TABLE 52 Description of studies included in the updated review (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results





Cases (CRC deaths) and controls (deaths
due to other causes or censored) were
matched on survival time and the
association of delay with death was
examined using logistic regression. OR
(95% CI) estimated using multivariate
regression analysis adjusting for
sociodemographic, tumour (histology, stage,
grade, location), and treatment factors.
Stratified analysis also conducted
according to and stage (and presenting
symptom in sensitivity analysis)
l Colon cancer patients with the longest
diagnostic delays (8–12 months vs.
14–59 days) had higher odds of all-
cause (OR 1.31, 95% CI 1.08 to 1.58),
but not CRC-specific, death
l Among rectal cancer patients, delays
were not associated with risk of
all-cause or CRC-specific death






OR (95% CI) estimated using multivariate
regression analysis adjusting for
sociodemographic, tumour (histology, stage,
grade, location), and treatment factors.
Stratified analysis also conducted
according to and stage (and presenting
symptom in sensitivity analysis)
l Colon cancer patients with the shortest
treatment delays (< 1 vs. 1–2 weeks) had
higher odds of all-cause (OR 1.23, 95% CI
1.01 to 1.49), but not CRC-specific, death
l Among rectal cancer patients, delays
were not associated with risk of
all-cause or CRC-specific death
Redaniel
2015101
Survival T8 <> 5-year survival 5-year EHRs (95% CI) were computed
using a generalised linear model with a
Poisson error structure. Univariable and
multivariable models built, for each cancer
site, and stratified by the nature of the
symptoms (NICE-qualifying alert vs. non-
alert). Multivariable models controlled for,
among others, the effects of period of
cancer plan implementation, Dukes’ stage,
tumour subsite (for CRC), and tumour
differentiation
There was no evidence of an association
between diagnostic interval and mortality.
EHR based on multivariate analysis for
all patients:
l < 1 month (reference)
l 1–2 months 0.94 (95% CI 0.82 to 1.07)
l 3–6 months 0.92 (95% CI 0.82 to 1.04)
l > 6 months 0.93 (95% CI 0.81 to 1.07)
The results showed significant lower
mortality associated with longer diagnostic
intervals for patients presenting with non-
alert symptoms (EHR > 6 months vs.
< 1 month: 0.85, 0.72 to 1.00; p = 0.049),
whereas no significant associations were



































intervala Association Outcome description Statistic test/method of analysis Results






l Analyses stratified according to the
GP’s interpretation of the presenting
symptoms: alarm or serious vs. vague.
OR (95% CI) obtained from logistic
regression using restricted cubic splines
and adjusting for comorbidity, age, and
sex. Each model tested against a model
with no diagnostic interval term using
the Wald test.
l Data on tumour stage and emergency
admission collected, and used to
describe patient characteristics and
compare the two groups, with alarm/
serious symptoms or vague symptoms
(Note: this appears to be the same CRC
cohort as Tørring, 2011136)
l Alarm/serious symptoms (n = 201): the
categorical analysis showed that both
very short and long diagnostic intervals
(first or fourth quartile compared with
second and third) were associated with
poor survival, but only the adjusted OR
for the former was statistically significant:
¢ Q1: 4.74 (95% CI 2.20 to 10.19)
¢ Q2 +Q3: reference
¢ Q4: 2.01 (95% CI 0.93 to 4.36)
l This association was confirmed by
the spline regression analyses, which
revealed convex (U-shaped) associations:
the risk of dying within 5 years decreased
with longer diagnostic intervals up to
approximately the 60th percentile and
then increased (p= 0.001)
l Vague symptoms (n= 67): the categorical
analysis showed that the first diagnostic
interval quartile was associated with poor
survival, compared with the second and
third, whereas the fourth was not, but
these findings were not statistically
significant. Adjusted OR for each quartile:
¢ Q1: 0.74 (95% CI 0.19 to 2.80)
¢ Q2 +Q3: reference
¢ Q4: 1.08 (95% CI 0.28 to 4.12)
l The corresponding spline regression
analyses did not show a significant



















































































































































































































































































































































TABLE 52 Description of studies included in the updated review (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results










Data taken from three studies using
different methods for identifying date of
first presentation. Data analysed for each
study separately and combined
The data were modelled in two ways:
1. Comparison of the first and fourth
diagnostic interval quartiles with the
second and third
2. Diagnostic interval rescaled and treated
as a continuous variable using restricted
cubic splines with four knots with the
50th percentile used as the reference
point
The 5-year HR (95% CI) estimated as a
function of the length of the diagnostic
interval and adjusted for tumour site
(colon/rectum), age and sex using
proportional hazard Cox regression. In the
analysis of the combined data, differences
were also allowed for in study-specific
baseline hazards. (Note that the GP
record-based study is Tørring 2011136)
GP-based study (n= 266) adjusted HRs for
each quartile:
l Q1: 1.73 (95% CI 1.16 to 2.59)
l Q2 +Q3: reference
l Q4: 1.75 (95% CI 1.17 to 2.63)
Patient-based study (n= 658) adjusted HRs
for each quartile:
l Q1: 1.26 (95% CI 0.95 to 1.66)
l Q2 +Q3: reference
Q4: 1.11 (95% CI 0.85 to 1.46)
Record-based study (n= 319) adjusted HRs
for each quartile:
l Q1: 1.20 (95% CI 0.84 to 1.71)
l Q2 +Q3: reference
Q4: 1.30 (95% CI 0.91 to 1.86)
Combined data (n = 1243) adjusted HRs
for each quartile:
l Q1: 1.33 (95% CI 1.10 to 1.61)
l Q2 +Q3: reference
Q4: 1.28 (95% CI 1.06 to 1.55)
The association between diagnostic interval
and survival was the same for all three types
of data: displaying a U-shaped association
with decreasing and, subsequently, increasing
mortality with longer diagnostic intervals (i.e.
U-shaped association observed using three
different data collection methods in different



































intervala Association Outcome description Statistic test/method of analysis Results







l Analyses stratified according to the
GP’s interpretation of the presenting
symptoms: alarm or serious vs. vague.
Logistic regression used to estimate
3-year mortality ORs (95% CIs) as a
function of the diagnostic interval using
restricted cubic splines and adjusting for
tumour site, comorbidity, age and sex.
Also reported were outcome data for
1-year mortality
l Data on tumour stage and emergency
admission collected, and used to
describe patient characteristics and
compare the two groups, with alarm/
serious symptoms or vague symptoms
l Alarm/serious symptoms (n = 201): the
cubic spline regression analysis revealed
that the risk of dying within 3 years
decreased with diagnostic intervals of
up to 5 weeks and then increased
(p = 0.002)
l Adjusted OR for diagnostic intervals:
¢ 0–4 weeks (n= 75), 2.56 (95% CI
1.29 to 5.05)
¢ 5–11 weeks (n= 90): reference
¢ ≥ 12 weeks (n = 36): 2.04 (95% CI
0.87 to 4.77)
l Vague symptoms (n= 67): the cubic
spline regression analysis revealed a
reverse effect, with increasing risk of
dying from day 1 up to ≈ 12 weeks, but
the association was not statistically
significant (p = 0.205)
l Adjusted OR for diagnostic intervals:
¢ 0–4 weeks (n= 10): comparison
not justified
¢ 5–11 weeks (n= 27): reference
¢ ≥ 12 weeks (n = 30): 0.71 (95% CI
0.32 to 2.91)
+, positive association, based on a statistically significant more favourable outcome; –, negative association, based on a statistically significant less favourable outcome; <>, findings
that were not statistically significant; EHR, excess hazard ratio; HR, hazard ratio; OS, overall survival; Q, quartile.


















































































































































































































































































































































Results of the studies included in the updated review
The ‘abbreviated results’ presented in Table 53 represent those used to populate Table 11. The results
provide a summary of the impact of ‘short intervals’ on outcome to correspond to the methods used in
the original review.
These abbreviated results, however, represent a very simplistic interpretation of the study findings.
Some studies assessed the interval as a categorical variable, whereby not all categories were
associated with a significant or the same findings. Some studies evaluated the impact of ‘long intervals’
(often referred to as ‘delay’), which were converted to represent the impact of ‘short intervals’. A brief
summary of the study findings are presented in the last column of Table 53 to show how our
‘abbreviated results’ were derived from the actual study results for these studies. It was not our
intention to extract detailed results of included studies for non-CRC sites; therefore, the brief
summaries relate mainly to the interpretation of studies reporting statistically significant findings.


















Murchie 2015102 Survival T9 – Very short intervals – poor outcomes
l Patients with very short intervals
(up to 4 weeks) had poor prognosis, but
longer delays were not associated with
worse survival
Murchie 2015102 Stage (III–IV) T9 – Very short intervals – poor outcomes
l Patients with very short intervals (up to
4 weeks) had poor prognosis, but longer
delays were not associated with more
advanced stage
Pace 2015103 Stage (advanced) T1 + Longer intervals – worse outcomes
l Intervals of ≥ 6 to < 12 and ≥ 6 months
only were significantly associated with
more advanced-stage disease (compared
with < 3 months)
l OR and 95% CI for the three interval
comparisons presented as a forest
plot only
¢ ≥ 3 to < 6 vs. < 3 months:
not significant
¢ ≥ 6 to 12 vs. < 3 months: OR
> 3 months with CI not crossing 1
¢ > 12 vs. < 3 months: OR > 3 months
with CI not crossing 1
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Summary of results for studies reporting
significant findings
Pace 2015103 Stage (advanced) T8 + Longer intervals – worse outcomes
l Intervals of ≥ 6 to < 12 months were
significantly associated with more
advanced-stage disease (compared with
< 3 months)
l OR and 95% CI for the three interval
comparisons presented as a forest
plot only
¢ ≥ 3 to < 6 vs. < 3 months:
not significant
¢ ≥ 6 to 12 vs. < 3 months: OR
> 3 months with CI not crossing 1
¢ > 12 vs. < 3 months: not significant
Unger-Saldaña
2015104
Stage (advanced) T3 + Longer intervals – worse outcomes
l For every increase of 1 month in the
‘patient interval’ (T3), there was a 1.8%
(p < 0.01) rise in the probability of
beginning cancer treatment in advanced
stages (stage III–IV vs. stage 0, I or II)
Unger-Saldaña
2015104
Stage (advanced) T14 + Longer intervals – worse outcomes
l For each increment of 1 month in the
‘provider interval’ (T14), the probability of
beginning cancer treatment in advanced
stages (stage III–IV vs. stage 0, I or II)
increased by 1% (p < 0.05)
Bladder
Bryan 2015105 Survival T5 <>
Bryan 2015105 Survival T12 <>
Bryan 2015105 Survival T2 <>
Bryan 2015105 Survival T10 <>
Bryan 2015105 Survival T14 <>
Bryan 2015105 Stage (advanced) T5 <>
Bryan 2015105 Stage (advanced) T12 <>
Bryan 2015105 Stage (advanced) T2 <>
Bryan 2015105 Stage (advanced) T10 <>
Bryan 2015105 Stage (advanced) T14 <>
Bryan 2015105 Tumour size
(> 2 cm)
T14 – Longer intervals – better outcomes
l Longer delays (> 20 days) in T3 were
associated with smaller tumour
size (p < 0.05)
l Number (%) of patients in each interval
group for tumour size of ≤ 2 cm and
of > 2 cm:
¢ ≤ 2 cm: > 20 days, n = 244 (37%) vs.
≤ 20 days, n = 302 (43%)
¢ > 2 cm: > 20 days, n = 412 (63%) vs.
≤ 20 days, n = 395 (57%)
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Summary of results for studies reporting
significant findings
Bryan 2015105 Tumour size
(> 2 cm)
T12 – Longer intervals – better outcomes
l Longer delays (> 68 vs. ≤ 68 days) in
‘Hospital Delay’ were associated with
smaller tumour size (p < 0.05)
l Number (%) of patients in each interval
group for tumour size of ≤ 2 cm and
of > 2 cm:
¢ ≤ 2 cm: > 20 days, n= 247 (36%) vs.
≤ 20 days, n = 303 (45%)
¢ > 2 cm: > 20 days, n= 439 (64%) vs.
≤ 20 days, n = 379 (55%)
Colorectal
Aslam 2017110 Survival T12 <>
l Chen 2017112 l Stage (III–IV) l T4 – (aged
< 50 years)
Shorter intervals – worse outcomes
Among younger patients, those with
advanced stage (stage III–IV) had shorter
symptom and workup durations than early
stage (stage I-II) CRC
l [No statistical analysis conducted,
but the difference in median interval
for patients with advanced vs.
non-advanced stage (for young-onset
CRC) was 40 days]
l Chen 2017112 l Stage (III–IV) l T1 – (aged
< 50 years)
Shorter intervals – worse outcomes
Patients with advanced stage had shorter
symptom durations than early stage
l No statistical analysis conducted, but for
young-onset CRC, the difference in
median ‘symptom duration’ for patients
with advanced and non-advanced stage
was 30 days
Chen 2017112 Stage (III–IV) T8 <> (aged
< 50/≥ 50 years)
Chen 2017112 Stage (III–IV) T4 <> (aged
≥ 50 years)
Chen 2017112 Stage (III–IV) T1 <> (aged
≥ 50 years)
Helewa 2013106 Survival T9 <>





Leiva 2017113 Stage (more
advanced)
T8 – (hospital) Longer intervals – better outcomes
l The diagnostic interval obtained from
hospital records was greater in those with
less advanced CRC (p = 0.021)
<> (GP)
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Summary of results for studies reporting
significant findings
Leiva 2017113l Stage (more
advanced)
T4 <>
Murchie 2014107 Stage (advanced;
C–D)
T9 <>




Patel 2018111 Survival T12 – Longer intervals – better outcomes
l Long-term survival was greatest in
elective patients who failed the standard,
with 52% alive in October 2011,
compared with 34% of elective cases
meeting the standard (p < 0.001)
Patel 2018111 Stage T12 – Longer intervals – better outcomes
l The proportion of early-stage disease
(Dukes’ stage A and B) was highest
in elective patients who failed the
standard (50%; p < 0.01) and lowest
in emergencies meeting the standard
(30%; p = 0.26)
Multisite
Urinary tract
Dregan 2013108 Survival T8 + Longer intervals – worse outcomes
l Longer diagnostic intervals were
associated with increased mortality
(HR 2.23, 95% CI 1.35 to 3.69)
Lung
Dregan 2013108 Survival T8 <>
Gastro-oesophageal
Dregan 2013108 Survival T8 <>
Colorectal
Dregan 2013108 Survival T8 <>
Prostate
Redaniel 2015101 Survival T8 – Longer intervals – better outcomes
Prostate cancer mortality was lower
in patients with longer diagnostic intervals,
regardless of type of presenting symptom
l Outcome =mortality; interval in months
¢ 1–2 months vs. < 1 month: EHR 0.64,
95% CI 0.42 to 0.98
¢ > 6 months vs. < 1 month: EHR 0.45,
95% CI 0.27 to 0.75
¢ (No significant difference for
3–6 months vs. < 1 month: 0.72,
95% CI 0.49 to 1.05)
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Summary of results for studies reporting
significant findings
Lung
Redaniel 2015101 Survival T8 – Longer intervals – better outcomes
l Interval – months
¢ 3–6 months vs. < 1 month: EHR 0.90,
95% CI 0.84 to 0.98
¢ > 6 months vs. < 1 month: EHR 0.87,
95% CI 0.80 to 0.94
¢ (No significant difference for
1–2 months vs. < 1 month: EHR 1.02,
95% CI 0.93 to 1.11)
Colorectal
Redaniel 2015101 Survival T8 <>
Breast
Redaniel 2015101 Survival T8 <>
Lung





T14 – Longer intervals – better outcomes
l The survival is longer in patients with a
longer treatment delay
l Interval in days
¢ ≥ 91 vs. 0–30 days: HR 0.64, 95% CI
0.43 to 0.96
¢ (No significant difference for –
– 31–60 vs. 0–30 days: HR 0.77,
95% CI 0.57 to 1.04
– 61–90 vs. 0–30 days: HR 0.66,





T15 – Longer intervals – better outcomes
l The survival is longer in patients with a
longer treatment delay
l Interval in days
¢ ≥ 61 vs. 0–30 days: HR 0.42, 95% CI
0.26 to 0.69
¢ (No significant difference for:
– 31–60 vs. 0–30 days: HR 0.81,











Kim 2016119 Stage (II, III vs. I) T13 – (NSCLC) Shorter intervals – worse outcomes
l Outcome = delayed (≥ 38 days)
‘diagnostic interval’:
¢ Stage II vs. I: OR 0.68, 95% CI 0.50
to 0.92
¢ Stage III vs. I: OR 0.54, 95% CI 0.44
to 0.68
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Summary of results for studies reporting
significant findings
Kim 2016119 Stage (III vs. I) T15 – (NSCLC) Shorter intervals – worse outcomes
l Having locally advanced disease (stage III
vs. I: OR 0.47, 95% CI 0.38 to 0.60)
protected against delayed treatment
intervals. (Stage II vs. I was not significant)
l Outcome = delayed (≥ 51 days)
‘treatment interval’
Kim 2016119 Stage (III vs. I) T14 – (NSCLC) Shorter intervals – worse outcomes
l Factors associated with prompt care
included stage III disease
l Locally advanced stage (stage III vs. I: OR
0.42, 95% CI 0.33 to 0.53) was highly
protective against delayed ‘system
intervals’ and was not found to be
collinear in the multivariable regression
modelling. (Stage II vs. I was not
significant)




Survival T1 <> (SCLC)
Radzikowska
2013115
Survival T8 – (SCLC) Shorter intervals – worse outcomes
l Patients who were diagnosed faster
(< 42 days) had a worse prognosis than
those diagnosed later. HR for death was
1.20 in group with interval of < 42 days
(vs. > 42 days, p = 0.001)
Živković 2014116 Survival T1 <>
















Keizer 2016122 Survival T4 <>
Keizer 2016122 Stage T4 <>
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T1 + Longer intervals – worse outcomes
l Stage at diagnosis was significantly
associated with ‘patient delay – 1’
(p = 0.001) (delay defined as > 3 months)
l Number (%) of patients with early or
advanced stage for those with and
without ‘delay’:
¢ Present: early, 6 (12.5%) vs. advanced,
42 (87.5%)









Stage (advanced) T5 + Longer intervals – worse outcomes
l The delayed patients (interval > 140 days)
were diagnosed in more advanced stage
than the patients without delay (OR 2.1,
95% CI 1.0 to 4.4)
Ovarian
Altman 2017126a Survival T8 + (after 30 days) l Longer intervals – no adverse outcomes
l Time to diagnosis was significantly related
to survival (p = 0.0309) in the analysis for
late-stage disease, but was not identified
as a significant factor for early-stage
disease
l OS was not negatively affected by longer
time to diagnosis up until 80 days, at
which point survival began decreasing
with longer diagnostic interval
l Emergency presentation was associated
with a worse OS (p = 0.0399) in late-
stage disease
Lim 2016125 Stage (advanced) T1 <> (type I and II)
Lim 2016125 Stage (advanced) T8 <> (type I and II)
Pancreatic
Gobbi 2013127 Survival T4 + Longer intervals – worse outcomes
Time to diagnosis (weeks) was a significant
and independent prognostic factor: HR 1.02,
95% CI 1.01 to 1.04. There was a significant
difference between the Kaplan–Meier curves
for different thresholds (p < 0.0001): < 4, 4–6
and > 16 weeks
Jooste 2016128 Survival T5 <>
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Summary of results for studies reporting
significant findings
Penile
Gao 2016129 Survival T1 + (2-year OS) Longer intervals – worse outcomes
l Patients with a delay of > 6 months
showed significantly inferior 2-year OS
l Interval – months
¢ > 6 months vs. ≤ 1 month: OR 5.19,
95% CI 1.05 to 25.60
¢ (No significant difference for:
– 1–3 months vs. ≤ 1 month: OR 0.98,
95% CI 0.13 to 7.21
– 3–6 months vs. ≤ 1 month: OR 2.9,
95% CI 0.51 to 16.59)
l Patient’s delay did not have an impact on
5-year OS
<> (5-year OS)
Gao 2016129 Stage (T1b–T4
vs. Tis/Ta/T1a)
T1 + Longer intervals – worse outcomes
l Patients with a delay of ≥ 3 months had
significant risk for more advanced stage
(T1b–T4) tumour (compared with a delay
of ≤ 1 month)
¢ 3–6 vs. months ≤ 1 month: OR 2.9,
95% CI 1.23 to 7.09
¢ > 6 months vs. ≤ 1 month: OR 6.42,
95% CI 2.99 to 13.79
¢ (No significant difference for
1–3 months vs. ≤ 1 month: OR 1.50,
95% CI 0.62 to 3.66)
Gao 2016129 Tumour size
(> 2 cm)
T1 + Longer intervals – worse outcomes
l Patients with a delay of ≥ 3 months had
significant risks for bigger (> 2 cm) lesion
size than patients with a delay of
≤ 1 month
¢ 3–6 months vs. ≤ 1 month: OR 3.29,
95% CI 1.53 to 7.07
¢ > 6 months vs. ≤ 1 month: OR 6.42,
95% CI 2.99 to 13.79
¢ (No significant difference for
1–3 months vs. ≤ 1 month: OR 1.43,
95% CI 0.67 to 3.02)
Gao 2016129 Metastases (M1) T1 + Longer intervals – worse outcomes
l Patients with a delay of ≥ 3 months
(vs. ≤ 1 month) had a significantly
increased risk of metastasis
Gao 2016129 Lymph node
involvement
(N1–3)
T1 – Longer intervals – worse outcomes
Patients with a delay of > 6 months had
significant risks for higher positive rate of
regional lymph nodes (compared with
patients with a delay of ≤ 1 month)
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Summary of results for studies reporting
significant findings
Prostate









De Boer 2014133 Stage [poor-risk
stage (vs. good
risk)]c
T1 + (HIV Kaposi’s
sacoma)
Longer intervals – worse outcomes
l Patients who experienced diagnostic delay
(> 3 months) were more likely than those
who did not delay (≤ 3 months) to have
poor-risk Kaposi’s sacoma stage (OR 3.41,










Urakawa 2015131 Survival T3 – Shorter intervals – worse outcomes
l Multivariate analysis revealed that
symptom interval of < 6 months was an
independent factor associated with poor
survival (p = 0.017)





Survival T1 + Longer intervals – worse outcomes
l Time to consultation of > 6 months was
an independent risk factor associated with
poorer OS (< 6 vs. ≥ 6 months, HR 18.0,
95% CI 1.78 to 182; p = 0.014)
Kobayashi
2014134
Stage (> II) T1 <>
Kobayashi
2014134
Size (larger; > 2
vs. ≤ 2 cm and
> 5 vs. ≤ 5 cm)
T1 + Longer intervals – worse outcomes
l There was a close and positive correlation
between time to consultation and primary
tumour size (Kruskal–Wallis test; p= 0.001)
+, positive association, based on a statistically significant more favourable outcome; –, negative association, based on a
statistically significant less favourable outcome; <>, findings that were not statistically significant; EHR, excess hazards
ratio; HIV, human immunodeficiency virus; HR, hazard ratio; N, node; NSCLC, non-small-cell lung cancer; OR, odds
ratio; OS, overall survival; SCLC, small-cell lung cancer.
a Ordered alphabetically by cancer site and then author, with studies evaluating more than one cancer reported under
‘multiple’ with each corresponding cancer site (the findings for these studies are presented in Table 11 under the
corresponding cancer site).
b See Figure 2 for the time intervals.
c Using the validated staging system for AIDS-associated Kaposi sarcoma;233 patients were classified as having overall
“good risk” or “poor risk” based on this system. The diagnostic areas included were: extent of tumour involvement
(T), immune system function (I), and presence of systemic illness (S). A patient with poor risk in all three areas,
(T1I1S1), is defined as having overall poor risk. Good risk for tumour extent indicates that all KS nodules, or lesions,
are confined to the skin or lymph nodes, and any oral involvement is confined to the palate only.
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Colorectal cancer studies
TABLE 54 Updated review: categories used for coding study aim
Index relating to aim
of study Definition
Interval Evaluate the influence of delay on patient outcomes (or association between interval
and outcomes)
Delay Describe the intervals (or identify delays). Includes comparison of intervals with
recommended guidelines also
Progress Changes in delay (intervals) over time
Symptoms Evaluation of which specific symptoms are associated with delay
Causes Identifying which factors are associated with delay (or determinants of delay). (Predictors
of delay)
Prognostic factors Identifying modifiable factors associated with patient outcomes (or identifying influence of
various factors). (Predictors of stage/survival)
Pathway Comparing different referral ‘type’ interventions or pathways, for example fast track vs.
conventional; rapid/urgent referral vs. non-urgent
Note that studies were excluded from the updated review for which this was the primary
aim, and for which the reference details in the EndNote library did not indicate that the
study also evaluated the impact of the interval on patient outcomes (survival or stage)
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screening (n= 275), but
not included in survival
analysis. Included
emergency admission










2329 Database maintained by

















at the Stanford Cancer
Institute between 2008
and 2014. Compared
data of patients with
young-onset CRC
(diagnosed at an age
< 50 years) with those
patients diagnosed
with CRC at an age of
≥ 50 years. Excluded
patients with
insufficient data, and,
for cohort ≥ 50 years,
those who were
asymptomatic. First
medical visit was with a
primary care provider






age < 50 years;
1377 at age
≥ 50 years)
354 for those aged




≥ 50 years, from
which a random





< 50 years; 232
aged ≥ 50 years)
Stanford Cancer Institute
Research Database
(clinical records) used to
identify cases, and obtain























































with a specific alarm
symptom (haematuria,
haemoptysis, dysphagia







































Patients for whom dates
of index contact could































Patients referred to, and
subsequently seen by,
a gastroenterologist
at St. Paul’s Hospital,
Vancouver, and had a
pathological diagnosis of
CRC, between 2010 and
2013. Patients with a
mass on rectal/physical
examination or a high
suspicion of malignancy
based on diagnostic
imaging at the time of
referral were excluded







Unclear (246) Patients identified via
hospital pathology
database and then cross-
referenced against EMR
to select those seen by
the gastroenterologists













































































































































































































































































































































































diagnosed with CRC at
one of nine public







19 no onset date),
hospital records




































via CRUX data set
(numbers not stated).
Those with signs and
symptoms > 2 years
prior to treatment were
excluded
NR Unclear 958 for survival;
868 stage
Linked data from four
data sets: CRUX data sets
(primary care data),
Scottish Cancer Registry
(for tumour stage and
grade), the Scottish















































electively or in an
emergency setting
(with patients who
did not go on to have
surgery within 72 hours
of admission reclassified

























































Older US adults (aged
≥ 66 years) with
invasive colon or































claims files from the
Centers for Medicare and
Medicaid Services











and for T15 those who
did not have treatment












or prostate cancers who
presented to a GP with
a cancer symptom
1 year prior to diagnosis
identified. Only English
cancer patients
diagnosed in the years














to a GP with a
cancer symptom





CPRD was linked to the
NCDR and to the 2007
English IMD data sets.
(NCDR captures data
from the merged Cancer
Registry, Hospital Episode




























































































































































































































































































































































































(Note that the CRC
cohort appears to be
the same as is Tørring
2011136)














Each patient’s GP was
subsequently identified
by linking the patient’s
data to the Health
Service Registry. Same
































Denmark (n= 2) and the
UK (n= 1). All newly
diagnosed CRC patients




(Note that one of the





































































































> 17 years during 1 year
(1 September 2004 to
31 August 2005).
Excluded patients

















l Data on interval
collected via
GP questionnaire





CRUX, Comparing Rural and Urban Cancer Care; EMR, emergency medical record; NCDR, National Cancer Data Repository; NR, not reported; ONS, Office for National Statistics.
Notes
Categories for study aim: interval – evaluate the influence of delay on patient outcomes; delay – describe the intervals (or identify delays); progress – changes in delay (intervals) over time; symptoms – evaluation of which
specific symptoms are associated with delay; causes – identifying which factors are associated with delay; prognostic factors – identifying modifiable factors associated with patient outcomes; pathway – comparing


















































































































































































































































































































































BOX 1 Updated review: bias assessment tool
Sample representativeness
Is the sample representative of the relevant cancer patient population? The population may be quite
specific, typified by age, stage, ethnicity or other factors.
Yes: only if this is clearly reported.
Can’t tell: if it’s reported in an ambiguous way.
Not reported: if it doesn’t say.
If none of the above – please qualify with free text (this may be a majority of studies).
Characteristics’ reporting
Was the reporting of participant characteristics complete?
Yes: only if this is clearly and fully reported.
Can’t tell: is if it’s reported in an ambiguous way.
Not reported: if it doesn’t say.
If none of the above – please qualify with free text (this may be the majority of studies, e.g. those that give
just age and sex).
Representativeness of participants
Were participants who participated (or whose data were used) representative of the sample from which
they (or it) were sourced?
Yes: only if this is clearly and fully reported.
Can’t tell: is if it’s reported in an ambiguous way.
Not reported: if it doesn’t say.
Not applicable: if all of sample participated – for example database study.
If none of the above – please qualify with free text.
Bias minimisation in measurement of symptom duration
Were steps taken (as stated by the investigators) to minimise and check for biases and inaccuracies
introduced due to the method used for measurement of symptom duration?
Yes: if clear evidence of this, please list information as free text: MANDATORY.
No: if no evidence of this.
Can’t tell: if unclear (this includes where results may be reported but no mention in methods).
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Independent variable assessment
Was the assessment symptom duration (explanatory variable) conducted independent of the assessment of
the outcome variable?
Yes: if reported as done.
No: if clearly reported that same researcher did it.
Not reported: if it doesn’t say.
Not applicable: if method does not require this to be done, for example database study.
A priori definition of outcome variable
Was the outcome variable specified/defined a priori?
Yes.
No.
Appropriate definition of outcome variable
Was the outcome variable clearly defined?
Yes: for example type of stage, type of survival – not necessary to enter detail.
No: anything other than yes.
Multivariate analysis




Was adjustment for important prognostic factors conducted as part of the analysis?
Yes: if clear evidence of this (e.g. performance status, age, smoking, comorbidity) please qualify with free
text MANDATORY.
No: if no evidence of this.
Can’t tell: if unclear (this includes studies for which results may be reported but no mention in methods)
please qualify with free text MANDATORY.
BOX 1 Updated review: bias assessment tool (continued)
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Outlier adjustment for symptom duration
Was adjustment for outliers conducted as part of the analysis?
Yes: if clear evidence of this – please qualify with free text MANDATORY.
No: if no evidence of this.
Not applicable: for example if there were no symptom durations greater than 2 years for more quickly
diagnosed cancers.
Can’t tell: if unclear (this includes studies for which results may be reported but no mention in methods)
please qualify with free text MANDATORY.
Confounder adjustment
Was adjustment for confounders (identified in advance of the study) conducted as part of the analysis?
Yes: if clear evidence of this, please qualify with free text MANDATORY.
No: if no evidence of this.
Can’t tell: if unclear (this includes where results may be reported but no mention in methods) please qualify
with free text MANDATORY.
BOX 1 Updated review: bias assessment tool (continued)
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Aslam 2017110 T12 Patients receiving
surgery
NR Yes No N/A Yes Yes No No No No
Chen 2017112 T4, T1,
T8
Yes Yes Cannot tell No N/A Yes Yes No (for outcome
of interest)
No No No





N/A Yes Yes Yes No No No
Helewa 2013106 T9 Patients receiving
surgery
Yes Cannot tell No N/A Yes Yes Yes Yes No Yes
Janssen 2016114 T11 Yes Yes Yes Yes N/A Yes Yes No No N/A No
Leiva 2017113 T8, T4 Yes Yes Cannot tell No NR Yes Yes Yes Yes No Yes
Murchie 2014107 T9 Yes Yes Cannot tell No N/A Yes Yes Yes Yes N/A Yes
Patel 2018111 T12 Yes Just age and
ASA gradec
Cannot tell No N/A Yes Yes No No No No
Pita-Fernández
2016109
T4 Yes Yes Cannot tell No NR Yes Yes Yes No (age, sex and
stage only)
No Yes
Pruitt 2013137 T8, T15 Older Medicaid
patients
Yes Yes Yesd N/A Yes Yes Yes Yes (histology,
grade, stage, location)
N/A Yes
Redaniel 2015101 T8 Yes Yes Yes Cannot tell N/A Yes Yes Yes Yes N/A Yes
Tørring 2013101 T8 Yes Yes Yes (16% excluded) No N/A Yes Yes Yes Yes (age, sex and
comorbidity only)
No Yes
Tørring 2012135 T8 Yes Yes Yes Yes N/A Yes Yes Yes No Unclear Yes
Tørring 2011136 T8 Yes Yes Yes Unclear N/A Yes Yes Yes No Unclear Yes
ASA, American Society of Anesthesiologists; GPRD, General Practice Research Database; N/A, not applicable; NR, not reported.
a See Figure 2 for the time intervals.
b Date of first alarm symptom obtained from database of GP records (GPRD) and date of diagnosis (and death) from the Cancer Registry or CPRD. There were some discrepancies between date of diagnosis in the Cancer
Registry and the GPRD. Sensitivity analysis conducted ignoring cases for whom data of diagnosis was prior to data of first alarm symptom (did not alter results).
c ASA grade is a widely used subjective assessment of comorbidity employed largely by anaesthetists to label anaesthetic risk.



















































































































































































































































































































































TABLE 57 Updated review: results of CRC studies
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Aslam 2017110 Survival T12 <> Median OS Log-rank test comparing median survival from
Kaplan–Meier curves. The study also included
patients referred via screening, survival
analysis limited to emergency, 2WW, urgent,
and routine referrals. Analysis also conducted
excluding emergency
There was no significant difference in OS
between the two interval groups (for 2WW,
urgent, and routine referrals combined):
< 62 days group: 7.1 years vs. > 62 days group:
6.54 years (p = 0.620)





(stage III–IV) vs. non-
advanced (stage I–II)
The median interval (days) from symptom
onset and/or workup to diagnosis was
compared for advanced and non-advanced
stage at diagnosis (but not statistically) within
each age group
The authors noted that the longest time to
diagnosis (T4) was observed in patients aged
< 50 years with non-advanced CRC at
diagnosis (stage I and II) followed by patients
aged < 50 years with advanced CRC at
diagnose (stages III and IV) (median days 174
vs. 124)
l Aged < 50 years, non-advanced vs.
advanced stage
¢ Median symptom duration (T1): 90 vs.
60 days
¢ Median workup duration (T8): 39 vs.
29 days
l Aged ≥ 50 years, non-advanced vs.
advanced stage:
¢ Median symptom duration (T1): 21 vs.
30 days






































intervala Association Outcome description Statistic test/method of analysis Results
Dregan
2013108
Survival T4 <> Overall mortality
(from diagnosis)
Adjusted HR (95% CI) obtained from Cox
regression model (adjusted for age and sex).
(Risk of death according to presence or
absence of alarm symptoms was also analysed)
l ≤ 14 days (n = 79), 1.07 (95% CI 0.65 to
1.77); p = 0.794
l 15–90 days (n= 217), reference category
l 91–180 days (n= 56), 1.28 (95% CI 0.73 to
2.25); p = 0.386
l 181–365 days (n= 44), 0.76 (95% CI 0.38 to
1.54); p = 0.448
l > 365 days (n = 55), 0.92 (95% CI 0.45 to
1.85); p = 0.806
(Patients with no preceding alarm symptoms
had shorter survival from diagnosis than those
presenting with relevant alarm symptoms)
Helewa
2013106
Survival T9 <> 5-year OS Adjusted HR (95% CI) and p-values obtained
from multivariate Cox proportional hazards
model using bootstrap resampling. Important
confounders that were adjusted for included,
among others, stage, emergency presentations
and location. Emergency presentations were
also analysed separately. An analysis limited to
stage I–III CRC was also conducted (excluding
stage IV and ‘unknown’)
Increased total wait time quartile was not
associated with worse survival (p = 0.4898)
l Q1: 0 to ≤ 43 days (n= 175), reference
l Q2: > 43 to ≤ 95 days (n= 135): 0.93
(95% CI 0.73 to 1.19)
l Q3: > 95 to ≤ 166 days (n = 115): 0.90
(95% CI 0.69 to 1.16)
l Q4: > 166 to ≤ 513 days (n = 113): 0.82
(95% CI 0.64 to 1.06)
When total wait time was considered as a
continuous variable (days), it was still not





T11 <> Node positivity, and
presence of distant
metastases
Chi-squared tests Node positive in < 60 days group: 42/102
(41%) vs. > 60 days group: 52/144 (36%)
(p = 0.42)
Distant metastases in < 60 days group:




















































































































































































































































































































































TABLE 57 Updated review: results of CRC studies (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Leiva 2017113 Stage
(advanced)
T8 – (Hospital) TNM tumour stage
(0, 1, 2, 3, 4,
unknown)
The Mann–Whitney U-test and the
Kruskal–Wallis test were used to assess the
association between diagnostic intervals and
various patient and clinical characterises
(including, among others, stage, emergency
presentation, location, symptoms at
presentation and perceived seriousness of
symptoms). The independent effect of variables
was assessed using Cox regression and then
the extension of the multivariate Cox
proportional hazards model with time-
dependent covariates
l Comparing three different information
sources for estimating ‘diagnostic intervals’:
patient recall, hospital records and GP
records. Interval defined as date from first
registry of symptoms to date of diagnosis
for GP and hospital records (T8), but for
patient recall this was time from patient
first experiencing symptoms to date of date
of diagnosis (T4)
l Univariate analysis indicated that a shorter
diagnostic interval was associated with
more advanced tumour stage using both GP
and hospital records, but this was only
significant for hospital records’
data (p = 0.021)
l Stage was not an independent predictor of a
shorter interval in the multivariate analysis





(0, 1, 2, 3, 4,
unknown)
As above l Univariate analysis indicated that a shorter
diagnostic interval was associated with
more advanced tumour stage for patient
recall, but this was not significant
l Stage was identified as one of the
independent predictors of shorter interval
in the multivariate analysis for patient-
recorded data (but not in the analysis of







































T9 <> Dukes’ stage was
collapsed into a
binary variable: early
(A or B) vs. advanced
(C or D)
OR (99% CI) obtained from logistic regression
model with a restricted cubic spline (to allow
for non-linear relationship), following
sequential adjustment (using 1–4 models; 1
representing unadjusted) of patient and
tumour factors (including, among others,
tumour grade, and signs and symptoms). Time
to treatment was modelled using four knots
corresponding to the 25th, 50th, 75th and
100th centile
The spline curves showed a significant non-
linear (p = 0.04) (and unadjusted, p = 0.002)
association between provider delay and stage.
Delays of between 4 and 34 weeks were
associated with earlier-stage disease, and
intervals beyond this were associated with
later-stage disease. However, the plot based on
a fully adjusted model showed wide CIs
According to the fully adjusted model, provider
delays of 40 and 60 weeks were associated
with later-stage disease at presentation, but
the OR did not reach statistical significance
l 4 weeks: reference
l 20 weeks: 0.87 (95% CI 0.54 to 1.39)
l 40 weeks: 1.46 (95% CI 0.93 to 2.31)
l 60 weeks: 1.58 (95% CI 0.96 to 2.61)
Murchie
2014107
Survival T9 <> All-cause survival
(from date of first
presentation)
HR (99% CI) obtained from Cox survival
models, both with a restricted cubic spline
(to allow for non-linear relationship), following
sequential adjustment (1–4 models) of patient
and tumour factors (including, among others,
tumour grade, emergency admission, and
signs and symptoms). Time to treatment was
modelled using four knots corresponding to the
25th, 50th, 75th and 100th centile. Stratified
analysis also conducted for rectal and colon
cancer
The spline curves showed a significant non-
linear (p < 0.001) (and unadjusted inverse,
p < 0.001) association between provider delay
and mortality. In the univariate analysis,
diagnostic interval of < 4 weeks was associated
with poor survival, but this was no longer
present after adjusting for confounders.
According to the fully adjusted model, provider
delays of 40 and 60 weeks were associated
with later-stage disease at presentation, but
the OR did not reach statistical significance
l 4 weeks: reference
l 20 weeks: 0.99 (95% CI 0.76 to 1.27)
l 40 weeks: 1.17 (95% CI 0.92 to 1.48)



















































































































































































































































































































































TABLE 57 Updated review: results of CRC studies (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Patel 2018111 Survival T12 – Long-term (mean)
survival
Proportion of patients still alive at long-term
follow-up (October 2011), and log-rank test
comparing Kaplan–Meier curves; 30-day
postoperative mortality and cause of death
were also assessed
Long-term survival was greatest in elective
patients who did not receive treatment
> 62 days (52% alive), compared with elective
cases treated ≤ 62 days (34% alive). This was
supported by the log-rank analysis (p < 0.001)
Operative mortality was higher in patients
treated ≤ 62 days (7% elective, 20%
emergency) than in those who were treated
> 62 days (4% elective, 7% emergency). The
most common cause of death was CRC in all
groups
Patel 2018111 Stage T12 – Stage (Dukes’ stage
A–B vs. C–D)
Proportions compared using chi-squared test Proportion of early-stage disease (Dukes’ stage
A–B) was highest in elective patients treated
> 62 days (50%) (p < 0.01) and lowest in
emergencies treated ≤ 62 days (30%) (p = 0.26)
Later-stage disease (Dukes’ stage C–D) was
most common in emergency patients treated
≤ 62 days (58%) and lowest in elective patients












































The influence survival was analysed in two ways:
1. Kaplan–Meier survival curves were
computed for each interval quartile, and
compared using the log-rank test
2. The interval was treated as a continuous
variable using restricted cubic splines with
four knots and using the 50th percentile
(3.4 months) as reference point
The 5-year HRs (95% CIs) were estimated as a
function of the duration of the delay interval
and adjusted for age and sex (model 1), and
subsequently stage (model 2), using
proportional hazard Cox regression
l The Cox regression model adjusting for age
and sex showed that, in rectum cancers,
patients within the first interval quartile had
lower survival (p = 0.003), but this was no
longer statically significant when also
adjusting for stage (p = 0.084)
l No significant differences were found for
colon cancer when adjusting for age and
sex (p = 0.282) or also adjusting for
stage (p = 0.160)
l Longer intervals were not associated with
poor survival in CRC patients. From age-,
sex- and stage-adjusted model:
¢ < 1.5 months: reference
¢ 1.5–3.4 months: 0.97 (95% CI 0.71 to 1.32)
¢ 3.4–6.4 months: 0.76 (95% CI 0.55 to 1.04)
¢ > 6.4 months: 0.77 (95% CI 0.56 to 1.05)
l The cubic splines regression analysis
revealed that, for rectum cancer, 5-year
mortality progressively increases for
intervals less than the median (3 months)
and decreases as the delay increases until
approximately 8 months. In colon cancer, no









T4 <> TNM tumour stage
(I, II–III, IV)
The association between the interval
(categorised into quartiles) and tumour stage
analysed using multivariate logistic regression
(adjusting for age and sex)
The interval was not found to be significantly
associated with stage at diagnosis (stage I:
3.6 months, stage II–III: 3.4 months, stage IV:




















































































































































































































































































































































TABLE 57 Updated review: results of CRC studies (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Pruitt 2013137 Survival T8 + (Colon) All-cause mortality,
and CRC-specific
mortality
Cases (CRC deaths) and controls (deaths due
to other causes or censored) were matched on
survival time, and the association of delay with
death was examined using logistic regression.
ORs (95% CI) were estimated using
multivariate regression analysis adjusting for
sociodemographic, tumour (histology, stage,
grade, location) and treatment factors.
Stratified analysis also conducted according
to and stage (and presenting symptom in
sensitivity analysis)
l Colon cancer patients with the longest
diagnostic delays (8–12 months vs. 14–59
days) had higher odds of all-cause (OR 1.31,
1.08 to 1.58), but not CRC-specific, death
l Among rectal cancer patients, delays were
not associated with risk of all-cause or
CRC-specific death
<> (Rectal)





OR (95% CI) estimated using multivariate
regression analysis adjusting for
sociodemographic, tumour (histology, stage,
grade, location), and treatment factors.
Stratified analysis also conducted according to
stage (and presenting symptom in sensitivity
analysis)
l Colon cancer patients with the shortest
treatment delays (< 1 week vs. 1–2 weeks)
had higher odds of all-cause (OR 1.23, 95%
CI 1.01 to 1.49), but not CRC-specific, death
l Among rectal cancer patients, delays were





Survival T8 <> 5-year survival 5-year EHRs (95% CIs) were computed using a
generalised linear model with a Poisson error
structure. Univariable and multivariable models
built, for each cancer site, and stratified by the
nature of the symptoms (NICE-qualifying alert
vs. non-alert). Multivariable models controlled
for, among others, the effects of period of
cancer plan implementation, Dukes’ stage,
tumour subsite (for CRC) and tumour
differentiation
There was no evidence of an association
between diagnostic interval and mortality. EHR
based on multivariate analysis for all patients:
l < 1 month: reference
l 1–2 months: 0.94 (95% CI 0.82 to 1.07)
l 3–6 months: 0.92 (95% CI 0.82 to 1.04)
l > 6 months: 0.93 (95% CI 0.81 to 1.07)
The results showed significant lower mortality
associated with longer diagnostic intervals for
patients presenting with non-alert symptoms
(EHR > 6 months vs. < 1 month: 0.85, 95% CI
0.72 to 1.00; p = 0.049), whereas no significant
associations were identified for patients


































intervala Association Outcome description Statistic test/method of analysis Results
Tørring
201399





l Analyses stratified according to the GP’s
interpretation of the presenting symptoms:
alarm or serious vs. vague. OR (95% CI)
obtained from logistic regression using
restricted cubic splines and adjusting for
comorbidity, age and sex. Each model tested
against a model with no diagnostic interval
term using the Wald test
l Data on tumour stage and emergency
admission collected, and used to describe
patient characteristics and compare the two
groups, with alarm/serious symptoms or
vague symptoms
l (Note that this appears to be the same CRC
cohort as Tørring 2011136)
Alarm/serious symptoms (n = 201): the
categorical analysis showed that both very
short and long diagnostic intervals (first or
fourth quartile compared with second and
third) were associated with poor survival, but
only the adjusted OR for the former was
statistically significant –
l Q1: 4.74 (95% CI 2.20 to 10.19)
l Q2 +Q3: reference
l Q4: 2.01 (95% CI 0.93 to 4.36)
This association was confirmed by the spline
regression analyses, which revealed convex
(U-shaped) associations: The risk of dying
within 5 years decreased with longer
diagnostic intervals up to approximately the
60th percentile, and then increased (p = 0.001)
<> (Vague
symptoms)
Vague symptoms (n = 67): the categorical
analysis showed that the first diagnostic
interval quartile was associated with poor
survival, compared with second and third,
whereas the fourth was not, but these findings
were not statistically significant. Adjusted ORs
(95% CIs) for each quartile:
l Q1: 0.74 (95% CI 0.19 to 2.80)
l Q2 +Q3: reference
l Q4: 1.08 (95% CI 0.28 to 4.12)
The corresponding spline regression analyses




















































































































































































































































































































































TABLE 57 Updated review: results of CRC studies (continued )
Study Outcome
Time
intervala Association Outcome description Statistic test/method of analysis Results
Tørring
2012135






Data taken from three studies using different
methods for identifying date of first
presentation. Data analysed for each study
separately and combined
The data were modelled in two ways:
1. Comparison of the first and fourth
diagnostic interval quartiles with
the second+ third
2. Diagnostic interval rescaled and treated as a
continuous variable using restricted cubic
splines with four knots, with the 50th
percentile used as the reference point
The 5-year HRs (95% CIs) estimated as
a function of the length of the diagnostic
interval and adjusted for tumour site (colon/
rectum), age and sex using proportional
hazard Cox regression. In the analysis of the
combined data, differences were also allowed
for in study-specific baseline hazards. (Note
that the GP record-based study is Tørring
2011136)
GP-based study (n= 266) adjusted HRs for
each quartile:
l Q1: 1.73 (95% CI 1.16 to 2.59)
l Q2 +Q3: reference





Patient-based study (n= 658) adjusted HRs for
each quartile:
l Q1: 1.26 (95% CI 0.95 to 1.66)
l Q2 +Q3: reference
l Q4: 1.11 (95% CI 0.85 to 1.46)
Record-based study (n= 319) adjusted HRs for
each quartile:
l Q1: 1.20 (95% CI 0.84 to 1.71)
l Q2 +Q3: reference




Combined data (n = 1243) adjusted HRs for
each quartile:
l Q1: 1.33 (95% CI 1.10 to 1.61)
l Q2 +Q3: reference
l Q4: 1.28 (95% CI 1.06 to 1.55)
The association between diagnostic interval
and survival was the same for all three types
of data: displaying a U-shaped association
with decreasing and subsequently increasing
mortality with longer diagnostic intervals
(i.e. U-shaped association observed using three
different data collection methods in different



































intervala Association Outcome description Statistic test/method of analysis Results
Tørring
2011136





l Analyses stratified according to the GP’s
interpretation of the presenting symptoms:
alarm or serious vs. vague. Logistic
regression used to estimate 3-year mortality
ORs (95% CIs) as a function of the
diagnostic interval using restricted cubic
splines and adjusting for tumour site,
comorbidity, age and sex. Also reported
outcome data for 1-year mortality
l Data on tumour stage and emergency
admission collected, and used to describe
patient characteristics and compare the two
groups, with alarm/serious symptoms or
vague symptoms
Alarm/serious symptoms (n = 201): The cubic
spline regression analysis revealed that the
risk of dying within 3 years decreased with
diagnostic intervals of up to 5 weeks and then
increased (p = 0.002). Adjusted OR for
diagnostic intervals:
l 0–4 weeks (n= 75): 2.56 (95% CI 1.29 to 5.05)
l 5–11 weeks (n= 90): reference




Vague symptoms (n = 67): the cubic spline
regression analysis revealed a reverse effect,
with increasing risk of dying from day 1 up to
≈ 12 weeks, but the association was not
statistically significant (p = 0.205). Adjusted OR
for diagnostic intervals:
l 0–4 weeks (n= 10): comparison not justified
l 5–11 weeks (n= 27): reference
l ≥ 12 weeks (n= 30): 0.71 (95% CI 0.32
to 2.91)
+, positive association, whereby shorter intervals are associated with statistically significant more favourable outcomes; –, negative association, whereby shorter intervals are
associated with statistically significant unfavourable outcomes; <>, no association, meaning the findings were not statistically significant; EHR, excess hazard ratio; HR, hazard ratio;
OR, odds ratio; OS, overall survival; Q, quartile.
a See Figure 2 for the time intervals.
Note



























































































































































































































































































































































Diagnostic interval T8 Tørring 2011136











T4 l Ermiah 2012243
l Warner 2012244

















T5 l Mommsen 1983249
l Wallace 2002247








T14 Gulliford 1991250 Wallace 2002247
Stage









T5 l Thompson 2011254
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intervala Positive association No association
Negative
association
Diagnostic interval T8 l Tørring 2011136
l Tørring 2012135
l Tørring 201399
l Pruitt 2013137 – colon
Pruitt 2013137 – rectal
Treatment interval T15 l Gort 2010259 – colon
l Yun 2012236 – rectal





Patient interval T1 Van Hout 2011261
Symptom onset to
referral




T3 Van Hout 2011261
Symptom onset to
diagnosis









Referral interval T6 l Valentín-López 2012264
l Ramsay 2012265 (routine
referral group)
l Guzman 2011266 – colon
Neal 2007256 l Ramsay 2012265
l Guzman 2011266
– rectal




















Referral interval T6 Brocken 2012268 Neal 2007256
Diagnostic interval T8 Tørring 201399 l Skaug 2011272
l Pita-Fernández 2003273





T13 Brocken 2012268 Gould 2008274
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T14 Loh 2006270 Gould 2008274











T5 Christensen 1997278 Yilmaz 2008277 Myrdal 2004279
Referral interval T6 Brocken 2012268 Neal 2007256
First seen in primary
care to specialist
T7 Yilmaz 2008277
Diagnostic interval T8 Pita-Fernández 2003273
Seen in primary care
to treatment
T9 Yilmaz 2008277























T4 Prabhu 1986283 – chronic
myeloid
Diagnostic interval T8 Friese 2011284 – chronic
lymphocytic






T4 l Jacobi 2008286 – follicular
l Maguire 1994252
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Patient interval T1 Tokuda 2009251
Oral/head/neck
Survival
Patient interval T1 l Koivenun 2001292 –
pharyngeal
l Teppo 2008293 –
pharyngeal and
laryngeal separately
l Teppo 2003294 –
laryngeal
l Teppo 2008293 – tongue
Symptom onset to
diagnosis
T4 l Wildt 1995295 – oral
l Seoane 2010296 – oral
Symptom onset to
treatment
T5 Hansen 2005297 –
nasophayngeal
McGurk 2005298 – head
and neck
Diagnostic interval T8 l Alho 2006299 – head
and neck
l Teppo 2003294 –
laryngeal
l Teppo 2008293 –
laryngeal
l Teppo 2008293 –
pharyngeal and tongue
l Koivunen 2001292 –
pharyngeal
Treatment interval T15 Sidler 2010300 –
nasopharyngeal
l Caudell 2011301 – head
and neck
l Brouha 2000302 –
laryngeal
Stage
Patient interval T1 l Kumar 2001303 – oral
l Brouha 2005304 –
pharyngeal and
laryngeal separately
l Sheng 2008305 –
nasopharyngeal
l Tromp 2005306 –
unspecified
l Tokuda 2009251 –
unspecified
l Allison 1998307 –
aerodigestive tract
l Al-Rajhi 2009308 –
nasopharyngeal
l Brouha 2005304 –
laryngeal
l Wildt 1995295 – oral











T3 Allison 1998307 –
aerodigestive tract
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T4 l Al-Rajhi 2009308 –
nasopharyngeal
l Lee 1997312 –
nasopharyngeal
l Miziara 1998313 –
laryngeal
l Scott 2005314 – oral
Symptom onset to
treatment
T5 McGurk 2005298 –
unspecified
First seen in primary
care to specialist
T7 Allison 1998307 –
aerodigestive tract
Diagnostic interval T8 Al-Rajhi 2009308 –
nasopharyngeal
l Teppo 2009309 –
vestibular schwannoma



























Referral to treatment T12 Crawford 2002320
Treatment interval T15 Elit 2003321
Stage
Patent interval T1 Tokuda 2009251
Symptom onset to
diagnosis
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Referral interval T6 Neal 2007256
Stage





















Treatment interval T15 Yun 2012236
Stage







Treatment interval T15 l Sundi 2012331
l Waldert 2010332
Stage
Treatment interval T15 Waldert 2010332
Prostate
Survival
Referral interval T6 Neal 2007256
Diagnostic interval T8 Tørring 201399
Treatment interval T15 O’Brien 2011333 l Korets 2012334
l Sun 2012335
Stage
Patient interval T1 Tokuda 2009251
Treatment interval T15 l Korets 2012334
l Sun 2012335
continued
DOI: 10.3310/hta24660 Health Technology Assessment 2020 Vol. 24 No. 66
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Medina-Lara et al. under the terms of a commissioning contract issued by the Secretary of
State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
277









Patient interval T1 Hanson 1993336 Fossa 1981337
Symptom onset to
diagnosis
T4 l Huyghe 2007338
l Moul 1990339 –
non-seminoma only
l Harding 1995340









Diagnostic interval T8 Fossa 1981337
Stage





T4 l Bosl 1981345
l Huyghe 2007338
l Moul 1990339 –
non-seminoma only
Harding 1995340




























Diagnostic interval T8 l Tørring 201399
l Metzger 1998352
Stage
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intervala Positive association No association
Negative
association
First seen in primary
care to specialist
T7 Montella 2002354






















Patient interval T1 Lim 1974364 Ziliotto 1987365
Symptom onset to
diagnosis







seen in primary care
to treatment
T9 Lim 1974364
Treatment interval T15 Yun 2012236
Stage
Patient interval T1 Tokuda 2009251
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T4 l Saithna 2008375 –
soft-tissue sarcoma
l Nakamura 2011376 –
soft-tissue sarcoma
l Rougraff 2007377 –
soft-tissue sarcoma













treatment and risk of
distant metastases




Treatment interval T15 Singal 2013381
Stage:
Patient interval T1 Tokuda 2009251
Renal
Stage
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Diagnostic interval T8 Tørring 201399 – breast,
lung, colorectal, prostate
and melanoma combined
MRC, Medical Research Council.
a See Figure 2 for the time intervals.
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Appendix 5 Economic decision-analytic
model
Search strategy for economic models in colorectal cancer
MEDLINE
Host: Ovid.
Date range searched: 1946 to September week 3 2017.








5. exp Economics, Hospital/
6. (economic$ or price or prices or pricing or priced or discount or discounts or discounted or
discounting or ration$ or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$
or pharmaco-economic$).ti,kf.
7. exp “Fees and Charges”/
8. (fee or fees or charge$ or preference$).tw.
9. (fiscal or funding or financial or finance).tw.
10. exp “Costs and Cost Analysis”/
11. exp Health Care Costs/
12. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.
13. (value adj2 (money or monetary)).ti,ab,kf.
14. exp Decision Support Techniques/
15. exp Models, Economic/
16. economic model*.ab,kf.
17. (decision adj2 (tree$ or analy$ or model$)).ti,ab,kf.
18. exp Decision Theory/
19. markov.ti,ab,kf.
20. markov chains/
21. monte carlo method/
22. monte carlo.ti,ab,kf.
23. (survival adj3 analy$).tw.
24. exp Health Expenditures/
25. Uncertainty/
26. exp Budgets/
27. Decision Support Systems, Clinical/
28. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or equation$).tw.
29. or/1-28
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30. exp Colorectal Neoplasms/
31. ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)).tw.
32. (MCRC or CRC).tw.
33. 30 or 31 or 32
34. 29 and 33
35. Early Detection of Cancer’/
36. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or
prognos$).tw.
37. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
38. 35 or 36 or 37
39. 34 and 38
40. Primary Health Care/
41. exp General Practice/
42. General Practitioners/
43. (primary care or general practi$ or family practi$).tw.
44. (primary adj3 (healthcare or health care)).tw.
45. 39 or 40 or 41 or 42 or 43
46. 39 and 44
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Date range searched: not applicable.




1. (economic$ or price or prices or pricing or priced or discount or discounts or discounted or
discounting or ration$ or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$
or pharmaco-economic$).ti,kf.
2. (fee or fees or charge$ or preference$).tw.
3. (fiscal or funding or financial or finance).tw.
4. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.
5. (value adj2 (money or monetary)).ti,ab,kf.
6. economic model*.ab,kf.
7. (decision adj2 (tree$ or analy$ or model$)).ti,ab,kf.
8. markov.ti,ab,kf.
9. monte carlo.ti,ab,kf.
10. (survival adj3 analy$).tw.
11. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or equation$).tw.
12. or/1-11
13. ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)).tw.
14. (MCRC or CRC).tw.
15. 13 or 14
16. 12 and 15
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17. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or
prognos$).tw.
18. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
19. 17 or 18
20. 16 and 19
21. (primary care or general practi$ or family practi$).tw.
22. (primary adj3 (healthcare or health care)).tw.
23. 21 or 22
24. 20 and 23
EMBASE
Host: Ovid.
Date range searched: 1974 to 28 September 2017.





2. exp Health Economics/
3. (economic$ or price or prices or pricing or priced or discount or discounts or discounted or
discounting or ration$ or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$
or pharmaco-economic$).ti,kw.
4. (fee or fees or charge$ or preference$).tw
5. (fiscal or funding or financial or finance).tw.
6. Cost/
7. (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ab,kf.





13. monte carlo method/
14. monte carlo.ti,ab,kw.
15. (decision adj2 (tree$ or analy$ or model$)).ti,ab,kw.
16. Decision Theory/
17. (survival adj3 analy$).tw.
18. Budget/
19. Decision Support System/
20. (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$
or equation$).tw.
21. or/1-20
22. exp Colorectal Cancer/
23. ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)).tw.
24. (MCRC or CRC).tw.
25. 22 or 23 or 24
26. 21 and 25
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27. Early Cancer Diagnosis/
28. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
29. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
30. 27 or 28 or 29
31. exp Primary Health Care/
32. General Practice/
33. General Practitioner/
34. (primary care or general practi$ or family practi$).tw.
35. (primary adj3 (healthcare or health care)).tw.
36. 31 or 32 or 33 or 34 or 35
37. 30 and 36
Health Management Information Consortium
Host: Ovid.
Date range searched: 1979 to July 2017.




1. exp Colorectal Cancer/
2. ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or rcinoma*
or adenocarcinoma* or “small cell” or squamous)).tw.
3. (MCRC or CRC).tw.
4. 1 or 2 or 3
5. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or
prognos$).tw.
6. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
7. 5 or 6
8. 4 and 7
9. exp Primary Care/
10. exp General Practice/
11. exp General Practitioners/
12. (primary care or general practi$ or family practi$).tw.
13. (primary adj3 (healthcare or health care)).tw.
14. 9 or 10 or 11 or 12 or 13
15. 8 and 14
Science Citation Index and Conference Proceedings Citation Index – Science
Host: Web of Science.
Date range searched: not applicable.
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Search strategy
1. TS=((pharmacoeconomic* or socioeconomics or economic* or pric* or cost* or cba or cea or cua or
“health utilit*” or “value for money”))
2. TS=((colorectal or colon* or rect* or bowel*) near/2 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous))
3. TS=(MCRC or CRC)
4. TS=(predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagno* or prognos*)
5. TS=. (2ww or 2 week wait or two week wait or 2 week rule or two week rule)
6. TS=. (primary care or general practi* or family practi*)
7. TS=(primary near/2 healthcare)
8. TS=(primary near/2 health care)
9. #3 OR #2
10. #5 OR #4
11. #8 OR #7 OR #6
12. #11 AND #10 AND #9 AND #1
NHS Economic Evaluation Database and Health Technology Assessment Database
Host: Cochrane Library.
Date range searched: HTA, Issue 4 of 4, October 2016; NHS EED, 2 of 4, April 2015.
Date searched: 29 September 2017.
Searcher: SR.
Hits: HTA: 0, NHS EED; total = 0.
Search strategy
1. ((colorectal or colon* or rect* or bowel*) near/3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)):ti,ab,kw
2. MeSH descriptor: [Colorectal Neoplasms] explode all trees
3. (MCRC or CRC):ti,ab,kw
4. #1 or #2 or #3
5. MeSH descriptor: [Primary Health Care] explode all trees
6. MeSH descriptor: [General Practice] explode all trees
7. MeSH descriptor: [General Practitioners] explode all trees
8. (“primary care” or “general practi*” or “family practi*”):ti,ab,kw
9. (primary near/3 (healthcare or “health care”)):ti,ab,kw
10. #5 or #6 or #7 or #8 or #9
11. MeSH descriptor: [Decision Support Techniques] this term only
12. MeSH descriptor: [Decision Support Systems, Clinical] this term only
13. (tool or tools or aid* or model or models or checklist* or “check list” * or rule or rules or algorithm*
or equation*):ti,ab,kw
14. #11 or #12 or #13
15. MeSH descriptor: [Early Detection of Cancer] this term only
16. (predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagnos* or prognos*):ti,
ab,kw
17. (2ww or “2 week wait” or “two week wait” or “2 week rule” or “two week rule”):ti,ab,kw
18. #15 or #16 or #17
19. #4 and #10 and #14 and #18
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Date range searched: not applicable.




1. TX ((colorectal or colon* or rect* or bowel*) N2 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous))
2. TX (MCRC or CRC)
3. TX (predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagno* or prognos*)
4. TX (2ww or 2 week wait or two week wait or 2 week rule or two week rule)
5. 1 or 2
6. 3 or 4
7. 5 and 6
Number of hits per database and in total
Database Hits (n)
MEDLINE 685
MEDLINE In-Process & Other Non-Indexed Citations 72
EMBASE 1177
HMIC 154
Web of Science (SCI and CPCI-S) 616




Total unique records 2129
SCI, Science Citation Index.
Revised search strategy for economic models in colorectal cancer
MEDLINE
Host: Ovid.
Date range searched: 1946 to November week 4 2017.
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Search strategy
1 (economic$ or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration$
or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$ or pharmaco-economic$).ti.
2 (fee or fees or charge$ or preference$).ti.
3 (fiscal or funding or financial or finance).ti.
4 (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ti.
5 (value adj2 (money or monetary)).ti.
6 economic model*.ti.
7 (decision adj2 (tree$ or analy$ or model$)).ti.
8 markov.ti.
9 monte carlo.ti.
10 (survival adj3 analy$).ti.
11 (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$ or equation$).ti.
12 or/1-11
13 exp Colorectal Neoplasms/
14 ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)).tw.
15 (MCRC or CRC).tw.
16 or/13-15
17 “Early Detection of Cancer”/
18 (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
19 (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
20 or/17-19
21 12 and 16 and 20
MEDLINE In-Process & Other Non-Indexed Citations
Host: Ovid.
Date range searched: not applicable.




1 (economic$ or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration$
or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$ or pharmaco-economic$).ti.
2 (fee or fees or charge$ or preference$).ti.
3 (fiscal or funding or financial or finance).ti.
4 (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ti.
5 (value adj2 (money or monetary)).ti.
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6 economic model*.ti.
7 (decision adj2 (tree$ or analy$ or model$)).ti.
8 markov.ti.
9 monte carlo.ti.
10 (survival adj3 analy$).ti.
11 (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$ or equation$).ti.
12 or/1-11
13 ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)).tw.
14 (MCRC or CRC).tw.
15 13 or 14
16 (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
17 (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
18 16 or 17
19 12 and 15 and 18
EMBASE
Host: Ovid.
Date range searched: 1974 to 9 December 2017.




1 (economic$ or price or prices or pricing or priced or discount or discounts or discounted or discounting or ration$
or expenditure or expenditures or budget$ or afford$ or pharmacoeconomic$ or pharmaco-economic$).ti.
2 (fee or fees or charge$ or preference$).ti.
3 (fiscal or funding or financial or finance).ti.
4 (cost* adj2 (effective* or utilit* or benefit* or minimi* or analy* or outcome or outcomes)).ti.
5 (value adj2 (money or monetary)).ti.
6 economic model*.ti.
7 (decision adj2 (tree$ or analy$ or model$)).ti.
8 markov.ti.
9 monte carlo.ti.
10 (survival adj3 analy$).ti.
11 (tool or tools or aid$ or model or models or checklist$ or check list$ or rule or rules or algorithm$ or equation$).ti.
12 or/1-11
13 exp colorectal cancer/
14 ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or carcinoma* or
adenocarcinoma* or “small cell” or squamous)).tw.
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15 (MCRC or CRC).tw.
16 or/13-15
17 early cancer diagnosis/
18 (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
19 (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
20 or/17-19
21 12 and 16 and 20
Health Management Information Consortium
Host: Ovid.
Date range searched: 1979 to September 2017.




1. exp Colorectal Cancer/
2. ((colorectal or colon* or rect* or bowel*) adj3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)).tw.
3. (MCRC or CRC).tw.
4. 1 or 2 or 3
5. (predict$ or assess$ or scor$ or risk$ or validat$ or decision$ or identif$ or diagno$ or prognos$).tw.
6. (2ww or 2 week wait or two week wait or 2 week rule or two week rule).tw.
7. 5 or 6
8. 4 and 7
NHS Economic Evaluation Database and Health Technology Assessment Database
Host: Cochrane Library.
Date range searched: Health Technology Assessment, issue 4 of 4, October 2016; NHS EED, 2 of 4,
April 2015.
Date searched: 11 December 2017.
Searcher: SR.
Hits: HTA: 0; NHS EED: 0; total = 0.
Search strategy
1. ((colorectal or colon* or rect* or bowel*) near/3 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous)):ti,ab,kw
2. MeSH descriptor: [Colorectal Neoplasms] explode all trees
3. (MCRC or CRC):ti,ab,kw
4. #1 or #2 or #3
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5. MeSH descriptor: [Early Detection of Cancer] this term only
6. (predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagnos* or prognos*):ti,ab,kw
7. (2ww or “2 week wait” or “two week wait” or “2 week rule” or “two week rule”):ti,ab,kw
8. #5 or #6 or #7
9. #4 and #8
EconLit
Host: EBSCOhost.
Date range searched: not applicable.




1. TX ((colorectal or colon* or rect* or bowel*) N2 (cancer* or neopla* or tumor* or tumour* or
carcinoma* or adenocarcinoma* or “small cell” or squamous))
2. TX (MCRC or CRC)
3. TX (predict* or assess* or scor* or risk* or validat* or decision* or identif* or diagno* or prognos*)
4. TX (2ww or 2 week wait or two week wait or 2 week rule or two week rule)
5. 1 or 2
6. 3 or 4
7. 5 and 6
Number of hits per database and in total
Database Hits (n)
MEDLINE 574
MEDLINE In-Process & Other Non-Indexed Citations 71
EMBASE 658
HMIC 32




Total unique records 772
Updated searches, 27 September 2018
Database Hits (n)
MEDLINE 249
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Database Hits (n)




Total unique records 546
American Joint Committee on Cancer and Dukes’ classification systems
The decision models in the literature are based on two different classification systems of CRC stages.
These are the AJCC and Dukes.
The American Joint Committee on Cancer staging system
The AJCC’s staging system384 classifies cancer following the TNM system, in which the first consideration
is the size and extent of the main tumour (or primary tumour), the second refers to the number of
nearby lymph nodes with cancer, and the third one refers whether or not the cancer has metastasised,
if the cancer has spread from the primary tumour to other parts of the body. The TNM system is the
most widely used cancer staging system (see www.cancer.gov/about-cancer/diagnosis-staging/staging;
accessed January 2019).
Primary tumours can be graded in six levels:
1. T0, no evidence of primary tumour
2. Tis, carcinoma in situ: intraepithelial or invasion of the lamina propria
3. T1, the tumour is confined to the submucosa
4. T2, the tumour has grown into (but not through) the muscularis propria
5. T3, the tumour has grown into (but not through) the serosa
6. T4, the tumour directly invades other organs or structures, and/or perforates visceral peritoneum.
The levels for lymph nodes are as follows:
l N0, no regional nodes involved
l N1, 1–3 regional nodes involved
l N2, four or more regional nodes involved.
Finally, metastasis can be:
l M0: no distant metastasis
l M1: distant metastasis present.
Tumour, number, metastasis combinations were grouped into five stages:
1. Stage 0, cancer is defined by Tis N0 M0, called carcinoma in situ, is related to the presence of
abnormal cells, but they have not spread to nearby tissue.
2. Stage I, a cancer defined by T1 N0 M0 or T2 N0 M0.
3. Stage II, a cancer defined by T3–4 N0 M0.
4. Stage III, represented by cancer defined by any T1–2, N1, M0, any T3–4, N1 M0, any T N2 M0.
5. Stage IV, represented by a cancer with any T, any N, M1, where the cancer has spread to distant
parts of the body.
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The Dukes’ staging system
The other staging system was initially defined by Dukes in 1932,385 but this has been revised several
times. This system has now largely been replaced by the TNM staging system, but it is currently used
in many of the English and UK economic models. This system has four stages:
1. Dukes’ A: invasion into but not through the bowel wall (90% chance of 5-year survival)
2. Dukes’ B: invasion through the bowel wall but not involving lymph nodes (70% chance of
5-year survival)
3. Dukes’ C: involvement of lymph nodes (30% chance of 5-year survival)
4. Dukes’ D: widespread metastases.
Comparison of the American Joint Committee on Cancer and Dukes’ staging systems
A conversion of the Dukes’ stages into TNM is represented in Table 59.
Excluded studies of full-text articles assessed for eligibility
Thirteen full texts were excluded because the models were not based on the Dukes’ or AJCC
classification staging (9/13), the models were screening models without a full disease progression
model component (3/13) or the study was a costing analysis for a screening programme (1/13).
Further details are chronologically summarised in this section.
Bolin et al.386 compared the costs of different strategies for CRC screening, including colonoscopy, to
provide a decision on early diagnosis for CRC in Australia. This model was based on a model developed
by the Office of Technology Assessment (OTA).246 Both models were excluded because the staging was
grouped into A + B and C +D, and did not use the Dukes’ full staging classification. The model by
Byers and Gorsky387 was also excluded because it too used the OTA model, which considers only two
stages based on an incomplete Dukes’ classification system.
Neilson and Whynes388 reported the development of a simulation model for assessing the cost-
effectiveness of CRC in the UK. The model was not included as it considers only two health states for
CRC (early- and late-detected CRC), which does not correspond with the Dukes’ staging classification.
Gow’s389 study was excluded on the basis of being a costing study of a programme in Australia for
screening CRC.
TABLE 59 Conversion of Dukes’ stages into TNM
Stage Dukes’ TNM
Tumour invasion confined to the mucosa A Tis, N0
Tumour invasion limited to the submucosa, no lymph node involvement A T1, N0
Tumour invasion limited to the submucosa, lymph node involvement C T1, N1–2
Limited tumour invasion into the muscle layer, no lymph node involvement A T2, N0
Limited tumour invasion into the muscle layer, lymph node involvement C T2, N1–2
During the whole muscle layer tumour involvement, no lymph node involvement B T3, N0
During the whole muscle layer tumour involvement, lymph node involvement C T3, N1–2
Tumours have kept the neighbouring organs, no lymph node involvement B T4, N0
Tumours have kept the neighbouring organs, lymph node involvement C T4, N1–2
Other factors notwithstanding distant metastases D T1–4, N0–2, M1
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Khandker et al.390 evaluated the guidelines of the American Gastroenterological Association for CRC
screening and surveillance programmes, using a cost-effectiveness framework for people at average
risk and increased risk in the USA. This study was not included because the stages of CRC were
dependent on anatomical extent (local, regional and distant) that only conceptually parallels with three
stages (A, B and C) of the Dukes’ staging classification.
The study by Sonnenberg et al.391 compared the cost-effectiveness of faecal occult blood testing,
flexible sigmoidoscopy and colonoscopy as strategies for screening CRC. The study was excluded
because the Markov models were for the screening strategies only and did not include a full disease
model component.
Reyes et al.392 was excluded because the authors were evaluating the clinical effectiveness and
incremental cost-effectiveness of four strategies to detect hereditary non-polyposis colorectal
carcinoma (HNPCC) gene carriers in individuals with CRC and the authors excluded a full disease
progression model.
Kievit et al.393 determined the clinical effectiveness, efficiency and feasibility of a new strategy based
on microsatellite instability analysis for the detection of HNPCC in the Netherlands. This study was
excluded because the Markov model included only one health state for CRC, without considering the
different stages of the disease.
Telford et al.394 estimated the incremental cost-effectiveness of 10 strategies for CRC screening in
Canada. The study was not included because the Dukes’ staging or other classification system that was
part of the inclusion criteria was not used.
The study by Allameh et al.395 was excluded because this was another screening cost-effectiveness
model that did not include a whole-disease progression model.
The study by Dan et al.396 was excluded because the cost-effectiveness analysis of single endoscopic
examination screening within a Markov framework was based on the risk for the population of
Singapore and based on a single health state (progression to CRC).
The methodological paper by Goh et al.341 was excluded because the study aimed to compute the
maximal and minimal values for the discounted value of the Markov chain for the transition
parameters of CRC disease in the USA. The staging used in this model was localised, regional and
distant cancer sites, which differs from the Dukes’ or other system classification specified in the
inclusion criteria.
Finally, a 2017 study by Atkin et al.397 was also excluded because the authors considered five mutually
exclusive health states (no adenomas, adenomas, preclinical CRC, diagnosed CRC and dead), and thus
omitted any type of staging classification.
DOI: 10.3310/hta24660 Health Technology Assessment 2020 Vol. 24 No. 66
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Medina-Lara et al. under the terms of a commissioning contract issued by the Secretary of
State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be
included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for
commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha
House, University of Southampton Science Park, Southampton SO16 7NS, UK.
295
Sensitivity analysis, parameter specification and incremental
cost-effectiveness ratio variation
TABLE 60 Sensitivity analysis, parameter specification and ICER variation
Study Type of analysis Parameters affecting ICER ICER variation




l Prevalence of IBD
l Time at which 90% of IBD
cases are diagnosed
l Risk of perforation
with colonoscopy
l Risk of haemorrhage
with colonoscopy
l Sensitivity of FS for IBD
l Age at entry in the
screening model
l Polyp prevalence
l Cost of colonoscopy
l Cost of FS
l The increase in IBD
prevalence (from 2.2% to
20%) increases the ICER of
colonoscopy, compared
with FS
l A prolonged time to diagnosis
of IBD (from 0.5 to 3.5 years)
increase the ICER of
colonoscopy, compared
with FS
l The increase in risk of
perforation of colon during
colonoscopy procedures
(from 0.001% to 2.14%)
increases the ICER of
colonoscopy, compared
with FS
l The increase in risk of
haemorrhage from
colonoscopy procedures
(from 0.24% to 4.6%) increases
the ICER of colonoscopy,
compared with FS
l The increase in FS sensitivity
(from 25% to 80%) reduces
the ICER of colonoscopy,
compared with FS
l The increase of FS sensitivity
for rectosigmoid polyps (from
75% to 98%) increases the
ICER of colonoscopy,
compared with FS
l The increase of age of entry
(from 40 to 80 years)
increases the ICER of all
invasive procedures
(colonoscopy, FS, FS +ACBE)
l The decrease of polyp
prevalence (from 27% to 7%)
increases the ICER of all
invasive procedures
(colonoscopy, FS, FS +ACBE)
l The increase in the cost of
colonoscopy (from US$200 to
US$2200) increases the ICER
of colonoscopy, compared
with watchful waiting,
FS and FS +ACBE
l The increase in the cost of FS
(from US$100 to US$844)
increases the ICER of FS,
compared with colonoscopy
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )









l 40% of individuals never
participate in screening




l 20% lower sensitivity for
FOBT and screening
l 10% FOBT sensitivity for
all adenomas
l 5% FOBT sensitivity for
low-risk adenomas and
10% FOBT sensitivity for
high-risk adenomas
l Double adenoma recurrence
rates following polypectomy
l Utility for all cancer
states= 0.50
l FS cost = colonoscopy cost
l Double cost of FOBT
l Best-case scenario for
calibrated natural history and
sensitivity parameters
l Worst-case scenario for
calibrated natural history and
sensitivity parameters
l The undiscounted costs and
effects reduces the ICER of
the strategies
l The adoption of 40% of
missed participants’ rate to
FOBT screening does not
affect the ICER
l The adoption of 60% of
compliance rate with follow-up
of colonoscopy increases the
ICER of FOBT screening
strategies
l The increase of CRC
treatment costs reduces the
ICER of screening strategies
l The reduction of FOBT
sensitivity and FS screening
increases the ICER of both
FOBT and FS screening
l The adoption of 10% of FOBT
sensitivity for all adenomas
reduces the ICER of FOBT
screening strategies
l The adoption of 5% FOBT
sensitivity for low-risk
adenomas and 10% of FOBT
sensitivity for high-risk
adenomas reduces the ICER
of FOBT screening strategies




l The adoption of the same
utility value (0.50) for all
cancer states increases
the ICER
l The adoption of the same cost
of colonoscopy for FS
increases the ICER
l The increase of FOBT
(doubled) increases the ICER
for FOBT screening strategies
l The adoption of best-case
scenario for calibrated natural
history and sensitivity
parameters reduces the ICER
l The adoption of worst-case
scenario for calibrated natural
history and sensitivity
parameters increases the ICER




l Cost of colonoscopy




l Treatment costs for CRC
l Discount rates
l The increase in the cost of
colonoscopy (from US$100 to
US$1000) increases the ICER
for all strategies
l The increase in the
compliance rate of screening
tests reduces the ICER
l The increase in FOBT
sensitivity (from 10% to
100%) reduces the ICER for
FOBT strategy
continued
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l The increase of FOBT
specificity (20%, 50% and
80%) reduces the ICER for
FOBT strategy
l The increase of treatment
costs for CRC reduces the
ICER for all strategies
l The adoption of discount
rate for cost and clinical
effectiveness increases the









l Increase in FIT cost
l Decrease of cancer stage III
and IV costs
l Biennial FIT screening
l Initial adherence of FIT,
FOBT, CTC and colonoscopy
l Decrease subsequent of
adherence rates for FITs
and FOBTs
l Administrative cost
l The increase in FIT cost (50%)
increases the ICER of FIT
screening strategies
l The reduction of cancer
stages III and IV costs
increases the ICER for
all strategies
l The adoption of biennial
screening reduces the ICER of
FIT screening strategies
l The adoption of initial
adherence rate for FIT, FOBT,
CTC and colonoscopy set at
60%, 50%, 40% and 30%
increases the ICER for
all strategies
l The subsequent decrease of
adherence rates for FITs and
FOBTs (from 63% to 40%)
reduces the ICER of FITs
and increases the ICER of
colonoscopy strategies. The
reduction from 63% to 20%
reduces the ICER of FITs and
colonoscopy strategies with
respect to no screening
strategies
l The adoption of administrative
costs added for all screening
tests (US$10) increased the
ICER of FIT-high strategy and
reduces the ICER of FIT-mid
strategy. The increase of
US$50 reduced the ICER of
colonoscopy




l Polyp detection sensitivity
l Lifetime treatment costs
l Screening costs
l Adverse event probability
l Adverse event cost
l Cancer detection sensitivity
l The decrease of the uptake
rates of the two screening
strategies (from 80% to 40%)
decreases the ICER for CTC,
compared with FOBT
l The polyp detection
sensitivity of CTC and FOBT
(from 75% to 56% for
low-risk CTC, from 96% to
84% for high-risk CTC, and
from 10% to 0% for all FOBT)
reduced the ICER for CTC,
compared with FOBT
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l The increase of lifetime
treatment costs of Dukes’
stage C and D cancer
(20% higher) the ICER of CTC
decrease when compared
with FOBT
l The decrease of screening
costs increases the ICER
of CTC when compared
with FOBT
l The increase of adverse event
probability increases the ICER
of CTC when compared
with FOBT
l The increase of adverse event
cost increases the ICER of
CTC when compared
with FOBT
l The cancer detection
sensitivity of CTC (from
96% to 84%) and FOBT
(from 50% to 30%) reduces




USA l Rescreening test
characteristics
l Adherence rates
l Cost of colonoscopy
l The adoption of use of CTC
rescreening after 5 years
from colonoscopy strategy
decreases the ICER, compared
with the use of colonoscopy
10 years after the previous
colonoscopy
l The increase of adherence
rates decreases the ICER of
all strategies
l The decrease of adherence
rates increases the ICER of
all strategies
l The increase in the cost of
colonoscopy (one half)









l Cost of FIT
l Cost of colonoscopy
l Lifetime costs of treating
CRC
l Discount rate
l The increase of FIT sensitivity
increases the ICER
l The increase in colonoscopy
sensitivity increases the ICER,
compared with no
screening strategy
l The increase in costs of FIT
increases the ICER, compared
with no screening strategy
l The increase in the cost of
colonoscopy increases the
ICER for all screening
strategies, compared with
no screening strategy
l The increase in the cost of
CRC treatment increases
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l The adoption of undiscounted
costs and benefits decreases








l Endoscopic test costs
l FIT sensitivity and specificity
l The increase of uptake (from
54% to 70%) decreases
the ICER
l The increase of endoscopic
test costs increases the ICER
l The adoption of FIT with higher
thresholds (150 and 200 ng







l The decrease of 50% of FIT
cost decreases the ICER
decreased of the two-sample
strategy, compared with the
one-sample strategy
l The capacity limit of five
colonoscopies per 1000
individuals per year decreases








l Polyp detection sensitivity of
imaging test (CTC, OC) for
polyps of < 5mm
l Polyp detection sensitivity of
imaging test (CTC, OC) for
polyps of between 6
and 9mm
l Polyp detection sensitivity of
imaging test (CTC, OC) for
polyps of > 10mm
l CRC detection sensitivity
l Discount rate
l Cost of OC test
l Cost of CTC test
l Lifetime treatment costs
l Utilities
l Utility values
l The increase of OC sensitivity
for detection of polyps of
< 5mm (from 0% to 96%)
decreases the INB, whereas
an increase of CTC sensitivity
for detection of polyps of
< 5mm (from 0% to 90%)
increases the INB for CTC,
compared with OC
l The increase of OC sensitivity
for detection of polyps of
between 6 and 9mm (from
60% to 100%) decreases the
INB, whereas an increase of
CTC sensitivity for detection
of polyps of between 6 and
9mm (from 60% to 100%)
increases the INB for CTC,
compared with OC
l The increase of OC sensitivity
for detection of polyps of
> 10mm (from 80% to 100%)
decreases the INB, whereas
an increase of CTC sensitivity
for detection of polyps of
> 10mm (from 80% to 100%)
increases the INB for CTC,
compared with OC
l The increase of OC sensitivity
for CRC detection (from 80%
to 100%) decreases the INB,
whereas an increase of CTC
sensitivity for CRC detection
(from 80% to 100%) increases
the INB for CTC, compared
with OC
l The increase of the discount
rate (from 0% to 5%)
increases the INB for CTC,
compared with OC
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l The increase of OC (30%
higher) increases the INB for
CTC, compared with OC
l The increase of CTC (30%
higher) decreases the INB for
CTC, compared with OC
l The increase of lifetime
treatment costs (30% higher)
increases the INB for CTC,
compared with OC
l The adoption of 0.5 as utility
value for all health states
increases the INB for CTC,
compared with OC
l The adoption of 0.8 as utility
value for all health states
















l Magnitude, duration of the
increase of presentation
rates
l Increase at Dukes’
stage presentation
l An increase of 1 month of
the duration of change in
symptomatic presentation
rate and an increase of 5% of
the magnitude of change in
symptomatic presentation
rate increases the ICER
l An increase of 1 month in
the duration of change in
symptomatic presentation
rate and an increase of 20%
in the magnitude of change in
symptomatic presentation
rate reduces the ICER
l An increase of 3 or 6 months
in the duration of change in
symptomatic presentation
rate and an increase of 5%,
10% or 20% of the magnitude
of change in symptomatic
presentation rate reduces
the ICER
l An increase of 1 month of
the duration of increase in
symptomatic presentation
rate and an increase of 5%,
10% or 20% of the magnitude
of change in symptomatic
presentation rate increases
the ICER
l An increase of 3 months of
the duration of increase in
symptomatic presentation
rate and an increase of 5% of
the magnitude of change in
symptomatic presentation
rate increases the ICER
continued
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l An increase of 3 months of
the duration of increase in
symptomatic presentation
rate and an increase of 10%




l An increase of 6 months of
the duration of increase in
symptomatic presentation
rate and an increase of 5%,
10% or 20% of the magnitude
of change in symptomatic
presentation rate reduces
the ICER
l The increase of presentation
rate at each CRC Dukes’








l Percentage change in
individual’s behaviour
l Cost of decision aid
l Cost of patient time to use
the decision aid
l The increase of percentage of
people who changed from no
screening to screening
decreases the ICER
l The decrease of the decision
aid cost decreases the ICER
l The increase of cost of
patient time increases
the ICER




l Sensitivity of FIT for
high-risk polyps
l Natural progression of CRC
l Specificity of FIT
l Prevalence of unidentified
high-risk polyps
l Adherence to colonoscopy
after referral
l Sensitivity of colonoscopy for
high-risk polyps
l The increase of sensitivity of
the FIT for high-risk polyps
(from 42% to 214%)
decreases the ICER
l The increase of the natural
progression of CRC (from
70% to 130%) decreases
the ICER
l The increase of the specificity
of the FIT (from 80% to
103%) decreases the ICER
l The increase of the
prevalence of unidentified
high-risk polyps (from
70% to 130%) decreases
the ICER
l The increase of the adherence
to colonoscopy after referral
decreases the ICER
l The increase of sensitivity of
colonoscopy for high-risk











l The decrease of FS
compliance rate (from
100% to 0%), increases
the ICER
l The increase of the
specificity of FS (from
60% to 90%) decreases
the ICER
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TABLE 60 Sensitivity analysis, parameter specification and ICER variation (continued )
Study Type of analysis Parameters affecting ICER ICER variation
l The increase of cost of
colonoscopy (from US$100 to
US$450) increases the ICER
of strategies for which
colonoscopy is included
l The increase of cost of FS
increases the ICER of the




DSA l FIT threshold
l Test positivity rates
(FIT sensitivity rate in





l Evaluation of clinical







l Mortality rate given
by colonoscopy
l Threshold for FIT assay
l Prevalence of CRC
l Cost test
l CRC mortality progression
l Probability of persisting in
symptoms after negative
test result
l High rate of mortality
associated with colonoscopy
l Exclusion of adverse events
associated with colonoscopy
l Second FIT/gFOBT for
patients with a negative test
result when symptoms
persist
l The increase in the mortality
rate given by colonoscopy
increases the ICER
l The adoption of a threshold
of 2 µg Hb/g faeces decreases
the ICER
l The adoption of 3% and 5.4%
for CRC prevalence decreases
the ICER for FIT, compared
with gFOBT
l The exclusion of CRC
progression mortality reduces
the ICER
l The inclusion of double
probability of persisting in
symptoms after a negative
test result decreases the ICER
l The inclusion of half
probability of persisting in
symptoms after a negative
test result decreases the ICER








l The adoption of a second
FIT/gFOBT for patients with
a negative test result when
symptoms persist increases
the ICER
ACBE, air-contrast barium enema; FS, flexible sigmoidoscopy; IBD, inflammatory bowel disease; INB, incremental net
benefit; N/A, not applicable; OC, optical colonoscopy.
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Critical appraisal of model-based economic evaluations







































S1: statement of decision problem/objective
Is there a clear statement of the
decision problem?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is the objective of the evaluation
and model specified and consistent
with the stated decision problem?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is the primary decision-maker
specified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S2: statement of scope/perspective
Is the perspective of the model
stated clearly?
Yes No No Yes Yes Yes Yes Yes Yes Yes Yes No Yes No Yes No Yes Yes
Are the model inputs consistent
with the stated perspective?
Yes Yes NR Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Has the scope of the model been
stated and justified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Are the outcomes of the model
consistent with the perspective,
scope and overall objective of
the model?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S3: rationale for model structure
Has the evidence regarding the
model structure been described?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is the structure of the model
consistent with a coherent theory
of the health condition under
evaluation?





































































Have any competing theories
regarding model structure been
considered?
No No No No No No No No No No No No No No No No No No
Are the sources of data used to
develop the structure of the model
specified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Are the causal relationships
described by the model structure
justified appropriately?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S4: structural assumptions
Are the structural assumptions
transparent and justified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Are the structural assumptions
reasonable given the overall
objective, perspective and scope of
the model?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S5: strategies/comparators
Is there a clear definition of the
option under evaluation?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Have all feasible and practical
options been evaluated?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is there justification for the
exclusion of feasible options?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
S6: model type
Is the chosen model type
appropriate given the decision
problem and specified causal
relationship with the model?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S7: time horizon
Is the time horizon of the model
sufficient to reflect all important
differences between options?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Is the time horizon of the model,
and the duration of treatment and
treatment effect described and
justified?


























































































































































































































































































































































































Do the disease states (state-
transition model) or the pathways
(decision tree model) reflect the
underlying biological process of
the disease in question and the
impact of the interventions?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
S9: cycle length
Is the cycle length defined and
justified in terms of the natural
history of the disease?
No Yes No Yes Yes No No Yes Yes No No No No N/A No No No Yes
Data
D1: data identification
Are the data identification
methods transparent and
appropriate given the objectives of
the model?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Where choices have been made
between data sources, are these
justified appropriately?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Has particular attention been paid
to identifying data for the
important parameters in the
model?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Has the process of selecting key
parameters been justified and
systematic methods used to
identify the most appropriate
data?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Has the quality of the data been
assessed appropriately?
Yes Yes Yes Yes Yes No No Yes Yes Yes No Yes No Yes Yes Yes Yes Yes
Where expert opinion has been
used, are the methods described
and justified?
No Yes N/A N/A N/A N/A No Yes Yes N/A N/A Yes No N/A Yes N/A Yes Yes
D2: pre-model data analysis
Are the pre-model data analysis
methodology based on justifiable
statistical and epidemiological
techniques?






































































Is the choice of baseline date
described and justified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes Yes Yes Yes
Are transition probabilities
calculated appropriately?
NR Yes Yes Yes Yes N/A N/A Yes Yes N/A Yes Yes Yes N/A Yes Yes Yes Yes
Has a half cycle correction been
applied to both cost and outcome?
NR N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
If not, has this omission been
justified?
NR N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
D2b: treatment effects
If relative treatment effects have
been derived from trial data, have
they been synthesised using
appropriate techniques?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Have the methods and
assumptions used to extrapolate
short-term results to final
outcomes been documented and
justified?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A
Have alternative assumptions been
explored through sensitivity
analysis?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Have assumptions regarding the
continuing effect of treatment
once treatment is complete been
documented and justified?
N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A No N/A N/A N/A N/A N/A No N/A
D2c: quality-of-life weights (utilities)
Are the utilities incorporated into
the model appropriate?
Yes Yes Yes Yes Yes No No Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
Is the source for the utility
weights referenced?
Yes Yes Yes Yes Yes No No Yes Yes No Yes Yes Yes Yes Yes Yes No Yes
Are the methods of derivation for
the utility weights justified?


























































































































































































































































































































































































Have all the data incorporated into
the model been described and
referenced in sufficient detail?
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes No Yes
Has the use of mutually
inconsistent data been justified
(i.e. are assumptions and choices
appropriate?)
No Yes Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes Yes Yes N/A Yes No Yes
Is the process of data
incorporation transparent?
Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes No No Yes Yes No No Yes
If the data have been incorporated
as distributions, has the choice of
distribution for each parameter
been described and justified?
No Yes N/A N/A N/A N/A N/A Yes Yes N/A Yes No N/A No Yes No No Yes
If data have been incorporated
as distributions, is it clear that
second-order uncertainty is
reflected?
No Yes N/A N/A N/A N/A N/A Yes Yes N/A No Yes N/A No Yes No No Yes
D4: assessment of uncertainty
Have the four principal types of
uncertainty been addressed?
No Yes No No No Yes Yes Yes Yes No No Yes Yes No Yes No No No
If not, has the omission of
particular forms of uncertainty
been justified?
No No No No No No No No No No No No No No No No No No
Have methodological uncertainties
been addressed by running
alternative versions of the model
with different methodological
assumptions?
Yes Yes No No No Yes Yes Yes Yes No Yes Yes Yes No Yes No No No
Is there evidence that structural
uncertainties have been addressed
via sensitivity analysis?
No Yes No No No Yes Yes Yes Yes No Yes Yes Yes No Yes No No No
D4c: heterogeneity
Has heterogeneity been dealt with
by running the model separately
for different subgroups?






































































Are the methods of assessment
of parameter uncertainty
appropriate?
Yes Yes Yes Yes Yes Yes No Yes Yes No No Yes Yes Yes Yes No No Yes
Has probabilistic sensitivity
analysis been done; if not, has this
been justified?
No N/A No No N/A N/A No N/A N/A Yes N/A N/A N/A No N/A N/A No Yes
If the data are incorporated as
point estimates, are the ranges
used for sensitivity analysis stated
clearly and justified?
Yes N/A Yes N/A Yes Yes N/A Yes Yes Yes Yes Yes Yes N/A No N/A N/A Yes
Consistency
C1: internal consistency
Is there evidence that the
mathematical logic of the model
has been tested thoroughly
before use?
Yes N/A N/A Yes Yes Yes N/A N/A Yes Yes N/A Yes N/A N/A N/A N/A N/A N/A
C2: external consistency
Are the conclusions valid given the
data presented?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Are any counterintuitive results
from the model explained and
justified?
No No No No No No No No No No No No No No No No No No
If the model has been calibrated
against independent data, have
any differences been explained
and justified?
N/A Yes No Yes Yes No No Yes Yes Yes No No No N/A No N/A No No
Have the results of the model
been compared with those of
previous models and any
differences in results explained?
No No No No No No No No No No No No No No No No No No
C, consistency; D, data; N/A, not applicable; NR, not reported; S, structure.


















































































































































































































































































































































Probabilities and costs of adverse events of diagnostic tests in
included studies





Allen 2005144 Probability Procedure complication rates for haemorrhage
from colonoscopy
0.007
Procedure complication rates for perforation
from colonoscopy
0.004
Mortality rate for colonoscopy 0.0001
Procedure complication rates for perforation from FS 0.001
Mortality rate for FS 0.00000006
Procedure complication rates for perforation from ACBE 0.0001
Mortality rate for ACBE 0.00002
Cost Costs of procedural complications of perforation US$13,598
Costs of procedural complications of haemorrhage US$4561
Tappenden 2007145 Probability Probability of perforation from colonoscopy
(without polypectomy)
0.0008
Probability of perforation from colonoscopy
(with polypectomy)
0.0017
Probability of death following perforation
for colonoscopy
0.0582
Probability of perforation (without polypectomy) from FS 0.000025
Probability of perforation (with polypectomy) from FS 0.000025
Probability of death following perforation for FS 0.0582
Probability of bleeding following FS 0.000295
Probability of bleeding following colonoscopy 0.00439
Cost Cost of treating bowel perforation (major surgery) £5407.74
Cost of admittance for bleeding £250.21
Heitman 2010148 Probability Risk of bleeding for diagnostic colonoscopy 0.0003
Risk of bleeding for therapeutic colonoscopy 0.005
Risk of perforation of diagnostic colonoscopy 0.0009
Risk of perforation of therapeutic colonoscopy 0.0024
Risk of perforation after FS 0.0002
Risk of death after endoscopic perforation 0.049
Cost Cost of complication for perforation CAN$31,223
Cost of complication for bleeding CAN$3194
APPENDIX 5
NIHR Journals Library www.journalslibrary.nihr.ac.uk
310





Lee 2010149 Probability Risk of bleeding from screening FOBT 0
Risk of bleeding from screening FS 0.000295
Risk of bleeding from screening colonoscopy 0.00439
Risk of bleeding from screening CTC 0
Risk of perforation from screening FOBT 0
Risk of perforation from screening FS 0.000025
Risk of perforation from screening colonoscopy 0.0008
Risk of perforation from screening CTC 0.0006
Risk of perforation from polypectomy FOBT 0.0017
Risk of perforation from polypectomy FS 0.000025
Risk of perforation from polypectomy colonoscopy 0.0017
Risk of perforation from polypectomy CTC 0.0017
Risk of mortality following perforation 0.00582
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Cost Cost of perforation from colonoscopy US$15,985
Cost of bleeding with transfusion from colonoscopy US$7784
Cost of bleeding without transfusion from colonoscopy US$1775
Cost of other gastrointestinal events from colonoscopy US$1195
Cost of perforation from CTC US$15,985
Sharp 2012151 Probability Probability of perforation from FS with polypectomy 0.00002
Probability of perforation from FS without polypectomy 0.00002
Probability of death after perforation FS 0.06452
Probability of (major) bleeding following FS 0.00029
Probability of perforation from colonoscopy
with polypectomy
0.00216
Probability of perforation from colonoscopy
without polypectomy
0.00107
Probability of death after following perforation 0.05195
Probability of (major) bleeding following colonoscopy 0.00379
Cost Cost of treating bowel perforation €10,200
Cost of admittance for bleeding €3079
Whyte 2012152 Probability Perforation rate from colonoscopy with polypectomy 0.003
Perforation rate from colonoscopy without polypectomy 0
Probability of death after perforation colonoscopy 0.052
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Perforation rate from FS with polypectomy 0.001
Perforation rate from FS without polypectomy 0
Probability of death after perforation FS 0.065
Probability of hospitalisation for bleeding after FS 0.0003
Probability of hospitalisation for bleeding after
colonoscopy
0.003
Cost Cost of treating bowel perforation (major surgery) £2164
Cost of admittance for bleeding (overnight stay on
medical ward)
£278
Goede 2013153 Probability Fatal complications rate after colonoscopy 0.0001
Cost Costs complications after colonoscopy €1250
Gomes 2013154 Probability Rate of complications from colonoscopy bleeding 0.0044
Rate of complications from colonoscopy perforation 0.002
Rate of polypectomy bleeding rate 0.02
Rate of polypectomy perforation 0.0038
FS bleeding rate 0.0003
Risk of death after perforation 0.0582
Cost Costs of admittance for bleeding £295
Cost of treatment of bowel perforation £5822
Tappenden 2013155 Probability Probability of perforation from colonoscopy 0.0013
Probability surgery for perforation 0.66
Probability FS perforation 0.2 × 10–4
Probability DCBE perforation 0.4 × 10–4
Probability CTC perforation 0.0005
Probability patient dies during perforation surgery 0.06
Probability patient dies during polyp surgery 0.04
Probability patient undergoes stenting 0.20
Probability stenting successful 0.72
Probability stent-related mortality 0.0025
Cost Emergency surgery postoperative mortality rate £294.77
Cost emergency surgery £7079.93
Cost emergency surgery for perforation £5088.91
Cost conservative management of perforation £881.99
Cost stent insertion £1012.73
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Decision model data and assumptions
Clinical effectiveness parameters
Distribution of disease stages at presentation
As, by definition, no data exist on the distribution of symptomatic patients by disease stage at first
presentation to the GP, we replicated the disease history model by Tappenden et al.145 and generated the
distribution of disease stages at presentation by age from that model. The model by Tappenden et al.143
was calibrated to data on CRC prevalence and incidence (see Chapter 6), and we verified that predictions
from our replication of that model matched the national mortality data on CRC incidence in England.398
Diagnostic accuracy of the faecal immunochemical test
A systematic review of diagnostic accuracy for FIT found no diagnostic accuracy studies for FIT at
thresholds of 10 µg Hb/g faeces and 20 µg Hb/g faeces evaluated in the low-risk population of interest
here, which was defined by the NICE Guideline Number 126 as that with a prevalence of 0.1–3%.161
Furthermore, only one study of those identified was conducted in a primary care setting, but, in this





Whyte 2014156 Probability Probability of perforation rate of colonoscopy
(with polypectomy)
0.003
Probability of perforation rate of colonoscopy
(without polypectomy)
0
Probability of death following perforation from
colonoscopy
0.052
Probability of hospitalisation for bleeding from
colonoscopy
0.003
Cost Cost of treating bowel perforation (major surgery) £5089
Cost of admittance for bleeding (overnight stay on
medical ward)
£278
Cantor 2015157 Not included Not included
Pil 2016158 Not included Not included
Wong 2016159 Probability Bleeding rate 0.002
Perforation rate 0.0002
Morality due to perforation 0.1
Cost Cost of bleeding US$3320
Cost of perforation US$10,790
Coldman 2017160 Not included Not included
Westwood 2017161 Probability Bleeding rate after colonoscopy 0.0026
Perforation rate after colonoscopy 0.0005
Death rate after colonoscopy 0.000029
Cost Cost of bleeding £603
Cost of perforation £3228
Cost of death £0
ACBE, air-contrast barium enema; DCBE, double-contrast barium enema; FS, flexible sigmoidoscopy.
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study, the FIT was evaluated in patients who were about to be referred to secondary care. The meta-
analysed values from four studies for FITs of 10 µg Hb/g faeces with the OC-Sensor (Palex Medical S.A.,
Sant Cugat del Vallès, Spain ) were 92.1% (86.9% to 95.3%) for sensitivity and 85.8% (78.3% to 91.0%)
for specificity;161 sensitivity and specificity of 100% and 76.6%, respectively, for HM-JACKarc (Hitachi
Chemical Co., Ltd, Tokyo, Japan) from one study were also reported, but are not considered here as
they were based on only 11 CRC cases. As these estimates may overestimate the sensitivity of the test,
we use these values for the sensitivity analysis. For our base-case analysis, we chose to use instead the
values reported by Murphy et al.175 for a screening programme for which a FIT of 20 µg Hb/g faeces,
the threshold with the highest sensitivity of those investigated, was reported to have sensitivity of 52.6%
and specificity of 98.8% for those aged 50–69 years, and specificity of 96.3% for those aged ≥ 70 years.
Excess mortality of symptomatic undiagnosed patients
Patients with false-negative results are exposed to delays in diagnosis and treatment, and we accounted
for the excess risks of death from lack of treatment experienced by an as yet undiagnosed CRC patient.
The only source of evidence that we identified was a study of newly diagnosed CRC patients who
refused treatment in Hong Kong and whose survival outcomes were compared with patients who
accepted treatment for CRC.177 The study subjects included patients with CRC at disease stages I–IV, in
whom a hazard ratio death of 2.66 (95% CI 2.49 to 2.84) was reported for refusing treatment. The study
did not report a treatment effect by disease stage. Therefore, we used this estimate for all disease stages
except for Dukes’ stage A, for which we conservatively assume that lack of treatment has no immediate
effect on survival, in line with previous models.145
Relative mortality of symptomatic undiagnosed patients
We estimate the CRC-related death probabilities from the relative survival curves by Dukes’ stage
depicted in Figure 9. We digitised the curves and fitted exponential survival models to the extracted
data (R2 values of 0.98, 0.99, 0.99 and 0.97 for relative survival curves of Dukes’ stages A, B, C and D,
respectively). The resulting estimates are presented in Tables 6 and 7. Admittedly, these estimates,
which were obtained from data of patients diagnosed between 1996 and 2002, are outdated, as 5-year
survival in CRC patients has increased since the time the data were collected. However, this is the
most recent available data by disease stage, and further sensitivity analyses revealed that this
parameter had limited influence on the study results.
It must be noted that using the same data Whyte et al.152 have reported net survival curves by disease
stage at diagnosis and age. Given the time constraints we faced and the limited influence that these
age-specific CRC survival data would have on the results, we did not incorporate these data into the
model. We note that, by using relative survival estimates instead of net survival ones, we implicitly
assume that there is no heterogeneity in survival outcomes, which is a strong assumption, but one
with no consequence to our results.
Costs
Faecal immunochemical test
Our unit cost estimate for a FIT was obtained from a screening programme evaluation.161 The figure
used for the model excludes the costs of research. This is lower than the £4.53 and £6.03 figures for
OC-Sensor and HM-JACKarc, respectively, used by a previous study.161 We explore the effect of these
alternative cost estimates in sensitivity analyses.
Colonoscopy
We obtained the costs of colonoscopy from the data reported by Whyte and Harnan.156 The original
figure of £563 was obtained from NHS reference costs399 and data from a single screening centre.156
The figure reflated to 2018 prices used in the model for this parameter is presented in Tables 6 and 7.
A previous study adopted a much lower cost of £372 from an average of outpatient diagnostic
colonoscopy with and without biopsy in NHS reference costs of 2014–15.161,400 We retained the
higher cost for our base-case analysis and used the lower cost for the sensitivity analysis.
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We use the same source to account for the costs of adverse events with colonoscopy, namely
perforation and bleeding.156 The NHS reference costs reported by the source, £5089 and £278 for
perforation and bleeding, respectively, are different from those used in the study by Westwood et al.161
of £3228 and £603, respectively, which were derived from length of hospital stay estimates of those
events reported in a 2012 study (1.7 and 9.1 days, respectively161,401). We use the former set of figures
for the base-case analysis, and the latter for the sensitivity analysis.
Treatment of colorectal cancer
Lifetime costs of treatment by Dukes’ disease stage and age were obtained from a previous study.152
This source derived its estimates from simulations of the disease history model by Tappenden et al.145
The estimates used in the model are those figures reflated to 2018 prices, and presented in Tables 6
and 7. Although no better source of estimates was identified, the value of these parameters was found
to have negligible influence on the study results.
Utilities
We adopted utility values by CRC disease stage used in the model by Tappenden et al.,145 which
obtained them from the study by Ness et al.184 These values were used by the existing study in the
field.161 These values were derived from individual interviews of 81 patients who had previously
undergone removal of colorectal adenoma; during the interviews, participants were presented with
stage-dependent outcome states and asked to assess their relative value using the standard gamble
technique. In the absence of utility data for treated patients, we assumed that these values are
applicable to both untreated and treated patients. In sensitivity analyses, we found that the choice of
values for these parameters did not affect the result in a significant way.
In addition, utility values for both patients with CRC and healthy individuals are applied background
utilities from the model by Ara and Brazier,402 which accounts for the non-linear decline of utility with
age, and differentiates between age and sex.
We found no available estimate on the negative impact on health-related quality of life of colonoscopy
or its adverse events. Therefore, we limited our analysis to explore the effect of a disutility of
colonoscopy of 0.0075 in the month when referral takes place, that is the equivalent of a loss of life in
full health of 5 hours.
Assumptions in Westwood et al.’s161 model versus assumptions in our model
Table 63 presents a comparison of the assumptions used in the previous diagnostic model161 relevant to
our analysis and our own model. Our modelled cycle length is 28 days, as opposed to Westwood et al.’s161
yearly length, which is too long to capture the small differences in the referral interval between the
diagnostic strategies that we investigated. We modelled the probability of delayed referral and diagnosis
in patients with a false-negative outcome after the initial tests in primary care, as opposed to the previous
model’s161 arbitrary assumption of a 6-month delay to diagnosis. In contrast to Westwood et al.’s161 model,
in our model an account is made for excess mortality during the time spent in a false-negative state.
In terms of resource use, our cost of colonoscopy (£596 in 2014/15 prices), based on Whyte and
Harnan,156 is higher than that used by Westwood et al.161 (£372), despite the fact that both are derived
from NHS reference costs. However, the difference is reduced to £89 because Westwood et al.161
include an additional cost of £135 for a follow-up appointment with a gastroenterologist to discuss
the colonoscopy results, which is not explicitly considered by Whyte and Harnan156 (who provide no
further detail). Unlike the Westwood et al.161 model, investigations for determining disease stage in
patients diagnosed with CRC are not considered in our analysis, but sensitivity analyses indicate that
these have a negligible effect on the results.
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TABLE 63 Assumptions in Westwood et al.’s161 model vs. assumptions in our model
Assumption
number Westwood et al.161 model Our model
1 A lifetime horizon with a 1-year cycle length
captures the probability of progression for treated
and untreated patients
Lifetime horizon with 4-weekly cycles is required to
measure outcomes with sufficient accuracy
2 Any differences in costs between the tests in
patients without CRC were assumed to occur
only in the first year
Any differences in costs between the tests in
patients without CRC were assumed to occur only
in the first month
3 Any differences in life expectancy between
intervention and comparator for patients without
CRC are due only to the difference in mortality due
to colonoscopy/CTC
Same assumption
4 Any differences in costs between intervention
and comparator for patients without CRC are
only due to difference in cost of gFOBTs and
colonoscopy/CTC
Any differences in costs between intervention and
comparator for patients without CRC are only due
to difference in cost of FIT and colonoscopy
5 Testing has no long-term (after 1 year) effect
on costs or QALYs in disease-negative people.
Thus, in patients without CRC, FOBTs would not
significantly delay diagnosis of the underlying cause
of presenting symptoms, and hence would not
incur any extra cost or effect on mortality
Same assumption but applies after 1 month
Diagnostic model
6 A time frame of 1 year was assumed for the
diagnostic model
Integrated within Markov model
7 A positive FIT/gFOBT result in referral to
colonoscopy
A positive (above the risk threshold) tool assessment
results in referral to colonoscopy, as does a positive
FIT result after a negative tool result in the
intervention or, in the control arm, in all patients
8 A negative FIT or gFOBT result in a watchful
waiting strategy, in which a colonoscopy/CTC will
be performed when symptoms persist. A repeat
FIT/gFOBT might also be performed, but referral
to colonoscopy/CTC is not modelled as being
contingent on the results of the repeat test
A negative FIT, in the control, or both tool and FIT,
in the intervention, results in a watchful waiting
strategy, in which repeat testing will be performed
when symptoms persist (which is assumed to occur
in all CRC cases and none of the non-CRC patients),
and referral to colonoscopy is modelled as being
contingent on the results of the repeat testing
9 The sensitivity and specificity of colonoscopy for
detection of CRC is 100%
Same assumption
10 The symptoms of all those patients with CRC who
receive a false-negative result will persist such that
they will all receive a colonoscopy and thus be
diagnosed (within 1 year) should they survive
(NG1516/expert opinion403)
Same assumption, but < 1% of patients will receive
colonoscopy beyond the 1 year – as determined by the
probability of a positive result after repeated monthly
trials of repeat visit and testing according to sensitivity
of the test. This corresponds with data available to
authors from the electronic primary care record
11 Patients who had a false-negative gFOBT or FIT
result, and whose symptoms persisted, have an
increased probability of progressing to a worse
cancer state because of the delay in diagnosis
Same, all false-negative patients have persistent
symptoms
12 Probability of delayed diagnosis of CRC was
assumed to be the probability of progression
within Dukes’ stages at 6 months
The probability of time to diagnosis was determined
by the sensitivity of the overall strategy, with the
probability of diagnosis at cycle t being given by
the Bernoulli formula for ‘success’ out of t trials
(cycles), that is [(1 – sensitivity)t − 1] × sensitivity,
which, when combined with the rate of disease
progression over Dukes’ disease stages, determined
the disease stage at diagnosis
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TABLE 63 Assumptions in Westwood et al.’s161 model vs. assumptions in our model (continued )
Assumption
number Westwood et al.161 model Our model
14 Only those patients with a negative test result, and
whose symptoms do not persist, do not receive a
colonoscopy/CTC
Patients with a negative test result who have CRC
have persistent symptoms and return every month for
testing and get referred to receive colonoscopy with
a probability determined by the sensitivity of the
strategy (see 13). All negative-testing patients without
CRC are assumed to clear the symptoms after the
initial test result and not to return to the GP
15 CT of the chest, abdomen and pelvis is performed
for all of the patients testing positive for CRC
after colonoscopy or CTC, to estimate the stage
(Dukes’ A–D) of the disease (NG126)
This cost element is not considered, but has a
negligible effect on the results
16 For the base-case scenario, we considered a
threshold of 10 µg Hb/g faeces, or equivalent, for
the detection of CRC using a single faecal sample.
Other options were explored in sensitivity analyses
For the base-case scenario, we considered a
threshold of 20 µg Hb/g faeces, as the evidence on
10 µg Hb/g faeces was derived from a population
different from that of interest
17 The prevalence of CRC in the base-case population
was 1.5%, as in NG126
The prevalence of CRC in the base-case population
was 1.5%
CRC Markov model
18 After the initial distribution of patients in the CRC
model is determined, patients may stay in their
current health state, progress to the health state
representing the next worsening in the condition or
die (from CRC or another cause) (NG126)
Same specification
19 Costs associated with the health states of the CRC
Markov model were estimated as lifetime costs
(i.e. one-off cost)
Same specification
Healthy population Markov model
20 Patients entering this model can either die of all of
the causes or stay in the ‘alive’ health state
Same specification
21 For the base-case scenario, patients aged
≥ 40 years (NG126)
For the base-case analysis, patients aged 70 years
22 The adverse events included in the diagnostic




23 Reduction of quality of life due to adverse events is
assumed to be negligible within a lifetime
(assumption)
Same assumption
24 No costs of patients who die owing to adverse
events of colonoscopy
Same assumption
25 Adverse events due to CTC were assumed to be
the same as those of colonoscopy
CTC was not included in the model
Test costs
26 Costs of laboratory staff to analyse the test were
assumed to be the same for FITs and gFOBTs
Irrelevant; FOBT was not considered as is not used
in practice
27 Training costs and the costs of the laboratory staff
for analysing the test results were not included in
the total costs because it was assumed that these
are the same for FITs and gFOBTs
Laboratory staff costs for analysis were included in
the cost of a FIT; training costs were not included,
to correspond with a measure of marginal costs
28 Costs of the material needed to analyse a sample
include costs of the reagents, buffer, reaction cells
and analyser cups
Same cost elements were included
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Sensitivity analyses
TABLE 63 Assumptions in Westwood et al.’s161 model vs. assumptions in our model (continued )
Assumption
number Westwood et al.161 model Our model
29 Costs of colonoscopy/CTC, adverse event costs and
CT costs were included in the diagnostic model
(NG126)
Same costs except CTC were included in the model
30 We assumed that the cost of colonoscopy/CTC
includes the costs of a follow-up appointment with
a gastroenterologist (assumption/expert opinion)
The cost of a follow-up appointment with
gastroenterologist is implicit in our chosen unit cost
of colonoscopy (£563 in 2011 prices, £596 after
reflation to 2014–15 prices), which was taken
from Whyte and Harnan156 and compares with
Westwood et al.’s161 £372 (in 2014–15 prices); the
difference (£224) is £89 higher than the £135 unit
cost of a gastroenterology outpatient appointment
used by Westwood et al.161 Whyte and Harnan’s156
reported source for the cost of colonoscopy is the
NHS reference costs (no further details provided),
as is Westwood et al.’s.161
31 For test-negative patients whose symptoms persist,
an additional GP appointment cost was considered
Negative-testing patients whose symptoms persist
are all false negatives and keep returning each
month to the GP until they test positive or die
without referral and diagnosis
32 Indirect costs parameters were not included in the
model, given the perspective of the NHS
Same specification
33 Zero excess mortality during delayed diagnosis in
CRC patients
Positive excess mortality during delayed diagnosis
in CRC patients
CT, computerised tomography; NG NICE Guideline.















1 visit 0.49 28 N/A 28 0.55 28
2 visits 0.24 28 0.61 28 0.19 28
3 visits 0.13 56 N/Ae N/A 0.14 56
4 visits 0.07 56 0.24 56 0.05 56
≥ 5 visits 0.08 95 0.15 102 0.07 94
Weighted average 1 39 1 46 1 38
N/A, not applicable.
a The modelled comparator strategy assumes that, every time the patient returns, two GP visits are required for a
referral decision to be made: one for the return visit and a second, follow-up visit for the review and discussion of
the results of primary care investigations ordered at the return visit.
b Positive test results with the tool result in referral after the first visit, whereas a positive test result with the FIT
after a negative result with the tool takes two visits.
c Derived from the sensitivity values for the component tests times the 80% rate of compliance of referral practice
with the test results, see Table 19.
d Positive test result with FIT alone results in referral after two visits: an initial visit and a follow-up visit to
discuss results.
e Values based on implicit sensitivity of 0.76 in Lyratzopoulos et al.173
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Probabilistic sensitivity analyses















1/2 visits 0.73 54 0.61 54 0.74 54
3/4 visits 0.20 51 0.24 51 0.19 51
5/6 visits 0.05 48 0.09 48 0.05 48
7/8 visits 0.01 45 0.04 45 0.01 45
9/10 visits 0.00 42 0.01 42 0.00 42
> 10 visits 0.00 40 0.01 ≤ 40 0.00 40
Weighted average 1 53 1 52 1 53
a Other parameters were set at base-values presented in Table 19 and it is at the end of the title of the table.
TABLE 66 Parameters varied in probabilistic sensitivity analysis, the base case was for a 70-year-old individual and
their distributionsa
Parameter Value Distribution Source
Clinical
Prevalence of CRC 0.015 Beta(1838,121683) Hippsley-Cox 201285
Sensitivity of QCancer 0.610 Beta(1198,765) Hippsley-Cox 201285
Specificity of QCancer 0.910 Beta(1111261,109968)
Sensitivity of FIT 0.526 Beta(73,65) FIT of 20 µg Hb/g faeces;
Murphy 2017175
Specificity of FIT: 50–69 years old 0.988 Beta(10148,123)
Specificity FIT: ≥ 70 years old 0.963 Beta(9891,380)
Compliance with colonoscopy referral 0.80 Beta(80,20) Assumption
Transition probabilities 4-weekly Whyte 2014156
Dukes’ A to Dukes’ B 0.0651 Beta(651,9349) Assumption. Tappenden 2007145
reported model calibration to CRC
incidence and stage at diagnosisDukes’ B to Dukes’ C 0.0787 Beta(787,9213)
Dukes’ C to Dukes’ D 0.1427 Beta(1427,8573)
Costs
Cost of colonoscopy £615 Uniform(555,676) Assumption, ± 10% following
Whyte 2011,404 appendix 4
a Other parameters were set at base-case values presented in Table 19.
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Appendix 6 General practitioner survey
Cover letter
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Aids to cancer diagnosis in primary care survey
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Other types of cancer decision support tools named by general
practitioners in the free text as being available to them
Cancer guideline summaries
l BMJ cancer guidelines chart
l BMJ flow charts on computer desktop
l BMJ Informatica
l Booklet from a GP ‘Update’ course
l Fast-track referral guidance/NICE guidelines
l GP update summary of cancer guidelines NICE 2015
l Macmillan Rapid Referral guidelines
l NICE guidelines 2WW form
l NICE/BMJ cancer assessment/referral guidelines poster
l NICE: suspected cancer recognition and referral
l Pathfinder (Northants)
l Scottish Referral Guidelines for suspected cancer (quick reference guide)
l Secure Grampian Cancer Network chart (NHS Grampian)
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Comments received
l GP unable to complete at present.
l GP unable to complete at present.
l GP unable to complete at present.
l GP unable to complete at present.
l Registrar – unable to complete at present.
l GPs do not use these tools.
l GPs do not use these tools.
l GPs do not use these tools.
l GPs do not use these tools.
l GPs do not use these tools.
l GPs do not use these tools.
l Registrar + 3 Year of military primary care experience.
l Unfortunately no time.
l Incomplete as GP has left.
l Q1 comment – Have Macmillan guidance.
l Tool itself was excellent. Did have Macmillan Tool kit for few months but abandoned – IT (local)
support inadequate.
l The surgery have advised that they have not heard of the cancer tools so will not complete
the survey.
l Never heard of QCancer I was unaware of it but having checked the computer it is there
and available.
l Likely if I am told that it picks up more cancer or reduces referrals in trials using eCDS. Also likely
if, when using, the tool, I can quote on the referral that the eCDS recommends referral and this
would be actioned by secondary care and not ignored.
l The practice have advised that they use SystmOne so do not have acess to the electronic cancer
decision support tools. Because of this they will not be returning the survey.
l I haven’t been using one regularly but would be interested in using a mousemat tool.
l Sorry GPs do not wish to participate.
l Declined.
l Q7 – I use it off the internet QCancer.
l Q2 – would if I had one – mousemat would be useful.
l Q4 – I tried to use when I was a GP in Wirral on EMIS Web but not successful & Q6 – I have seen
in action at Macmillan conference.
l Q1 – Did have mousemat but don’t any longer.
l Not completed – too time-consuming.
l Not completed – too time-consuming.
l Not completed – too time-consuming.
l Not completed – too time-consuming.
l I raised this as an option & past partners felt concerned that not acting on a certain risk would
make them more likely to be sued. It never went any further.
l Flipchart – had one but too much paper – not practical for daily use, too ‘fussy’.
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Copy of email received
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